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ABSTRACT 
 Natural product discovery is in the midst of a transition from a largely serendipity-based 
effort to an informatics-driven one. For most of the 20th century, natural product discovery relied 
on genome-blind bioassay-guided isolation. This was initially exceptionally productive, yielding 
the golden age of antibiotics. The fact that a majority of all medicines—especially antibiotics—
are in some way derived from or inspired by natural products is a testament to the importance of 
understanding and harnessing the chemical strategies for biological interaction that have evolved 
over millions of years. Unfortunately, the overwhelmingly frequent rediscovery rate of known 
compounds among screened natural extracts meant that what was initially a life-saving torrent of 
new drugs eventually dried up into a costly trickle. Unfortunately, this has coincided with the rise 
of drug-resistance superbugs as our initial stockpiles of antibiotics have become overdeployed. 
Fortunately, we are now poised to enact an antibiotic renaissance powered by the ease and 
affordability of large-scale genomic analysis. The ability to genome-gaze has not only revealed 
hundreds of thousands of yet-untapped secondary metabolites in sequenced organisms but also can 
facilitate strain prioritization, novelty determination (dereplication), structure elucidation, three 
principal bottlenecks in the discovery process, as reviewed in Chapter 1. We report here progress 
in the use of genomics to facilitate the discovery and contextualization of new chemical matter. 
In Chapter 2, we report the discovery, isolation, and structural elucidation of 
streptomonomicin (STM), an antibiotic lasso peptide from Streptomonospora alba, and report the 
genome for its producing organism. STM-resistant clones of Bacillus anthracis harbor mutations 
to walR, the gene encoding a response regulator for the only known widely-distributed and 
essential two-component signal transduction system in Firmicutes. Our results demonstrate that 
understudied microbes remain fruitful reservoirs for the rapid discovery of novel, bioactive natural 
product and also highlight the usefulness of genomics in combination with NMR and HR-MS/MS 
for determining the structure of ribosomal natural products. 
In Chapter 3, we use HR-MS/MS, reactivity-based screening, NMR, and bioinformatic 
analysis to identify Streptomyces varsoviensis as a novel producer of JBIR-100, a fumarate-
containing hygrolide. Using a combination of NMR and bioinformatic analysis, we elucidated the 
stereochemistry of the natural product. We investigated the antimicrobial activity of JBIR-100, 
with preliminary insight into mode of action indicating that it perturbs the membrane of Bacillus 
subtilis. S. varsoviensis is known to produce compounds from multiple hygrolide sub-families, 
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namely hygrobafilomycins (JBIR-100 and hygrobafilomycin) and bafilomycins (bafilomycin C1 
and D). In light of this, we identified the biosynthetic gene cluster for JBIR-100, which, to our 
knowledge, represents the first reported for a hygrobafilomycin. Finally, we performed a 
bioinformatic analysis of the hygrolide family using our RODEO algorithm from Chapter 4, 
describing clusters from known and predicted producers. Our results indicate that potential remains 
for the Actinobacteria to yield novel hygrolide congeners and provides a survey of the hygrolide 
landscape. 
In Chapter 4, we report RODEO (Rapid ORF Description and Evaluation Online), an 
algorithm which combines hidden Markov model-based analysis, heuristic scoring, and machine 
learning to identify biosynthetic gene clusters and predict RiPP precursor peptides. We initially 
focused on lasso peptides, which display intriguing physiochemical properties and bioactivities, 
but their hypervariability renders them challenging prospects for automated mining. Our approach 
yielded the most comprehensive mapping of lasso peptide space, revealing >1,300 compounds. 
We characterized the structures and bioactivities of six lasso peptides, prioritized based on 
predicted structural novelty, including an unprecedented handcuff-like topology and another with 
a citrulline modification exceptionally rare among bacteria. These combined insights significantly 
expand the knowledge of lasso peptides, and more broadly, provide a framework for future high-
throughput genome mining.  In addition to lasso peptides, RODEO provides the ability to analyze 
local genomic regions using custom profile hidden Markov models (pHMMs) and is suitable for 
RiPP, polyketide (PKS), nonribosomal peptide (NRPS), and other natural product biosynthetic 
gene cluster types; as part of an effort to make it available as a community resource we have 
created a web portal with its code and tutorials.
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CHAPTER 1: GENOMICS AND STRUCTURAL ELUCIDATION 
This work has been previously published in part.* 
1.1 Introduction 
 Natural products (NPs), beyond serving as an inspiration for synthetic chemists, are a 
privileged source of chemical matter for biomedical purposes.1 This was made obvious in the early 
years of anti-infective development with the discovery of bountiful life-saving metabolites like 
penicillin2 and streptomycin,3-5 which fueled pharmaceutical interest in the systematic screening 
of microorganisms for bioactive compounds. During the pre-genomic era, however, the antibiotic 
fountain began to dry up with increased compound rediscovery,6 and a consensus emerged that the 
most useful natural products had been found—reasonable, in the absence of evidence for other 
metabolites. With the revelations of the genomic era, however, this conclusion has been overturned: 
it has been estimated that we have discovered far less than 10% of nature’s medicine cabinet even 
in the most explored taxa. This is a heartening revelation in the face of the rise of extensively drug-
resistant pathogens, among other medical crises.7,8 
 The revolutions of molecular biology and of informatic technology also provide a strong 
impetus to seek natural products. Indeed, biological interactions are often the result of complex 
steric displays between macromolecules, meaning that the compounds that Nature has evolved to 
perturb these interactions are often themselves larger and more complex than one would normally 
encounter in a synthetic compound library. Protein folds tend to be highly conserved, and natural 
products can thus potentially interact with a diversity of biological targets; as such, natural 
products or natural product-like structures serve as an inspiration for compound screening or 
synthesis efforts.9 This is consistent with the fact that despite their phylogenetic distance from 
eukaryotes, bacteria provide a wealth of bioactive compounds useful in human medicine.10 Beyond 
simply co-opting microbial metabolites for clinical use, their interactions with biological targets 
can also be studied as the basis for the design of novel therapeutics and can shed light on 
physiology and ecology.11 Further, anti-infective drugs tend to be natural products, or at the very 
least, natural product-like: higher MW, numerous stereocenters, architectural complexity, etc.1 
This has spurred interest in natural product mimicry in synthetic efforts (diversity-oriented 
                                                 
* This chapter was adapted in part from Tietz, J.I. and Mitchell, D.A. “Using genomics for natural product structure 
elucidation.” Curr. Top. Med. Chem. 2016, 16 (15), 1645-1694, with permission from Bentham. J.I.T. wrote the 
paper with editorial input from D.A.M. 
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synthesis,12-14 complexity-to-diversity15,16) and also led to renewed biotech and pharma interest in 
the natural product-like space.17,18  
 Genomics-driven natural product discovery has thus become a rapidly evolving field.19-21 
Whereas in 1995 only a single microbial genome (Haemophilus influenzae) had been sequenced,22 
and the first Streptomyces genome was not completed until 2002,23 today many thousands of 
bacterial genomes are publicly available. This has resulted in a plethora of innovative techniques 
aimed at discovering biosynthetic gene clusters. Genomics-driven natural product discovery in 
general has been reviewed extensively in several key overviews.20,21,24-32  
 As it stands now, finding biosynthetic gene clusters (BGCs) in many cases can be done 
quickly in silico. However, linking genes to molecules—the process of isolation, structure 
determination, and evaluation—is still the most time-consuming, rate-limiting step.  
 Genomics has not yet arrived in every natural product laboratory, which is not surprising, 
given that the first papers utilizing genome mining as a discovery technique were only published 
about a decade ago.33-37 As a consequence, the proportion of natural products for which 
corresponding biosynthetic genes are confidently assigned is low—around one thousand,38,39 
representing less than a percent of known natural products. Although a natural product chemist 
must by necessity have in their arsenal the ability to interpret MS, NMR, UV, IR, combustion, and 
other analytical data, only a small subset routinely employ the techniques of genomics and 
bioinformatics. This is remarkable in light of two realities: (a) all natural products have a genetic 
basis; and (b) genetic information is becoming exponentially available and analyzable. We argue 
herein that genomics is an invaluable technique for structure elucidation, especially of particularly 
complex compounds. It is our recommendation—and indeed, prediction—that gene cluster 
analysis will become a standard (and expected) technique used synergistically with the workhorse 
spectrometric analyses. 
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1.1.1 Biosynthetic logic and the extended central dogma 
The central dogma of molecular biology—the transmittance of information from DNA to 
RNA to protein—can be extended to encompass the central dogma of biosynthesis, sometimes 
also called the extended central dogma (Figure 1.1a).20 All natural products have a genetic basis. 
That is, each metabolite is synthesized in a cell by a process of chemical tailoring of substrate 
molecules by biosynthetic enzymes, each of which is itself encoded genetically.32 This concept 
implies that knowledge of biosynthetic genes and biosynthetic protein reactivity can be used to 
characterize and predict natural products—and vice versa—by what might be called biosynthetic 
logic. This is conceptually analogous to how one might analyze a chemist’s starting materials, 
reagents, and conditions in order to predict what target molecule he or she is preparing. 
The biosyntheses of many natural product classes follow what is essentially (simplified) a 
two-step process of (i) assembly of building blocks into a natural product backbone and (ii) 
enzymatic tailoring of the backbone, yielding the mature natural products. Nonribosomal peptide 
synthetases (NRPSs) and polyketide synthases (PKSs), for instance, adopt a modular (and often 
linear) architecture in which monomeric substrates are sequentially assembled and modified with 
a variety of tailoring enzymes.32,40,41 Natural products of ribosomal origin (ribosomally 
synthesized and post-translationally modified peptides, or RiPPs for short) follow a similar 
scheme, starting as genetically-encoded and ribosomally-synthesized precursor peptides that are 
then enzymatically modified to give scaffolds that, upon maturation, frequently do not resemble 
peptides at all.42,43 Understanding of biosynthetic pathways and of the reactions performed by the 
enzymes commonly found in those pathways, therefore, informs structural analysis (Figure 1.1b). 
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Figure 1.1 Genomics in the context of natural products discovery. 
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1.1.2 Genomics and the structural elucidation workflow 
 So where can genomics inform structure determination efforts? The general structure 
elucidation workflow is depicted in Figure 1.1b. Generally, an elucidation effort starts with an 
assay hit. This can range from biological activity of a fractionated extract to the presence of an 
interesting peak on an LCMS trace to the predicted presence of a gene by bioinformatic methods. 
Traditionally, physicochemical and biological methods are used to guide isolation efforts, with 
various spectrometric techniques used to provide insights into molecular substructures which are 
then assembled into a reasonable hypothetical structure. Corroboration of all techniques—
sometimes supplemented with total synthesis−is used to confirm and validate this hypothesis. 
Genomic analysis is complementary to traditional physicochemical analysis, and indeed the two 
can inform each other. Genetic manipulation of BGCs, for instance, can guide hit identification 
and compound isolation. Database-oriented bioinformatic analysis can be used to compare BGCs 
to those for other known compounds, allowing partial or even complete structure prediction based 
on gene similarity or biosynthetic logic. Additionally, comparison of a proposed structure to a 
connected biosynthetic pathway can clarify ambiguous structural regions or prompt further 
physicochemical analysis. 
 In the present review, we aim to illustrate how structure elucidation efforts can benefit—
both indirectly and directly—from the utilization of genomic information, illustrated in particular 
by a number of examples. We focus particularly on compounds of bacterial and fungal origins, for 
which genomic methods have been most fruitful. Our intended audience includes not only 
microbiologists, bioinformaticians, and chemical biologists already familiar with genetic 
techniques, but especially also natural product chemists and organic chemists who may be new to 
these tools. We have organized our discussion into three main sections. First, we provide an 
overview of sources of genomic information and the analytical tools available, with an emphasis 
on nonspecialist usability and suitability to structural elucidation tasks. Second, we discuss 
methods for deciphering which genes are involved in the production of a particular metabolite 
responsible for an assay hit (biological, physicochemical, or bioinformatic). Last, we explore the 
ways in which genomic information can provide structural insight once the biosynthetic genes are 
known.  
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1.2 Tools of the trade: Databases and algorithms 
1.2.1 Obtaining genomic information 
 The advent of massively parallel DNA sequencing means that genome sequences can be 
now obtained quickly and inexpensively—especially for bacteria. Indeed, a bacterial genome can 
now usually be sequenced in less time and at lower cost than obtaining the NMR spectra for the 
bacterium’s unknown metabolites. The genome of an average bacterium is ~1,000-fold smaller 
than that of a human. Considering claims, then, of an attainable $1,000 human genome, it is not 
surprising that the cost of bacterial sequencing is exceptionally low and expected to fall much 
lower.44 
 The quickest and cheapest way to get genomic information is to utilize free databases of 
already-sequenced, publicly available genomes. The most familiar and broadly used are the NCBI 
GenBank (http://www.ncbi.nlm.nih.gov/genbank/),45 the EMBL-ENA (European Nucleotide 
Archive; http://www.ebi.ac.uk/ena),46 and the DDBJ (DNA Database of Japan; 
http://www.ddbj.nig.ac.jp/).47,48 All three are members of the International Nucleotide Sequence 
Database Collaboration49 and include web portals with search and analysis tools as well as the 
ability to download data. It is important to note that all three databases are synchronized with each 
other regularly. Another database and analysis resource is IMG (Integrated Microbial Genomes; 
http://img.jgi.doe.gov/),50,51 which is maintained by the U.S. Department of Energy’s Joint 
Genome Institute (JGI). The IMG contains genomic information from GenBank as well as other 
publicly- and privately-deposited genomes. The amount of data in these various archives cannot 
be overstated. GenBank, for instance, now contains records for in excess of 30,000 bacteria, nearly 
4,000 of which are complete genomes—staggering when contrasted to a report from 2005, wherein 
the 250 total then-available bacterial genomes were described as an “enormous amount of 
sequence data”;52 even in 2010 GenBank contained only about 1,000.32 As sequencing techniques 
grow even cheaper, these archives are expected to continue to grow dramatically, especially 
considering various large-scale sequencing efforts (for instance, the recent sequencing of hundreds 
of actinomycete genomes specifically for natural product discovery purposes53). 
 In the event that a producing organism’s genome is not already available, rapid “next-
generation” sequencing techniques are abundant, increasingly inexpensive, and available at a wide 
range of academic and industrial settings. These sequencing techniques vary in terms of quality, 
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cost, speed, and read length. A discussion of the available technologies and their advantages and 
limitations are beyond the scope of this manuscript but have been reviewed recently.44,54,55  
 It is possible to detect and sequence BGCs of interest without full or near-full genome 
coverage; this was historically useful prior to today’s “next-generation sequencing” technologies 
that enabled both good coverage and high throughput as well as increasing sensitivity for low 
sample sizes. In a technique known as genome scanning, described in 2003,56 random shotgun 
libraries of ~700 bp DNA segments are prepared from an organism’s DNA and sequenced, giving 
genome sequence tags (GSTs); those containing partial BGCs are then used as starting points for 
full-cluster sequencing in the producing organism. Genome scanning relies on the statistical 
likelihood of detecting gene clusters based on average cluster size, predicted genome coverage, 
and average distance between random GSTs. Ecopia BioSciences Inc. successfully used genome 
scanning for the discovery of numerous polyketides, the structures of which were often predicted 
prior to isolation.57-60  
 Beyond obtaining raw genomic data, the assembly and analysis of the resulting information 
can usually also be performed commercially. Thus, a lab today does not need in-depth expertise in 
genetics in order to obtain and analyze a whole genome—a fact that is particularly empowering to 
researchers engaged in the chemical side of natural product discovery. 
1.2.2 Databases useful for genomics-oriented natural product discovery 
 A number of chemical databases are suited to genomics-based natural product discovery 
in that they contain information about the producing organisms and on related compounds (Table 
1.1). The Dictionary of Natural Products (DNP; http://dnp.chemnetbase.com/) is a curated 
database, with a searchable online interface, maintained by Chapman & Hall/CRC and intended to 
be comprehensive. DNP includes literature references for each compound as well as the producing 
organism. PubChem (https://pubchem.ncbi.nlm.nih.gov/) is an NCBI-maintained chemical 
database; primarily, information in PubChem pertains to biological activities of compounds, but it 
also allows searching by structural similarity. ChEMBL61,62 and ChEBI63 are similar bioactivity-
oriented databases maintained by the European Bioinformatics Institute (EBI) of the European 
Molecular Biology Laboratory (EMBL). PubChem, ChEMBL, and ChEBI, although not limited 
to natural product entries, frequently contain literature references for the natural product gene 
clusters. Several databases aimed specifically at particular families of natural products have also 
been developed: NORINE (http://bioinfo.lifl.fr/norine/index.jsp) is a nonribosomal peptide (NRP) 
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database,64 Bactibase (http://bactibase.pfba-lab-tun.org/) is a bacteriocin and RiPP database,65,66 
and ThioBase (http://db-mml.sjtu.edu.cn/THIOBASE/) is a database of thiopeptides.67 Some 
structural databases are ecologically-constrained: the database StreptomeDB 
(http://www.pharmaceutical-bioinformatics.de/streptomedb/) details thousands of compounds 
isolated specifically from the soil-dwelling bacterial genus Streptomyces,68 while MarinLit 
(http://pubs.rsc.org/marinlit/; not open-access) contains records for compounds sourced from 
marine organisms, and NuBBeDB (http://nubbe.iq.unesp.br/portal/nubbedb.html) is devoted to 
natural products originating from Brazilian biodiversity.69 One of the largest natural product 
databases, however—and the largest open-access one—is Super Natural II 
(http://bioinformatics.charite.de/supernatural).70,71 The database contains hundreds of thousands 
of natural product records and in some cases also contains information on their biosynthetic 
pathways via integration with KEGG (Kyoto Encyclopedia of Genes and Genomes).72  
 For MS-based, genome-guided informatic search methods, the metabolite-centered MS 
database METLIN (https://metlin.scripps.edu/), currently containing about 64,000 structures, is 
useful.73 METLIN contains features including MS/MS matching, has been used for genome-
guided methods,74 and is integrated with KEGG.72 
 In contrast with the number of databases for compound structures, comparatively few 
databases are dedicated to the BGCs encoding natural products. Most of these are PKS- and/or 
NRPS-oriented, including ClusterMine360 (http://www.clustermine360.ca/),75 DoBISCUIT 
(Database of Biosynthesis Clusters Curated and Integrated; http://www.bio.nite.go.jp/pks/),76 and 
CSDB (ClustScan Database; http://csdb.bioserv.pbf.hr/csdb/ClustScanWeb.html)77; each of these 
has on the order of a hundred or more BGCs. ClusterMine360 also integrates with antiSMASH78-
80 (described below). 
 An exciting BGC database recently brought online is MIBiG (Minimal Information about 
a Biosynthetic Gene Cluster; http://mibig.secondarymetabolites.org/), a project of the Genomic 
Standards Consortium (GSC).38,81 The MIBiG database is intended to be a curated and 
comprehensive collection of known natural product/gene cluster links that also provides 
information on the empirical basis for the genotype/chemotype linkages, the first unified database 
of this kind (some extensive collections of gene/molecule correlations do exist, such as the 732-
molecule/cluster training set used by Cimermancic and coworkers for the ClusterFinder 
algorithm39 and included in that paper’s Supplemental Information). MIBiG is also the name of an 
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accompanying data standard intended to help unify and standardize annotations of BGCs in 
genome databases.  The recent release of MIBiG is timely, easing one of the major hurdles to 
determining the most likely structure of a metabolite from sequence information alone. As noted 
above, the MIBiG database has already been implemented in antiSMASH 3 (described below) and 
is responsible for the ability of the algorithm to now provide the natural product corresponding to 
the most similar gene cluster to each identified hit.80 Similar implementation is in progress for the 
JGI-IMG50 system via its new Atlas of Biosynthetic Gene Clusters (IMG-ABC, described below) 
as well as the chemical databases ChEMBL61,62 and ChEBI.63  
 Along these lines, JGI-IMG recently implemented its own Atlas of Biosynthetic Gene 
Clusters (IMG-ABC) database (https://img.jgi.doe.gov/ABC/). This database is conceptually 
similar to MIBiG, containing information about BGCs and associated natural products, and indeed 
even draws information from MIBiG. A large number of predicted but not-yet-characterized BGCs 
are also included. The interface is integrated with the JGI-IMG sequence database described above, 
and as such, provides the ability to perform sequence similarity searching of biosynthetic genes 
against public databases or against the genome records in IMG itself. IMG-ABC contains 
structural information about each included NP as well as information about its biological source 
of isolation, gene cluster, and accession numbers in other databases. 
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Table 1.1 Useful bioinformatic analysis tools. 
  
Tool URL Type Usage 
NUCLEOTIDE DATABASES 
International Nucleotide Sequence Database Collaboration: 
    NCBI GenBank http://www.ncbi.nlm.nih.gov/gen
bank/ 
Database Database of publicly available gene sequences 
    EMBL-ENA (European Nucleotide Archive) http://www.ebi.ac.uk/ena Database Database of publicly available gene sequences 
    DDBJ (DNA Database of Japan) http://www.ddbj.nig.ac.jp/ Database Database of publicly available gene sequences 
IMG (Integrated Microbial Genomes) http://img.jgi.doe.gov/ Database Database of publicly available gene sequences 
COMPOUND DATABASES 
PubChem https://pubchem.ncbi.nlm.nih.gov
/ 
Database Structure and biological activity database for small molecules; 
structural similarity searching 
ChEMBL https://www.ebi.ac.uk/chembl/ Database Structure and biological activity database for small molecules 
ChEBI http://www.ebi.ac.uk/chebi/ Database Structure and biological activity database for small molecules 
Norine http://bioinfo.lifl.fr/norine/index.js
p 
Database Database of nonribosomal peptides including bioactivity and 
producing organisms 
Bactibase http://bactibase.pfba-lab-tun.org/ Database Database of bacteriocins and ribosomal natural products 
Dictionary of Natural Products http://dnp.chemnetbase.com/ Database Curated database of known natural products and producing 
organisms 
StreptomeDB http://www.pharmaceutical-
bioinformatics.de/streptomedb/ 
Database Database of compounds isolated from Streptomyces. 
MarinLit http://pubs.rsc.org/marinlit/ Database Database of compounds from marine organisms; not open-access 
Super Natural II http://bioinformatics.charite.de/s
upernatural 
Database Open-access database of natural products, including some 
biosynthetic pathways 
NuBBE DB http://nubbe.iq.unesp.br/portal/n
ubbedb.html 
Database Database of compounds originating from Brazilian biodiversity, 
including producing organisms 
ThioBase http://db-
mml.sjtu.edu.cn/THIOBASE/ 
Database Database of thiopeptide compounds and biological activities 
METLIN https://metlin.scripps.edu/ Database Database of MS/MS spectra for metabolites 
GENE CLUSTER DATABASES 
CSDB and rCSDB (ClustScan Database) http://bioserv.pbf.hr/cms/index.p
hp?page=clustscan-database 
Database Database of PKS and NRPS gene clusters and associated natural 
products 
DoBISCUIT (Database of Biosynthetic Gene 
Clusters Curated and Integrated) 
http://www.bio.nite.go.jp/pks/ Database Database of PKS and NRPS gene clusters and associated natural 
products 
ClusterMine360 http://www.clustermine360.ca/ Database Database of PKS and NRPS gene clusters and associated natural 
products 
MIBiG (Minimal Information about a 
Biosynthetic Gene Cluster) 
http://mibig.secondarymetabolite
s.org/ 
Database Database of biosynthetic gene clusters correlated with known 
natural products 
Atlas of Biosynthetic Gene Clusters (IMG-ABC) https://img.jgi.doe.gov/ABC Database Database of predicted and confirmed biosynthetic gene clusters 
correlated with natural products 
GENE COMPARISON TOOLS 
NCBI-BLAST http://blast.ncbi.nlm.nih.gov/Blast
.cgi 
Program Sequence similarity determination and alignment 
EFI-EST (Enzyme Similarity Tool) http://efi.igb.illinois.edu/efi-est/ Program Generation of sequence similarity networks 
EFI-GNT (Genome Neighborhood Tool) http://efi.igb.illinois.edu/efi-gnt/ Program Generation of gene neighborhood networks 
MultiGeneBlast http://multigeneblast.sourceforge
.net/ 
Program BLAST searching for gene clusters 
HMMER Web Server http://www.ebi.ac.uk/Tools/hmm
er/ 
Program Hidden Markov model-based homology analysis of genes 
BIOSYNTHETIC GENE CLUSTER DISCOVERY 
antiSMASH http://antismash.secondarymeta
bolites.org/ 
Program Discovery and analysis of biosynthetic gene clusters, all classes 
BAGEL3 http://bagel.molgenrug.nl/index.p
hp/bagel3 
Program Discovery and analysis of ribosomal natural product gene clusters 
SMURF http://jcvi.org/smurf/index.php Program Discovery of biosynthetic gene clusters in fungal genomes 
eSNaPD http://esnapd2.rockefeller.edu/ Program Identification and analysis of biosynthetic diversity from 
metagenomic data 
ClusterFinder http://github.com/petercim/Cluste
rFinder 
Program Discovery of biosynthetic gene clusters; source code, not interface 
NP.searcher http://dna.sherman.lsi.umich.edu
/ 
Program Discovery of PKS and NRPS biosynthetic gene clusters; structural 
suggestions 
NaPDoS (Natural Product Domain Seeker) http://napdos.ucsd.edu/ Program Discovery of PKS and NRPS biosynthetic gene clusters; 
dereplication 
PRISM (Prediction Informatics for Secondary 
Metabolomes) 
http://magarveylab.ca/prism/ Program Discovery and analysis of PKS and NRPS biosynthetic gene 
clusters; structural prediction and dereplication 
ThioFinder http://db-
mml.sjtu.edu.cn/ThioFinder/ 
Program Discovery and annotation of thiopeptide gene clusters and 
associated database 
Pep2Path http://pep2path.sourceforge.net/ Program Discovery of gene clusters for peptidic natural products from MS/MS 
fragmentation data 
RiPPquest http://cyclo.ucsd.edu/ Program Discovery of RiPP gene clusters from MS/MS fragmentation data 
and genomic information 
NRPquest http://cyclo.ucsd.edu/ Program Discovery of NRPS gene clusters from MS/MS fragmentation data 
and genomic information 
GENE CLUSTER ANALYSIS 
NRPS/PKS Analysis Web-Site http://nrps.igs.umaryland.edu/nrp
s/ 
Program Analysis of PKS and NRPS clusters with substrate prediction for 
individual domains 
NRPS-PKS-substrate-predictor http://www.cmbi.ru.nl/NRPS-
PKS-substrate-predictor 
Program Prediction of PKS or NRPS A or AT domain substrate specificity 
NRPSpredictor 2 http://nrps.informatik.uni-
tuebingen.de/ 
Program Prediction of NRPS adenylation domain substrate specificity 
LSI-based A domain function predictor http://bioserv7.bioinfo.pbf.hr/LSI
predictor/AdomainPrediction.jsp 
Program Prediction of NRPS adenylation domain substrate specificity 
GNP (Genes to Natural Products) / iSNAP 
(Informatic Search Algorithm for Natural 
Products) 
http://magarveylab.ca/gnp/ Program Analysis of NRPS and PKS clusters with substrate prediction for 
individual domains; dereplication by comparison of MS/MS data to 
databases 
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1.2.3 Programs and databases for biosynthetic gene cluster analysis and structure prediction 
 Naturally, genomic data is only useful given sufficient tools to analyze it. Fortunately, the 
evolution of the information age and of inexpensive computing power has meant that a number of 
readily-accessed analysis tools have been developed. Programs and algorithms for in silico 
analysis of genomic information are numerous and have been reviewed recently,82-85 and so here 
we focus on a few programs which are most generally useful with respect to natural product 
structure determination (Figure 1.2; Table 1.1). 
 The program antiSMASH (Antibiotics and Secondary Metabolite Analysis Shell) is one of 
the most broadly useful and comprehensive for BGC identification and interpretation.78-80 An 
important aspect of antiSMASH is that it is one of the few programs that is intended to provide a 
broad biosynthetic survey of a given genome and is not limited to one or even a few natural product 
classes (briefly, the authors list that its scope includes polyketide, NRP, terpenoid, lanthipeptide, 
bacteriocin, aminocyclitol, β-lactam, aminocoumarin, indole, butyrolactone, ectoine, siderophore, 
phosphoglycolipid, melanin, aminoglycoside, oligosaccharide, phenazine, thiopeptide, 
homoserine lactone, phosphonate, and furan gene clusters).78-80 First released in 2011 and now in 
its third version, the pipeline is accessible freely online 
(http://antismash.secondarymetabolites.org/) or as a downloadable standalone program for 
Windows, Linux, or Mac OS X. The antiSMASH pipeline builds on and incorporates a number of 
the previously-developed biosynthesis-based bioinformatic programs, providing a centralized 
interface for their use. For basic analysis, one specifies a genome (or, realistically, any annotated 
or unannotated nucleotide sequence), which the program analyzes for natural product biosynthesis 
signatures (based on statistical models of known gene clusters) and provides an output list of 
putative BGCs, along with predicted information about structural aspects (for lanthipeptides, 
polyketides, and NRPs, where possible) as well as information about the most closely related 
known gene clusters.  The program outputs an HTML document (Figure 1.3) containing the 
information about the clusters and external links for further analysis. It is worth noting that 
structural information from antiSMASH is not complete—although substrate specificities of 
NRPS and PKS modules can be analyzed, the algorithm does not take non-linearity, module-
skipping, cyclizations, or modifications into account. However, the output from antiSMASH and 
the embedded tools still provide a wealth of information that can rapidly narrow down structural 
possibilities. If one has an unknown natural product, querying antiSMASH can provide a candidate 
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list of possible gene clusters, which is especially useful if the class of natural product (e.g. 
lanthipeptide) is known. Even if the biosynthetic class is unknown, the output gives an idea of 
possible natural product classes to consider. Importantly, antiSMASH provides for each cluster a 
list and alignment of other homologous gene clusters, allowing determination of other organisms 
that might produce a similar or identical product. In the most recent version of antiSMASH, 
alignments to clusters known to produce particular natural products are also given. This 
information, enabled by the in-development community-annotated MIBiG database,38 is especially 
valuable for rapidly determining if a known compound (or scaffold) is present. 
 The antiSMASH pipeline is most suited for identification of BGCs of known classes—a 
potential limitation if a natural product’s BGC is sufficiently divergent from known sequences. 
However, it is also possible to use the open-source ClusterFinder algorithm (a version of which 
antiSMASH itself employs78) in a less biased manner in order to discover even BGCs of unknown 
classes, as detailed by Cimermancic et al.39 
 Two whole-genome search programs that are focused on PKS and NRPS domain 
identification and analysis are NP.searcher86 (http://dna.sherman.lsi.umich.edu/) and NaPDoS87 
(Natural Product Domain Seeker; http://napdos.ucsd.edu/). Notably, NP.searcher provides 
structural predictions that take into account some modifications, including the generation of 
several candidate structures based on different possible cyclization sites; as such, NP.searcher 
often provides more thorough structural prediction for PKS and NRPS products than does 
antiSMASH. An example of NP.searcher prediction based on the echinomycin gene cluster, as 
given by Li, is shown in Figure 4.86 Here, seven chemical structures were predicted based on 
various possibilities of dimerization, cyclization, and intramolecular disulfide formation. One of 
the structures, an ester-cyclized dimer bearing an intramolecular disulfide (Figure 1.4a), was very 
similar to the actual core structure of echinomycin (Figure 1.4b). Echinomycin bears a thioacetal 
crosslink in place of the predicted disulfide; this is, however, a consequence of enzymatic 
modification of the disulfide, which is indeed present in echinomycin’s biosynthetic precursor, 
triostin A (Figure 1.4b).88 It is clear that automated structural prediction is rarely completely 
accurate or thorough,82 and results are highly variable as to accuracy (i.e. it is unwise to expect an 
example like echinomycin to be the rule). However, when combined with biosynthetic logic, 
spectrometry, and manual prediction, automated mining methods can be quite useful.  
 SMURF89 (Small Molecule Unique Regions Finder; www.jcvi.org/smurf/) is another 
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genome analysis tool specifically for fungi. For a given fungal genome, SMURF will provide a 
list and genomic locations of putative secondary metabolism gene clusters, but further analysis 
with other programs is necessary for structural or phylogenetic insights. Other, earlier, analysis 
programs include ClustScan90 and CLUSEAN91 (Cluster Sequence Analyzer); both are limited to 
analysis of PKS and NRPS pathways. For RiPPs, BAGEL392 (Bacteriocin Genome Mining Tool; 
http://bagel2.molgenrug.nl/index.php/bagel3), the successor to the two previous93,94 BAGEL 
versions, is a targeted genome survey tool. BAGEL3 is particularly useful for detection of certain 
classes of ribosomal natural products whose BGCs may currently evade antiSMASH.92 
  eSNaPD (Environmental Surveyor of Natural Product Diversity; 
http://esnapd2.rockefeller.edu/) is a web-based bioinformatics tool particularly aimed at analysis 
of metagenomic data but also suitable for genomic libraries;95 eSNaPD is useful for predicting 
compound novelty or dereplication but initially is aimed primarily at PKS and NRPS products. 
NaPDoS (Natural Product Domain Seeker; http://napdos.ucsd.edu/), mentioned previously, as also 
particularly apt for dereplication efforts.87 NaPDoS can take as input either protein or nucleotide 
information and acts by analyzing diagnostic sequence tags within detected ketosynthase (KS) or 
condensation (C) domains in polyketide and nonribosomal peptide BGCs, respectively. The degree 
to which identified domains are similar to those corresponding to known natural products is output 
by the proram and enables an inference of compound novelty. Also useful for dereplication is the 
web-based platform PRISM (Prediction Informatics for Secondary Metabolomes; 
http://magarveylab.ca/prism/), which analyzes an input gene cluster or genome and provides some 
structural predictions as well as estimates of natural product novelty based on similarity to known 
BGCs. PRISM is a web-based tool and is not yet the subject of a publication. Due to inherent 
differences in scope and utility, it is pertinent to utilize multiple genome/BGC analysis tools in 
parallel.  
 A number of more focused tools also exist that are tailored to the analysis of specific gene 
clusters and are hence useful in manual prediction of substructures from sequences. ThioFinder 
(http://db-mml.sjtu.edu.cn/ThioFinder/) identifies thiopeptide gene clusters and is hosted 
alongside ThioBase, a thiopeptide structure and bioactivity database.67  In parallel to the fact that 
PKS and NRPS modular biosynthetic pathways tend to be more predictable and understandable 
than for many other natural product pathways, most of these programs focus on these two classes. 
These tools include the NRPS/PKS Analysis Web-Site (http://nrps.igs.umaryland.edu/nrps/),96 
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NRPS-PKS-substrate-predictor (http://www.cmbi.ru.nl/NRPS-PKS-substrate-predictor),97 
NRPSpredictor/NRPSpredictor2 (http://nrps.informatik.uni-tuebingen.de/),98,99 and the LSI-based 
A-domain function predictor 
(http://bioserv7.bioinfo.pbf.hr/LSIpredictor/AdomainPrediction.jsp).100 Many of these have been 
reviewed recently.82,83 Unfortunately, the websites of many previously reviewed and well-known 
web-based tools have recently gone defunct, including NRPSsp,101 SBSPKS,102 SEARCHPKS,103 
SEARCHGTr,104 PKSIIIexplorer,105 and PKminer106 (these sites were not accessible at the time of 
preparation of this manuscript).  
 The program/database DECIPHER was developed by Ecopia BioSciences more than a 
decade ago and provided robust structural prediction abilities for polyketide (PK) and 
nonribosomal peptide (NRP) natural products. Although never itself a subject of a publication, 
DECIPHER was employed by Ecopia (and later Thallion Pharmaceuticals when Ecopia was 
acquired) to reportedly elucidate more than 60 natural products, especially polyketides, including 
the former clinical candidate ECO-4601.60 As a result of its proprietary nature, DECIPHER was 
unfortunately never made publicly available and no longer appears to be in commercial use 
following the acquisition of Thallion. 
 Several freely-available programs have recently been developed to identify biosynthetic 
gene clusters of molecules that are partially or entirely peptidic. Pep2Path 
(http://pep2path.sourceforge.net/) is a downloadable software that takes MS/MS fragmentation 
mass shifts as an input and locates, with the RiPP2Path and NRP2Path algorithms, ribosomally-
produced and nonribosomally-produced peptide BGCs, respectively.107 The NRP2Path algorithm 
itself utilizes NRPSPredictor299 and antiSMASH78 in its sequence analysis. Importantly, the 
RiPP2Path algorithm was designed to be more general than the related RiPPquest108 algorithm, 
which currently is designed specifically for lanthipeptides. Useful in cases that the producing 
organism’s genome is not known or it is unculturable, Pep2Path is able to search all known 
GenBank NRPS clusters, which can reveal closely-related orthologous BGCs in similar organisms. 
RiPPquest108 and NRPquest109 (both at http://cyclo.ucsd.edu/) are two MS/MS networking analysis 
based programs that take LC-MS/MS data and a specified genome as input and then use statistical 
methods to locate the corresponding gene clusters and predict structural aspects of RiPP and NRP 
natural products, respectively. NRPquest utilizes NRPSpredictor299 and has an advantage over 
genome-only prediction methods in that it can accommodate nonlinear and highly modified NRP 
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scaffolds. Another useful prediction and dereplication platform is the recently-developed GNP 
(Genes to Natural Products; http://magarveylab.ca/gnp/). GNP is designed to analyze a genome or 
gene cluster for NRPS and PKS enzymes, including predicted specificity of the detected 
biosynthetic modcules. Of particular interest, GNP also utilizes the program iSNAP 
(http://magarveylab.ca/gnp/#!/isnap), which uses an in silico-generated library of possible 
structural mass fragments, as well as statistical comparison these fragments to tandem MS/MS 
data of unknown compounds, in order to guide structural prediction or assessment of novelty.110 
The capabilities of iSNAP have recently been updated.111 
 For pairwise comparison of gene sequences, the most familiar and widely-used tool is 
BLAST (Basic Local Alignment Search Tool; http://blast.ncbi.nlm.nih.gov/Blast.cgi),112 an 
algorithm that takes a protein or nucleotide sequence as input and searches a given database for 
similar sequences. The details of its function and use are beyond the scope of this review, but 
BLAST searching is critical to gene-guided natural product discovery, as predictions of enzyme 
function rely on sequence-based comparisons. MultiGeneBlast 
(http://multigeneblast.sourceforge.net/), a recently-developed, downloadable program, extends 
BLAST functionality from individual genes to the comparison of entire gene clusters;113 the value 
of this is evidenced by the fact that antiSMASH uses the MultiGeneBlast algorithm.78 HMMER,114 
now on its third iteration as HMMER3,115 is a sequence homology analysis algorithm that is more 
mathematically elaborate, and able to detect more distant homologues, than BLAST. HMMER, 
accessible via download for local use (http://hmmer.janelia.org/) or via a web interface 
(http://www.ebi.ac.uk/Tools/hmmer/),116,117 is also utilized behind the scenes by many other 
bioinformatics tools. 
 Another useful analysis strategy uses sequence similarity networks (SSNs) for 
visualization of the relatedness of large numbers (thousands or more) of genes.118 SSNs represent 
nucleotide or protein sequences as nodes, with edges (lines) between nodes indicating relatedness 
above a specified threshold; importantly, the resulting diagrams contain information about the 
relatedness of all the analyzed sequences not just to the query sequence but also to each other. 
Nodes are grouped together based on relatedness, allowing one to quickly assess the phylogenetic 
context of a particular gene. Generation of an SSN can be done easily via a freely-accessible web 
server, the EFI-EST (Enzyme Function Initiative119 Enzyme Similarity Tool; 
http://efi.igb.illinois.edu/efi-est/).120 Another similar tool, the EFI-GNT (Genome Neighborhood 
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Tool; http://efi.igb.illinois.edu/efi-gnt/), takes an SSN as an input and analyzes the nodes and 
groups based on the genes commonly located nearby each in the genome. This can rapidly allow 
assignment of a particular cluster to a biosynthetic class based on other genes in the gene cluster. 
The output of the EFI-EST or EFI-GNT tools can be analyzed with an open-source network 
visualization program such as Cytoscape.121,122 Although SSNs are not yet a widely-adopted 
technique in natural product discovery, their use will likely increase due to being able to interpret 
larger datasets in a more intuitive manner than many other analysis methods, including 
phylogenetic trees and simple pairwise alignment. With the number of sequenced genomes 
growing exponentially, this kind of “big data” analysis will likely become increasingly invaluable. 
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Figure 1.2 Usefulness of bioinformatic tools in a representative workflow. 
Figure 1.3 Example output in antiSMASH 3.0. Shown is an example output for Streptomyces coelicolor A3(2). 
Each of the 25 detected gene clusters are labeled and classified by biosynthetic class (‘Type’). Also shown are the 
coordinates of each gene cluster as well as the most similar cluster known to correlate to a particular natural product. 
In the HTML output, biosynthetic classes are color-coded. 
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Figure 1.4 Example of predicted natural product structure from NP.searcher. (a) NP.searcher predicts seven 
possible structures from the echinomycin gene cluster based on possible disulfide, cyclization, and dimerization 
modifications. One of the predicted scaffolds, the ester-cyclized disulfide dimer, is close to the actual structure of 
echinomycin. (b) Structures of echinomycin and its biosynthetic precursor triostin. Note that while the predicted 
disulfide linkage has been further modified in echinomycin, it is present intact in triostin. Sites where the core structure 
was correctly predicted by NP.searcher are highlighted in grey. 
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1.3 From hits to genes: Identification of biosynthetic machinery 
 Using genomic information for structural elucidation purposes first requires identification 
of the biosynthetic genes corresponding to the metabolite of interest. Depending on the assay 
responsible for identifying the unknown molecule, this can range from trivial to challenging. When 
an organism is genetically tractable, gene inactivation (or activation) can be a useful strategy, and 
expression of the whole gene cluster in a heterologous host provides compelling indication of gene 
involvement; indeed, the combination of inactivation and heterologous expression are the gold 
standard for demonstration of the necessity and sufficiency of a BGC for natural product 
biosynthesis. Methods not requiring genetic manipulation are also quite feasible, however, using 
either biosynthetic logic (based on known or predicted properties of the compound) or 
spectrometry-coupled informatics methods. Such approaches are likely to become increasingly 
important as natural products chemists venture toward less well-studied organisms in the seach for 
new metabolites. 
1.3.1 Gene inactivation or activation 
 The most conceptually straightforward method for identifying a biosynthetic gene cluster 
(BGC) using genetic manipulation is by gene inactivation. If a gene is essential for biosynthesis, 
then comparative analysis techniques—such as comparative LCMS123,124 or differential NMR125—
reveal an absence of the compound of interest in the disrupted strains. Indeed, gene inactivation 
and comparative HPLC was vital to the correlation of coelichelin—the first natural product to be 
described from a genome-mining effort and hence a historically prototypical example—and its 
BGC.126 The use of gene inactivation as a biological and biochemical technique is well-established 
and widely used in genomics-driven natural product discovery in general (it is not practical to 
comprehensively cite all instances of its use). Thus, herein we present a few illustrative examples 
of its usefulness. 
 A screening effort by a team at Bristol-Myers Squibb Co. led to the identification of 
bacillaene A, a prokaryote-selective protein synthesis-inhibiting antibiotic (Figure 1.5a), from a 
strain of Bacillus subtilis strain ATCC 55422.127 Despite NMR and MS analysis, however, the 
compound’s structure was elusive. Initial efforts revealed partial substructure information, 
including the presence of a conjugated hexaene moiety (characteristic UV absorbance) and three 
more double bonds, three carbonyl groups (based on 13C NMR), and several tetrahedral carbons; 
a chemical formula was proposed (Figure 1.5a) based on high-resolution MS. Bacillaene and its 
20 
biosynthetic intermediates tend to undergo decomposition upon handling or dissolution;127-129 this 
stymied its full structure elucidation until a genome-enabled effort in 2007.129 Genomic analysis 
of Bacillus amyloliquefaciens FZB42 revealed three large PKS gene clusters; comparison to 
known compounds, gene disruption by insertion of antibiotic resistance cassettes, and functional 
expression of the gene cluster in a heterologous host, thus linked the hybrid PKS-NRPS ~72 kb 
megasynthase bae (Figure 1.5b) to the production of bacillaene.130 An orthologous cluster, pksX, 
was found also in B. subtilis, the originally-described bacillaene producer.130,131 However, since 
the cluster also contained two NRPS modules in baeJ and baeN, it was apparent that at least two 
nitrogens should be present in the mature natural product—in contrast to the previously-described 
molecular formula. Generation of a bacillaene-silent mutant in B. subtilis allowed for differential 
2D NMR of minimally-purified extracts, thereby sidestepping the purification steps that previously 
had resulted in troublesome degradation.129 Thus, despite the complexity of the extracts, spectral 
overlay enabled the identification of the resonances involved in the deleted gene cluster. In this 
way, the full structure, including alkene stereochemistry, was obtained (Figure 1.5a) in the context 
of the producing organism. 
 At the time, the structure of bacillaene could not be accurately predicted from 
bioinformatics. In retrospect, this is not surprising, given the unconventional nature of the 
biosynthetic machinery (e.g. trans-AT PKS as well as exceptions to co-linearity rules) and 
polyketide tailoring (e.g. β,γ- rather than typical α,β-unsaturation in the triene moiety as well as an 
enamide group).128 Additionally, later analysis revealed that bacillaene A is processed further via 
glycosylation to form bacillaene B (Figure 1.5a) despite the absence of a discernable 
glycosyltransferase in the local genomic region (Figure 1.5b). However, bioinformatic analysis 
played an essential role in partial structure prediction (presence of two nitrogens from NRPS 
machinery) and structural confirmation (via analysis of a consistent, proposed biosynthetic 
pathway).129,130,132  
 In another example, a PCR-targeted gene replacement method specifically for 
Streptomyces (and previously used to determine the genes involved in biosynthesis of the soil odor 
sesquiterpene geosmin133) was used to link uncharacterized type III PKS clusters to the production 
of several germicidins in Streptomyces coelicolor A3(2).134 Comparative LCMS between the 
deletion and wild type strains showed perturbation of 5 compounds, the production of which was 
regained by restoration of the genes. Although two compounds, germicidins A and B (Figure 1.6), 
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were not novel, this inactivation approach led to the discovery of three previously-unknown 
compounds: germicidin C and isogermicidins A and B. Importantly, the simultaneous discovery 
of the biosynthetic genes expanded the scope of known PKS extender units and shed insight into 
germicidin biosynthesis. 
 From the fungus Aspergillus nidulans, all 32 PKS genes were systematically deleted, and 
analysis of the resulting mutant library led to the linkage of the expressed polyketide metabolites 
to their biosynthetic genes.135 This mutant library-construction approach is particularly useful in 
that it requires only knowledge of the class of natural product in order to systematically prioritize 
candidate genes for inactivation. 
 Gene inactivation was crucial for the discovery and structural elucidation of plantazolicin 
(Figure 1.24b).136 In this case, many known NRPS and PKS biosynthetic genes had been 
inactivated in the producing organism, Bacillus amyloliquefaciens FZB42; however, extracts still 
exhibited some natural product production, leading to a discovery of the novel compound 
plantazolicin and its associated gene cluster (which was itself, in turn, inactivated to verify its 
involvement). In the case of the xenoamicins, inactivation of a putative gene cluster aided in 
stereochemical determination (section 1.4.6).137 
 Bok et al. used genetic profiling of deletion and overexpression mutants of laeA, a nuclear 
protein involved in secondary metabolite regulation, to discern which gene clusters in Aspergillus 
nidulans were involved in natural product production.138 This led to the identification of, among 
others, the gene cluster for the production of terrequinone (Figure 1.6), which was confirmed by 
targeted gene deletion. 
 Several other illustrative instances of the use of gene inactivation in chemotype-genotype 
correlation include the discovery of emericellamides C-F (Figure 1.6) in A. nidulans139 and the 
myxochromides S1-3 from Stigmatella aurantiaca.36  
 An alternative to gene inactivation is to instead activate the gene cluster of interest—
typically by replacement of its promoter or by perturbation of a regulatory gene—in order to boost 
production levels. This has the advantage of simultaneously confirming the involvement of a gene 
cluster and providing higher titers of the natural product for isolation purposes. 
 This strategy was employed in the structural elucidation of the product of a cryptic PKS-
NRPS hybrid gene cluster from pathogenic Burkholderia species.140 Due to the unusual 
composition of the cluster, a structure was not directly predicted; however, insertion of a 
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constitutive promoter into the normally-silent gene cluster yielded abundant production of the 
corresponding natural product, burkholderic acid (Figure 1.6), aiding isolation efforts. Another 
group, who independently and contemporaneously discovered the compound, naming it 
malleilactone, similarly activated the cluster via rhamnose induction.141 Both gene inactivation and 
activation (by overexpression of a cluster-associated transcription factor) were used in the 
discovery and isolation of the burkholdacs/thailandepsins (discussed in section 1.4.4).142,143 The 
prenylated anthracenone neosartoricin (Figure 1.6) from Neosartorya fischeri was only detectable 
under laboratory conditions upon activation of its gene cluster by overexpression of a cluster-
specific transcription factor.144 Additionally, this strategy was crucial for structural elucidation of 
the stambomycins (Figure 1.15), which were not detectably expressed in the wild type strain of 
Streptomyces ambofaciens.145 
 Within the model myxobacterium Myxococcus xanthus DK1622 genome, several NRPS 
and PKS genes were found without known natural products.146 Using a combination of targeted 
gene knockouts and comparative LCMS employing principal component analysis (PCA) as a 
statistical technique, a low abundance metabolite was correlated to a single 43-kb, 12-module 
NRPS/PKS biosynthetic gene (encoding a massive 1.55 MDa protein—for perspective, the 
bacterial ribosome is about 2.5 MDa). Here complete structure prediction from the gene sequence 
was elusive, and the final structural analysis revealed only about half of the bioinformatics-based 
NRPS substrate predictions to be correct. NMR efforts were stymied by the exceptionally low 
abundance of the metabolite, myxoprincomide (Figure 1.6), in culture extracts. Screening of 98 
other M. xanthus isolates for increased production of the compound yielded strain A2, which was 
then engineered for myxoprincomide overproduction by insertion of a promoter upstream of the 
biosynthetic gene. Even with the increased production level (30-fold greater than wild-type strain 
DK1622), only 1.2 mg of myxoprincomide was obtained from a 100 L culture of the engineered 
strain, highlighting the challenge of performing physicochemical analysis of the molecule in the 
absence of genetic manipulation. 
 A combination of gene inactivation and activation is sometimes necessary. In connecting 
asperfuranone (Figure 1.6), a metabolite of A. nidulans, to its gene cluster, gene activation was 
used to first boost production levels.147 Necessity of the genes was confirmed by inactivation of 
the gene cluster in the engineered strain, which was not possible in the wild-type strain, as the 
compound was below the detection threshold prior to gene inactivation. 
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 It is important to note that reliance on gene inactivation/activation by itself can lead to 
missing important genomic information that could be useful for structural elucidation. Some 
natural products are produced by the interaction of not one but multiple gene clusters that are not 
co-localized (e.g. rhodochelin in Rhodococcus jostii RHA1148), are produced by crossover between 
gene clusters for two separate biosynthetic pathways (e.g. pyrrolamides dystamicin and 
congocidine in Streptomyces netropsis DSM40846149), or have a substrate located somewhat 
distantly in the genome from the main cluster (e.g. many thiazole/oxazole-modified peptidic 
natural products150). Accordingly, knocking out one cluster may halt metabolite production but 
would not yield the entire suite of necessary biosynthetic machinery. 
 
 
Figure 1.5 Bacillaene and its biosynthetic gene cluster. (a) Structure of bacillaene. Portions of the structure derived 
from NRPS are highlighted. The original formula proposed by Patel and coworkers (1995) lacks the two key amide 
moieties installed by the NRPS machinery. (b) Bacillaene megasynthases. Depicted is the cluster bae from B. 
amyloliquefaciens FZB42, which is orthologous to pksX from B. subtilis. NRPS portions, which install nitrogens, are 
in yellow; PKS portions are in green. Involvement of megasynthases in bacillaene biosynthesis was confirmed by 
gene deletion, which also enabled differential NMR of crude and semipurified extracts. 
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Figure 1.6 Representative natural products whose genotype and chemotype were connected by gene 
activation/inactivation. 
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1.3.2 Heterologous expression 
 Heterologous expression, in which the biosynthetic genes of interest are introduced to an 
alternate host organism, is a powerful method for connecting genotype to phenotype in metabolite 
biosynthesis. The most common uses of heterologous expression specifically for structural 
elucidation purposes are (i) when the native producing organism does not produce enough of the 
material for spectroscopy; (ii) when the producing organism is unknown, difficult to work with, 
or unculturable—as is the case often with clusters detected through metagenomics; or (iii) to 
unambiguously confirm the involvement of a gene cluster in the biosynthesis of a natural 
product—which allows greater confidence in using structural predictions from the gene cluster. 
 A number of workhorse organisms for heterologous expression have been developed and 
are in common use, including Gram negative bacteria (e.g. Escherichia coli), Gram positive 
bacteria (e.g. Streptomyces lividans and Streptomyces avermitilis and Streptomyces albus), and 
fungi (e.g. Saccharomyces cerevisiae and A. nidulans). Heterologous expression is used 
extensively in synthetic biology also for construction of combinatorial biosynthetic pathways and 
engineered expression of known compounds and has been thoroughly reviewed elsewhere; we 
discuss it here only briefly with representative examples.151,152  
 It is not uncommon for heterologous expression to be the only viable strategy to provide 
enough material for NMR analysis in the case of low expression levels in the native host (examples 
are too numerous to be comprehensive). This was the case for geobacillin I, for example, whose 
original gene cluster from Geobacillus thermodenitrificans was expressed in E. coli; indeed, the 
original strain was not readily available, and closely-related strains did not produce the compound 
in sufficient abundance.153 In another similar example, heterologous expression from 
Photorhabdus luminescens led to the discovery of luminmycins A–C and luminmides A and B 
(Figure 1.7).154,155 
 For compounds or BGCs discovered through metagenomic methods, a producing organism 
is frequently elusive or unculturable (the bona fide producing organism may even be unknown).  
Thus, heterologous expression is often crucial during structure elucidation in these cases, as the 
BGC itself can frequently be identified by metagenomic analysis of biological communities, 
environmental DNA, etc. A number of examples of heterologous expression in this context (Figure 
1.7) include the discovery of the cytotoxins borregomycin156 and erdasporine,157 arimetamycin,158 
microviridin variants,159,160 the aromatic polyketides tetarimycin A161 and fasamycin A and 
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B,161,162 the pentacyclic compound erdacin,163 utahmycins A and B,164 and the arixanthomycins.165 
Additionally, the topic of metagenomic natural product discovery has been reviewed 
recently.28,31,166 This methodology provides an alternative path to diversifying collections of 
natural products from environmental samples, sidestepping the often-challenging aspect of 
culturing new, exotic species. 
 As mentioned above, heterologous expression is frequently used to confirm BGC 
involvement, which engenders greater confidence in bioinformatic predictions arising from the 
particular genes. The BGC of capistruin, the first lasso peptide discovered and elucidated through 
a genomic approach from Burkholderia thailandensis E264, was confirmed in this way by 
expression in E. coli.167 The BGCs of the ribosomal patellamides, cyanobactin cyclic molecules 
originally surmised to be nonribosomal in origin, were confirmed by heterologous expression from 
the sea squirt symbiotic cyanobacterium Prochloron didemni into E. coli.168 This approach is 
particularly important—as in these examples—when a gene cluster is the first in its natural product 
subclass. 
 From a practical standpoint, it is worth considering that the successful heterologous 
expression of a pathway in a familiar laboratory-engineered organism provides not only genetic 
insight into the pathway but also a way to sustainably produce quantities of the metabolite (e.g. 
with the patellamides,169 for whom isolation from E. coli is more attractive than difficult 
aquaculture of the host sea squirts). This is quite appealing if considering the exhaustive and 
sometimes prohibitive efforts frequently required to produce such compounds synthetically (e.g. 
discodermolide,170,171 in practice, is only isolable in an environmentally-disadvantageous and low-
yielding manner [0.002% w/w] from a sea sponge, as the BGC is still unknown, and required 
lengthy total synthesis for biomedical evaluation) or from the native host (e.g. psymberin [Figure 
1.7],172,173 for which the structure elucidation required “combining 600 extracts prepared over the 
course of 11 years” when isolated from the original sponge host—metagenomics revealed its actual 
pathway to be from a symbiotic bacterium172). 
 There are practical considerations with heterologous expression, including limitations on 
the sizes of gene cluster that can be utilized, codon usage by the native and host organisms, and 
the complexity of the biosynthetic pathway. Sometimes the genes also require substantial further 
engineering, including promoter replacement, for expression.157,161 Additionally, natural product 
production may be limited by toxicity to the producing organism. In spite of the challenges, even 
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large BGCs have been successfully expressed in this way; daptomycin, which originates from a 
128 kb region of Streptomyces roseosporus (Figure 1.7), has been heterologously expressed in S. 
lividans.174 
 
Figure 1.7 Representative natural products whose chemotypes and genotypes were connected via heterologous 
expression and/or metagenomics. 
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1.3.3 Biosynthetic logic 
 If even some information about the final natural product is known—exact mass, MS/MS 
fragmentation pattern, biosynthetic class of natural product, and presence of specific functional 
groups—biosynthetic logic can be used to hypothesize which BGC is involved. 
 For ribosomally synthesized and post-translationally modified peptide (RiPP) natural 
products, each BGC contains a precursor peptide corresponding to the unmodified structural 
template of the mature natural product.43 This means that if a partial putative sequence can be 
gleaned from preliminary spectrometric characterization, the BGC can often be identified by using 
that sequence tag as a search query against the genome. Such a strategy was used for the linaridin 
family of natural products (Figure 1.8). Linaridins are enzymatically-modified peptides containing 
α,β-unsaturated dehydrated amino acid (DHAA) residues and an unusual C-terminal 
aminovinylcysteine moiety. The first known linaridin was cypemycin, an antibiotic whose 
structure was determined by conventional means in 1993.175,176 It was hypothesized that the 
peptide scaffold of cypemycin was produced ribosomally, and so part of the peptide sequence was 
used as a search query during a genome scanning effort of Streptomyces sp. OH-4156.177 This 
revealed a consistent putative precursor peptide, which indirectly corroborated the original 
structural assignment and confirmed cypemycin’s ribosomal origin.177 The biosynthetic genes in 
the immediate vicinity of the precursor peptide were used to predict the presence of new linaridins 
in other sequenced organisms. Investigation of these genes in Streptomyces griseus IFO 13350 
yielded grisemycin, and the assignment of the BGC was confirmed by heterologous expression.178 
Due to the knowledge of cypemycin’s structure and gene cluster, the structure and modifications 
of grisemycin could be almost completely predicted before isolation (with an exception of an Ile 
residue whose possible isomerization was in question) (Figure 1.8). 
 Iorio et al. obtained by NMR a preliminary partial amino acid sequence of the antibacterial 
and antinociceptive glycosylated lanthipeptide NAI-112 (discovered by phenotypic screening).179  
This was used to search the genome, revealing the corresponding gene cluster (including the 
template precursor peptide) and, in conjunction with amino acid analysis, guiding spectrometric 
assignment of the structure to the natural product.  
 The first identified thiopeptide BGCs were discovered by searching genomes for a putative 
precursor peptide consistent with the structure of the corresponding natural products. This was 
accomplished in 2009, interestingly, nearly simultaneously by four separate research groups;180-183 
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this occurred long after exhaustive synthetic efforts184 toward the prototypical thiopeptide, 
thiostrepton, and more than 50 years after its initial isolation.185 Although the exact BGC-
identification approaches differed slightly, each group located the responsible genes by means of 
biosynthetic logic, inferring the identity of the precursor amino acid at each site in the molecule 
retrobiosynthetically based on likely enzymatic modifications (dehydration, cycloaddition, etc.) 
(Figure 1.9). In each case, this led to the discovery of a BGC containing a precursor peptide bearing 
the appropriate amino acid sequence as well as several biosynthetically-consistent modification 
enzymes in the BGC. This also highlights the importance of understanding the gene/structure 
correlation—with this approach experimentally validated, several other thiopeptide BGCs, 
including those for GE2270A and berninamycin A, as well as several then-unknown thiopeptides, 
were also inferred.180,183 Biosynthetic logic was also used in the assignment of the gene cluster for 
the thiopeptide cyclothiazomycin C (described later in section 1.4.4).186 Cox et al. used a 
chemoselective labeling technique to determine the presence of a functional group (dehydrated 
amino acids, or DHAAs) in a particular compound in an organic extract of a Streptomyces species 
(Figure 1.14a,b). Using the detected molecular weight and knowledge of the enzymes 
(dehydratases and cyclodehydratases) known to install the functional group, a bioinformatic search 
yielded the gene cluster for cyclothiazomycin C (Figure 1.14c). 
 Zhou and coworkers used the amino acid composition of xenoamicin A to distinguish 
which NRPS in the genome of a producing organism was essential for its biosynthesis and thereby 
to decipher its stereochemistry.137 Likewise, the structure of the polyketide gulmirecin was used 
by Schieferdecker to infer its biosynthetic pathway, thereby revealing which PKS in the producing 
organism’s genome was responsible for production and revealing the absolute stereochemistry of 
the molecule.187 
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Figure 1.8 Linaridin gene clusters via biosynthetic logic. (a) Knowledge of cypemycin’s structure was used to 
discover its precursor peptide and biosynthetic gene cluster. Prediction in another organism revealed grisemycin, 
whose structure was predictable from the precursor peptide sequence and knowledge of cypemycin’s modifications. 
(b) Structures of cypemycin and grisemycin. Sites of enzymatic modification by the gene cluster are highlighted in 
light grey. 
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Figure 1.9 Discovery of thiopeptide biosynthetic gene clusters using biosynthetic logic. (a) Structures of three 
thiopeptides whose BGCs were determined through biosynthetic logic. Precursor amino acids and peptide sequence 
are indicated for each. (b) Precursor peptide TclE (identical to TclFGH) identified for thiocillin A, consisting of a 
leader region and a core (structural) region. (c) BGC for thiocillin (tcl). Genes that correspond to particular structural 
features are indicated; the sites of modification by these genes are traced onto the structure in panel (d). 
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1.3.4 Spectrometric-based informatic search methods 
 Mass spectral analysis is incredibly sensitive, and MS/MS fragmentation is inherently 
connected to chemical structure. This, combined with the robust suitability of MS/MS to “big 
data”-like informatic analysis means that algorithms have been developed to semi-automatically 
apply biosynthetic logic (as above) to vast datasets, often revealing structure and BGCs 
simultaneously even with small quantities of material. 
 Taking advantage of the fact that peptide natural products can be structurally quite diverse 
yet are all derived from genetically-encoded templates (ribosomal peptides) or modular pathways 
(nonribosomal peptides),188 Kersten et al. described a strategy known as natural product 
peptidogenomics (NPP) wherein MS/MS fragmentation-derived amino acid sequence tags are 
used to search a given genome for biosynthetic machinery consistent with their production.189 The 
NPP approach takes into account possible post-translational modification and relies on 
biosynthetic logic for identification of BGCs, as a given sequence tag by itself may give several 
hits in a genome. As a proof of concept, NPP was used to locate the gene clusters and confirm the 
structures of several natural products, including known and novel stendomycin lipopeptides from 
Streptomyces hygroscopicus ATCC 53653, the known lanthipeptide AmfS from S. griseus IFO 
13350, and a novel lasso peptide SVO-2083 from Streptomyces sviceus ATCC 20983, among 
others. Importantly, the elucidation of the SVO-2083 gene cluster represented the first such cluster 
reported for its particular structural subclass of lasso peptide. The authors also noted, at the time, 
the increased versatility of their method compared to previous proteomics platforms, including 
Mascot190 and InsPecT,191 which were not specifically designed for peptidic natural products. In 
conjunction with MS-based imaging, NPP was also used for the MS sequence tag-based 
identification of the antibiotic arylomycin from S. roseosporus and its corresponding gene 
cluster.192 Although the particular NPP methodology described by Kersten et al. is not automated, 
it is conceptually straightforward to implement.  
Peptidogenomic methods are readily expanded with MS/MS networking analysis.193,194 
Networking analysis inspects a suite of MS/MS spectra obtained on a whole crude extract, 
clustering detected analytes by spectral similarity. In this way, it is possible to get information on 
related metabolites in an extract in a semi-automated manner, providing rapid access to natural 
product congeners or biosynthetic intermediates. Visualization of the generated molecular 
networks also provides a broad overview of the metabolic composition of an extract. 
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Peptidogenomics can be used on MS/MS mass shift series, as described above, to locate putative 
BGCs. Using this approach, Liu et al. surveyed the molecular network of the daptomycin-
producing microbe S. roseosporus (Figure 1.10).194 This revealed the BGCs for several molecules, 
including streptothricin, an NRPS-produced antibiotic isolated in 1974 from a soil bacterium in 
Iran (Figure 1.10),195 as well as a number of analogues. As with other MS-integrated genomic 
methods, an important strength with an MS/MS networking strategy is that structural information 
is obtained simultaneously with gene cluster identification. Another appealing aspect of genomics-
interfaced MS/MS networking is that due to the rapid evolution of MS techniques, analysis is not 
limited to extracts but can also be done on intact organisms—this can reveal the biological role of 
a natural product by testing for the presence of metabolites in simulated culture conditions, giving 
information on compound localization as well as structure. Watrous et al. applied the strategy to 
whole-colony labeling using atmospheric-pressure nanoDESI MS.193 In addition to profiling the 
small-molecule interaction of colonies of S. coelicolor A3(2) and B. subtilis PY79, the authors 
identified the BGC for and partial structure of an antifungal lipopeptide compound, thanamycin, 
in Pseudomonas sp. strain SH-C52, using targeted gene inactivation in concert with the above 
analytical strategy.193 The gene cluster had previously been described in the organism; however, 
it had not been correlated to thanamycin production, nor had its structure or biological activity 
been deciphered.196 Additionally, MS/MS networking is extensible to the analysis of a large 
number of metabolomes at once; Nguyen et al. combined spectra from 60 sequenced and 
unsequenced bacteria into a single network.197 In conjunction with data from publicly-available 
genomes, this enabled the assignment of clusters of related molecules to families of gene clusters; 
mostly notably, the gene clusters for the Pseudoalteromonas sp. bromoalterochromide natural 
products were discovered. Although initially limited to NRPs, this technique presents a powerful 
prospect: given increasing amounts of genomic and LC-MS/MS datasets (assuming they are 
accessible and well-curated, such as Global Natural Products Social Molecular Networking 
[GNPS], http://gnps.ucsd.edu/, or METLIN, http://metlin.scripps.edu/),73 it will become 
increasingly straightforward to automatically prioritize compounds and assign BGCs to maximize 
discovery of novel scaffolds.  
 Mohimani et al. recently developed RiPPquest (http://cyclo.ucsd.edu/), a genome mining 
tool aimed at finding RiPP biosynthetic gene clusters and providing structural predictions (Figure 
1.11a).108 RiPPquest has been initially aimed at lanthipeptides, although the software is intended 
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to be extensible to other classes of RiPPs in the future. The program takes MS/MS fragmentation 
data and a genome as input information. Based on analysis of the genome, the program generates 
an in silico library of all conceivable lanthipeptides. An MS/MS molecular networking analysis is 
performed on the MS/MS data and the putative structures are statistically scored based on how 
well they match it. An exciting aspect of this kind of analysis is that it the BGC does not need to 
be known beforehand, and manual annotation of the MS/MS fragmentation data is not initially 
required. As a proof of concept, the authors surveyed several Streptomyces spp. via untargeted LC-
MS/MS. This resulted in the assignment of BGCs to several known natural products, including 
SRO-2212, SRO-3108, AmfS, SapB, and SAL-2242. Additionally, a novel lanthipeptide, 
informatipeptin, was discovered via the LC-MS/MS analysis of a butanol extract of Streptomyces 
viridochromogenes DSM 40736. The biosynthetic class of peptide was assignable based on the 
identified gene cluster, and the network-based spectral/structure statistical analysis led to four 
possible structures (Figure 1.11b,c). Although this did not provide only one structure, one needs 
only look at the size and complexity of informatipeptin (>2100 Da) to appreciate the acceleration 
of the structural elucidation effort; indeed, future spectroscopic analysis would be reduced to 
distinguishing, presumably trivially, between the four possibilities. 
 A highly-related program by the same authors is NRPquest (http://cyclo.ucsd.edu/), aimed 
at NRP natural products.109 This was designed to address limitations of previous algorithms for de 
novo NRP sequencing that did not account for possible substrate modification or cyclization 
possibilities and did not provide links to putative gene clusters.198 NRPquest relies on 
NRPSpredictor299 to predict substrate specificity of detected NRPS gene clusters. The NRPquest 
algorithm first predicts NRPSs in a genome and then enumerates a collection of possible resultant 
NRPs—usually hundreds of millions, taking various cyclization or modification possibilities into 
account—in silico. These are then statistically compared against an MS/MS data set and a spectral 
network is constructed to reveal related compounds in the sample, acting to statistically improve 
prediction accuracy. NRPquest was validated with a number of known structurally-complex NRP 
natural products, including daptomycin, arylomycin, pristinamycin, plipastatin, surfactin, and 
tyrocidine. Notably, RiPPquest and NRPquest are complementary tools and can be used to 
distinguish between these two classes of peptidic natural products. 
 Medema et al. recently developed the Pep2Path program (http://pep2path.sourceforge.net/) 
for the identification of RiPP or NRP biosynthetic gene clusters from MS/MS fragmentation data 
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of the resulting natural product (described above).107 Pep2Path takes MS/MS fragmentation data 
as input; from this, the program interprets the mass shifts as a peptide sequence and uses statistical 
methods to match them to a database of possible RiPP or NRPS gene clusters—from specific 
datasets, which can include metagenomic data, up to the entire GenBank database. Medema et al. 
also pointed out the relatively small sequence tags (2–4 residues within a species; 5–8 within a 
larger, genus-wide dataset) needed to confidently assign NRPS clusters in this way and 
demonstrated the usefulness of the algorithm by discovering putative BGCs for five previously-
discovered NRPs (trichotoxin, ferintoic acid, plusbacin, amphibactin B, and tripropeptin A). 
Unlike RiPPquest, Pep2Path does not utilize network-based analysis; it is designed to be more 
generally-applicable to most classes of RiPPs (RiPPquest presently focuses on the lanthipeptide 
subfamily), but it is not as equipped for structural prediction and does not currently take into 
account post-translational modifications. Despite this, the ability to link MS/MS fragmentation 
data to BGCs from assembled genomes or even metagenomic datasets highlights the shrinking 
barrier to assigning genes to function. 
 In analogy to peptidogenomics, MS-based glycogenomics allows for the mining of 
glycosylated natural products (a modification found to occur in some members of all major natural 
product classes) based on the predictable fragmentation of glycosylated molecules and the 
tendency of glycosyltransferases to be present with their respective aglycone BGCs.74 Kersten et 
al. thus constructed an “MS-glycogenetic code” based on known sugars, MS data of existing 
glycosylated natural products, and known or predicted nucleotide sequences. As a proof of concept, 
the authors analyzed an extract of Streptomyces sp. SPB74 by LC-MS/MS; the resulting 
fragmentation data indicated a glycosylated compound. The resulting analysis of the genome for 
gene clusters containing sugar metabolism genes reveals a type II PKS cluster harboring several 
genes associated with aminodeoxyglycoside biosynthesis—consistent with the MS results. 
Analysis of the PKS machinery and similarity of the cluster to that of aclacinomycin led to 
prediction of the molecule’s chemotype as an anthracycline polyketide; this was confirmed by 
NMR. Although the compound, cinerubin B (Figure 1.12), was already known, it had not been 
isolated in that organism and, as such, the method provided both rapid dereplication, and for the 
first time, revealed cinerubin B’s biosynthetic origin. The authors also used the approach for the 
discovery of a novel disaccharide-functionalized aromatic polyketide, arenimycin B (Figure 1.12), 
from Salinispora arenicola CNB-527; the sugar types were predicted from the genome. 
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 Related MS-based strategies rooted in proteomics are PrISM199 (proteomic investigation 
of secondary metabolism) and natural product proteomining,200 which entail the direct detection 
of expressed genes involved in natural product biosynthesis and allow simultaneous discovery of 
a metabolite and its BGC, without prior information on either. PrISM is aimed at targeted detection 
of PKs or NRPs and their corresponding gene clusters.199 Relying on the tendency of these 
molecules to derive from high molecular weight megasynthases, the proteins from lysed bacterial 
cultures that exhibit the slowest migration by gel electrophoresis are subjected to extensive 
tandem-MS-based peptide sequencing. The resulting sequences are used to design PCR primers to 
amplify and sequence the corresponding gene clusters, which can then be analyzed further to 
inform structural elucidation. The technique was used to discover a panel of novel 
lipoheptapeptides, as well as their gene clusters. The PrISM methodology has since been 
successfully used in a number of cases. The linear NRPs gobichelin A and B (Figure 1.13) were 
found this way in Streptomyces sp. NRRL F-4415, and their structures were correctly predicted 
prior to NMR analysis.201 Evans et al. used PrISM to discover koranimine (Figure 1.13), a cyclic 
imine produced by an unsequenced soil-dwelling Bacillus, although the resultant structure was not 
entirely congruent with sequence-based predictions.202 A broad-scale demonstration was 
performed by Chen et al., who screened 26 actinomycetes by PrISM; in 6 strains with detected 
NPRS or PKS synthases, sequence information was used to infer structural features to guide 
detection and isolation of the corresponding metabolites. Ultimately, this led to the novel 
assignment of gene clusters and biosynthetic pathways to two previously-known compounds, 
foroxymithine and antibiotic S 213L (Figure 1.13), for which BGCs had not yet been found.203 
PrISM was also used by Chen et al. to identify in Streptomyces sp. NRRL F-6652 the structure and 
BGC of the flavopeptins (Figure 1.13), aldehyde-bearing NRPs with antiproliferative activity.204 
The case of the flavopeptins highlights an appealing feature of proteomics-based methods: using 
DNA primers, the authors noted that the sequences of the proteomics-identified genes were 
identical to those of a different strain, Streptomyces flavogriseus ATCC 33331, with a full reported 
genome; this enabled the bioinformatic prediction of a C-terminal modification that gratifyingly 
matched the confirmed structure. Hence, the genome of the exact producing organism is not always 
required if a closely-related genome is available. 
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Proteomining is a more general technique that relies on using varied culture conditions to 
perturb biosynthetic pathways; metabolomic and quantitative proteomic analysis of the various 
conditions then allow statistical linkage of chemotypes and genotypes.200 As with PrISM, 
proteomining does not require knowledge of a gene cluster or structure beforehand; additionally, 
proteomining is not limited to natural product classes utilizing megasynthases. The authors initially 
demonstrated correlation between protein expression levels and metabolite levels for several 
natural products before using the technique to discover a novel compound, juglomycin C amide 
(Figure 1.13), and its BGC from the previously undescribed soil isolate Streptomyces sp. MBT70. 
 Glycogenomics, peptidogenomics, and similar strategies thus present an appealing strategy: 
if part of a molecule’s structure can be deduced (i.e. a partial amino acid sequence tag, the presence 
of a glycosylation, etc.), the corresponding BGC can often quickly be found, giving further insight 
into the structure of the remainder of the molecule. 
38 
 
Figure 1.10 MS/MS networking and peptidogenomics analysis of S. roseosporus. The MS/MS-based network is 
shown centrally with nodes corresponding to spectra (molecules) and lines indicating a degree of statistical similarity. 
Stenothricin, representative MS shifts used in pathway identification, and the resulting biosynthetic gene cluster are 
indicated. Figure adapted from Liu et al. with permission.184 
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Figure 1.11 Informatipeptin gene cluster and structural predictions via RiPPquest. (a) The lanthipeptide BGC 
identified by RiPPquest. The precursor peptide is indicated in black; the protease and lanthipeptide synthase biosynthetic genes are 
in grey. Below, the precursor is depicted with leader and core (structural) regions indicated; in bold are sites of post-translational 
modifications. (b) Four predicted structures consistent with the MS/MS fragmentation data. (c) Full chemical structure of one of 
the four predicted structures from (b). 
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Figure 1.12 Molecules with gene clusters identified through glycogenomics. Sugars whose MS/MS data was used 
to locate the BGCs are indicated in grey. 
 
Figure 1.13 Representative natural products correlated to gene clusters through proteomics strategies. 
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1.3.5 Chemical labeling 
 Knowledge of bioinformatically-predicted functional groups (and their corresponding 
chemical reactivity) can be used to guide the connection of assay hits to genes and to guide 
structural predictions. Thiopeptides are RiPPs and accordingly are especially suited towards 
bioinformatic analysis, as their precursor structures are direct gene products.26,43,205 Cox et al. 
utilized a bioinformatic strain-prioritization approach, wherein actinomycete strains were chosen 
on the basis of the presence of natural product biomarkers—genes responsible for thiopeptide 
biosynthesis.186 Using the bioinformatically-predicted presence of dehydrated amino acid (DHAA) 
moieties (α,β-unsaturated carbonyl/imines derived from Ser/Thr) as a chemically-reactive 
“handle”, organic extracts of the chosen bacteria were subjected to a chemoselective labeling 
reaction with a soft nucleophile, dithiothreitol (DTT) (Figure 1.14a). This nucleophilic 1,4-
addition resulted in mass spectra with peaks that proportionally shifted by the number of labeled 
moieties (Figure 1.14b). This information, in conjunction with a bioinformatically-predicted gene 
cluster containing DHAA-installing proteins (Figure 1.14c), revealed a predicted precursor peptide, 
CltA. Based on the structural similarity of the gene cluster to that reported for cyclothiazomycin 
A, the sequence of the core region of the precursor peptide, and the predicted functions of the 
biosynthetic enzymes (Figure 1.14d), a structural prediction was correctly made and confirmed by 
NMR and HR-MS/MS (Figure 1.14e). Importantly, this “reactivity-based screening” approach 
serves not only to quickly identify natural products from genes based on chemical logic but also 
enables quick gene cluster assignment corroboration, allowing for rapid dereplication or structural 
prediction. 
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Figure 1.14 Chemoselective labeling and bioinformatic analysis leading to cyclothiazomycin C structure. (a) A 
chemical labeling strategy was employed using dithiothreitol (DTT) to enact nucleophilic 1,4-addition into dehydrated 
amino acid (DHAA) moieties. (b) Extracts were allowed to react and mass shifts corresponding to the addition of DTT 
were noted by comparative MS. (c) Genomic analysis revealed the presence of a gene cluster containing enzymes 
predicted to install DHAA residues. Comparison to the closest characterized homologue and analysis of the predicted 
precursor peptide allowed structural prediction. (d) Modifications to the core peptide can be mapped onto (e) the 
structure of the final natural product. The number of DHAA moieties in the final product corresponds to the number 
of labels observed by chemoselective labeling in (b).  
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1.4 From genes to molecules: Structure from genomic information 
 Once a correlation between an unsolved natural product and a biosynthetic gene cluster 
(BGC) has been made, structural information can be inferred from the genome. A wide range of 
information can be obtained depending on the complexity of the gene cluster, similarity to known 
natural products, class of molecule, etc. At the simplest level, comparison to known gene clusters 
can inform the researcher if a molecule is known or at least similar to already-discovered 
compounds—potentially allowing rapid assessment of a compound’s novelty. Structural insight 
may be gained based on prediction of similarity to known compounds or prediction of properties. 
The most powerful prospect, however, is that based on understanding of the enzymology and 
phylogeny of natural product gene clusters, the substrates and stereospecificity of the biosynthetic 
enzymes can often be predicted, meaning that aspects of the resulting structures can be predicted 
or confirmed de novo. 
1.4.1 Assessment of compound novelty 
 If gene clusters for unknown metabolites are sufficiently similar to gene clusters for known 
compounds, expensive scale-up and spectrometric efforts can be avoided. The process of 
determining whether a detected natural product is novel—and by extension, whether to pursue it 
further or ignore it—is known as dereplication.  
 During the previously-mentioned reactivity-based screening effort, Cox et al. identified a 
tentative hit compound containing several electrophilic dehydrated amino acid (DHAA) 
moieties.186 A survey of the genome of the organism revealed that it harbored a BGC for 
grisemycin, an already-known compound with a mass and structure consistent with the MS and 
reactivity observed. In this way, the compound could quickly be discarded as non-novel before 
scaleup or purification were attempted, usingly only rapid MS spectrometry on crude material. 
 Due to the high sensitivity of modern MS methods, gene-guided analysis methods, 
including RiPPquest,108 NRPquest,109 and Pep2Path107 (discussed elsewhere herein) are 
particularly powerful dereplication methods for peptide-derived natural products. 
 Another application of genomics for dereplication is prediction of compound novelty; 
indeed, if the predicted structure or gene cluster is sufficiently divergent from known compounds 
or clusters, one can reasonably expect a new and/or interesting structure. In Thermobifida fusca, 
for instance, an NRPS cluster was identified, and the compound—fuscachelin (Figure 1.15a)—
was predicted to be novel based on the sequence-inferred NRPS module amino acid substrate 
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specificity.206 Similar predictions are possible for PKS-derived natural products; McAlpine and 
coworkers, for instance, predicted novelty of ECO-02301 on the basis of its genome-inferred PKS-
derived backbone prior to full structural elucidation efforts.58 Likewise, a search of the predicted 
linear core of the 51-membered macrocycle stambomycin (Figure 1.15) against chemical databases 
suggested it to be a novel compound.145 
 One useful application of dereplication is finding alternative organisms that may produce 
a compound at a higher level than the original source (i.e. looking not for novel structures but for 
increased abundance). For instance, Chiang et al. used a genome-centric approach to discover that 
A. nidulans produces emericellamide A (Figure 1.15) at a much higher level than the bacterium 
from which it was originally isolated.139 The biosynthetic pathway for ET-743 (Figure 1.15), an 
FDA-approved anticancer drug isolated only in low quantities from an invertebrate tunicate 
Ecteinascidia turbinata, was deciphered specifically for this purpose, revealing a microbe, 
Candidatus Endoecteinascidia frumentensis, with production capabilities.207 Sudek et al. located 
the BGC for the bryostatins (Figure 1.15), a family of natural products of which some are in clinical 
trials.208 Previously, isolation was only achieved at low levels through the uncultured symbiotic 
bacterium Candidatus Endobugula sertula, and the authors proposed heterologous expression as 
an alternate production method. Indeed, the prospect of being able to rapidly find alternate 
producers highlights the value of knowing the gene cluster for metabolites of interest. 
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Figure 1.15 Representative natural products for which genomics was important for (a) dereplication or estimation 
of novelty, (b) discovery of biosynthetic capability in alternate organisms/genomes, (c) clarification of structural 
ambiguities, (d) corroboration of spectrometrically-derived structure, or (e) similarity-based discovery. 
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1.4.2 Clarifying ambiguities 
 It is possible to use gene cluster information to resolve specific structural features that are 
ambiguous or difficult to resolve by other methods. This was the case for ECO-02301 (discussed 
in section 1.4.5), a long conjugated polyene for which not all atoms were assignable by NMR alone; 
here, analysis of the PKS gene cluster provided clarity on the location and length of various 
moieties.58 This was also the case for salinilactam A (Figure 1.15).209 Conventional structure 
elucidation of the molecule was plagued by its instability and by the presence of eight chemically-
similar conjugated olefins which were difficult to resolve and assign by NMR. Fortunately, 
analysis of the gene cluster furnished the nature and locations of the olefins and corroborated the 
NMR-derived total structure. 
 A challenge to structure prediction (and elucidation) of many natural products is that 
although the nature of certain chemical modifications can often be predicted, there is often a 
question of their location. Thus, even with predicted gene functions and templates, many structural 
possibilities can exist, and confirmation bias can lead to false structural assignments. However, 
using statistical methods, it is feasible to enumerate all possible structures (based on a set of 
possible modifications) and analyze which is best represented by MS/MS fragmentation data. This 
method, called hypothetical structure enumeration and evaluation (HSEE), was recently described 
by Zhang et al. (Figure 1.16a)210 In HSEE, which focuses on RiPPs, a BGC is first analyzed for 
the template precursor peptide and post-translational modifications (based on the presence of 
tailoring enzymes). Using this information and the detected molecular mass (and accordingly, 
molecular formula), a number of hypothetical structures are enumerated. The natural product is 
then subjected to MS/MS fragmentation analysis; the resulting spectra are statistically compared 
to the theoretical fragmentation spectra of the hypothetical structures and ranked. Conceptually, 
HSEE is similar to the program iSNAP (discussed previously), which was developed for NRP 
natural products.110 
 Deschloromicrobisporicin (DC-MIB, Figure 1.16c) was one of several metabolites used to 
validate the HSEE strategy, as its structure and gene cluster were complex, but previously 
known.211,212 Like many RiPPs (lanthipeptides, thiopeptides, and linaridins, for instance), DC-MIB 
bears modifications entailing the dehydration of Ser and Thr residues to form the α,β-unsaturated 
carbonyls dehydroalanine (Dha) and dehydrobutyrine (Dhb),43 which can then either remain intact 
in the mature molecule or react with thiols (i.e. cysteine) to form thioether bridges. Additionally, 
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DC-MIB contains a dihydroxyproline motif and an aminovinylcysteine. From sequence alone, the 
structure would be difficult to assign (Figure 1.16b); indeed, 49 possible structures compliant with 
the precursor peptide and modifications were evaluated by HSEE, which predicted the correct 
structure as the top-scoring hit. The authors proceeded also to use the technique for structural 
elucidation of a novel compound, prochlorosin 1.2 (Figure 1.16d), the structure of which had been 
elusive due to spectral ambiguities, as well as the elucidation of in vitro biosynthetic intermediates 
in other systems, including prochlorosin, lanthipeptide, and azole-containing peptide pathways.210 
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Figure 1.16 Hypothetical structure enumeration and evaluation (HSEE). (a) Overview of HSEE workflow. From 
a known biosynthetic gene cluster and an empirically-determined exact mass, possible structures compliant with 
predicted modifications are listed (“hypothetical structure enumeration”). MS/MS fragmentation data is then 
compared to predicted fragmentation patterns for the hypothetical structures and mathematically scored to determine 
which is the most accurate match (“evaluation”). (b) Predicted template and modifications for 
deschloromicrobisporicin (DC-MIB). Modifications present in the final structure are shown and can be rationalized 
by the gene cluster. Depicted is the unmodified core peptide with possible modification sites shown; notably, there 
are a large number of possible thioether bridge sites. (c) Structure of DC-MIB, shown with condensed notation. 
Structures of DHAAs and thioether bridges are shown to the right of the structure. (d) Structure of prochlorosin 1.2 
(Pcn1.2) as determined by HSEE, shown with condensed notation.  
  
49 
1.4.3 Structure confirmation 
 In cases where a structure is obtained before the corresponding genome is reported, 
genomic information can be useful in verifying that the spectrometrically-derived assignments are 
correct, or at least consistent with biosynthetic logic. 
 Metelev et al. isolated a bioactive, high molecular weight compound (>2300 Da) from the 
halophilic actinomycete Streptomonospora alba YIM 90003, whose genus contained no 
sequenced genomes and no previously known natural products.213 The resulting compound, 
streptomonomicin (Figure 1.17a,b), was revealed through NMR and HR-MS/MS to be a lasso 
peptide213—a subclass of RiPPs43 that are enzymatically modified into a three-dimensional 
conformation that endows the resulting molecule with a rigidified structure as well as thermal and 
proteolytic stability.214,215 Here, genomics was useful in confirming the spectral assignments, due 
to a large number of repeated residues with overlapping spectral properties (3 Ser, 3 Tyr, 3 Pro, 3 
Leu, 3 Ile), some of which were isobaric and thus indistinguishable by MS (Leu/Ile) (Figure 1.17c). 
MS/MS analysis was made more difficult by the N-terminal macrocycle, which was recalcitrant 
to fragmentation until linearized by enzymatic digestion (Figure 1.17c). Complicating the NMR 
assignment was the compact nature of the highly-folded peptide; the large number of through-
space NOESY contacts made exact residue order assignment difficult by conventional 
residue/residue NOESY-walk experiments. Thus, the authors sequenced the genome of the 
organism and used their proposed peptide sequence as a search query. This revealed the presence 
of a lasso peptide BGC and confirmed and clarified the structure of streptomonomicin (Figure 
17d). 
 It is not uncommon for the spectrometrically-determined structure of an isolated natural 
product to be corroborated by the corresponding gene cluster for “proofreading” purposes. An 
example is teixobactin (Figure 1.15d), a depsipeptide recently discovered from the newly 
discovered organism Eleftheria terrae; the bioinformatically-identified two-gene NRPS cluster 
was found to contain eleven modules whose predicted specificities exactly matched the elucidated 
structure.216 
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Figure 1.17 Streptomonomicin structure confirmed by genomic information. (a) Schematic structure of 
streptomonomicin, showing amino acid residues and positions. (b) Solution-state NMR ensemble structure of 
streptomonomicin with backbone atoms displayed. (c) Difficulties with traditional spectrometric techniques 
necessitated structural confirmation by genome sequencing. The N-terminal macrocyclic region of the intact molecule 
did not yield sequence information by tandem MS/MS fragmentation, and 6 residues were isobaric. Additionally, 
NMR spectral analysis was complicated by the overlap of many chemically similar residues (highlighted in grey). (d) 
Sequencing yielded the streptomonomicin gene cluster (genes ACEBD are known to be involved in lasso peptide 
biosynthesis), and analysis of the StmA precursor peptide confirmed the spectrometric structure assignment. Sites of 
enzymatic modification are indicated in bold (isopeptide linkage) or with an asterisk (leader region cleavage). 
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1.4.4 Similarity-based structure prediction 
 It is possible to predict, partially or entirely, the structure of a molecule from the gene 
cluster if another highly similar gene cluster has been linked to a characterized molecule. The 
question does arise of how similar two gene clusters must be to make the exact same molecule, 
but confidence correlates positively with percent identity.84 Regardless, for absolute certainty of 
compound structure, compound isolation and spectrometry are still required; nonetheless, having 
an educated guess of a possible structure can substantially accelerate the elucidation process—in 
some cases reducing NMR and MS/MS analysis to a quick confirmation.186 
 Gene cluster similarity can be used to find natural products with similar functional groups 
or structures to known compounds, providing a head start on structural elucidation. Using the gene 
cluster for the FDA-approved depsipeptide HDAC inhibitor FK228 from Chromobacterium 
violaceum no. 968 as a search query (Figure 1.18c), a similar hybrid PKS/NRPS gene cluster was 
uncovered in B. thailandensis E264 (Figure 1.18c), leading to the discovery of thailandepsins A 
and B (Figure 18d).143 Here, targeted gene activation and HPLC-based comparative metabolic 
profiling led to correlation of the natural products with their three-enzyme hybrid NRPS/PKS gene 
cluster. Notably, production of sufficient material for physicochemical analysis was aided by RT-
PCR-based transcriptional analysis of various culture conditions—this relied on the “central 
dogma”-derived tenet (Figure 1.1a) that production of natural product(s) requires the transcription 
of the associated biosynthetic genes. Excitingly, this transcription-based strategy allows for 
optimization of culture conditions before a structure (or even a mass) has even been determined. 
Thailandepsin structural elucidation was informed by genomic predictions but relied upon HR-MS 
and NMR. Crystallographic analysis later supported the NMR assignment of thailandepsin A.217 
Wang et al. had predicted a structure prior to scale-up, based on analysis of the BGC and the 
structure of FK228 (Figure 1.18b).143 Although much of the prediction was correct, much also was 
not—which the authors recognized as showing the current state of capabilites and limitations of 
such techniques. Importantly, however, the key disulfide warhead moiety thought to be responsible 
for FK228’s bioactivity was present in the thailandepsins, as expected (Figure 1.18a,d). 
 The thailandepsins were discovered near-simultaneously by another group and named the 
burkholdacs. Here, Biggins and coworkers overexpressed several different putative transcription 
factors in B. thailandensis E264 located nearby in the genome to predicted NRPS/PKS gene 
clusters.142 One of these, located adjacent to an uncharacterized NRPS/PKS gene cluster (Figure 
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1.18c), resulted in the increased production of two metabolites which were named burkholdac A 
and B.  HRMS and NMR furnished the structures, supported by biosynthetic arguments based on 
the gene cluster; burkholdac B is identical to thailandepsin A (Figure 1.18d). The authors noted 
the presence of only one epimerase domain among the three NRPS modules in the cluster and thus 
predicted that the Val/Ile and Met-derived substructures would retain their natural L-
stereochemistry whereas the Cys residue would be D (Figure 1.18e); however, they noted that 
NMR evidence intended to confirm the stereochemical assignments was inconclusive. Burkholdac 
A218 and B219 (i.e. thailandepsin A) stereochemistry was eventually confirmed by total synthesis. 
Interestingly, the bioinformatically-informed stereochemical predictions of Biggins and coworkers 
were not completely correct, as although a D-Cys moiety was present, Met and Ile were also 
present as their D rather than L forms, despite the lack of an apparent associated epimerase of their 
biosynthetic modules.  
 The thailanstatins A–C (Figure 1.15e) were found by discovery of a gene cluster in B. 
thailandensis MSMB43 very similar to that of the anticancer compound FR901464.220 The novel 
compounds were very structurally similar to FR901464; however, while maintaining comparable 
biological activity, they also exhibited improved solution stability. 
 It is frequently possible to predict the subclass or scaffold of a natural product from a BGC. 
For example, a single-gene homolog probe for pentangular polyphenol biosynthesis was used in a 
metagenome survey. This allowed prediction of the class of molecule; the identified large PKS 
BGC was assembled into a bacterial artificial chromosome, introduced into yeast by 
transformation-associated recombination (TAR), and then integrated into S. albus, yielding the 
arixanthomycins A–C (Figure 1.7).165 Various groups have also mined genomes for the presence 
of natural product BGCs encoding enediyne scaffolds—of interest due to their intriguing 
biological “warhead” properties.56,221 Silent clusters predicted to encode polycyclic prenylated 
polyketides were activated in N. fischeri, leading to the isolation of neosartoricin (Figure 1.6).144 
 In mining the genome of Aspergillus niger, Zabala et al. noted the presence of numerous 
PKS and PKS/NRPS hybrid gene clusters, including one exhibiting high similarity to that of 
asperfuranone (Figure 1.19b).222 This similarity-based prediction and isolation led to the structures 
of the novel azaphilones azanigerone A–F (Figure 1.19a). Although the precise structure of the 
compounds was not predicted, they belonged to, as expected, the azaphilone family hallmarked by 
a heavily oxygenated bicyclic core. 
53 
 
Figure 1.18 Thailandepsin and burkholdac structures. (a) Structure of HDAC inhibitor FK228. Two modification 
sites responsible for the disulfide warhead are indicated, as are the genes from gene cluster DEP in panel (c) 
responsible for their installation. (b) Thailandepsin structure predicted by bioinformatics. Areas of correct prediction 
are highlighted in grey, whereas incorrectly predicted structural features are encircled with dashed lines. Predictions 
were based on the BHC/TDP gene cluster from panel (c). (c) Gene clusters for FK228 (DEP) and the thailandepsins 
(i.e. burkholdacs) (BHC/TDP). Genes shared by the clusters are depicted in white; genes that differ substantially are 
in black. The DEP gene cluster was used by one group to locate cluster BHC/TDP and predict its structure, as in (b), 
prior to isolation. Another group used the BHC/TDP cluster to predict burkholdac stereochemistry (panel e). TR in 
the BHC/TDP gene cluster indicates the overexpressed transcriptional regulator. (d) Structures of the 
thailandepsins/burkholdacs, as confirmed by NMR, total synthesis, and crystallography. (e) Bioinformatically-
predicted stereochemistry; the two sites of disagreement with the crystallographically-verified structure are 
highlighted in grey. 
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Figure 1.19 Structures and gene clusters of representative azaphilones. (a) Structures of a representative 
azaphilone, citrinin, along with structures of azanigerone and asperfuranone. The hallmark oxygenated bicyclic core—
most often pyranoquinone in nature—is highlighted in grey. (b) Gene clusters aza and afo encoding machinery for the 
biosynthesis of azanigerone and asperfuranone, respectively. Genes with homology between the clusters are color-
coded as such. The two genes containing PKS machinery are indicated. 
 
Figure 1.20 Predicted and actual structures of coelichelin. (a) Two tripeptide structures were originally proposed. 
(b) The predicted structures omitted a fourth peptide found in coelichelin (red); however, aside from this the prediction 
was remarkably accurate. 
1.4.5 Substrate-based structure prediction 
 If the predicted enzymatic machinery in the gene cluster associated with a novel metabolite 
is well-understood, it is possible to predict some or all of the structure of the molecule even in the 
absence of previously-reported analogous structures.  
 Many gene clusters—including those bearing PKS and NRPS machinery—are organized 
in a multimodular fashion with the order of the biosynthetic enzymes frequently aligning with the 
building block order in the corresponding natural products, a concept known as “co-
linearity”.40,41,223-227 This forms the basis for many bioinformatically-derived predictions of natural 
product structure as well as biosynthetic corroboration of the spectrally derived structure.  
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 Perhaps the first natural product to be predicted and isolated via a genome-mining approach 
was coelichelin, a siderophore from S. coelicolor A3(2) that was first predicted in 2000 
(interestingly, prior to completion of its genome)126 and fully elucidated in 2005.33 The initial 
prediction was not entirely correct, as detailed in Figure 1.20 (a tripeptide was predicted rather 
than a tetrapeptide); however, it is historically important, as it marked the transition into genome-
driven structure assignment that is now commonplace for NRPS and PKS natural products. It is 
worth noting that the function of the natural product, a siderophore, was indeed correctly predicted 
based on the genomic context of the gene cluster and the predicted structure.126 In the ten years 
since, predictive methods have greatly improved, as detailed herein. 
 In one early, prominent example among PKS natural products, McAlpine and coworkers 
used a genome scanning56 technique to analyze Streptomyces aizunensis NRRL B-11277, 
revealing the presence of a type I PKS gene cluster (Figure 1.21a), along with 10 other BGCs.58 
Analysis of the numerous PKS modules present in the gene, including knowledge of their building 
block substrates and chemical modifications, yielded a prediction of a linear polyene structure 
bearing a glycosidic linkage at an unknown location (Figure 1.21b). Comparison of the backbone 
to databases indicated novelty of the structure prior to isolation or spectroscopy. Importantly, 
physicochemical properties including an approximate molecular mass and the UV absorbance 
characteristic of the polyene motif were used to guide purification. Here, genomics was critical for 
structural determination—indeed, the authors write that “spectrosocopic work was reduced to a 
confirmation of structure rather than a first principle determination.” The overlap of many 
resonances would have prevented complete NMR assignment in the absence of the BGC 
information, but HMBC correlations complemented the genomics by providing the attachment site 
of the sugar residue. A similar genome-scanning approach was used for the discovery and structure 
elucidation of a number of other compounds, including ECO-0501,59 E-837,228 E-492,228 and E-
975.228 Much of this prediction-guided discovery was powered by DECIPHER (section 1.2.3). 
 In a search for PKS genes in Streptomyces halstedii HC34, a type I PKS unattributable to 
the organism’s known polyketide, vicenistatin, was found and later confirmed by gene 
inactivation.35,229 The structures of the corresponding molecules, halstoctacosanolides A and B, 
were partially predicted by homology searches of the PKS domains in the cluster, which also 
indicated their structural novelty.35 The predictions, which represented a substructure of the full 
compound, were almost entirely accurate. Laureti and coworkers, likewise, found a 150 kb PKS 
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megacluster in S. ambofaciens.145 Genome-guided substrate predictions were used to infer the pre-
cyclization, linear polyketide core of the molecule. A number of structural features of the resulting 
51-membered macrolide, stambomycin (Figure 1.15a) were elusive to sequence-based prediction, 
including the site of glycosylation and the nature of the side chain; however, the degree to which 
the substructure was predicted (including stereochemical aspects and the nature of the 
glycosylation) was impressive and enough to ensure structural novelty. Other natural products for 
which genome-guided, PKS substrate-based structural predictions proved useful are thailandamide 
A from B. thailandensis E264230,231 and elansolid D from Chitinophaga pinensis DSM 2588.232 
The thailandamide example, interestingly, was part of a bioinformatics analysis that showed that 
simple phylogenetic analysis of ketosynthase (KS) domains—without knowledge of any other 
modules—is sufficient to provide ample structural information.230 
 It is worth noting that even in cases where PKS substrate prediction is accurate, the 
presence of unaccounted-for tailoring enzymes may result in substantial differences from the 
predicted backbone. This was the case as just mentioned for the stambomycins, which underwent 
glycosylation and macrocyclization, as well as elansolid D. Similarly, the BGC responsible for the 
production of coelimycin P1 was identified in 2007 in S. coelicolor A3(2), and the substrates and 
stereochemistry of the PKS were correctly predicted.233 However, eventual identification and full 
elucidation of the mature natural product revealed extensive and unpredicted modification of the 
backbone.234 Nonetheless, the predicted backbone could be traced into the structure (Figure 1.22).  
 NRPS module substrate specificity,227 as discussed previously, can also be predicted—
NRPS megasynthases are organized in a manner analogous to PKS clusters. It is not uncommon, 
then, for predicted monomer order and composition to be used in conjunction with other analytical 
methods. Heterologous expression and the contribution of substantial bioinformatic analysis of 
NRPS/PKS megasynthases from Photorhabdus luminescens subsp. luminescens str. TT01, in 
conjunction with routine spectrometric techniques, yielded the structures of luminmycin A and 
luminmides A and B (Figure 1.7).155 The aureusimines, pyrazinone natural products of NRPS 
origin, were found in Staphylococcus aureus via genome mining and reasonably-accurate 
structural prediction from an NRPS cluster, based on predicted substrate specificity for Tyr and 
Val (Figure 1.23a).235 Structural predictions also enabled compound isolation by narrowing down 
expected the mass window for LCMS. Interestingly, another group independently reported the 
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aureusimines as phevalin and tyrvalin, along with a third congener, leuvalin (Figure 1.23b), and 
also employed structural predictions.236 
Scholz and coworkers reported a bioactive compound in an engineered strain of B. 
amyloliquefaciens FZB42 in which the NRPS and PKS gene clusters had been inactivated.136 Due 
to this genetic modification, the molecule’s hydrophobicity, and the moderately high molecular 
weight of the compound (1335 Da), the authors postulated it to be a heavily-modified bacteriocin 
of ribosomal origin. As a thiazole/oxazole-modified peptide BGC had previously been predicted 
in the organism,237 the authors inactivated it to confirm its involvement in biosynthesis.136 Based 
on the presence of heterocycle-installing cyclodehydratase/ dehydrogenase enzymes in the gene 
cluster as well as a methyltransferase, the authors were able to propose structural modifications to 
a predicted precursor peptide consistent with the observed mass and scarce MS/MS fragmentation 
(Figure 1.24a).136 This bioinformatic information guided full structure elucidation, which 
primarily employed HR-MS/MS to rationalize the predicted ten dehydrations, nine 
dehydrogenations, proteolysis, and two methylations of the core peptide, resulting in the mature 
compound, plantazolicin.238,239 Notably, plantazolicin’s structure, which contains two series of five 
contiguous, heterocycles, an abundance of carbons without attached protons, and numerous 
isolated proton spin systems (Figure 1.24b), would have been quite difficult to solve in the absence 
of the genomic information. Indeed, to fully confirm the structure by NMR, the producing 
organism had to be grown on 15N-enriched culture media for 1H-15N HMQC and HMBC 
experiments to assign the sequence of the heterocycles resonances.238 Even this was challenging, 
as still not all heterocycles could be connected, and so biosynthetic logic was still vital. From the 
predicted precursor and tailoring enzymes, the authors assigned all stereochemistry as the natural 
amino acid configurations; two later total synthetic efforts showed this to be correct.240,241 
 An important, biomedically-relevant class of RiPPs, the lanthipeptides bear hallmark post-
translational modifications including dehydration of Ser/Thr residues and thioether (lanthionine) 
bridges between Cys and dehydrated Ser/Thr sites.43,242 The presence of macrocyclic rings in the 
resulting molecules frustrates structural elucidation efforts by MS/MS, disrupting the 
fragmentation patterns useful for linear peptide sequence determination; however, as the precursor 
peptide is a directly gene product, a great deal of the structure can be obtained from the genome. 
The use of genomic information is now commonplace in lanthipeptide discovery, with a number 
of important examples. The structural elucidation of geobacillins I and II relied on bioinformatics: 
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for geobacillin II, not enough material was isolated for NMR studies.153 For geobacillin I, the NMR 
evidence was insufficient to establish conclusively the presence of a particular lanthionine (Lan) 
linkage; however, from sequence-derived biosynthetic logic, only one possibility existed after all 
other linkages had been established, allowing confident structural assignment. Lichenicidin was 
discovered nearly simultaneously by three groups who used genomic evidence in the structural 
determination process.243-245 One group in particular noted that NMR evidence was inadequate for 
structure elucidation and had to be complemented with genomics.245 The lanthipeptide SapB, 
associated with S. coelicolor aerial mycelium formation, provides another example; it was 
originally reported and characterized in the late 1980s/early 1990s, with 18 amino acids predicted, 
although a full structure was elusive.246,247 A decade later, genome-driven analysis based on the 
predicted amino acid content and mass revealed a compatible lanthipeptide BGC, allowing 
confident structural assignment in concert with tandem MS/MS.248 Interestingly, this revealed that 
the original amino acid analysis had been incorrect, which was speculated to be an artifact of 
improper purification. Other recent representative examples wherein genomic information proved 
important include the cerecidins,249 carnolysins,250 paenicidin A,251 catenulipeptin,252 
curvopeptin,253 elgicins,254 venezuelin,255 haloduracins,256,257, and salivaricin D258 (here, no NMR 
or full MS/MS was performed); in some cases, bioinformatic evidence in concert with MS/MS and 
amino analysis is considered sufficient structural evidence as to obviate the need for NMR or 
greatly simplify its interpretation. 
 Genomic prediction and spectroscopic determination of lanthipeptide ring topology is 
challenging, given the large number of possible ring topologies from a primary sequence;259 as 
such, several recent MS/MS algorithms integrated with genomics, including RiPPquest,108 
HSEE,210 and Pep2Path,107 (discussed previously) have sought to address this issue. These tools, 
however, do not address stereochemistry. It is also worth mentioning that the antiSMASH platform 
has recently been updated with a   module dedicated specifically to lanthipeptide prediction. This 
enables antiSMASH to more accurately predict structural aspects of identified lanthipeptides, 
including post-translational modifications and molecular weight.260 
 The structure of trichamide, a cyanobacterial RiPP, was predicted first from genomics 
based on the presence of a precursor peptide and several identified modification enzymes in 
analogy to the then recently-described patellamide gene cluster.261 This approach was particularly 
useful given the difficulty in characterizing cyclic peptides purely by spectrometric means. Mass 
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spectrometry subsequently confirmed the predicted structure, although stereochemistry was not 
assigned. Novel microcyclamides from the cyanobacterium Microcystis aeruginosa PCC 7806 
were similarly discovered.262 The structures of a variety of cyclic peptides, the anacyclamides, 
from strains of the cyanobacterial genus Anabaena, were solved utilizing knowledge of their 
precursor peptide sequences. In this case, chemical synthesis was also employed to corroborate the 
assigned stereochemistry.263 The structures of large RiPPs containing extensive cyclization or 
crosslinking, such as the cyclotides, also benefit greatly from sequence-based analysis. By way of 
example, Hermann et al. used MS/MS in concert with analysis of cDNA isolates to solve the 
structures of several cytotoxic cyclotides from the alpine violet plant, Viola biflora.264 This is 
especially useful in the case of isobaric residues—such as Ile/Leu—that are difficult to distinguish 
by MS alone. 
 Lasso peptides (e.g. streptomonomicin, Figure 1.17), a class of RiPPs, are particularly good 
candidates for sequence-based structure prediction; despite their stereochemical and topological 
complexity, their gene clusters are small and their post-translational modifications are chemically 
simple (i.e. adenylation of a side chain carboxylate and leader peptidolysis; the latter forms a new 
N-terminus which displaces ADP from the modified carboxylate to yield an isopeptide linkage215). 
Thus, numerous examples exist in the literature of lasso peptide structural prediction—including 
conformation—prior to isolation,214,265-270 although one report highlighting an “unthreaded” lasso 
peptide underscores the need for caution in such predictions.271 
 The enzymes responsible for individual structural features, such as a polyketide backbone, 
aromatic residues, or appended sugars, are often present as smaller “sub-clusters” within a BGC; 
the genes within these sub-clusters frequently co-evolve with each other but somewhat 
independently from the BGC as a whole.272 In addition to allowing nature to enact combinatorial 
chemistry, this has the advantage of making the presence of certain functional groups inferrable 
by the bioinformatic identification of such subclusters. This has been exploited for natural product 
structural elucidation. Liu et al. used the presence of the genes nosE and nosF for nonproteinogenic 
amino acid 4-methylproline biosynthesis as a discovery tool, screening over 100 cyanobacterial 
strains via PCR.273 This led to the identification and structural elucidation of eleven new cyclic 
NRPs, the nostopeptolides L1–L4 and nostoweipeptins W1–W7, each containing the reliably-
predicted moiety. Shen and coworkers have used the genes responsible for the installation of 
enediyne moieties as a handle for discovery of molecules containing this substructure.56,221. 
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Additionally, Cox et al. used the presence of a combination of genes to infer the presence of azole 
heterocycles and dehydrated amino acid moieties in the discovery of cyclothiazomyin C.186 It is 
worth noting that the bioinformatics program antiSMASH contains, as of its second version, a 
“SubclusterBlast” module capable of identifying key sub-clusters that are diagnostic of certain  
natural product substructures.78 
 Based on predicted enzyme substrate specificity, the feeding of specified precursors can be 
used to guide structural elucidation. The genomisotopic approach utilizes isotopically-labeled 
precursors.274 In a notable example, Gross et al. identified an NRPS gene cluster in Pseudomonas 
fluorescens Pf-5, analysis of which suggested the product to be a novel cyclic lipopeptide, which 
the authors named orfamide A. Amino acid monomers and their order were predicted, although 
the nature of the lipid side chain was elusive by this method. The authors noted that four of the 
predicted amino acids were present only in the orfamide BGC and not in the other NRPS clusters 
in the organism, suggesting the potential for selective labeling. As four Leu were predicted in 
orfamide A, the 15N-labeled amino acid was added to the producing organism’s culture medium. 
The resulting isotopically enriched natural product could then be subjected to NMR-guided 
isolation, which furnished the structure of orfamide A in agreement with biosynthetic predictions 
(Figure 1.25a). The success of a genomisotopic strategy relies on the ability to exclusively label a 
target metabolite as well as one’s confidence in bioinformatic predictions of substrate specificity. 
 A conceptually similar strategy was used upon the identification of an oxidosqualene 
cyclase in the genome of the model plant Arabidopsis thaliana.34 Based on functional prediction 
of the terpenoid synthase enzyme, a biosynthetic precursor, oxidosqualene (not isotopically 
labeled), was exogenously added to a yeast homogenate harboring the cloned Arabidopsis gene; 
tracking of the resulting metabolite revealed the triterpenoid thalianol (Figure 1.25b) and a related 
epoxide. For this study lacking isotopically-labeled compounds, feeding of exogeneous substrate 
allowed for increases in the downstream pathway flux to identify new metabolites. 
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Figure 1.21 Genome-based structural elucidation of ECO-02301. (a) Gene cluster for ECO-02301 biosynthesis. 
Genes are shaded on the basis of their use for prediction of ECO-02301 substructures, which are shown in panel (b). 
Open reading frame (ORF) numbers are depicted over genes. ORFs 9–17 were PKS genes from which the polyketide 
core and its sequential modifications were predicted. ORFs 18, 26, 27, and 32 encode machinery for synthesis of an 
aminobutyryl group and incorporation of it into the PKS machinery. ORFs 8 and 22–24 encode enzymes for 
preparation of a 6-deoxyhexose and synthesis of the glycosidic linkage. ORFs 33–35 are predicted to synthesis an 
aminohydroxycyclopentenone moiety. (c) Structure of ECO-02301, as determined by HRMS, NMR, and analysis of 
the gene cluster. Sites where NMR was not able to provide assignments—and where, accordingly, genomic analysis 
was essential—are highlighted in grey. 
 
Figure 1.22 Backbone prediction and actual structure of coelimycin P1. The originally-predicted backbone is 
transformed via a series of putative biosynthetic steps (shown) into the mature natural product; the 12-carbon chain is 
still evident but has been extensively modified. 
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Figure 1.23 NRPS substrate-based prediction of aureusimine structure. (a) Predicted structure and biosynthetic 
origin for aureusimine A, based on a two-module NRPS cluster. (b) Actual structures of aureusimine A (tyrvalin), 
aureusimine B (phevalin), and leuvalin. 
 
Figure 1.24 Biosynthesis and structure of plantazolicin. (a) The bioinformatically-identified plantazolicin gene 
cluster, bam, from B. amyloliquefaciens FZB42 is shown. BamA is a precursor peptide. BamCD comprise the 
cyclodehydratase. BamB is an FMN-dependent dehydrogenase. BamL is a SAM-dependent methyltransferase. Using 
the detected high-resolution modified mass, the mass of the unmodified core region, and the MS/MS data, a structure 
could be inferred. (b) The structure of plantazolicin contains two sets of cross-conjugated heterocycles and numerous 
carbons without attached protons that complicated physicochemical analysis. 
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Figure 1.25 Representative natural products identified by feeding bioinformatically predicted enzyme 
substrates. (a) Genomisotopic identification of orfamide A. Based on predicted NRPS substrates, 15N-labeled Leu 
was fed to the producing organism and the resulting lipopeptide, orfamide A, was identified by NMR-guided 
fractionation. (b) On the basis of classification of an enzyme as an oxidosqualene cyclase, oxidosqualene was added 
to a genetically manipulated yeast homongenate from which thalianol was isolated. 
1.4.6 Stereochemical determination 
 Gene sequence-derived knowledge of biosynthetic pathways can be used to infer natural 
product stereochemistry, either to confirm spectroscopic characterization or to provide a prediction 
in the event that NMR and/or crystallographic efforts are insufficient or elusive. Predictions can 
be based on knowledge of substrates (for instance, RiPPs are ribosomal in origin and often, but 
not always, retain natural amino acid stereochemistry43) or tailoring enzymes (epimerase domains 
in NRPS,40,275 RiPP,276 or other BGCs,277 as well as reductase domains in PKS genes40,226,278 can 
toggle stereocenters). 
 RiPPs are ribosomally-synthesized; as such, the natural product starting materials always 
contain L-amino acids (and glycine) by default, but post-translational modifications can impart 
epimerization at certain stereocenters in some natural products, including the cyanobactins, 
proteusins, and lanthipeptides.43,276 However, based on biosynthetic pathways, stereochemistry 
can often be predicted. The Nocardiopsis metabolite TP-1161 was assigned to the thiopeptide 
family upon structural elucidation, and biosynthetic logic was used to assign all amino acid-
originating stereocenters as L (except, of course, glycine).279 This was actually done before the 
gene cluster was confirmed,280 highlighting the usefulness of understanding the relationship 
between biosynthetic pathways and structure. 
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 NRPS modules typically employ L-amino acids as substrates and modulate stereocenters 
via co-localized epimerase domains; as a consequence, in silico methods for stereochemical 
determination are available based on the presence of these domains.82 In the illustrative example 
of the hydrophobic depsipeptides xenoamicin A-H, isolated from the bacterial entomopathogen 
Xenorhabdus mauleonii DSM17908, structure elucidation relied primarily upon NMR and M/MS, 
revealing a 13-residue depsipeptide.137 Amino acid stereochemical configuration was determined 
by hydrolysis and advanced Marfey’s analysis,281 but this provided only partial information, as the 
compound contained a mixture of five D/L Val residues which could not be localized in this way. 
Furthermore, although through-space ROESY signals had been used to assign macrocycle 
connectivity and determine Pro cis/trans geometry, clarifying the stereochemistry of the five Val 
residues by NMR was not possible. Thus, genomic analysis was used. The original producer, X. 
mauleonii DSM17908, did not have an available genome, but a closely-related, already-sequenced 
organism, Xenorhabdus doucetiae DSM17909, was found to produce the compound. The 
DSM17909 genome was searched for NRPS gene clusters using antiSMASH;78,79 biosynthetic 
logic based on the known amino acid composition was used to identify which one, xab, was 
involved in biosynthesis. Gene disruption confirmed its involvement. Within the gene cluster, 13 
NRPS modules across four genes (xabABCD) were found to be consistent with the order and 
composition of the structure (Figure 1.26b) (although substrate prediction using a PKS/NRPS web 
server96 was not entirely accurate). The presence of combined condensation/epimerization 
domains was accordingly used to determine which amino acids were D and L, in good agreement 
with the chiral amino acid analysis. Importantly, this clarified the NMR-ambiguous Val 
stereochemistries (Figure 1.26a). 
 Genomic analysis was used also in the assignment of the stereochemistry and structure of 
the paenilarvins, lipopeptides produced by the honey bee pathogenic bacterium Paenibacillus 
larvae; in this case, gene-based predictions for amino acid identity, order, and stereochemistry 
were entirely consistent with the spectrometrically-derived structure.282 Stereochemical 
configuration was also bioinformatically-inferred for erythrochelin, a siderophore natural product 
from Saccharopolyspora erythraea NRRL 23338,283 although another group determined 
configuration of the same molecule via chiral amino acid analysis.284 Genomic insight also helped 
reassign the stereochemistry of an asparagine residue of daptomycin, originally thought to be in 
65 
its L configuration; the D configuration at this site was corroborated by chemical means and was 
found to be important for biological activity.174 
 Noting some limitations of several bioinformatic methods at determining NRPS monomer 
stereochemical configuration, Caradec et al. recently described a workflow, named Florine, based 
on the identification of certain sequence signatures in NRPS condensation (C) and epimerization 
(E) domains.285 Although the workflow is not implemented in a downloadable or web-based 
program and must thus be performed manually, the authors highlighted its ability to assign some 
modules misassigned by other methods, including NaPDoS, and used it to suggest a revision of 
the previous ambiguously-assigned stereochemistry of the syringafactin family of lipopeptides 
(Figure 1.27). Interestingly, the syringafactin structures were elucidated without any use of NMR 
via bioinformatics, amino acid analysis, and tandem HR-MS/MS, highlighting the ability of 
genome-based analysis to reduce, in certain cases, the experimental effort required for structural 
elucidation.286 
 PKS enzymes also operate in an assembly-line fashion with and, as such, genomics can 
also inform polyketide stereochemistry, as a number of reports have shown generally.82,287-291 
Schieferdecker et al. isolated gulmirecin A and B from Pyxidicoccus fallax HKI 727, a bacterium 
that utilizes a “wolf-pack” strategy to prey selectively on Gram-positive bacteria (Figure 1.28a).187 
NMR, MS, and IR analysis furnished the planar structure; 2D NOESY NMR was used to assign 
the relative configuration of the double bonds and tetrahedral stereocenters. However, while the 
stereochemistry of the furanose moiety was assigned by cleavage, derivatization, and comparison 
to known standards, absolute configuration of the polyketide core was elusive by these means. A 
derivatization effort aimed at Mosher ester formation was also hampered by indiscriminate 
reactivity of the gulmirecin hydroxyl groups. Thus, biosynthetic logic was employed to infer the 
compound’s biosynthetic pathway and locate its gene cluster—which must necessarily feature an 
acetate starter unit, three malonyl-CoA extender modules, and three methylmalonyl-CoA extender 
modules−in the producing organism’s draft genome. One gene cluster, a 35 kb locus including six 
PKS genes, best fit the structure of gulmirecin (Figure 1.28c). Acyltransferase substrate specificity 
was predicted on the basis of single-amino-acid identity according to previous methods (Figure 
28b),288,291 and the ketoreductase stereospecificity responsible for hydroxyl group configuration 
was predicted in a similar sequence-based manner,290 revealing the 3R, 7R, 11R absolute 
configuration of gulmirecin A (Figure 1.28d). One hydroxyl moiety was installed via a nearby 
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cytochrome P450 enzyme, and its stereochemistry was thus not inferred bioinformatically. 
Importantly, the predicted absolute configurations at each PKS-derived hydroxyl site also matched 
the spectroscopically-determined relative configuration. This instance highlights the ability of 
sequence-based predictions to furnish absolute configuration in the absence of crystallography, 
degradation, or derivatization, and perhaps to reduce the burden of total synthesis in 
stereochemical assignment. 
 The use of sequence-based stereospecificity prediction has been quite successful for other 
PKS gene products, often in the event of material scarcity, ambiguous spectroscopy, chemical 
instability, or simply as a complementary method to confirm spectrally-derived assignments. It is 
worth noting that often these configurational assignments can be made based on the identity of a 
single amino acid in the KR domain and, as such, do not usually necessitate sophisticated statistical 
methods. Representative cases include chivosazole A (the first, prototypical PKS example),292 
thuggacins A-C,293 etnangien,294 ajudazols A and B,295 disciformycins A and B,296 β-lipomycin,297 
and salinilactam A209 (Figure 1.29). For the thuggacins, etnangien, and the ajudazols in particular, 
the presence of flexible side chains in each molecule highlights the difficulties in NMR 
interpretation and usefulness of gene-based prediction.293-295 For the disciformycins, genomic 
analysis served a confirmatory technique rather than elucidation.296 The β-lipomycin elucidation 
was accompanied by an improved profile hidden Markov model (HMM)-based method that could 
also classify methyl group stereoconfiguration.297 
 A healthy dose of caution is necessary when utilizing only bioinformatic predictions for 
stereochemistry, however. Of the three NRPS-derived moieties in the burkholdacs (section 1.4.4), 
for instance, only one stereocenter was correctly predicted,142 as subsequently determined by 
crystallography and total synthesis.143,217-219 Moreover, not all epimerase domains are active, such 
as in the case of myxochromides S1-3 (section 1.4.7).36 Additionally, D amino acids may be directly 
utilized by certain NRPS gene clusters, presumably epimerized by enzymes elsewhere in the 
genome and thus not easy discernable through bioinformatics.298 Thus, bioinformatic predictions 
are best trusted when they can be corroborated with some spectroscopic or synthetic evidence. It 
is worth noting, however, that bioinformatic predictions of ajudazol A and B stereochemistry, for 
example, have been used to guide confirmatory total synthesis efforts,295 so even in the absence of 
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complete certainty, genomics can greatly reduce expended effort. 
 Genetic manipulation of producing organisms or heterologous hosts, interestingly, can also 
be used for stereochemical assignment. Haynes et al. were able to assign the relative 
stereochemistry of streptorubin B, a prodiginine alkaloid from S. coelicolor A3(2), as anti on the 
basis of NOESY NMR experiments; however, the absolute configuration was elusive.299 Using 
knowledge of the biosynthetic pathway (Figure 1.30a), the authors generated a mutant of the 
producing organism unable to produce a biosynthetic precursor, 2-undecylpyrrole. By feeding the 
organism a stereoselectively deuterium-labeled synthetic precursor and observing the resulting 
metabolite by NMR, the authors were able to determine the absolute configuration of the major 
species as 7′S (Figure 1.30b). Here, the choice of the deuterium labeling site relied on the marked 
difference in chemical shift of two diastereotopic protons in the eight-membered ring of 
streptorubin B. 
 E. coli served as a heterologous expression host to determine the stereochemistry of 
xenotetrapeptide, an NRPS product of Xenorhabdus nematophila.300 The mutant E. coli strain used 
in this study bore deletions in five amino transaminases; thus, by incorporation of deuterium labels 
into specific precursor amino acids, MS could be used to see if epimerization was occurring in 
biosynthesis (accompanied by loss of the isotope label). This allowed stereochemical assignment 
without the need for isolation of sufficient material for Marfey’s analysis; however, the authors 
pointed out that further transaminases need to be deactivated before the method is extensible to all 
amino acids. Unlabeled amino acids could also be used, in concert with deuterated solvent, in the 
event that labeled amino acids were prohibitively expensive. 
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Figure 1.26 Genome-mediated stereochemical assignment of xenoamicin A. (a) Structure of xenoamicin A. The 
stereochemistry of the five Val residues, which were a mixture of D and L stereoisomers, could not be localized by 
NMR. (b) Xenoamicin biosynthesis was linked to the xabABCD NRPS gene cluster, which contained 13 sequential 
modules that correlate to the 13 sequential amino acid moieties in (a). The presence of associated combined 
condensation/epimerase domains was used to assign the Val stereocenters as D or L (indicated by grey arrows). For 
non-Val residues, Marfey’s analysis agreed with bioinformatic-based epimerase predictions. 
 
Figure 1.27 Stereochemistry assigned by the Florine workflow. Sites containing D amino acids, as determined 
bioinformatically, are depicted in grey. 
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Figure 1.28 Genomics-driven absolute configuration assignment of gulmirecin. (a) Structure of gulmirecin A. 
Sites at which the absolute configurations were determined through genomic analysis are highlighted in grey 
throughout the figure. (b) Hydroxyl configuration in polyketides can be deduced through sequence-based 
categorization of the ketoreductase (KR) domains responsible for their formation. (c) Gene cluster (gul) for gulmirecin 
biosynthesis. Genes gulABCDEF encode PKS modules, whereas gulG encodes a cytochrome P450 monooxygenase. 
Beneath the cluster are depicted sequence-predicted extender/initiator domain CoA substrates as well as predicted 
hydroxyl group configurations (and KR type) where relevant. (d) Schematic of the inferred biosynthetic pathway of 
the polyketide core of gulmirecin. KR domains important for determining absolute stereochemistry are depicted in 
black; DH and ER domains inactive in gulmirecin A biosynthesis but presumably active in gulmirecin B biosynthesis 
are shaded in grey. 
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Figure 1.29 Representative polyketides highlighting the usefulness of gene-based stereochemistry prediction. 
Sites where genomic analysis was used to confirm or predict absolute configuration are highlighted in grey. 
 
Figure 1.30 Stereochemical determination of streptorubin. (a) Partial biosynthetic pathway of streptorubin B. By 
inactivating redL, a mutant deficient in 2-undecylpyrrole biosynthesis was obtained. The two diastereotopic protons 
used for stereoselective labeling are highlighted in grey. (b) Example of a stereoselectively-labeled 2-undecylpyrrole 
and the resulting labeled derivative of streptorubin B. 
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1.4.7 Structural revision 
 Using gene cluster similarity—which implies evolutionary and structural similarity—is it 
also possible to revise existing structures in the literature. Wenzel et al., in the course of screening 
a cosmid library from the myxobacterium S. aurantiaca DW4/3-1 for hybrid PKS/NRPS clusters, 
discovered by gene inactivation and comparative MS that one such cluster produced three 
compounds, later named myxochromides S1–3.36 Sequencing of the cosmid yielded the gene cluster 
(Figure 1.31c), and the structure was determined with NMR, MS, and chiral amino acid analysis 
(Figure 1.31a). The gene cluster bore several unexpected features that would have limited a priori 
structure prediction: six NRPS modules were present despite only five amino acids being present 
in the structure; an epimerase domain was present in one module despite the natural amino acid 
stereochemistry at the position; and the type I PKS machinery appeared to display, unexpectedly, 
iterative activity.36 The gene-predicted substrate specificities for the non-skipped NRPS modules 
did, however, agree with the structure and a biosynthetic pathway could be proposed. The presence 
of the inactive epimerase and the sixth, vestigial, NRPS module led the authors to speculate an 
evolutionary link to the previously-reported natural product myxochromide A (Figure 1.31b), 
reported 12 years earlier from Myxococcus virescens str. Mx v48.301 Myxochromide A, in contrast 
to S1–3, contains six amino acids, including the extra Pro present in the myxochromide S1–3 gene 
cluster, and the epimerase provides D-Ala in the final compound (epimerase inactivity in S1–3 was 
ascribed to a mismatch with its paired substrate, Leu). Although a gene cluster for myxochromide 
A, isolated in 1993, had not yet been reported, the authors pointed out that its originally proposed 
structure was inconsistent with the biosynthetic logic of its PKS/NRPS origins (Figure 1.31d) and 
suggested a structural revision (Figure 1.31b), pointing out the limited NMR evidence in the 
original report.36,301 Interestingly, the gene cluster was cloned from the producing organism into 
E. coli, where it was engineered for optimal expression in pseudomonads before finally being 
heterologously expressed in Pseudomonas putida in high yields (40 mg/L of liquid culture; 5 times 
the yield from the natural producer in one third of the time)302 and later expressed in great 
abundance in the thermophilic myxobacterial heterologous host Corallococcus macrosporus GT-
2 (600 mg/L)303—demonstrating the value of having an associated gene cluster for a molecule if 
scaled-up production is desired. Later genomic and NMR evidence from M. xanthus also revealed 
the myxochromide A gene cluster and corroborated the earlier biosynthetic logic-based structural 
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revision.304 Thus, even with an unusual gene cluster—or lack of one—genomic information and 
logic can sometimes be used to check or revise existing natural product structures. 
 Updates in bioinformatic analysis methods can also provide structural revision. Using a 
novel Florine workflow, Caradec and coworkers proposed a revision of the previously assigned 
stereochemistry of the syringafactins; this stereochemistry superseded the predictions originally 
provided by earlier bioinformatic methods.285 Thus, evolution in bioinformatic methods allows for 
increased confidence in structural predictions.  
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Figure 1.31 Structural revision of myxochromide A based on the gene cluster for myxochromides S1–3. (a) 
Structure of myxochromides S1-3. Regions derived from PKS (mchA) and NRPS (mchB, mchC) genes are indicated, 
as are the five incorporated amino acids. (b) Original and revised structures of myxochromide A. The difference 
between the structures—the ester connectivity of the Gln/Thr residues—is highlighted in grey. The six incorporated 
amino acids, including the epimerized Ala at the second position, are indicated. (c) Gene cluster for myxochromide S 
biosynthesis. ORF labels are depicted above the genes. PKS and NRPS genes are indicated in black, with functions 
as annoted in (d). (d) Proposed biosynthetic pathway of myxochromide S1. The ultimate step consists of a ring-forming 
intramolecular thioester cleavage by the nucleophilic hydroxyl group of the N-terminal Thr. The original connectivity 
proposed for myxochromide A is inconsistent with this ring-forming mechanism and biosynthetic pathway. Module 
4 is inactive but is presumed to install Pro, as in myxochromide A. Inactive modules are depicted in grey.  
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1.4.8 Property prediction 
 Often structural aspects corresponding to unique physicochemical properties, which can 
guide isolation efforts, can be predicted even if a structure can not. For example, the isolation of 
the aspoquinolones from A. nidulans in 2006 was guided by prediction of the physicochemical 
properties of these prenylated alkaloids; specifically, the authors screened the extracts for nitrogen-
containing aromatic compounds.305 In the discovery of ECO-02301 (discussed previously), a long 
polyene, predicted UV and MS properties aided in isolation.58 
 The presence of chemical functional groups can be inferred by the presence of enzymes 
responsible for their installation. For instance, the presence of readily-identified homologues of 
pepM (phosphoenoylpyruvate mutase) in a BGC signifies the presence of a phosphonate or 
phosphinate (C-P bond)-containing natural product;306 these have diagnostic 31P NMR shifts which 
can be used to guide isolation,306 as in the isolation of novel phosphonates from Streptomyces 
regensis.307 The presence of halogenase enzymes has also been used to predict halogenation in 
natural product frameworks.308 
 Thus, given some predictive information about the class or chemical content of a 
metabolite, some structural information can be inferred and screening efforts can be better focused. 
1.4.9 Nosperin: a summary example 
 The structural elucidation of nosperin (Figure 1.32a) provides a useful recent example that 
encompasses most of the strategies described above and demonstrates the power of genomics as 
an additional technique in elucidating the structure of low-abundance metabolites.309 Kampa et al. 
initially noticed a PKS-NRPS gene cluster nsp, in the metagenome of the terrestrial lichen 
Peltigera membranacea, that exhibited significant homology to the BGC responsible for 
biosynthesis of pederin (Figure 1.32b). Perhaps appropriate to its origin in a lichen—composite 
organisms whose biosynthetic products tend to vary quite a bit from standalone bacteria—the gene 
cluster was described as “an evolutionary mosaic of trans- and cis-AT PKS fragments from 
diverse sources.”309 The structure was partially predicted by bioinformatic analysis of the BGC, 
including substrate specificity analysis of individual NRPS and PKS modules, comparison to 
pederin and onnamide biosynthesis, and functional prediction of tailoring enzymes. Although 
some aspects of the structure eluded prediction, the preliminary partial assignment was used as a 
guide during compound isolation from extracts of Nostoc sp. cyanobacteria isolated from the 
lichen; cyanobacteria were prioritized for screening by PCR-guided confirmation of the presence 
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of the appropriate gene cluster. After obtaining a metabolite consistent with the predicted 
biosynthetic pathway, full structure elucidation by NMR was possible; the resulting structure was 
well in agreement with predicted structural aspects, with two unexpected exceptions (Figure 1.32d). 
Notably, stereochemical assignment relied on both bioinformatic analysis and NMR, and only two 
stereocenters were elusive by this strategy (Figure 1.32c). All told, through the synergistic use of 
genomics (for substrate and stereochemistry prediction) and traditional physicochemical analysis, 
the structure of nosperin was assigned using only 30 µg of the natural product. 
 
Figure 1.32 Nosperin and related molecules and gene clusters. (a) Structures of nosperin, pederin, and onnamide 
A. (b) Comparative view of gene clusters responsible for the biosynthesis of the natural products in (a). PKS/NRPS 
genes are in grey, blue, or purple. Color indicates homology between clusters specifically used by the authors for 
comparisons. (c) Origin of stereochemical assignments. (d) Two features, a hydroxyl group and an amide, were 
mentioned as being unexpected by predictions. 
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1.5 Limitations and future directions 
 Structure determination can quite easily become an exercise in confirmation bias, and the 
same is true with using genomics-guided analysis for structural elucidation purposes. Being able 
to confidently predict structure from nucleotide sequence alone is a tall order and relies on having 
data in both high quantity and high quality for the purpose of model-building. As such, a number 
of limitations still exist with regards to genomics-guided structure elucidation. 
1.5.1 The class barrier 
 The examples selected herein are mainly drawn from the PKS, NRPS, and RiPP literature 
and tend to be medium-to-large, complex products. This highlights the current strengths and 
challenges of genomics-based predictions with respect to structure prediction. For biosynthetic 
classes that have modular gene clusters (PKS, NRPS)40,41,224,225 or directly-encoded, templated 
precursors (RiPPs),43 the relationship between gene and molecule is more well understood. This is 
fortunate, given that these families of gene clusters tend to produce some of the largest, most 
complex, synthetically challenging, and structurally elusive secondary metabolites, for which 
genetic knowledge is most helpful.    
 Other classes have proven much more challenging to predict. Terpenoids, 
phenylpropanoids, and alkaloids, for instance, are indeed often even combinatorial in their 
biosynthetic pathways, resulting in multiple products per BGC. However, it is reasonable to expect 
that given enough information and analysis, these more challenging natural product classes will 
also be subject to genomic analysis. This is especially true in light of recent projects, such as the 
Enzyme Function Initiative (EFI, http://enzymefunction.org),119 aimed at broad-scale functional 
characterization of the enzymes (terpenoid synthases, for instance310) involved in biosynthesis of 
these classes. 
1.5.2 Taxonomic limitations 
 We have also focused predominantly on bacterial and fungi, who tend to cluster their 
natural product biosynthetic genes.32,311 Plants represent a greater challenge: their genomes are 
larger and more complex, and it has also long been thought that plants do not cluster their 
biosynthetic genes.32 Additionally, sequencing the genome of a plant is usually more expensive 
than for a bacterium or fungus. Hence, readily obtaining BGCs and predicting information from 
them cannot yet be done with the same ease as for microbes and awaits the evolution of appropriate 
analytical procedures.  
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 Excitingly, it is becoming increasingly apparent that gene clustering is not as uncommon 
as previously thought in plants, challenging earlier notions to the contrary.312 Indeed, plant natural 
product biosynthetic genes can be clustered and coexpressed in a manner akin to bacterial 
operons,313 and despite an absence of tailored tools such as those aimed at microbes, some 
biosynthetic genes can be identified bioinformatically.314 Given that plants are the source of a 
number of valuable biomedically, agriculturally, and culinarily-relevant molecules,314 
bioinformatic analysis of plant natural product BGCs may thus soon see a similar revolution.  
 Natural products from other eukaryotes also provide a genomic challenge, and indeed it is 
not uncommon to see novel natural products isolated from snails, insects, frogs, corals, sponges, 
sea squirts, etc. A major challenge is typically in the frustratingly small amounts isolated, 
sometimes necessitating heroic total synthesis efforts to obtain enough material for biological 
evaluation and structure confirmation, as with the marine sponge-harvested cytotoxin 
discodermolide, whose gene cluster is still unknown.170,171,315 However, many of these natural 
products are increasingly being found to actually be the products of microbial symbionts living 
within the animal hosts; for instance, the anticancer patellamide family isolated from the sea squirt 
Lissoclinum patella in 1981316 was later shown to be produced by its cyanobacterial symbiont P. 
didemni.168 This has implications for bioinformatic-driven discovery and elucidation efforts, as 
metagenomics methods allow the discovery of BGCs in these biological niches and for production 
by heterologous expression.166,317 Even humans are sources of natural products from symbionts: 
recently, via metagenomic methods the thiopeptide lactocillin was discovered from a member of 
the vaginal microbiome.318 
 In light of current taxonomic limitations, it is worth pointing out that although natural product 
discovery efforts so far have focused primarily on plants (~70% of all natural products), microbial 
metabolites (~10% of all natural products) have been shown to be an order of magnitude more 
likely to display bioactive properties or become useful drugs.10 In conjunction with the advanced 
analysis tools for microbial genome analysis, we anticipate that fungi and bacteria will become an 
increasingly important (and perhaps dominant) source of new chemical matter in the future. 
1.5.3 Get it together! 
 As mentioned previously, a major limitation of informatics-guided methods is the 
dependence of success upon the quality and quantity of available information. Despite an 
abundance of bioinformatic programs and databases, there is no comprehensive, unified natural 
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product BGC database. Thus, finding characterized gene clusters similar to one of interest can be 
an arduous endeavor. This will likely change in the future as community efforts such as MIBiG38 
take hold. However, the fact remains that most known natural products still have not been 
correlated with gene clusters. As information on the genetic basis for a natural product greatly 
empowers research related to the compound, we view the connecting of known natural products 
to BGCs to be a worthwhile pursuit, and recommend—where possible—reporting the BGCs for 
novel compounds, whether or not genomics is required for their structural elucidation. Informatic 
analysis based on large amounts of data has been quite fruitful for the study of protein function, 
evolution, and structure, and will likely be just as powerful for natural products. 
1.6 Conclusion 
 With the abundance of genome sequence data and the availability of open-access 
informatic analysis techniques, genomic analysis is maturing into what might be regarded as a 
bona fide analytical method for the elucidation of natural product structures. Well-established 
methods now exist for the linking of natural products and corresponding biosynthetic gene clusters 
(BGCs). Additionally, harnessing knowledge of enzymology and phylogeny, gene sequences can 
give structural insights ranging from prediction of physicochemical properties, clarification of 
spectrally ambiguous substructures, and elucidation of stereochemistry, to complete a priori 
prediction of complex structures. Analysis of BGCs, in tandem with biosynthetic logic, also 
provides an important strategy to corroborate spectrally-derived assignments in an effort to avoid 
confirmation bias or misassignment. However, it is worth bearing in mind that most genomic 
analysis is descriptive, not prescriptive; as such, it is much better at characterizing gene clusters 
that are similar to known clusters for known scaffolds. Being able to accurately and precisely 
predict gene cluster function from first principles—and hence the structures of truly new, 
divergently exotic scaffolds− is still a distant hope that awaits significant progress in a variety of 
fields. 
 It is reasonable to expect that, given enough data, the bulk of secondary metabolites could 
be predicted from their corresponding genomes. However, this requires good curation of an 
extensive amount of data linking genes to molecules. As this time, only a minority of small-
molecule natural products have been assigned to BGCs, and assignment of novel compounds to 
BGCs remains uncommon, limiting the ability of bioinformatic analysis to shed light on new 
pathways. It is thus our hope that, in addition to the standard, required characterization data 
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accompanying descriptions of novel metabolites (NMR, MS, etc.), the corresponding gene cluster 
or producing organism’s genome will come to be routinely (and expectedly) reported in tandem.  
 As illustrated above, gene sequence-based insights are subject to the same dangers of 
confirmation bias as more common physicochemical analysis techniques. And indeed, it is rarely 
possible to completely divine a natural product structure from sequence alone. More commonly, 
genomic analysis provides incomplete information that must be corroborated with other methods. 
However, it must be pointed out that the same is true of any analytical technique, as NMR, MS, 
UV, or IR by themselves are each insufficient. It is our opinion that genomics should be added to 
the more common analytical techniques as a routine structure elucidation tool. With the decreasing 
costs and increasing ease of genome sequencing, we anticipate that this will become a reality. 
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CHAPTER 2: STREPTOMONOMICIN, AN UNUSUAL LASSO PEPIDE 
This work has been previously published.* 
 
2.1 Introduction 
Microbial biosynthesis represents the most important historical source of chemical matter 
for the understanding of biology and the development of medicines.1 However, despite the value 
of natural products as medicinal leads, the frequent rediscovery of known compounds renders 
traditional screening methods (i.e. bioassay-guided isolation) increasingly unappealing and 
economically disadvantageous.2 In response, a number of modern natural product discovery 
strategies have been developed, including genome-guided discovery,3 antibiotic resistance-
mediated isolation,4 reactivity-based screening,5 PCR-based strain prioritization,6 mass 
spectrometry-based network analysis,7 heterologous expression,8 and metagenomics,9 with the 
general aim of reducing the burden of rediscovery and thereby accelerating the drug discovery 
process. 
In widely-studied organisms, it is frequently the case that the abundant natural products are 
already known; undiscovered compounds are often believed to be silent or at least below a 
detection threshold. This can complicate identification, purification, structural elucidation, and 
mechanism-of-action determination efforts. Moreover, broad metabolic and bioinformatic analysis 
shows that natural product biosynthetic capability tends to parallel bacterial speciation;3 hence, 
rather than to solely concentrate on screening many strains of one particular known producing 
species, it may also be useful to seek new species in underexplored taxa. Understudied 
organisms—those that are lab-cultivable yet unsequenced or metabolically uncharacterized—thus 
present the prospect of discovery of novel, abundant bioactive metabolites with lower rates of 
                                                 
* This chapter is adapted in part from Metelev, M.; Tietz, J.I.; Melby, J.O.; Blair, P.M.; Zhu, L.; Livnat, I.; Severinov, 
K.; Mitchell, D.A. “Structure, bioactivity, and resistance mechanism of streptomonomicin, an unusual lasso peptide 
from an understudied halophilic actinomycete.” Chem. Biol. 2015, 22 (2), 241-250. doi: 
10.1016/j.chembiol.2014.11.017. M.M. and J.I.T. were co-first authors. This work was supported in part by a NIH 
Director’s New Innovator Award Program (DP2 OD008463 to D.A.M.), the David and Lucile Packard Fellowship for 
Science and Engineering (to D.A.M.), the Robert C. and Carolyn J. Springborn Endowment (to J.I.T.), and the NIH 
(R01 NS031609 for I.L.). M.M. was supported by a Ministry of Education and Science of Russian Federation project 
(14.B25.31.0004 to K.S.). The Bruker UltrafleXtreme MALDI TOF/TOF mass spectrometer was purchased in part 
with a grant from the National Center for Research Resources, National Institutes of Health (S10 RR027109 A). M.M. 
performed and analyzed genomic and microbiological experiments and compound isolation; J.I.T. performed and 
analyzed NMR experiments with critical input from L.Z.; J.O.M. performed and analyzed MS experiments; P.M.B. 
performed microscopy and microbiological experiments; I.L. performed chirality analysis; D.A.M. conceived of and 
managed the project; J.O.M., P.M.B., L.Z., I.L., and K.S. assisted in revisions during the writing process; J.I.T. wrote 
the paper with significant editorial assistance from M.M. and D.A.M. 
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rediscovery.10 Among these organisms are the Streptomonospora, a genus within the family 
Nocardiopsaceae.11 Members of the genus are slow-growing halophiles, typically requiring 
cultivation for a month or more in high-salt media (10–25% w/v NaCl). At least nine distinct 
Streptomonospora species have been reported; however, no corresponding genome sequences are 
available. These characteristics have rendered Streptomonospora sp. markedly unattractive both 
from the standpoint of traditional high-throughput natural product screening campaigns and more 
modern genome-driven discovery efforts. Perhaps for this reason, the biosynthetic capacity of the 
Streptomonospora has gone entirely neglected in the 13 years since their first description. As 
actinomycetes in general have been shown to be unusually talented biosynthetic chemists, we 
reasoned that investigating an understudied, yet tractable, genus would shed light on the natural 
product repertoire of these organisms and guide future genome-mining programs. We thus 
acquired Streptomonospora alba YIM 90003.12 
The cultured S. alba produces an abundant natural product, streptomonomicin (STM), 
which we isolated and subjected to structural and biological characterization. We have also 
performed genomic characterization of Streptomonospora alba, revealing STM’s biosynthetic 
origin and shedding light into the biosynthetic capability of the genus. 
2.2 Isolation of streptomonomicin 
The MALDI-TOF mass spectra of intact S. alba YIM 90003 cells and a non-lytic methanol 
extract were dominated by the presence of an intense peak (m/z 2256, [M+Na]+), indicating an 
abundant, exported natural product (Figure 2.1a). Extracts from the organism were fractionated 
using a C18 Sep-Pak, and the resulting fractions containing m/z 2256 displayed antibacterial 
activity against Bacillus subtilis in a preliminary bioassay. Accordingly, we named the compound 
“streptomonomicin”, and by subjecting MeOH extracts of scaled-up cultures of S. alba to 
purification via Sep-Pak C18 cartridge and high-performance liquid chromatography (HPLC), 
isolated additional material for structural elucidation and further refinement of bioactivity 
(Appendix B.1.1). Yields obtained on solid media ranged from 10–14 mg/L. 
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Figure 2.1 Mass spectrometry analysis of streptomonomicin. (a) MALDI-TOF mass spectrum of an extract of 
Streptomonospora alba YIM 90003 showing the compound as the dominant peak (m/z 2256, [M+Na]+). (b) An m/z 
scan of purified STM that was directly infused into an 11T FTMS resulted in a 2+ charge ion consistent with the 
calculated m/z for STM (Appendix B.1.2a). The ion was fragmented and produced the resulting spectra. A diagram 
of STM is shown with the observed b- and y-ions labeled on the structure and in the spectra. (c) An m/z scan of 
purified, carboxypeptidase Y- and thermolysin-digested STM that was directly infused into an 11T FTMS resulted 
in a 1+ charge ion consistent with the 10 N-terminal residues of STM (Appendix B.1.2b). The ion was fragmented 
and produced the resulting spectra. A diagram of carboxypeptidase Y- and thermolysin-digested STM is shown with 
the observed b- and y-ions labeled on the structure and in the spectra.  
2.3 Structure elucidation of streptomonomicin 
The structure of STM was determined by the synergistic use of mass spectrometry (MS), 
nuclear magnetic resonance (NMR) spectroscopy, amino acid analysis, and genome sequencing. 
The compound was submitted to a full suite of NMR experiments (1H; 1H-1H DQF-COSY, 
TOCSY, NOESY; 1H-13C HSQC and HMBC; Appendix B.1) as well as high-resolution Fourier 
transform (FT) MS/MS analysis (Figure 2.1 and Appendix B.1). The FT-MS/MS data (Figure 2.1 
and Appendix B.1) and 1H-1H TOCSY (Appendix B.1.5) revealed STM to be a peptide, consistent 
with its UV absorbance spectrum (Appendix B.1.1c). Analysis of the TOCSY spectrum revealed 
the presence of 21 amino acids, which were predominantly hydrophobic: 3 each 
Leu/Ile/Tyr/Ser/Pro, 2 Gly, 2 Asx (1 Asn, 1 Asp, as later determined, vide infra), 1 Ala, 1 Val 
(Appendix B.1.5 and B.1.16). This amino acid composition was consistent with subsequent 
quantitative amino acid (QAA) analysis (Appendix B.1.16). Mild hydrolysis and chiral analysis of 
STM indicated that all residues were the L stereoisomer (Appendix B.1.16). Resonances of the 
spin systems were assigned primarily by analysis of TOCSY, HSQC, and HMBC experiments; 
intra-residue connectivity was established by TOCSY and DQF-COSY.   
Importantly, initial MS/MS analysis provided a partial sequence of the C-terminal 11 
residues of the peptide (residues 10–21): Ile/Leu-Ile/Leu-Gly-Tyr-Pro-Ala-Ile/Leu-Ile/Leu-Val-
Ile/Leu-Tyr-Pro (Figures 2.1b and Appendix B.1.2). This sequence was supported by the 
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HMBC/NOESY data (Appendix B.1.6, B.1.8, B.1.12, and B.1.13). Interestingly, additional 
MS/MS fragmentation was not seen N-terminal to this sequence. Moreover, the FT-MS data 
supported a chemical formula of C107H160N22O30 with an error of <1 ppm, corresponding to the 
above 21 amino acids with the loss of a single H2O. Integration of the 1H NMR spectrum taken in 
CD3OH revealed that all the backbone amide resonances corresponded to a single proton each, 
with the absence of a free N-terminal amine (Figure 2.2a). Taken together with the lack of MS/MS 
fragmentation, this indicated that the 9 N-terminal residues were cyclized. Analysis of NOESY 
spectra revealed one of the earlier-identified Asx residues to be Asn; the other residue displayed a 
strong NOE correlation to one of the Ser NH resonances, and was thus assigned as a Ser-Asp 
isopeptide linkage, forming a 9-residue ring (Figure 2.2b). 
To establish the amino acid sequence of the 9-residue ring, we first treated STM with 
carboxypeptidase Y. Although this did not result in complete C-terminal tail truncation, the 
enzymatic digestion yielded a mixture primarily containing three products wherein either residues 
11–21, 18–21, or 19–21 were removed to give N-terminal macrocycle-containing fragments of 10, 
17, or 18 residues, respectively. The 10-residue peptide was further treated with thermolysin, 
providing a linearized fragment of STM. The MS/MS fragmentation pattern of digested STM 
allowed partial sequence assignment of the N-terminus and supported the presence of the 
isopeptide Ser-Asp linkage (Figures 2.1c and Appendix B.1.2).  
With the constituents of the macrocycle established, we sought to fully assign the sequence. 
Using HMBC and NOESY correlations, each of the earlier-identified NMR spin systems was 
unambiguously assigned, clarifying the identity of the triplicate residues (Tyr, Ser, Pro) and MS-
ambiguous Ile/Leu residues and confirming the assigned sequence within the ring (Appendix 
B.1.6, B.1.8, B.1.12, B.1.13, and B.1.15). In conjunction, we also sequenced the full genome of S. 
alba YIM 90003 (see later). Using our spectrometrically-obtained primary sequence as a query in 
a TBLASTN search, we identified a peptide encoded in the S. alba genome whose C-terminal 21 
residues corresponded to our structure, thereby corroborating our sequence assignment (Figures 
2.3a and 2.5). 
106 
 
Figure 2.2 NMR analysis of streptomonomicin. (a) Integrations of amide protons from 1H NMR spectrum in CD3OH 
indicate a single NH proton is present for each residue. Residue assignments are shown above the spectrum. Peaks 
(ppm) are shown above residue assignments. Integrations are shown below the spectrum. (b) Expansion of 1H-1H 
NOESY spectrum in CD3OD showing amide/side chain through-space correlations. The isopeptide Ser1-Asp9 linkage 
is indicated by the strong NOE crosspeak between the Ser1 NH and the β protons of Asp9, as highlighted in red. (c) 
Overlaid 1H NMR spectra taken in CD3OD shortly after sample dissolution (black) and 1 d later (red). Residue 
assignments are shown above the spectrum. Significant resistance to deuterium exchange is evident for many peaks.   
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2.4 Three-dimensional solution structure of streptomonomicin 
Two aspects of the NMR data pointed to a highly-ordered three-dimensional structure. 
First, many amide protons in the ring and the N-terminal half of the tail showed resistance to 
deuterium exchange (Figure 2.2c). Second, a large number of long-range NOE correlations were 
apparent, particularly from the methyl group of Ala15 to a number of the ring residues (e.g. Ser1, 
Ser5, Tyr7, Asn8, Asp9) (Appendix B.1.6 and B.1.12). Additionally, the ring/tail topology is 
characteristic of lasso peptides, a class of conformationally-constrained peptidic natural products 
wherein a 7- to 9-membered N-terminal ring is nearly always threaded by a C-terminal tail; this 
conformational lock protects them to a degree from degradation and has resulted in recent interest 
in these scaffolds.13-15 However, lasso peptide conformation cannot be assumed from sequence 
alone, as one recently-described lasso peptide is reported to be unthreaded.16 As such, we sought 
to determine the three-dimensional solution structure of STM.  
Using NOE distance constraints derived from the NOESY spectra and dihedral angle 
restraints extracted from the DQF-COSY, an ensemble solution structure was calculated using 
XPLOR-NIH (Figures 2.3b and 2.3c and Table 2.1) (Protein Data Bank [PDB] code 2MW3). The 
resulting STM structure contains the characteristic right-handed lasso; the ring encircles the tail 
between residues 14–16 (Figure 2.3b). The constrained ring and loop of STM are well-ordered 
(0.26 Å rmsd against lowest conformer for the backbone for residues 1–17), and occlude solvent 
from inward-oriented amide protons, rationalizing the observed slow deuterium exchange of many 
residues of the ring and the N-terminal half of the tail (Figures 2.2c and 2.3c). The C-terminal 
portion of the tail (residues 18–21) is more disordered, consistent with the observed rapid 
deuterium exchange (Figure 2.2c). In lasso peptides without disulfide bonds, bulky residues on the 
tail immediately flanking the ring serve as steric locks (Table 2.2).17 Inspection of the van der 
Waals surface of the ring (residues 1–9) and the tail residues that thread the ring suggests that 
Leu16 serves as this steric lock, preventing the ring from unthreading (Figures 2.3c and 2.4a). 
Ala15 is in close contact with the ring but is unlikely to be bulky enough to prevent unthreading. 
Pro14 may also play a role in biasing the conformation of the tail, although mutational studies 
would be necessary to confirm this. Threaded lasso peptides are typically resistant to 
carboxypeptidase Y digestion;18,19 in contrast, STM is unusually susceptible. However, the 
complete tail digestion expected for unthreaded lasso peptides was not observed, and a mixture of 
partially truncated peptides was instead obtained. We hypothesize that the comparatively small 
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steric lock of STM (Leu/Ala) combined with its large, 9-member macrocycle render it particularly 
prone to this digestion.  
Unlike other lasso peptides, STM is unusually hydrophobic, consisting of 5% hydrophilic 
and 52% hydrophobic residues. Known class II lasso peptides (those without disulfide bonds, like 
STM) are 10–43% hydrophilic and almost always contain a charged residue (Table 2.2). 
Interestingly, STM’s amino acid composition is closer to that common for class I and III lasso 
peptides (those conformationally restrained by two or one ring-tail disulfide bonds, respectively). 
RP-71955, the siamycins, and BI-32169, like STM, contain 5% hydrophilic and 43-53% 
hydrophobic residues, being rich in Leu/Ile/Val/Ala (Table 2.2). Additionally, despite little 
primary sequence identity, the structure of STM aligns closely (backbone rmsd 1.03 Å for residues 
1-17 against lowest energy conformer of STM) to the crystal structure of BI-32169 (PDB code 
3NJW), a lasso peptide of streptomycete origin (Figure 2.4b).20,21  
Markedly, although a Ser-Glu isopeptide linkage has been recently reported in the 
caulonodins, no lasso peptide with a Ser-Asp isopeptide linkage was formerly known.22 Before the 
caulonodins and STM, it was thought that the first residue of lasso peptides was invariantly Gly or 
Cys, as amino acid substitutions at this site had not been found in nature; even conservative 
substitutions at this site were not tolerated by the enzymatic machinery for microcin J25, 
capistruin, or astexin-1, for instance.19,23,24  
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Figure 2.3 Structure of streptomonomicin. (A) Schematic representation of the structure of STM with the isopeptide 
Ser1-Asp9 linkage indicated. Residues 1–9 (gray) comprise the ring and residues 10–21 (white) are the tail. (B) 
Ensemble of the 15 lowest energy conformers of NMR solution structure; backbone atoms are depicted. (C) Stereo 
view of one conformer of STM with side chains shown. Backbone atoms are depicted in red for the ring and blue for 
the tail. Side chains are depicted in orange for residues 14–16, which thread the ring. Images in panels B and C were 
generating using PyMOL.  
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Figure 2.4 Additional views of streptomonomicin solution structure. (A) The solution structure of STM is shown 
with the ring (grey) and threading residues (orange) depicted with spheres indicating the van der Waals radius of the 
atoms. The structure indicates that the Ala15/Leu16 pair acts as a steric lock, preventing unthreading of the tail through 
the ring. (B) Alignment of STM (blue; lowest-energy conformer) with BI-32169 (red; PDB code 3NJW), a class III 
lasso peptide with the closest structural similarity, of known lasso peptides, to STM. The structures align with a 
backbone atom rmsd of 1.03 Å (residues 1-17). 
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total restraints used 339 
total NOE restraints 328 
   intraresidue 137 
   sequential (|i – j| = 1) 82 
   medium (1 < |i – j| ≤ 4) 30 
   long range (|i – j| > 4) 79 
dihedral   
   φ angles 11 
rmsd from experimental distance restraints   
   bonds (Å) 0.003 ± 0.000 
   bond angles (deg) 1.011 ± 0.236 
   improper torsions (deg) 0.373 ± 0.022 
average rmsd from lowest energy model (Å)   
   backbone atoms in ring/loop region (1–17) 0.26 
   all backbone atoms (residues 1–21) 1.19 
   all heavy atoms in ring/loop region (1–17) 0.89 
   all heavy atoms (residues 1–21) 1.89 
Table 2.1 List of restraints used in NMR structure calculation and statistical analysis of the resulting structure. 
Name Category Sequence (core peptide) Length, aa 
(ring-tail) 
Hydrophilic 
residues, %a 
Hydrophobic 
residues, %b 
streptomonomicin Class II SLGGSPYNDILGYPALIVIYP  9-12 5 52 
caulonodin V Class II SIGDSGLRESMSSQTYWP 9-9 17 28 
BI-32169 Class III GLPWGCPSDIPGWNTPWAC 9-10 5 53 
RP-71955 Class I CLGIGSCNDFAGCGYAVVCFW 9-12 5 43 
siamycin I Class I CLGVGSCNDFAGCGYAIVCFW 9-12 5 43 
siamycin II Class I CLGIGSCNDFAGCGYAIVCFW 9-12 5 43 
SSV-2083 Class I CVWGGDCTDFLGCGTAWICV 9-11 10 40 
anantin Class II GFIGWGNDIFGHYSGDF 8-9 18 35 
astexin-1 Class II GLSQGVEPDIGQTYFEESRINQD  9-14 26 26 
astexin-2 Class II GLTQIQALDSVSGQFRDQLGLSAD 9-16 17 38 
astexin-3 Class II GPTPMVGLDSVSGQYWDQHAPLAD 9-15 17 46 
burhizin Class II GGAGQYKEVEAGRWSDRIDSDDE 8-15 43 22 
capistruin Class II GTPGFQTPDARVISRFGFN  9-10 16 42 
caulonodin I Class II GDVLNAPEPGIGREPTGLSRD 8-13 29 38 
caulonodin II Class II GDVLFAPEPGVGRPPMGLSED 8-13 24 52 
caulonodin III Class II GQIYDHPEVGIGAYGCEGLQR 8-13 24 29 
caulosegnin I Class II GAFVGQPEAVNPLGREIQG  8-11 16 47 
caulosegnin II Class II GTLTPGLPEDFLPGHYMPG  9-10 16 47 
caulosegnin III Class II GALVGLLLEDITVARYDPM  9-10 21 58 
lariatin A Class II GSQLVYREWVGHSNVIKP  8-10 22 39 
lariatin B Class II GSQLVYREWVGHSNVIKPGP 8-12 20 40 
microcin J25 Class II GGAGHVPEYFVGIGTPISFYG  8-13 10 43 
propeptin Class II GYPWWDYRDLFGGHTFISP 9-10 21 42 
RES-701-1 Class II GNWHGTAPDWFFNYYW  9-7 12 44 
rhodanodin Class II GVLPIGNEFMGHAATPGITE 8-12 15 50 
rubivinodin Class II GAPSLINSEDNPAFPQRV 9-9 17 50 
sphingonodin I Class II GPGGITGDVGLGENNFGLSDD 8-13 19 29 
sphingonodin II Class II GMGSGSTDQNGQPKNLIGGISDD 8-15 17 22 
sphingopyxin I Class II GIEPLGPVDEDQGEHYLFAGGITADD 9-17 31 38 
sphingopyxin II Class II GEALIDQDVGGGRQQFLTGIAQD 8-15 22 35 
SRO15-2005 Class II GYFVGSYKEYWSRRII 9-7 25 31 
sungsanpin Class II GFGSKPIDSFGLSWL  8-7 13 47 
syanodin I Class II GISGGTVDAPAGQGLAGILDD 8-13 14 43 
xanthomonin I Class II GGPLAGEEIGGFNVPGISEE 7-13 20 40 
xanthomonin II Class II GGPLAGEEMGGITTLGISQD 7-13 15 35 
zucinodin Class II GGIGGDFEDLNKPFDV 8-8 31 38 
lassomycin Non-threaded GLRRLFADQLVGRRNI 8-8 31 44 
a Hydrophilic residues are defined as D, E, R, K, and H. 
b Hydrophobic residues are defined as F, I, L, M, V, W, and P. 
Table 2.2 Comparison of streptomonomicin to known lasso peptides. Representative lasso peptides reported in the 
literature are shown. Amino acids corresponding to the ring are depicted in red, and steric-locking residues of class II 
peptides, where known, are highlighted blue. Of special interest are caulonodin V and BI-32169; the remaining lasso 
peptides are grouped by structural category. STM exhibits a high degree of hydrophobicity relative to other lasso 
peptides and has similar amino acid content to BI-32169 and caulonodin V. 
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2.5 Biosynthetic gene cluster for streptomonomicin 
Lasso peptides belong to a class of ribosomally synthesized and post-translationally 
modified peptides (RiPPs) whose biosynthetic enzymes and precursor peptides are readily 
identified through bioinformatic analysis.14 The biosynthesis of highly-ordered lasso topologies 
like that of STM is a compelling topic of study because of the general inaccessibility of such 
structures by chemical peptide synthesis. In the interest of characterizing STM’s biosynthetic 
origin and shedding light on the biosynthetic potential of the genus Streptomonospora, we 
performed whole-genome sequencing of S. alba YIM 90003. This revealed a gene cluster (stm) 
containing biosynthetic genes (stmABCDE) homologous to those known to be involved in lasso 
peptide biosynthesis (Figure 2.5 and Table 2.3). Of the characterized lasso peptide gene clusters, 
stmABCDE most resemble larABCDE, the genes in Rhodococcus jostii K01-B0171 responsible 
for production of lariatin;25 however, we have annotated the STM gene cluster in agreement with 
the community consensus.14 The gene stmA encodes the 41-residue precursor peptide (StmA) 
comprised of a 20-amino acid N-terminal leader sequence and the 21-member C-terminal core 
peptide that is subsequently modified to give the mature natural product. StmB is a 
transglutaminase homolog; its homologs in lasso peptide genes clusters are believed to function as 
ATP-dependent cysteine proteases implicated in leader peptidolysis. StmC is homologous to 
asparagine synthase B and putatively catalyzes macrolactam formation via adenylation of the Asp9 
side chain, activating it towards nucleophilic attack by the N-terminus of the core peptide. StmD 
is an ATP-binding cassette (ABC) transporter likely involved in exporting the mature STM 
product. Last, StmE is homologous to a protein of unknown, but essential, function that is present 
in the lariatin biosynthetic cluster but not in the clusters for capistruin or microcin J25.17,25 In 
addition to the requisite biosynthetic machinery, the stm cluster includes a number of other genes 
stmF–M (Figure 2.5 and Table 2.3). Although these genes have not previously been reported, they 
are conserved across a series of additional predicted lasso peptide gene clusters (Figure 2.6 and 
Tables 2.4 and 2.5).  
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Figure 2.5 Biosynthetic gene cluster for streptomonomicin. Streptomonomicin’s gene cluster architecture closely 
resembles that of lariatin. The stm operon containing the biosynthetic gene cluster for STM (stmABCDE) is shown 
above the characterized larABCDE gene cluster responsible for lariatin production in Rhodococcus jostii. Several 
genes, stmF-M, are present in the operon but have not been predicted to be required for biosynthesis. Predicted 
function/homology is indicated in Table 2.3. 
CDS Size (aa) 
Lar Homolog  
(identity, %/ 
aa length coverage) 
Proposed Function (Pfam) 
StmA 41 LarA (34/35) Precursor peptide 
StmC 628 LarB (25/538) Lasso peptide cyclase (PF00733) 
StmE 87 LarC (28/83) Unknown (PF05402) 
StmB 143 LarD (35/107) Lasso peptide protease (PF13471) 
StmD 628 LarE (34/590) ABC transporter (export; PF00005, PF00664) 
StmF 248 - ABC-type multidrug transport system (PF00005) 
StmG 224 - ABC-2 family transporter (PF12730) 
StmH 250 - ABC-2 family transporter (PF12730) 
StmI 190 - Hypothetical, no identifiable homologs  
StmJ 253 - Hypothetical, no identifiable homologs  
StmK 204 - Hypothetical, no identifiable homologs  
StmL 209 - Response regulator (PF00072, PF00196) 
StmM 418 - Signal transduction histidine kinase (PF07730, PF02518) 
Table 2.3 Proteins in streptomonomicin BGC. Proteins are depicted along with identified biosynthetic roles based 
on homology to characterized enzymes in the lariatin biosynthetic cluster. For proteins without LarABCDE homologs, 
proposed functions are given based on homologous gene families; Pfam domains are given in parentheses. 
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Figure 2.6 Gene clusters with similar neighbor genes to the streptomonomicin biosynthetic gene cluster. Gene 
clusters for lasso peptide biosynthesis in Rhodococcus jostii K01-B0171 (lariatin), S. alba (STM), and four previously 
unidentified producers. An alignment of the predicted precursor peptides is shown. StmIJK (main text) have no 
identifiable homologs and are not included in the analyses. The complete genome for the lariatin producer has not 
been reported and so the sequence is not available beyond the gene cluster, as represented by hash marks.  
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Gene 
Accession number 
N. halophila P. acidifaciens X. cellulosilytica S. salivarius R. jostii 
A WP_017539740.1 WP_021796478 WP_012876875 WP_014634056 BAL72546 
C WP_017539741 WP_021796471 WP_012876876 WP_014634057 BAL72547 
E WP_017539742 WP_021796473 WP_012876877 WP_014634058 BAL72548 
B WP_017539743.1 WP_021796481 WP_012876878 FR873482 (531899 - 532315) BAL72549 
D ANAD01000138  (14450 - 16375) WP_021796460 WP_012876879 WP_014634062 BAL72550 
F WP_017539745 WP_021796470 WP_012876882 WP_014634059 - 
G WP_017539746 WP_021796459 WP_012876883 WP_014634060.1 - 
H WP_017539747 - WP_012876884 - - 
L WP_017539744 WP_021796462 WP_012876880 WP_014634055 - 
M WP_017539739 WP_021796467 WP_012876881 WP_014634055 - 
Table 2.4 Accession numbers for biosynthetic gene clusters of streptomonomicin homologs. Accession numbers 
of genes A–M in bioinformatically identified homologous gene clusters of potential lasso peptide producers N. 
halophila, P. acidifaciens, X. cellulosilytica, and S. salivarius. Accession numbers for genes in the lariatin gene cluster 
from R. jostii are also shown. Clusters were identified via BLAST searching. 
G
en
e 
Le
ng
th
 
(a
a)
 
 
Functional 
annotation (Pfam) 
% Identity / % Similarity (length coverage, aa) 
N. halophila 
P. 
acidifaciens 
X. cellulo-
silytica S. salivarius R. jostii 
A 41 Precursor peptide 54/58 (41) 49/59 (37) 
 
63/72 (40) 
 
43/70 (37) 34/51 (35) 
C 628 Lasso peptide cyclase 
(PF00733) 
43/55 (616) 33/49 (587) 49/62 (581) 28/47 (534) 25/43 (538) 
E 87 Unknown 
(PF05402) 
24/53 (84) 45/56 (80) 43/64 (81) 25/54 (85) 28/50 (83) 
B 143 Lasso peptide 
protease (PF13471) 
46/58 (140) 48/55 (106) 48/61 (141) 35/51 (143) 35/50 (107) 
D 628 ABC transporter 
(PF00005, PF00664) 
50/68 (505) 44/62 (592) 51/66 (594) 34/57 (593) 34/52 (590) 
F 248 ABC-type multidrug 
transport system 
(PF00005) 
73/81 (237) 54/67 (230) 62/77 (231) 45/60 (227) - 
G 224 ABC-2 family 
transporter (PF12730) 
46/61 (224) 24/45 (193) 44/62 (228) 0/0 - 
H 250 ABC-2 family 
transporter (PF12730) 
43/60 (244) - 45/57 (210) - - 
L 209 Response regulator 
(PF00072, PF00196) 
34/49 (165) 37/50 (211) 40/53 (209) 26/46 (106) - 
M 418 Signal transduction 
Histidine kinase 
(PF07730, PF02518) 
30/50 (212) 31/43 (251) 27/40 (187) 0/0 - 
Table 2.5 Gene similarities for streptomonomicin homolog biosynthetic gene clusters. Gene identities for S. alba 
are given, along with identified protein domains and similarity to homologous genes in potential lasso peptide 
producers and the producer of lariatin (R. jostii). StmABCDE encode proteins homologous to those in known lasso 
peptide biosynthetic gene clusters. Identity/similarity between genes was determined by BLASTP. Domains were 
identified by a search of the Pfam database (http://pfam.xfam.org/). aa, amino acids. 
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2.6 Analysis of biosynthetic gene clusters within the S. alba genome 
Streptomonospora resides in the Streptosporangiales, a suborder of the Actinobacteria; 
these organisms, based on a survey of 14 known genomes, harbor on average about 15 biosynthetic 
gene clusters, although some contain zero.3 Using the bioinformatics-based prediction algorithm 
antiSMASH,26,27 we analyzed the genome of S. alba to evaluate its biosynthetic repertoire. This 
revealed the presence of at least eleven other putative biosynthetic gene clusters, including those 
containing terpenoid, type I and III polyketide synthase (PKS), non-ribosomal peptide synthase 
(NRPS), lanthipeptide, and thiopeptide machinery (Table 2.6). As the biosynthetic capability of 
an organism has been closely linked to phylogeny,3 this result suggests by extension that the genus 
Streptomonospora harbors the ability to produce a diverse array of secondary metabolites.  
# Predicted 
natural 
product  
Contig, locus tags of biosynthetic genes 
1 Ectoine  contig_3 (22680 – 33090), LP52_00895 (L-ectoine syntase), LP52_00900 (diaminobutyrate--2-oxoglutarate aminotransferase). 
2 Thiopeptide-
lanthipeptide 
contig_5 (93232 – 120866), LP52_02740 (Lantibiotic dehydratase domain protein), LP52_02725 (YcaO), LP52_02715 (Lantibiotic dehydratase 
domain), LP52_02690 (aminotransferase class-III), LP52_02685 (dehydrogenase) 
3 Terpene-
lanthipeptide 
contig_8 (1 – 27813), LP52_04780 (lycopene cyclase), LP52_04785 (methyltransferase), LP52_04800 (phytoene synthase), LP52_04805 
(phytoene dehydrogenase), LP52_04815 (serine/threonine protein kinase), LP52_04820 (Lanthionine-containing peptide SapB) 
4 Type III PKS contig_10 (50780 - 91838), LP52_06435 (flavin reductase domain protein FMN-binding) , LP52_06440 (acyl-CoA dehydrogenase type 2), 
LP52_06445 (alpha/beta hydrolase fold protein), LP52_06475 (methionyl-tRNA formyltransferase), LP52_06495 (methionine 
aminopeptidase),LP52_06500 (FAD dependent oxidoreductase), LP52_06505 (monooxygenase FAD-binding), LP52_06515 (chalcone and 
stilbene synthase domain protein), LP52_06550 (sugar-binding lipoprotein), LP52_06580 (cytochrome P450) 
5 NRPS contig_10 (183766 - 222606), LP52_07005 (Dioxygenase TauD/TfdA), LP52_07010 (AMP-dependent synthetase and ligase), LP52_07030 
(condensation domain-containing protein), LP52_07050 (alkyl hydroperoxide reductase subunit), LP52_07055 (short-chain 
dehydrogenase/reductase SDR) 
6 Type I PKS contig_14 (77281 - 120289), LP25_08665 (NAD-dependent epimerase/dehydratase), LP25_08680 (cytochrome P450), LP25_08740 (acyl-CoA 
dehydrogenase), LP25_08745 (phosphopantetheine-binding domain-containing protein), LP25_08750 (Beta-ketoacyl synthase), LP25_08760 (3-
oxoacyl-ACP synthase), LP25_08765 (FkbH like protein), LP25_08785 (thioesterase), LP25_08790 (cytochrome P450), LP25_08820 (mandelate 
racemase/muconate lactonizing enzyme) 
7 Type I PKS contig_19 (37487 - 72424), LP25_11195 (glycosyltransferase, MGT family), LP25_11200 (oxidoreductase), LP25_11210 (Beta-ketoacyl 
synthase), LP25_11215 (Beta-ketoacyl synthase), LP25_11220 (Beta-ketoacyl synthase) 
8 Thiopeptide contig_29 (115995 - 171782), LP52_15490 (NADH:flavin oxidoreductase/NADH oxidase), LP52_15495 (3-hydroxyisobutyrate dehydrogenase), 
LP52_15500 (crotonyl-CoA reductase / alcohol dehydrogenase), LP52_15515(crotonyl-CoA reductase / alcohol dehydrogenase), LP52_15520 
(crotonyl-CoA reductase / alcohol dehydrogenase), LP52_15550 (short-chain dehydrogenase/reductase SDR), LP52_15605 (monooxygenase 
FAD-binding), LP52_15610 (methyltransferase ), 136547 - 139579 (Beta-ketoacyl synthase), 141598 - 142917 (cytochrome P450), LP52_15635 
(precursor peptide), LP52_15640 (Lantibiotic dehydratase domain protein), 147222 - 148223 (Lantibiotic dehydratase domain protein), 152787 - 
154802 (YcaO-containing protein), LP52_15675 (acyl-CoA dehydrogenase) 
9 NRPS contig_47 (34532 - 64100), LP52_22745 (mbtH-like protein), LP52_22755 (putative siderophore biosynthesis protein), LP52_22765 (putative 
siderophore biosynthesis protein), LP52_22770 (phosphopantetheine-binding domain-containing protein) 
10 Terpene contig_53 (22573 – 35325), LP52_23810 (Terpene synthase/cyclase metal-binding domain protein) 
11 NRPS contig_ 72 (1-7918) condensation domain-containing protein 
Table 2.6 Bioinformatic prediction of additional biosynthetic gene clusters from S. alba YIM 900003. 
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2.7 Streptomonomicin bioactivity and resistance 
STM’s antibiotic activity was tested against a panel of Gram-positives, Gram-negatives, 
and fungal species via a microbroth dilution assay (Table 2.7). Although STM was inactive against 
fungi and Gram-negatives, it was active against several Gram-positives. STM most potently 
inhibited the growth of Bacillus anthracis, the causative agent of anthrax, with minimum inhibitory 
concentrations (MICs) of 2–4 µM. MICs against other members of the Bacillus genus ranged from 
4–7 µM with the exception of B. subtilis (29 µM). Weak activity was seen against other Firmicutes, 
including Listeria monocytogenes, Enterococcus faecalis, and Staphylococcus aureus. A time-
course growth curve of B. anthracis str. Sterne challenged mid-exponential phase with STM 
showed an immediate cessation of growth upon addition of the compound (Figure 2.7a). 
Additionally, the minimum bactericidal concentration (MBC) was determined to be 24 µM. 
To gain preliminary insight into the mechanism of action by means of investigating 
bacterial resistance to STM, we selected STM-resistant mutants in B. anthracis. Whole-genome 
sequencing revealed that all resistant strains harbored point mutations in walR, including five 
instances of mutations in the coding region and one mutation in the upstream region of the gene 
(Figure 2.8a). WalR, a response regulator, forms a two-component regulatory system (TCS) with 
the histidine kinase WalK that in characterized cases, such as B. subtilis, S. aureus, Streptococcus 
pneumoniae, and Streptococcus mutans, controls genes related to cell wall metabolism and cell 
division.28,29 In the WalK/WalR TCS, formerly known as YycG/YycF,30 the membrane-associated 
WalK is involved in extracellular signal sensing and subsequent His autophosphorylation. This 
phosphoryl group is then transferred to a conserved aspartate (Asp54) in WalR, a cytosolic 
response regulator composed of an N-terminal receiver domain (containing Asp54) and a C-
terminal DNA-binding ‘effector’ domain. Transcription is activated by the dimeric binding of the 
activated response regulator to specific repeated DNA sequences and to RNA polymerase.29 The 
WalK/WalR TCS is highly conserved in Firmicutes and been shown to be the only widely-
distributed TCS essential for cell viability.29,31 Although no formal demonstration of essentiality 
has been reported for B. anthracis, it is generally thought that WalK/WalR is essential in 
Firmicutes.29 
Three of the substitutions (V176P, H215P, P216S) in our STM-resistant strains are on the 
C-terminal DNA-binding domain of WalR, whereas two substitutions (D84Y, D88N) are on the 
N-terminal receiver domain (Figure 2.9a). Homology modeling with MtrA (PDB 2GWR; 50% 
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identity to WalR) allowed visualization of the point mutation locations.32,33 In the receiver domain, 
Asp84 and Asp88 are located on the same surface in spatial proximity to the active site, Asp54, 
but distant enough that the mutants would be expected to remain somewhat functional (ca. 14 and 
10 Å, respectively) (Figure 2.9b). In the effector domain, which adopts a winged helix-turn-helix 
DNA-binding motif, two of the mutated residues (His215, Pro216) are found in the α3-β5 loop 
immediately following the α2/α3 helix-turn-helix motif (Figure 2.9b); this loop (especially 
Ser214–Pro216) has been previously implicated in DNA binding.34 The other mutated residue 
(Val176) is found immediately preceding the helix-turn-helix (Figure 2.9b).  
WalR substitutions have previously been shown to correlate to growth defects or 
perturbation in protein function. WalR bearing a H215A or H215P substitution exhibits 
significantly attenuated DNA-binding, and B. subtilis with WalR-H215P are 
thermosensitive.31,34,35 Amino acid changes in the helix-loop-helix region of WalR often display 
phenotypes consistent with the alteration of cell wall metabolism, including intermediate 
vancomycin resistance and cell wall thickening.36,37 STM-resistant B. anthracis mutants displayed 
obvious phenotypic defects, including visible clumping of cells in liquid culture and recalcitrance 
to pelleting by centrifugation. Differential interference contrast (DIC) microscopy revealed that 
STM-resistant strains displayed extremely long chain lengths, indicative of a septal cleavage defect 
(Figures 2.7b, 2.7c, and 2.8b). This chaining phenotype in Bacillus sp. is well known from deletion 
studies of particular autolysins (peptidoglycan hydrolases), such as LytE (formerly CwlF), LytF, 
CwlS, and BslO.38-41 In addition to cell separation, LytE, in collaboration with the CwlO autolysin, 
has been implicated in cell elongation.42  
Intriguingly, the WalK/WalR TCS in B. subtilis is known to control the expression of the 
autolysin lytE29,43,44 and in B. anthracis the predicted regulon includes also the cell division ABC 
transporter ftsE;28 this suggests a likely mechanism for the chaining phenotype displayed by the 
STM-resistant strains. To confirm if the WalK/WalR TCS in B. anthracis controls the expression 
of these genes, we compared the expression levels between wild-type and STM-resistant B. 
anthracis strains by qRT-PCR. These experiments confirmed that, relative to wild-type, the STM-
resistant strains downregulated both ftsE and lytE (Table 2.8). A similar analysis of STM-treated 
wild type B. anthracis showed an upregulation of liaI and liaH, genes that are induced as part of 
the cell wall stress regulon (Table 2.8).45,46 These combined data are consistent with STM directly 
or indirectly inducing cell wall stress and with resistance arising by a strategic, but costly, 
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perturbation in cell wall metabolism. Excitingly, this potential mechanism stands in contrast to the 
antimicrobial activities of the lasso peptides for which the mechanism of action has been 
characterized, which target RNA polymerase (capistruin and microcin J25) or the ATP-dependent 
ClpC1 protease (lassomycin).16,47,48 However, as our evidence primarily relates to the resistant 
mechanism rather than a biological target, further biochemical characterization will be required to 
ascribe a precise mechanism of action to STM. 
 
Phylum Strain MIC (µM) 
Firmicutes 
Bacillus anthracis str. Sterne ∆LF 2 
Bacillus anthracis str. Sterne 4 
Bacillus halodurans 4 
Bacillus cereus ATCC 4342 4 
Bacillus cereus ATCC 13472 7 
Bacillus sp. Al Hakam 7 
Bacillus subtilis  29 
Listeria monocytogenes 14 
Enterococcus faecalis  29 
Staphylococcus aureus  57 
Actinobacteria Mycobacterium smegmatis >57 
Proteobacteria Escherichia coli  >57 Pseudomonas putida  >57 
Ascomycota 
Saccharomyces cerevisiae >57 
Talaromyces stipitatus >57 
Aspergillus niger >57 
Trichoderma longibrachiatum >57 
Table 2.7 Spectrum of antimicrobial activity for streptomonomicin.  
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Figure 2.7 Bioactivity of streptomonomicin. (a) Growth curve (595 nm absorbance) depicting effect of addition of 
STM to wild-type B. anthracis str. Sterne ΔLF. Cultures were grown at 37 °C to mid-exponential phase (OD600 = 0.4) 
before the addition of 1×, 2×, or 4×MIC of STM. (b) Wild-type B. anthracis forms chains of usually fewer than 8 cells 
under standard culturing conditions, as evidenced by DIC microscopy. (c) A representative DIC image of one STM-
resistant mutant (WalR-H215P) shows the resistant strains display an exaggerated chaining phenotype. Scale bars, 10 
μm. 
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Consequence Location of mutations Locus Tag 
WalR D88N 5207381 (C->T),  
 
BAS5319 
Upstream region  
of WalR (-89, -95) 
5207731 (G->A),  
5207737 (G->A),  
 
upstream of BAS5319 
WalR V176F 
 
5207117 (C->A),  
 
BAS5319 
WalR  H215P 
 
5206999 (T->G),  
 
BAS5319 
WalR P216S 
 
5206997 (G->A),  
 
BAS5319 
WalR D84Y 5207393 (C->A),  
 
BAS5319 
 
 
 
Figure 2.8 Comparison of walR mutants in streptomonomicin-resistant bacteria. (a) STM-resistant mutants. The 
nature of the mutations are shown. Five mutations result in amino acid substitutions in the WalR protein, whereas one 
mutation is a double nucleotide substitution upstream of the translational start site. (b) Differential interference 
contrast (DIC) microscopy images of the remaining STM-resistant B. anthracis strains show that all of the mutants 
exhibit the same chaining phenotype as WalR-H215P. Scale bars, 10 µm.  
  
A 
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Figure 2.9 Comparison of walR mutants in streptomonomicin-resistant bacteria (a) Alignment of the WalR 
protein sequence between wild type (top) and 6 STM-resistant mutants of B. anthracis. The sites of the DNA-binding 
and receiver domains are labeled.  (b) Sites of mutations depicted on a homology model of B. anthracis WalR. 
Mutation sites are labeled in red and the active site Asp54 is labeled in green. The model was predicted using the 
SWISS-MODEL workspace (http://swissmodel.expasy.org/), using the DNA-binding response regulator MtrA (PDB 
ID 2GWR; 50% identity with WalR) as a template. 
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Gene  Fold change (range) 
 
(1) Addition of STM 
 
(2) walR mutant (upstream) 
 
 
(3) walR mutant (H215P) 
liaI 46.3 (43.7 .. 49.1) -1.3 (-1.1 .. -1.3) -1.1 ( -0.8 .. -1.4) 
liaH 22.6 (21.1 .. 24.2) -1.1 (-0.9 .. -1.3) 1.9 (1.7 .. 2.0) 
lytE -2 (-1.9 .. -2.2) -10.1(-8.6 .. -11.7) -4.2 (-3.9 .. -4.5) 
ftsE -2 (-1.9 .. -2.1) -3.8 (-3.3 .. -4.4) -1.5 (-1.45 .. -1.52) 
Table 2.8 qRT-PCR data. The liaI and liaH genes are involved in the cell wall stress response and are induced by 
antibiotics that act on the cell wall or membrane. Genes lytE and ftsE have been predicted to be members of the 
WalK/WalR regulon based on reported protein-DNA binding and/or in analogy to the same regulon in B. subtilis. FtsE 
is a cell division ABC transporter and LytE is a vegetative peptidoglycan hydrolase (autolysin). Nucleotide primers 
used in qRT-PCR experiments are listed in the Supplemental Experimental Procedures (below). (Column 1) 
Comparison of gene expression between STM-treated and non-treated Bacillus anthracis. The results are consistent 
with STM-induced cell wall stress. (Columns 2, 3) Comparison of gene expression between two STM-resistant 
mutants in B. anthracis and the parental B. anthracis strain from which the resistant mutants were selected. The results 
indicate that the resistant mutants display a modest downregulation of cell wall metabolism genes predicted to be in 
the WalK/WalR regulon. 
 
2.8 Conclusions 
The discovery of streptomonomicin (STM) illustrates that understudied lab-cultivable 
bacteria (here, Streptomonospora alba) remain sources of readily-discoverable natural products. 
The long cultivation times required for the Streptomonospora, compared to most commonly-
screened antibiotic producers, has limited their exploration. Here, we report the first genome 
sequence of any Streptomonospora (S. alba) revealing a diversity of biosynthetic gene clusters and 
setting the stage for genome-guided discovery within this genus. STM itself is significant in several 
regards. First, it represents the first reported natural product from Streptomonospora. Second, STM 
adopts a threaded lasso peptide structure with an unprecedented isopeptide linkage between Ser-
Asp. Third, STM is among the most hydrophobic of the lasso peptides and more hydrophobic than 
any previously reported class II lasso peptide; hydrophobicity is linked to in vivo bioavailability 
and cell permeability, and STM thus represents a potentially useful expansion of lasso peptide 
chemical space. Fourth, STM exhibits antibiotic activity against several Gram-positive organisms, 
most notably Bacillus anthracis, the causative agent of anthrax. Last, spontaneous resistant 
mutants to STM exhibit visible growth defects by mutations to walR, a gene encoding a response 
regulator in a broadly-distributed two-component signal transduction system involved in cell wall 
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metabolism which has been shown to be essential in several Gram-positive bacteria. Our data, 
including this resistance phenotype, microscopy, and RT-PCR of STM-treated cells, are consistent 
with STM inducing cell envelope stress, potentially indicating a biological activity different from 
the activities reported for all other lasso peptides. 
2.9 Experimental 
2.9.1 Bacterial strains and growth conditions 
Streptomonospora alba YIM 90003 was obtained from the USDA Agricultural Research 
Service (ARS) Culture Collection and grown on ISP medium no. 5 (1 L contains 1 g L-asparagine, 
1 g K2HPO4, 20 g agar, 10 g glycerol, 1 mg FeSO4·7H2O, 1 mg ZnSO4·7H2O, 1 mg MnCl2·7H2O) 
with 10% (w/v) NaCl at 30 °C. Bacillus anthracis strain Sterne ∆LF, Bacillus anthracis strain 
Sterne, Bacillus halodurans, Bacillus cereus ATCC 4342, Bacillus cereus ATCC 13472, Bacillus 
sp. Al Hakam, Bacillus subtilis strain 168, Escherichia coli DH5α, Pseudomonas putida KT2440 
were grown in Luria-Bertani (LB) medium (1 L contains 10 g NaCl, 5 g yeast extract, 10 g 
tryptone) at 37 °C. Listeria monocytogenes strain 4b F2365, Enterococcus faecalis U503 
(vancomycin-resistant), Staphylococcus aureus USA300 (methicillin-resistant) were grown in 
brain-heart infusion (BHI) medium at 37 °C. Mycobacterium smegmatis was grown in ATCC 
medium no. 172 (1 L contains 10 g glucose, 5 g yeast extract, 5 g N-Z Amine Type A, 20 g soluble 
starch, 1 g CaCO3) at 30 °C. Saccharomyces cerevisiae, Talaromyces stipitatus, Aspergillus niger 
and Trichoderma longibrachiatum were grown in yeast extract-peptone-dextrose (YPD) medium 
(1 L contains 10 g yeast extract, 20 g peptone, 20 g glucose) at 30 °C.  
2.9.2 Evaluation of bioactivity 
The broth microdilution assay for determination of minimum inhibitory concentration 
(MIC) was used for evaluation of STM activity. Bacterial strains were grown in 10 mL of their 
corresponding media at 37 °C to stationary phase. The cultures were adjusted to an OD600 of 0.01 
in fresh media. STM was serially diluted 2-fold in a 96-well microplate and an equal volume of 
prepared bacterial culture was added to each well (final concentration of STM in wells ranged 
from 0.5–128 µg/ml [0.2–57 µM]; final volume, 100 µL/well). Plates were covered and incubated 
at 37 °C with shaking. The MIC reported is the concentration of STM that resulted in no visible 
growth after 18 h. 
Fungal strains S. cerevisiae, T. stipitatus, A. niger, and T. longibrachiatum were grown in 
YPD media for 48 h at 30 °C. Cultures were diluted 1:100 into fresh media. STM was serially 
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diluted 2-fold in 96-well microplates, and an equal volume of fungal culture was added to each 
well (final concentration of STM in wells ranged from 0.5–128 µg/mL, 0.2–57 µM). Plates were 
covered and incubated at 30 °C with shaking. The MIC reported is the concentration of STM that 
resulted in no visible growth after 36 h. 
2.9.3 Mass spectrometry 
MALDI-TOF MS analysis. Mass spectra were obtained using a Bruker Daltonics 
UltrafleXtreme MALDI TOF/TOF mass spectrometer in positive reflector mode. The instrument 
was calibrated using a peptide calibration kit (AnaSpec – Peptide Mass Standard Kit). Samples 
(0.5 µL) were spotted on a steel plate with 3 µL of α-cyano-4-hydroxycinnamic acid (CHCA) 
matrix solution (sat., 1:1 MeCN/H2O containing 0.1% trifluoroacetic acid [TFA]) and air-dried at 
rt. Data were analyzed using flexAnalysis 3.3 (Bruker). 
FT-MS/MS analysis. STM was dissolved in 80% aq. MeCN containing 1% (v/v) formic 
acid (FA). Using an Advion Nanomate 100, STM was directly infused into a Thermo Scientific 
LTQ-FT hybrid linear ion trap operating at 11 T (calibrated weekly). The FT-MS was operated 
using the following parameters: minimum target signal counts, 5,000; resolution, 100,000; m/z 
range detected, dependent on target m/z; isolation width (MS/MS), 5 m/z; normalized collision 
energy (MS/MS), 35; activation q value (MS/MS), 0.4; activation time (MS/MS), 30 ms. Data 
were analyzed using the Qualbrowser application of Xcalibur (Thermo Scientific). 
2.9.4 Screening of cell extract 
S. alba was grown on ISP medium no. 5 containing 10% (w/v) NaCl for 21 d at 30 °C. 
Exported metabolites were extracted from cells using 70% aq. MeOH at rt for 1 h. The intact cells 
were removed by centrifugation (4000 × g, 10 min), and the extract was analyzed by MALDI-TOF 
MS. 
2.9.5 Purification of streptomonomicin 
S. alba was grown on agar plates of ISP medium no. 5 containing 10% NaCl for 30 d at 30 
°C (90 plates × 15 cm diameter; 5 L in total, performed in 5 portions). Plates were air-dried for 2 
d, and exported metabolites were extracted with MeOH (2 L) for 12 h. The extract was centrifuged 
(4000 × g, 10 min), filtered, and dried by rotary evaporation. The dried material was dissolved in 
25% aq. MeOH (500 mL), filtered, loaded onto a Waters Sep-Pak C18 cartridge (125 Å pore size; 
2 g sorbent; 55–106 µm particle size), and washed with 20% aq. MeCN (ca. 100 mL) containing 
0.1% (v/v) TFA. The STM-containing fraction was eluted with 60% aq. MeCN containing 0.1% 
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(v/v) TFA (20 mL). Subsequent purification employed an Agilent 1200 HPLC system outfitted 
with a Thermo Scientific Betasil C18 column (100 Å; 250 × 10 mm; 5 µm particle size) operating 
at 4.0 mL/min. The column was equilibrated with 5% aq. MeCN containing 0.1% (v/v) FA and 
purified via a linear gradient of 5–60% aq. MeCN containing 0.1% (v/v) FA over 40 min. 
Absorbance was monitored at 220 nm. The STM-containing fraction was dried using a vacuum 
concentrator to afford a slightly yellow solid (yields ranged from 10–14 mg/L of media, 0.6–0.8 
mg/plate). 
2.9.6 Protease treatment 
100 µg of purified STM was treated with 0.5 U carboxypeptidase Y (from baker’s yeast; 
Sigma-Aldrich) in a buffer containing 50 mM MES and 1 mM CaCl2 at pH 6.7 for 6 h at 25 °C. 
The reaction mixture was then purified with an Agilent 1200 HPLC system outfitted with an 
Agilent G1956B single quadrupole mass analyzer and a Thermo Scientific Biobasic C18 column 
(300 Å, 250 × 4.6 mm, 5 µM particle size) operating at a flow rate of 1.0 mL/min and separated 
with a linear gradient of 5–60% aq. MeCN containing 0.1% (v/v) FA over 40 min. Absorbance 
was monitored at 220 nm. Fractions were collected manually and analyzed by MALDI-TOF MS. 
The fraction containing a mass ion of m/z 1057.1 ([M+Na]+) was dried, dissolved in 100 µl of 
buffer solution (50 mM Tris-HCl pH 8, 100 mM NaCl), and digested by thermolysin (from 
Bacillus thermoproteolyticus rokko; Sigma-Aldrich) (1 U) for 1 h at 37 °C.  The products of the 
reaction were separated by HPLC using a Biobasic C18 column (300 Å, 250 × 4.6 mm, 5 µM 
particle size) (Thermo Scientific) operating at a flow rate of 1.0 ml/min with a linear gradient of 
5–60% aq. MeCN containing 0.1% (v/v) FA over 40 min. Fractions were collected manually, 
screened by MALDI-TOF MS, concentrated, and analyzed by FT-MS/MS.  
2.9.7 NMR spectroscopy 
Samples were prepared by dissolving ca. 4 mg of STM (HPLC-purified and lyophilized) 
in 500 µL of either methanol-d4 (CD3OD; 99.96 atom % D; Sigma-Aldrich) or methanol-
d3 (CD3OH; 99.8 atom % D; Sigma-Aldrich). NMR spectra were recorded on an Agilent VNMRS 
750 MHz narrow bore magnet spectrometer equipped with a 5 mm triple resonance (1H-13C-15N) 
triaxial gradient probe and pulse-shaping capabilities. Samples were held at 25 °C during 
acquisition. Standard Varian pulse sequences were used for each of the following 
experiments: 1H, 1H-1H DQF-COSY, 1H-1H TOCSY (80 ms mixing time), 1H-13C HSQCAD, 1H-
13C HMBCAD, and 1H-1H NOESY (400 ms mixing time). Solvent suppression by presaturation 
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(PRESAT) was employed when CD3OH was used as the solvent. Spectra were recorded with 
VNMRJ 3.2A software and data was processed using MestReNova 8.1.1, nmrPipe,49 and Sparky.50 
Resonances were referenced internally to the solvent peak (3.30 ppm, methanol). 
2.9.8 Structure calculations 
STM’s solution structure was calculated by simulated annealing using distance and angle 
restraints within XPLOR-NIH v 2.36.51,52 Standard XPLOR-NIH potentials for bond angles, 
improper angles, van der Waals, and favored/allowed Ramachandran regions were used. The Ser1-
Asp9 isopeptide linkage was generated using a manual patch of the “protein-1.0.top” XPLOR-
NIH file (Figure 2.10). Distance restraints were derived from peak area integrations in the NOESY 
data sets, which were binned into specific distance categories (2.5, 3.5, 5.0, and 6.0 Å). nmrPipe 
was used for processing of raw NOESY data and conversion from Varian to UCSF format 
(Sparky), and Sparky was used for peak picking, volume integration, and creation of the XPLOR 
distance restraint table.  Peptide backbone dihedral restraints were derived from coupling constants 
determined from DQF-COSY. Three hundred structures were calculated, of which the 15 
structures of lowest energy were chosen for structural analysis. The quality of the NMR structures 
was evaluated using PROCHECK-NMR.53,54  
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presidue ISON               ! isopeptide linkage - mod of ISOP - N terminal 
                            !  2014/09/09   + is N-term    - is ASP 
  group 
   modify   atom -CG   charge = 0.480  end 
   modify   atom -OD1 type=O  charge = -0.480  end 
   delete   atom -OD2       end 
  group 
   delete   atom +HT3       end 
   delete   atom +HT2       end 
   delete   atom +HT1    charge = 0.260  end 
   add    atom +HN  type=H  charge = 0.260  end 
   modify   atom +N  type=NH1 charge = -0.360  end 
 
  add bond -CG +N 
  add bond +N +HN 
  add angle -CB -CG +N 
  add angle -OD1 -CG +N 
  add angle -CG +N +CA 
  add angle -CG +N +HN 
   
      ADD DIHEdral  -CB   -CG     +N   +HN 
      ADD DIHEdral  -CB   -CG     +N   +CA 
      ADD DIHEdral  -OD1  -CG     +N   +HN  ! double dihedral 
      ADD DIHEdral  -OD1  -CG     +N   +HN  ! double dihedral 
      ADD DIHEdral  -OD1  -CG     +N   +CA 
 
  add improper -OD1 -CG +N +CA 
  add improper -CB  -CG +N +CA 
end 
Figure 2.10 Isopeptide patch file for three-dimensional structural calculations of STM. Included below is the 
patch file amendment used in structural calculations. The above code was added to the “protein-1.0.top” file in 
XPLOR-NIH v. 2.36 immediately following the ISOP patch. The included ISON patch manually connects the N-
terminus to an Asp side chain carboxylate in an input PSF topology file. 
2.9.9 Generation of resistant mutants 
Six independent cultures (10 mL) of B. anthracis str. Sterne ∆LF were grown overnight in 
LB media at 37 °C. A portion (100 µL) of each culture was spread onto LB agar plates containing 
4, 7, or 14 µM STM. The plates containing 4 µM STM yielded resistant mutants after 24 h of 
incubation at 37 °C. No bacterial growth was detected at higher concentrations of STM after 48 h. 
The MIC of all six STM-resistant strains was 7 µM and was obtained as decribed above. 
2.9.10 Whole-genome sequencing 
Genomic DNA from S. alba YIM 90003 as well as wild-type and four STM-resistant 
mutants of B. anthracis str. Sterne ∆LF was isolated using an UltraClean Microbial DNA Isolation 
Kit (MO BIO). The shotgun genomic libraries were then prepared with an Illumina-Compatible 
KAPA DNA Library Preparation Kit (Kapa Biosystems). Paired-end sequencing with read length 
100 nt was conducted by the Roy J. Carver Biotechnology Center (Univ. Illinois, Urbana, IL, 
United States) using an Illumina HiSeq2500. The genome of S. alba YIM 90003 was assembled 
and mapped with CLC Assembly Cell software (CLC bio) and deposited in GenBank. Breseq 
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software was used for finding mutations in the genomes of wild-type and STM-resistant mutants, 
relative to a reference genome (AE017225 for chromosomal DNA and NC_007322 for pXO1 
plasmid).55 Nucleotide substitutions which were present in STM-resistant mutants but not in the 
wild-type strain, in comparison to the reference genome, were identified and verified with PCR 
amplification and Sanger sequencing. Nucleotide substitutions in two STM-resistant mutants 
whose genomes were not sequenced were identified by Sanger sequencing alone.  
2.9.11 Microscopy 
Stationary-phase cultures of B. anthracis str. Sterne ∆LF (wild-type and STM-resistant 
strains) were used to inoculate LB media (200 µL into 5 mL). Cultures were grown to an OD600 of 
0.5 before an aliquot (1 mL) was removed, harvested by centrifugation, and resuspended in 250 
µL phosphate-buffered saline (PBS). Due to the abnormal growth of the STM-resistant mutants, 
the wild-type culture was used to determine cell density. 10 µL aliquots of each resuspended 
culture were combined with 10 µL liquefied low gelling temperature agarose (10 µL, 2%) on a 
microscope slide. Cell morphology was analyzed by differential interference contrast (DIC) 
microscopy. DIC microscopy analyses were conducted using a Zeiss LSM 700 Confocal 
Microscope outfitted with a 405 nm laser. Linear contrast was applied when deconvoluting images 
in ZEN 2012 software (Carl Zeiss). 
2.9.12 Amino acid analysis 
Quantitative amino acid analysis. Quantitative amino acid analysis was performed by the 
Texas A&M University Protein Chemistry Lab (College Station, TX, United States). Analysis 
results are included in Figure S3A.  
Chiral amino acid analysis. Test acid hydrolysis was performed in the vapor phase at 150 
°C for 30 min in a CEM Discover 3000 microwave (CEM). The reactions were carried out in 6 M 
deuterium chloride (DCl) in D2O. To enhance separation, D- and L-amino acids were then 
derivatized with Marfey's reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) 
(Thermo-Fisher Scientific). For derivatization, the amino acids from the acid hydrosylates were 
dried and reconstituted in 25 µl of 0.5 M aq. NaHCO3. 20 µl of FDAA in MeCN (10 mg/ml) were 
added to these amino acids, and the labeling was allowed to proceed for 2 h at 40 °C. A standard 
mixture of the glycine and the L- and D- forms of the 19 common chiral amino acids was 
derivatized and used to compare retention times. The LC-MS/MS-MRM system used an Advance 
ultra-high performance LC (UPLC) module with a Bruker EVOQ triple quadrupole-MS (Bruker) 
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with a Kinetex Phenyl-Hexyl column (100 Å, 100 × 2.1 mm; 2.6 µm particle size) (Phenomenex) 
operating at 300 µl/min. A binary solvent system was used, with the following linear gradient: 0 
min (5% B), 3 min (5% B), 8 min (20% B), 19 min (40% B), 24 min (100% B), 26 min (100% B), 
30 min (5% B), with mobile phase returning to the initial conditions for equilibration for 2 min. 
Solvent A: 25 mM aq. NH4OAc, pH 7.0. Solvent B: MeCN. EVOQ MRM chromatograms were 
analyzed using Data Review (Bruker). Analysis results are included in Appendix B.1. 
2.9.13 Minimum bactericidal concentration (MBC) determination 
Two stationary phase cultures of B. anthracis str. Sterne were diluted to OD600 = 0.013 and 
treated with two-fold serial dilutions of STM in DMSO (concentrations ranged from 0.375 to 48 
µM; DMSO concentration 0.48% v/v). The positive control was vancomycin and the vehicle 
control was DMSO. After treatment for 12 h at 37 °C with shaking, cultures in which no visible 
cell growth was observed were plated onto LB agar and incubated overnight. The MBC was 
determined as the concentration at which no cells recovered after treatment with STM. 
2.9.14 Quantitative RT-PCR analysis 
B. anthracis str. Sterne ∆LF (wild-type and STM-resistant strains) was grown in LB 
medium at 37 °C to stationary phase, then diluted 100-fold and grown to mid-exponential phase 
(OD600 = 0.7). STM was then added to a wild-type culture to a final concentration of 2 µg/ml 
(0.5×MIC); the control wild-type culture and the STM-resistant cultures did not contain STM. 
After 30 min, 1 ml of each cell culture was harvested by centrifugation and resuspended in 0.5 ml 
of 20 mM Tris-HCl buffer (pH 8, 50 mM NaCl). Cells were lysed by the addition of 0.5 ml of 
phenol/chloroform/isoamyl alcohol (25:24:1); the aqueous phase after centrifugation (12000×g, 5 
min) was separated and mixed with 0.5 ml of chloroform/isoamyl alcohol (24:1) and again 
subjected to centrifugation (12000 × g, 5 min). RNA from the aqueous phase was purified using 
an RNeasy Mini Kit (QIAGEN) according to the manufacturer's protocol. RNA concentration was 
determined by measuring absorbance at 260 nm using a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific). For each reaction, 0.5 ug of total RNA was reverse-transcribed to 
cDNA using M-MuLV (Moloney Murine Leukemia Virus, NEB) reverse transcriptase and a 
random primer mix (NEB) according to the manufacturer's protocol. Reverse-transcribed cDNA 
was then diluted 100-fold and used as a template for RT-qPCR. RT-qPCR was performed on a 
LightCycler 480 Instrument II (Roche) using iTaq Universal SYBR Green Supermix (BioRad) 
according to the manufacturer’s protocol. Each reaction (10 µl) contained 5 µl of iTaq Universal 
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SYBR Green Supermix, 0.5 µl of diluted reverse-transcribed DNA, and 500 nM of each primer. 
Reactions for each sample were performed in triplicate with amplification cycle (95 °C, 10 s; 55 
°C, 10 s; 72 °C, 10 s). The primer pairs used are listed below in Table 2.9. The 16S rRNA level 
was used as an internal control for normalization of the level of expression of other genes. 
Gene Primer (5′-3′) Purpose 
walR GCTATTTACCGGGCAGTAAGACT Sanger sequencing  (forward primer) 
walR GAGTACAAATTTTAAATGAATAGATTGA Sanger sequencing  (reverse primer) 
16S rRNA CGGAATTATTGGGCGTAAAG TCTCCCAGTTTCCAATGACC qRT-PCR 
walR TTCACGGCAAACCTCTAAGC AATTGTAATGGCACACGATGG qRT-PCR 
ftsE ATCGGCAATTACGACTTTCG TCTTGAAGATCGTGCAGACG qRT-PCR 
lytE CTGGTGTCGGTTCTGGTTTT AAACAACGGTGGACAAGCTC qRT-PCR 
liaI GGAGCAGGAGTTGTGTACTGG GATGGACAAGCCGATTAAACC qRT-PCR 
liaH ATCAAAGCAAGCGCTTATCG TTCTAATCGAGTTACTTGCCCTTC qRT-PCR 
Table 2.9 Nucleotide primers used for STM-related characterization. The following sequences were used for 
qRT-PCR and/or for Sanger sequencing verification of mutants. 
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CHAPTER 3: BIOINFORMATIC INSIGHTS INTO THE HYGROLIDES 
This work has been previously published in part.* 
3.1 Introduction 
The plecomacrolide natural products feature 16- or 18-membered macrolactone rings 
(hygrolides and concanamycins, respectively) containing two conjugated diene units and a 
tetrahydropyran ring.1 The hygrolide subfamily (Figure 3.1a) contains nearly 50 known members, 
including the bafilomycins,2-8 hygrolidin,9,10 and hygrobafilomycin,11 among others, all of which 
are produced by Actinobacteria from the Streptomyces, Kitasatospora, Micromonospora, and 
Nocardia genera. Macrolide natural products such as the hygrolides arise from the linkage of acyl 
thioester monomers through decarboxylative Claisen condensations mediated by type I polyketide 
synthases (PKSs). Prototypical PKSs are large, multimodular enzymes consisting of several 
catalytic domains with specific functions that act in an assembly line-like fashion to select and 
successively reduce polyketide monomer units.12 The polyketide monomer sequence typically 
follows the domain sequence of the associated PKS, which enables homology-based in silico 
prediction of the polyketide structure as well as functional prediction based on biosynthetic 
precedence.13,14 Conversely, the structure of an isolated compound, coupled with polyketide 
biosynthetic logic, can be leveraged to identify the corresponding BGC.14,15 
A multitude of biological activities have been ascribed to hygrolide subfamily members, 
including antibacterial and antifungal,2 antiplasmodial,16 antiparasitic,17 insecticidal,3 
herbicidal,18,19 antiviral,20-23 anti-atherosclerotic,24-26 and neuroprotective effects.27,28 A number of 
hygrolides inhibit the transmembrane vacuolar-type H+-ATPases (V-ATPases), a family of ATP-
driven proton pumps that regulate the pH of intracellular compartments, including lysosomes, 
                                                 
* This chapter was adapted in part from Molloy, E.M.; Tietz, J.I.; Blair, P.M.; and Mitchell, D.A. “Biological 
characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of 
natural products.” Org. Biomol. Chem. 2016, doi: 10.1016/j.bmc.2016.05.021. Reprinted with permission from 
Elsevier. E.M.M. and J.I.T. were co-first authors. E.M.M. performed microbiological experiments, compound 
isolation, and mutant generation and sequencing. J.I.T. performed compound isolation, NMR analysis, 
microbiological experiments, and bioinformatic analysis. P.M.B. performed MS analysis, microbiological 
experiments, microscopy, and assisted in the writing and revision process. E.M.M. and J.I.T. wrote the paper with 
significant editorial insight from D.A.M. This work was supported in part by a NIH Director’s New Innovator Award 
Program (DP2 OD008463 to D.A.M.), the David and Lucile Packard Fellowship for Science and Engineering (to 
D.A.M.), the Robert C. and Carolyn J. Springborn Endowment (to J.I.T.). P.M.B. and J.I.T. were supported in part 
supported by ACS Division of Medicinal Chemistry predoctoral fellowships. The Bruker UltrafleXtreme MALDI-
TOF/TOF mass spectrometer was purchased in part with a grant from the National Center for Research Resources, 
National Institutes of Health (S10 RR027109 A). We thank Parth Patel for contribution of bioinformatics code used 
for gene cluster analysis. We also thank Dr. Courtney L. Cox for helpful bioinformatics advice and Dr. Lingyang Zhu 
(Univ. Illinois NMR Laboratory) for assistance with collection of NMR spectra. 
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phagosomes, and secretory vesicles.29 The most well-studied hygrolide, bafilomycin A1, potently 
and selectively inhibits V-ATPases, but not P-ATPases or F-ATPases.30 Thus, it has found use as 
a tool for both distinguishing V-ATPases and determining their cellular functions.31 As well as 
being critical for various physiological processes, V-ATPases have been implicated in a number 
of diseases.32 As a result, hygrolides have attracted considerable research attention as potential 
therapeutics, e.g. to block the excessive bone resorption associated with osteoporosis33 and to slow 
tumor cell growth and metastasis.34-36 Bafilomycin A1 has been extensively used in the study of 
autophagy due to its ability to impede fusion between autophagosomes and lysosomes by 
inhibition of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump rather than V-
ATPase37. Additionally, bafilomycin A1 has been shown to disrupt mitochondrial function by 
acting as carrier type K+ ionophore.38 
Although etiologically linked to several diseases, the essential role of V-ATPases in 
various physiological processes means that therapeutic application of the plecomacrolides, 
including the hygrolides, may be limited.39 However, there is hope that toxic effects can be 
overcome by identifying or designing inhibitors to target specific V-ATPase subunit isoforms. To 
this end, chemical modification of the hygrolides has been undertaken to provide insights into 
structure-activity relationships (SAR) and perhaps even improve pharmacokinetic properties and 
efficacy.40,41 In addition to total- and semi-synthetic approaches, accessing natural chemical 
diversity helps to shape our understanding of promising pharmacophores. Indeed, screening of 
actinobacterial extracts has been successful in yielding hygrolide congeners with differing 
functional groups. After more than 30 years of investigation, the production of a hygrolide was 
definitively linked to a biosynthetic gene cluster (BGC) in 2012.42-44 Armed with this knowledge, 
genome mining can allow prioritization of strains for investigation. Furthermore, knowledge of 
these BGCs raises the possibility that rational bioengineering can be applied to produce new 
hygrolide analogues.45,46  
In the present study, we used HR-MS/MS, reactivity-based metabolite labeling, NMR, and 
bioinformatics to identify Streptomyces varsoviensis as a novel producer of the hygrolide JBIR-
100. Comparative analysis of 16S rRNA sequences indicated that S. varsoviensis is distinct from 
the previously known JBIR-100 producer, Streptomyces sp. IR027-SDHV6.47 Nucleophilic 1,4-
addition-based labeling proved useful in connecting the JBIR-100 BGC to its corresponding 
metabolite, vastly simplifying the structure elucidation process. We confirmed the structure of 
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JBIR-100, and for the first time, propose its complete stereochemistry using a combination of 
NMR and bioinformatic analysis. In terms of its core scaffold, JBIR-100 most closely resembles 
hygrobafilomycin, also produced by S. varsoviensis.11 Unfortunately, hygrolide nomenclature is 
not unified in the literature, and similar names do not always denote a common core scaffold. For 
clarity, we refer to hygrolides with a hygrobafilomycin-type scaffold (defined by 2-C methyl 
group, a 23-C isopropyl group, and 16-membered macrolactone ring), including JBIR-100, as 
hygrobafilomycins (Figure 3.1b). We used purified JBIR-100 to gain preliminary insights into its 
antimicrobial activity, particularly against Bacillus subtilis. Finally, we sought to reconcile the 
available bioinformatic data on the hygrolide family of natural products. Thus, we surveyed the 
hygrolide genomic landscape and identified and contextualized BGCs for numerous known and 
predicted hygrolide producers, with several of the newly described BGCs potentially encoding 
novel compounds. 
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Figure 3.1 Structural variety of the hygrolide family. (a) Sites of known structural variability in hygrolide 
antibiotics are indicated. Variations include stereochemistry, glycosylation, acylation, methylation, oxidation state, 
and ring-opening, among others. (b) Six main scaffolds of the hygrolide antibiotics. Names under the drawings indicate 
scaffold name rather than the exact name of the natural product(s). (c) Structure of JBIR-100 with the fumarate moiety 
containing an electrophilic alkene suitable for nucleophilic addition highlighted with a yellow circle. 
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3.2 Identification of a novel producer of JBIR-100 by nucleophilic 1,4-addition  
In addition to powerful genetic approaches, a number of chemical strategies can aid in 
connecting a BGC to its product(s). For example, in the so-called genomisotopic approach, target 
molecules can be labeled by biosynthetic incorporation of 13C- or 15N-enriched precursors 
followed by NMR detection.48 A similar methodology involves growing the microorganism of 
interest in fully labeled 13C or 15N medium supplemented with a non-labeled precursor, with 
precursor incorporation into specific molecules being detected by mass spectrometry.49 Another 
method targets genetically encoded functional groups with a suitable probe, then uses comparative 
MS to indicate the masses in a microbial extract that may represent the molecule(s) of interest. For 
example, dehydrated amino acids, which are common to several classes of ribosomally synthesized 
and post-translationally modified peptide (RiPP) natural products, can be covalently labeled at 
activated alkenes (i.e., α,β-unsaturated carbonyl/imine moieties) with a thiol probe.50 Coupled with 
bioinformatic analysis of putative BGCs, this strategy allowed targeted screening of strains and 
resulted in the identification of a novel RiPP of the thiopeptide class, the antibiotic 
cyclothiazomycin C.50 
As part of a screen based on thiol-mediated nucleophilic labeling,50  we treated a cell 
surface extract of S. varsoviensis NRRL B-3589 with dithiothreitol (DTT) in the presence of a 
mild base. MALDI-TOF MS analysis revealed the production of an exported compound that was 
covalently modified by DTT (Figure 3.2a). We surveyed the S. varsoviensis genome using the 
web-based tool antiSMASH 3.051 and the MiBIG database52 for BGCs corresponding to potential 
electrophile-containing natural products. Indeed, we noticed that one of the BGCs showed high 
similarity to that of bafilomycin C1, a hygrolide bearing a fumarate moiety.53 Using HR-MS/MS 
and NMR, we confirmed that the natural product labeled with DTT was identical to the fumarate-
containing hygrolide JBIR-100 (also known as TS155-2) (Figure 3.1c);47,54,55 the structure was 
corroborated by comparison of its spectroscopic data with those in the literature and by 
bioinformatic analysis (see later).47 
A sample of the unlabeled isolated material was subjected to HR-ESI-MS. The observed 
mass (m/z 727.4055 Da, [M+Na]+) was consistent with a molecular formula of C39H60O11 
(theoretical m/z 727.4033 Da, [M+Na]+, error 3.0 ppm) possessing 10 degrees of unsaturation 
(Figure 3.2b–d). Nucleophilic labeling of JBIR-100 with DTT suggested at least one degree of 
unsaturation to be due to an electrophilic alkene (Figure 3.2a); accordingly, collision-induced 
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dissociation (CID)-based fragmentation yielded a prominent fragment consistent with the loss of 
a fumaric acid motif (observed m/z 611.3911 Da, [M+Na]+; theoretical m/z 611.3924 Da, 
[M+Na]+; error 2.1 ppm) relative to the parent ion (Figure 3.2b–d). As predicted, LTQ-FT-MS/MS 
analysis of DTT-labeled JBIR-100 indicated that DTT was incorporated in the fragment containing 
the fumarate moiety (Figure 3.2e–g). This result extends reactivity-based labeling50 beyond RiPPs 
to members of the polyketide natural product class and demonstrates its utility to quickly narrow 
down a list of candidate BGCs. Additionally, the data suggest that the fumarate moiety, or other 
similar electrophiles, are viable chemical handles for future discovery efforts. 
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Figure 3.2 Mass spectrometry characterization of JBIR-100 and DTT-labeled JBIR-100. (a) MALDI-TOF MS 
of JBIR-100 nucleophilic labeling performed in the context of an organic, cell surface extract of Streptomyces 
varsoviensis NRRL B-3589. The black spectrum (top) is an unreacted control, while the red spectrum (bottom) 
resulted from DTT-labeling. JBIR-100 was visibly labeled by one DTT molecule. (b) High resolution LTQ-FT-MS 
mass spectrum of the [M+Na]+ species of JBIR-100, which was used to calculate exact mass. (c) CID spectrum of the 
[M+Na]+ species of JBIR-100. Labeled peaks correspond to identified fragments of JBIR-100, shown on the structure 
in panel (d). (e) High resolution LTQ-FT-MS mass spectrum of the [M+Na]+ species of DTT-labeled JBIR-100, which 
was used to calculate exact mass. (f) CID spectrum of the [M+Na]+ species of DTT-labeled JBIR-100. Labeled peaks 
correspond to identified fragments of DTT-labeled JBIR-100, shown on the structure in panel (g). 
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3.3 Structure determination of JBIR-100 
Full structural characterization by NMR was performed using one- and two-dimensional 
experiments (1H, 1H-1H DQF-COSY, 1H-1H TOCSY, 1H-13C HSQC, and 1H-13C HMBC) with 
CD3OD as solvent (Appendix B.2). Spin systems were assigned by 1H, DQF-COSY, and TOCSY. 
Carbons directly attached to protons were assigned by multiplicity-edited HSQC, and unattached 
carbons were assigned by HMBC. Exchangeable peaks from three hydroxyl protons and one 
carboxyl proton were not detected/assigned. Ten methyl groups and one methoxy group were 
detected; each was localized using HMBC, DQF-COSY, and TOCSY. Attachment of the fumarate 
at 21-C was verified by HMBC peaks between 21-H and 1′-C. The site of macrocyclization was 
confirmed by correlations between 15-H and 1-C. Unlike prototypical bafilomycins (e.g. B1 and 
C1, Figure 3.10b), the molecule has a methyl rather than methoxy group attached to 2-C. Only 
weak 1H-1H correlations were observed between 6-H/7-H, 15-H/16-H, 17-H/18-H, and 23-H/24-
H, although coupling was confirmed by close inspection of the DQF-COSY, as well as analysis of 
J-values; 1H-13C HMBC correlations were also observed for these positions. Overall, the NMR 
data were consistent with a structure with atomic connectivity identical to JBIR-100, a known 
metabolite from Streptomyces sp. IR027-SDHV6.47  
It was noted by Ueda et al. that the configurations at the 12 stereocenters of JBIR-100 were 
not known.47 We thus analyzed the vicinal coupling constants for the protons at these positions 
using 1H and DQF-COSY NMR (Figure 3.3 and Appendix B.2). The coupling between protons 
22-H/23-H (J22-H/23-H = 10.4 Hz) and 21-H/22-H (J21-H/22-H = 10.9 Hz) in the six-membered ring 
indicated a trans-diaxial relative configuration, which we propose as 21R,22S,23R. Due to 
ambiguity in J-values, we have assigned the two diastereomeric protons of 20-C primarily on 
chemical shift basis, given the propensity for equatorial protons in six-membered rings to usually 
display downfield shifts (equatorial: 2.30 ppm, J20-Hax/21H = 4.8 Hz; axial: 1.31 ppm, no detected 
coupling to 21-H). For analysis of the stereocenters at 6-C, 7-C, 8-C, 14-C, 15-C, 16-C, 17-C, and 
18-C, we compared vicinal coupling constants of these sites in JBIR-100 to dihedral angles 
obtained from the crystal structure of bafilomycin A1 [Cambridge Crystallographic Data Centre 
(CCDC) 1159422] and 21-O-methyl-24-demethyl-bafilomycin A1 (CCDC 707561) using the 
Karplus equation.7,56,57 The high consistency between these values enabled us to assign the 
structure as 6R,7S,8S,14S,15R,16S,17R,18S. Coupling constants and chemical shifts of stereogenic 
centers were also consistent with those previously observed for bafilomycin-type compounds with 
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the above stereochemistry.2,9,58 J-values for the opposite configuration were predicted to be 
substantially different from those observed at each stereocenter, with the exception of 8-C, for 
which the difference between predicted and observed J7-H/8-H was small (ΔJ < 2 Hz). However, 
Hertweck and coworkers assigned 8S configuration to the co-metabolites bafilomycin C1, C2, and 
D, which are also produced by S. varsoviensis; the co-metabolite hygrobafilomycin showed 
NOESY correlations also suggestive of this stereochemistry.11 Thus, due to their common 
biosynthetic origin and closely aligned chemical shifts, we also assigned this center as 8S.  
On the basis of coupling constants, the fumaryl alkene (J2′-H/3′-H = 15.8 Hz) and the 
disubstituted alkene at 12-C/13-C (J12-H/13-H = 15.0 Hz) were assigned as E-configuration. 
Assignment of the trisubstituted alkenes at 2-C/3-C, 4-C/5-C, and 10-C/11-C as E was made in 
analogy to the chemical shifts at this position for hygrobafilomycin, which is consistent with other 
members of the family.2,11  
We assigned the configuration of the acetal at 19-C as R based on similarity of chemical 
shifts in the immediate vicinity to those of previously-characterized bafilomycins;11,56 in the crystal 
structure of bafilomycin A1 (CCDC 1159422), the hydroxyl moiety (R-configuration) at this site 
is involved in intramolecular hydrogen bonding, which, combined with the anomeric effect as well 
as the equatorial placement of the remaining substituents, is likely to favor this 
stereoconfiguration.56 This is also consistent with the biosynthetic origin of this stereocenter, 
which arises from nucleophilic attack of the 23-C hydroxyl moiety into a ketone at 19-C. We also 
bioinformatically substantiated this assignment (see later). 
Interestingly, we noted by NMR a tendency of JBIR-100 to gradually isomerize or degrade 
over several days at ~22 °C in CD3OD. By ESI-MS we observed that this corresponded to an 
incorporation of CD3OD into the molecule (data not shown). Under mildly acidic conditions in 
chloroform, we also observed rapid elimination of the fumarate moiety and gradual decomposition 
of the molecule as a pink solution that eventually became pale yellow with time. Intermediates 
observed by NMR during decomposition were similar to several reported isolated bafilomycin-
like compounds, including bafilomycins L and I, suggesting that these might be degradation 
artifacts rather than bona fide biosynthetic products.4-7 For instance, it has been noted that 
hygrolidin K2 forms a methyl acetal in methanol at reflux,17 the methyl acetal of the hygrolide 
leucanicidin results during isolation with methanol and is not detectable in culture,59 and the 
original disclosure of bafilomycins A, B, and C ascribed the methyl acetals to isolation artifacts.2 
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Figure 3.3 Atom numbering, chemical shift assignments, correlations, and J-values of JBIR-100. 
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3.4 Antimicrobial activity of JBIR-100 
Many questions remain regarding the features that dictate the diverse bioactivities of 
hygrolides. To date, the main focus of investigations into hygrolide bioactivity has been on 
eukaryotic targets, with the result that little is known about antibacterial SAR. The first report on 
the bioactivity of bafilomycin A1 (which does not contain a fumarate moiety), B1 and C1 (fumarate-
containing) showed that all three compounds have antifungal activity, indicating that the fumarate 
might be dispensable for this bioactivity. However, while bafilomycin B1 and bafilomycin C1 have 
antibacterial activity, bafilomycin A1 displays no detectable antibacterial activity.2 Similarly, a 
recent report found that bafilomycin L, which does not contain a fumarate moiety, has no antibiotic 
activity.6 These observations lead us to speculate that the fumarate might contribute to antibacterial 
activity and we thus determined the minimum inhibitory concentration (MIC) of JBIR-100 against 
a number of bacteria. We determined that Mycobacterium smegmatis and the Proteobacteria tested 
were insensitive to JBIR-100 up to the maximum concentration used (64 µM) (Table 3.1). The 
lack of activity towards Gram-negative bacteria is in agreement with previous observations for 
hygrolides. In contrast, JBIR-100 showed antimicrobial activity against all Firmicutes examined, 
with MICs as low as 4 µM observed against Bacillus sp. Al Hakam and Staphylococcus aureus 
USA300 (Table 3.1). In addition, we tested five fungi for sensitivity to JBIR-100 and only 
observed significant activity towards Debaryomyces hansenii (Table 3.1). It is notable that 
hygrobafilomycin was far more pronounced in its antifungal than antibacterial effects,11 while in 
the case of JBIR-100, the opposite was true. Although not the only structural difference between 
hygrobafilomycin and JBIR-100, the former lacks the fumarate moiety. 
To further evaluate antibacterial activity, a growth curve of B. subtilis (MIC = 8 µM) 
challenged at mid-exponential phase with various concentrations of JBIR-100 showed a sharp 
reduction in growth immediately upon addition of the compound (Figure 3.4). The minimum 
bactericidal concentration (MBC = 16 µM) was also determined against B. subtilis, classifying 
JBIR-100 as bactericidal towards this organism.60 
Despite several reports on the antibacterial activity of the hygrolides, to our knowledge 
there are no published data on the bacterial molecular targets or mode of action (MOA). In light 
of this, we chose B. subtilis as an investigative model for further study. The cationic, cell-
impermeable, fluorescent dye propidium iodide (PI) was used as an indicator of membrane 
integrity. PI is well known to enter cells that have suffered membrane damage, causing the 
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membrane-compromised cells to become fluorescent. After treatment with JBIR-100, uptake of PI 
by B. subtilis was visualized by confocal fluorescence microscopy. While untreated cells did not 
display any PI fluorescence, we observed a dose-dependent increase in the number and brightness 
of B. subtilis cells stained with PI, indicating membrane permeabilization by JBIR-100 (Figure 
3.4). Flow cytometry was then used to examine possible changes in the polarization of the B. 
subtilis membrane upon exposure to sub-MIC levels of JBIR-100 (up to 1 µM or 0.125 × MIC) 
using the membrane potential-sensitive dye 3,3′-diethyloxacarbocyanine iodide [DiOC2(3)].61 
Treatment of B. subtilis with concentrations of JBIR-100 greater than 0.2 µM (0.025 × MIC) 
resulted in a significant decrease in fluorescence intensity, with the data showing a dose-dependent 
depolarization of the B. subtilis membrane (Figure 3.6). Taken together, these experiments 
indicate that JBIR-100 perturbs the B. subtilis cell membrane, although it remains to be determined 
if this is a direct or indirect consequence of its MOA. 
In order to gain further insight into the antibacterial action of JBIR-100, we selected and 
mapped resistance-conferring polymorphisms in B. subtilis.62 Our initial attempts to obtain 
spontaneous mutants of B. subtilis resistant to JBIR-100 were unsuccessful, perhaps indicating that 
there is no straightforward path to resistance and that JBIR-100 might interact with multiple 
bacterial targets. We therefore employed a dose-escalation approach to gradually select for JBIR-
100 resistance. We began by culturing B. subtilis in the presence of a sublethal concentration of 
JBIR-100 in triplicate, then gradually increased the concentration with the number of passages.63 
After ten serial passages, the resistance of the resulting B. subtilis strains (P10A, P10B, P10C) to 
JBIR-100 was only modestly increased (MICs = 16 µM) compared to the parent B. subtilis (MIC 
= 8 μM). There were no major differences in morphology of strains P10A, P10B, and P10C 
compared to the parent by differential interference contrast (DIC) microscopy (data not shown). 
As is often the case for antibiotic resistant bacteria,64 all three strains incurred fitness costs as a 
result of the polymorphisms accrued. Not only was a significant delay observed for the onset of 
exponential phase for strains P10A–C, we also noted that strains P10B and P10C failed to reach a 
stationary phase density comparable to the parent (Figure 3.7). 
We next isolated genomic DNA from the parent and JBIR-100-resistant strains for whole 
genome sequencing (WGS). Polymorphisms detected in P10A, P10B, and P10C relative to the 
parent strain were mapped and confirmed by Sanger sequencing (Table 3.2). A number of 
polymorphisms were identified in each resistant strain, as expected in mutants derived from 
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extensive passaging in the presence of antibiotic. Interestingly, all three mutants contained a 
frameshift mutation in yusO, a putative transcriptional regulator of the MarR (multiple antibiotic 
resistance repressor) family. MarR functions as a repressor in E. coli until bound by structurally 
diverse compounds including antibiotics, organic solvents, and other toxic chemicals.65 
Subsequent expression of the transcriptional activator MarA then leads to upregulation of a 
multidrug efflux system. Moreover, loss of function mutations in MarR or MarR homologues are 
known to cause clinically relevant drug-resistant phenotypes, in particular towards 
fluoroquinolones.66-69 While these results potentially implicate the mar locus in JBIR-100 
resistance, the general nature of this resistance mechanism means mutation of yusO is unlikely to 
give meaningful insight into biological target(s) of JBIR-100. It also complicates our interpretation 
of the potential contribution of the other polymorphisms to the resistance phenotypes of these 
strains. 
To determine whether resistance to JBIR-100 was concurrent with resistance to other 
antibiotics of known mechanism, and to provide insight into the fitness of the resistant mutants, 
JBIR-100-resistant strains P10A, P10B, and P10C were challenged with a panel of structurally and 
mechanistically diverse antibiotics (Table 3.3). Susceptibility was unchanged for ampicillin, 
triclosan, and ciprofloxacin. Some mutants displayed modest increases in susceptibility (2-fold) to 
chloramphenicol and vancomycin, and all three mutants were more susceptible (2- to 4-fold) than 
the parent strain to kanamycin. Interestingly, the mutations present in P10A, P10B, and P10C 
conferred cross-resistance only against rifampicin, with a 2- to 4-fold increase in MIC. 
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Figure 3.4 Growth curve (optical density at 595 nm) depicting the effect of addition of JBIR-100 to B. subtilis 
ATCC 47096. The dashed line denotes the point at which JBIR-100 was added at concentrations of 1× (8 µM), 2× 
(16 µM), and 4× (32 µM) MIC as indicated; 0× MIC curve represents the vehicle (DMSO)-treated control. JBIR-100 
appeared to be growth-suppressive at all concentrations tested. Data depicted is the average of three independent 
replicates. 
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Figure 3.5 Fluorescence microscopy reveals the uptake of propidium iodide (PI) by B. subtilis ATCC 47096 
after treatment with JBIR-100. Cells were exposed at mid-log phase to vehicle alone (DMSO), 1× (8 µM), 4× (32 
µM), or 8× (64 µM) MIC of JBIR-100, which was followed by washing and treatment with PI. Left panels, 
fluorescence of PI; middle panels, differential interference contrast (DIC); right panel, overlay of PI and DIC channels. 
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Figure 3.6 JBIR-100 depolarizes the B. subtilis ATCC 47096 cellular membrane. Red/green ratios were calculated 
using mean fluorescence intensities of cells treated for 30 min at ~22 °C with 0.1 µM DiOC2(3) and vehicle (DMSO) 
(negative control), 5.0 µM CCCP (positive control), 0.1 µM JBIR-100, 0.2 µM JBIR-100, 0.5 µM JBIR-100, 1.0 µM 
JBIR-100. Data were normalized to the negative control sample and are depicted from three independent replicates. 
Error is given as standard deviation with n = 3. P-values are given relative to the negative control with * indicating < 
0.05 and ** indicating < 0.005. Abbreviations: DiOC2(3), 3,3′-diethyloxacarbocyanine iodide; CCCP, carbonyl 
cyanide m-chlorophenyl hydrazone. 
 
Figure 3.7 Growth defects of JBIR-100-resistant B. subtilis mutants. Growth rates (monitored at optical density at 
595 nm) depicting the growth defects of JBIR-100-resistant mutants B. subtilis P10A, P10B and P10C compared to 
the parental strain, B. subtilis ATCC 47096. Data depicted is the average of two independent replicates. 
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Phylum Strain MIC (μM) 
Firmicutes 
Bacillus anthracis Sterne ΔLF  4 
Bacillus cereus ATCC 4342  4 
Bacillus subtilis subsp. subtilis str. 168  8 
Bacillus subtilis ATCC 47096 8 
Bacillus sp. Al Hakam 4 
Enterococcus faecium U503 (VRE1) 16 
Staphylococcus aureus USA300 (MRSA2) 4 
Actinobacteria Mycobacterium smegmatis B-14616 > 64 
Proteobacteria 
Escherichia coli DH5α  > 64 
Escherichia coli MC1061 > 64 
Pseudomonas putida KT2440  > 64 
Ascomycota 
Candida albicans > 128 
Debaryomyces hansenii 8 
Kluyveromyces lactis > 64 
Saccharomyces cerevisiae > 64 
Zygosaccharomyces rouxii 32 
1Vancomycin-resistant Enterococcus. 2Methicillin-resistant Staphylococcus aureus 
Table 3.1 Spectrum of antimicrobial activity for JBIR-100. MICs are reported as the modal value obtained from 
three experiments with three independent cultures each. 
Strain Polymorphism  Position and Type 
Locus 
Tag/ 
 Gene 
Annotation Consequence 
P10C 1,234,377_1,234,378insT BSU11550 / yjbH 
putative thiol 
management 
oxidoreductase 
component  
p.I46fsX67 (nonsense at aa 67 of 
299 aa protein) 
P10A 1,741,429C>T BSU16690 / pnpA 
polynucleotide 
phosphorylase  
p.Q683X (nonsense at aa 683 of 705 
aa protein) 
P10B 2,451,421_2,451,422insA 
Between 
BSU2354
0 / yqkK & 
BSU2355
0 / mleA 
 
hypothetical protein & 
NAD-dependent malic 
enzyme 
N/A – intergenic region 
P10A 3,118,362C>T BSU30450 / ytrB ABC transporter  p.V165M (missense, conserved) 
P10A, 
P10B, & 
P10C 
3,374,721delA BSU32870 / yusO 
putative transcriptional 
regulator (MarR family) 
p.Q77fsX92 (nonsense at aa 92 of 
155 aa protein) 
P10B 3,947,564C>A BSU38460 / tyrZ tyrosyl-tRNA synthetase p.P136H (missense, non-conserved) 
Table 3.2 Description of polymorphisms identified in JBIR-100-resistant mutants of B. subtilis ATCC 47096. 
Position of polymorphism corresponds to DNA location in reference genome (AL009126.3). Abbreviations: >, 
substitution; del, deletion; ins, insertion, r., RNA sequence; p., protein sequence; fs, frameshift; X, stop codon; aa, 
amino acid. 
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Antibiotic ATCC 470961 P10A
1 P10B1 P10C1 
Ampicillin 0.125 0.125 0.125 0.125 
Chloramphenicol 8 4 8 8 
Ciprofloxacin 0.125 0.125 0.125 0.125 
Kanamycin 256 128 64 64 
Rifampicin 0.0625 0.25 0.125 0.125 
Triclosan 8 8 8 8 
Vancomycin 0.125 0.125 0.0625 0.0625 
1 MIC values given in µM 
Table 3.3 MICs of B. subtilis JBIR-100-resistant mutants for various antibiotics compared to the parental B. 
subtilis ATCC 47096. MICs are reported in µM as the modal value obtained from three experiments with three 
independent cultures each. 
3.5 Biosynthetic origin of hygrobafilomycins  
To our knowledge, no hygrobafilomycin BGC has been reported. Additionally, we believe 
S. varsoviensis marks the first sequenced microorganism found to produce multiple hygrolide sub-
families—in this case, hygrobafilomycins (JBIR-100 and hygrobafilomycin) and bafilomycins 
(bafilomycins C1 and D).11 We wondered whether this phenomenon was due to the presence of 
multiple BGCs or the promiscuity within a single BGC. We thus sought to identify the biosynthetic 
origin of JBIR-100/hygrobafilomycin. We used antiSMASH 3.051 to survey two S. varsoviensis 
genomes, NRRL ISP-5346 and NRRL B-3589. Both contained a BGC that was logically consistent 
with the structure of JBIR-100. Although the BGC was fragmented between small contigs in the 
NRRL B-3589 genome (GenBank accessions NZ_JOFN01000036, NZ_JOFN01000065, and 
NZ_JOFN01000038), the ISP-5346 genome harbored the entire BGC within a single contig 
(GenBank accession NZ_JOBF01000033). All coding sequences in the BGC were identical at the 
protein level between NRRL ISP-5346 and NRRL B-3589, with the exception of HbaAII (99% 
protein sequence identity). PRISM,70 BLAST,71 and antiSMASH 3.051 were used to annotate the 
functions for each gene in the ISP-5346 BGC (Table 3.4).  
The JBIR-100/hygrobafilomycin BGC hbaA–hbaK consists of 15 open reading frames 
(ORFs), which we have named analogously to the bafilomycin BGC from Streptomyces lohii 
(Table 3.4, Figure 3.8a).42 The cluster contains several PKS genes, hbaAI (68% protein sequence 
identity, 74% similarity), hbaII (69% id, 76% sim), hbaAIII (67% id, 74% sim), hbaAIV (68% id, 
76% sim), and hbaAV (62% id, 70% sim), homologous to the five PKS genes from S. lohii. 
Although hbaAI is annotated in GenBank as a single pseudogene of comparable length to bafAI, 
analysis with PRISM and antiSMASH indicated this region was split into two smaller ORFs, 
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hbaAIa (consisting of the PKS loading module) and hbaAIb (consisting of PKS modules 1–3). The 
modifications encoded by individual modules in the PKS domains in hbaAIa–hbaAV exactly 
coincide with the linear scaffold of JBIR-100 and hygrobafilomycin (Figure 3.8b,c). The PRISM-
predicted acyltransferase (AT) substrate specificity for each extender module (malonyl-, 
methylmalonyl-, or methoxymalonyl-CoA) matched that of the linear scaffold. Interestingly, 
PRISM predicts not only AT5 but also AT11 to be specific for methoxymalonyl-CoA, despite 
AT11’s utilization of methylmalonyl-CoA in hygrobafilomycin biosynthesis; however, S. 
varsoviensis also produces compounds with a methoxy substitution at the 2-C position, indicating 
AT11 substrate promiscuity.11 
Immediately downstream of hbaAV are five genes, hbaB–hbaF, which are homologous to 
bafB–bafF. Homologues of bafB–bafF have been implicated in methoxymalonyl PKS extender 
unit biosynthesis from 1,3-bisphosphoglycerate,72,73 and their function was previously assigned as 
methoxymalonyl-CoA generation in the biosynthesis of bafilomycin A–C.42,43 Schuhmann and 
Grond used feeding studies to determine that this unit originates as glycerate in bafilomycin A1.74 
In this case, HbaE (80% protein sequence identity to BafE, 86% similarity) would be responsible 
for ligating glycerate to the acyl carrier protein (ACP) HbaC (73% identity to BafC, 80% 
similarity). HbaB (78% identity to BafB, 83% similarity) and HbaD (73% identity to BafD, 79% 
similarity) could then oxidize the glycerate, and HbaF (77% identity to BafF, 86% similarity) 
would O-methylate the resulting hydroxymalonyl-ACP to yield the methoxymalonyl unit. 
Two regulatory proteins are encoded in the hba cluster: the AfsR-family regulator HbaG 
(67% protein sequence identity to BafG, 76% similarity) and the LuxR-family regulator HbaI 
(72% identity to the protein encoded by orf1 in S. lohii, 85% similarity).  
HbaH encodes a type II thioesterase (TEII)75 with similarity to BafH (67% protein 
sequence identity, 76% similarity). HbaJ encodes an AT homologue of the S. lohii gene product 
of orf2 (79% identity, 86% similarity). The hbaK gene encodes a putative acyl-CoA ligase that is 
a homologue of orf3 (82% identity, 87% similarity). It has been speculated that homologues of 
HbaJ and HbaK could be involved in fumaryl attachment, although this has not been investigated 
experimentally.43 Interestingly, Hertweck et al. reported that hygrobafilomycin bears an unusual 
fumaryl-like monoalkylmaleic anhydride moiety,11 which may be installed by the same machinery 
as the fumarate. 
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In contrast to any other known hygrolide BGC, homologues of bafX, bafY, and bafZ are 
absent from the JBIR-100 cluster. Although tailoring genes can sometimes be located distal to the 
core polyketide BGC (e.g. the methoxymalonate subcluster in galbonolide biosynthesis),76 there 
are no obvious homologues of this trio in any S. varsoviensis genome. Homologues of the bafXYZ 
subcluster have been linked to installation of a 5-aminolevulinate-derived 2-amino-3-hydroxy-
cyclopent-2-enone ring,42-44,77 which is consistent with the absence of this moiety from any 
hygrolide metabolites isolated from S. varsoviensis.11 Finally, the genes flanking hbaAI–hbaK 
share no similarity to genes adjacent to any of several other identified bafilomycin, hygrolidin, or 
concanamycin gene clusters (Table 3.4), suggesting the cluster boundaries are the same as for the 
baf BGC. 
Another important aspect of JBIR-100 biosynthesis is the resulting configuration of its 12 
stereocenters, which we elucidated using NMR. To corroborate this assignment and to furnish the 
absolute configuration, we bioinformatically analyzed several of the ketoreductase (KR) domains. 
McDaniel and Caffrey previously determined key sequence signatures that separated KR domains 
into A- and B-type,78,79 and this approach has been further expanded by more sophisticated 
methods including hidden Markov model (HMM)-based sequence classification.80 This sequence-
based approach has been used successfully to assign the absolute configuration of several 
polyketides and has been corroborated by analysis of the crystal structures of several representative 
KRs.14,81-83 Using PRISM,70 we extracted the KR sequences from modules 1, 2, 4, 5, and 9 (KR1–
KR9) of the S. varsoviensis BGC, which are responsible for setting the stereocenters at 7-C, 15-C, 
17-C, 21-C, and 23-C, respectively. KR1 and KR5 are B-type (d alcohol configuration), whereas 
KR2, KR4, and KR9 are A-type (l alcohol configuration), as determined by the presence of 
signature sequence motifs in each (Figure 3.9). Kitsche and Kalesse demonstrated that KR 
sequence could also occasionally distinguish methyl stereochemistry;80 indeed, using their HMM-
based classification program ScoreDiff, KR9 is confidently predicted to give rise to an l α-methyl 
branch, although KR2, KR4, and KR5 methyl stereochemistry could not be reliably predicted 
using this method. The KR9 stereospecificity classification is especially important in the context 
of the spectroscopic ambiguity of the 8-C stereocenter. These sequence-based classifications 
provide a strong prediction of the absolute stereochemistry and corroborated our NMR-derived 
assignments, as well as those of hygrobafilomycin11 (Figure 3.9b,c). 
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1  WP_030890302 183  - - - - 
hypothetical protein  
QR77_18815 
[Streptomyces sp. 150FB] 
KIF75396 187 63 
2  WP_048832934 266  - - - - 
phytanoyl-CoA  
dioxygenase  
[Streptomyces sp. 150FB] 
WP_052488889 265 73 
3  WP_030890308 452  - - - - hypothetical protein  [Streptomyces aureocirculatus] WP_030560004 446 69 
4  WP_030890312 169  - - - - hypothetical protein  [Allokutzneria albata] WP_030432205 164 42 
5 
HbaAIa 
IF55_RS32365 (locus) 
1325 polyketide synthase,  loading module BafAI ADC79616 4884 68     
HbaAIb 3866 polyketide synthase,  module 1+2+3 
6 HbaAII WP_048832936 5105 polyketide synthase,  module 4+5+6 BafAII ADC79617 5145 69 
    
7 HbaAIII IF55_RS32375 (locus) 3935 polyketide synthase,  module 7+8 BafAIII ADC79618 3968 67 
    
8 HbaAIV WP_037966908 3473 polyketide synthase,  module 9+10 BafAIV ADC79619 3511 68 
    
9 HbaAV IF55_RS32385 (locus) 2098 polyketide synthase,  module 11 BafAV ADC79620 2103 62 
    
10 HbaB WP_048832937 294 glyceryl-ACP oxidase BafB ADC79621 296 78     
11 HbaC WP_048832938 100 acyl carrier  protein (ACP) BafC ADC79622 93 73 
    
12 HbaD IF55_RS32400 (locus) 385 acyl-ACP  dehydrogenase BafD ADC79623 363 73 
    
13 HbaE WP_048832952 374 glycerate ACP ligase BafE ADC79624 365 80     
14 HbaF WP_030890472 220 O-methyl transferase BafF ADC79625 220 77     
15 HbaG WP_030890475 637 AfsR family regulator BafG ADC79626 609 67     
16 HbaH WP_030890478 249 thioesterase BafH ADC79627 253 67     
17 HbaI WP_037966912 72 LuxR family regulator orf1 ADC79628 117 72     
18 HbaJ WP_030890486 319 putative malonyl  transferase orf2 ADC79629 320 79 
    
19 HbaK WP_048832939 366 putative CoA-ligase orf3 ADC79630 332 82     
20  WP_030890492 162  - - - - hypothetical protein  [Saccharothrix syringae] WP_033433816 185 33 
21  WP_030890495 270  - - - - alpha/beta hydrolase  [Streptomyces violaceorubidus] WP_030191810 269 68 
22  WP_048832953 268  - - - - 
ABC transporter  
permease  
[Streptomyces violaceorubidus] 
WP_051777733 255 53 
23  WP_030890502 315  - - - - 
daunorubicin resistance 
 protein DrrA family  
ABC transporter  
ATP-binding protein  
[Saccharothrix sp. NRRL B-16314] 
WP_033438336 309 65 
24  WP_030890505 138  - - - - aspartate decarboxylase  [Streptomyces decoyicus] WP_030076920 138 90 
25  WP_048832940 270  - - - - hypothetical protein  [Streptomyces globisporus] WP_037675397 270 77 
Table 3.4 Genes in the S. varsoviensis NRRL ISP-5346 biosynthetic gene cluster (hba) for the hygrobafilomycin 
JBIR-100. Genes are given with their homologs from the baf cluster from S. lohii. For flanking genes, where no baf 
homolog was found, the nearest BLAST hit is provided. 
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Figure 3.8 Biosynthetic gene cluster for hygrobafilomycin/JBIR-100. (a) The newly-identified cluster for JBIR-
100 and related bafilomycin/hygrobafilomycin compounds, identified in Streptomyces varsoviensis NRRL ISP-5346, 
is shown aligned to the reported bafilomycin C1 and B1 gene cluster from Streptomyces lohii. Notably, the S. 
varsoviensis cluster is missing the bafXYZ trio thought to be involved in installation of the 5-aminolevinulate-derived 
2-amino-3-hydroxy-cyclopent-2-enone moiety found in bafilomycin B1 and similar compounds; this substructure has 
not been found in any polyketides from S. varsoviensis. (b) The baf cluster and hba cluster share the same PKS domain 
organization. Both clusters harbor 11 type I PKS modules and one loading module within 6 distinct ORFs. AT, 
acyltransferase. ACP, acyl carrier protein. KS, ketosynthase. KR, ketoreductase. DH, dehydratase. ER, 
enoylreductase. TE, thioesterase. (c) The domain architecture shown in (b) is consistent with the linear structure (left) 
and mature structure (right) of JBIR-100. Modules responsible for installation of each section of the scaffold are 
indicated along with the extender substrate utilized by that module. iBu, isobutryl-CoA. MeM, methylmalonyl-CoA. 
M, malonyl-CoA. MeOM, methoxymalonyl-CoA. Based on the isolation of compounds containing either Me or MeO 
at the module-11 site, this module can accept MeM (giving hygrobafilomycin compounds like hygrobafilomycin or 
JBIR-100) or MeOM (giving bafilomycin compounds like bafilomycin C1).  
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Figure 3.9 Stereospecificity prediction of KR domains. (a) Alignment of KR domains from the JBIR-100 BGC of 
S. varsoviensis NRRL ISP-5346. Sequence alignment was generated using MUSCLE (v. 3.8.31) on default settings 
and visualized using MView (v. 1.54). Key diagnostic residues are highlighted. (b) ScoreDiff values using prediction 
tool by Kitsche and Kalesse (https://akitsche.shinyapps.io/profileHMM_App) for classification of KR domains.80 
Positive ScoreDiff values indicate predicted D stereochemistry, whereas negative ScoreDiff values predict L 
stereochemistry. ScoreDiff values with larger magnitudes indicate increased certainty. Methyl stereochemistry of 
KR2, KR4, and KR5 could not be confidently predicted. (c) Structure of JBIR-100 labeled with KRs responsible for 
setting stereocenters. 
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3.6 Comparison of known hygrolide biosynthetic gene clusters and structures  
Reports have shown that a hygrolide scaffold from a single producer can be decorated with 
a variety of structural patterns, including ring-opening, methyl acetal formation, aminolevinulate 
attachment, fumaryl attachment, etc., possibly resulting from premature termination of 
biosynthesis, combinatorial biosynthesis, or degradation.2,3 However, other structural aspects, such 
as variation within the macrocyclic ring scaffold or at the terminus of the molecule, are likely to 
be genetic in origin. In light of the structural diversity present among the more than 48 members 
of the hygrolide family, we sought to compare the known and predicted BGCs of bafilomycin, 
hygrolidin, hyrobafilomycin, and concanamycin (although the biosynthesis of concanamycin is 
similar, it is not a technically a hygrolide as it contains an 18-membered rather than 16-membered 
macrolactone). We posited that this would provide insight into what structural variation could be 
genetic in nature, with the intent of guiding novel discovery efforts and providing a phylogenetic 
context for (hygro)bafilomycin biosynthesis.  
We thus assembled the sequences from reported clusters as well as some clusters newly 
identified herein (Figure 3.10 and Table 3.5). We analyzed 48 hygrolide structures from 30 
reported producers to gain insight into the molecular phylogeny. The hygrolides group structurally 
into what we classify as six main families, based on substitutions at 2-C and 23-C: bafilomycins 
(2-OMe/23-iPr), demethylbafilomycins (2-OMe/23-Et), hygrobafilomycins (2-Me/23-iPr), 
hygrolidins (2-Me/23-Et), micromonospolides (2-OMe/23-pentadiene), and 
didemethylbafilomycins (2-OMe/23-Me) (Fig. 3.1b). Within each family, numerous substitutions 
are found at various sites, including 7-O, 17-O, 19-O, 21-O, as well as a number of apparent 
elimination or ring-opening products, sometimes giving a diversity of compounds from the same 
organism (bafilomycin A, B, and C, for instance, are typically seen together) (Figure 3.1a). 
However, reports of multiple families being isolated from the same organism are restricted to S. 
varsoviensis, justifying the above family grouping. Compared to the BGCs from other known 
hygrolide-producing Actinomycetes, which share high amino acid identity to each other and form 
a distinct clade in a phylogenetic tree, the S. varsoviensis BGC shows considerably more sequence 
divergence (Figure 3.11 and Table 3.5).  
Obtaining direct relationships between structure and phylogeny in the hygrolidin family is 
difficult because (i) typically only new compounds are reported from a given organism, and thus 
knowledge of the full biosynthetic complement of each is presumed incomplete; and (ii) genomic 
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information, or even 16S rRNA sequence, for many reported producers is not available. In spite of 
these knowledge gaps, general conclusions can be drawn from our bioinformatic analysis.  
The hygrolidin BGC from Streptomyces halstedii was fragmented between three small 
contigs; of note, S. halstedii produces leucanicidin, a bafilomycin-scaffold compound bearing a 
glycan instead of a fumaryl appendage, and its cluster was not previously known.84 In the course 
of writing this manuscript, it was reported that Kitasatospora sp. MBT66 also produces 
leucanicidin. The BGC for leucanicidin was revealed, including the glycosyltransferase 
responsible for rhamnose installation.59 The three known leucanicidin producers (including also 
Streptomyces olivaceus) do not tightly cluster by 16S rRNA sequence nor by BafD/ORF3 
similiarity (Figures 3.11 and 3.12); they appear to be more closely related to other hygrolide 
producers than to each other. In light of the leucanicidin cluster disclosure, we briefly surveyed 
the genetic potential for each BGC to append sugars to its cognate natural product(s) by analyzing 
the local genomic regions for the presence of glycosyltransferases using PF00201 or PF00534 
profile HMMs (pHMMs) in HMMER3, revealing six total BGCs harboring these enzymes (Figure 
3.11);59,85 this suggests that hygrolide glycosylation may be relatively infrequent. However, the 
BGC from S. halstedii, a known leucanicidin producer, does not encode a predicted 
glycosyltransferase, which shows that our prediction of glycosylation frequency is probably 
underestimated. Encoded elsewhere in the S. halstedii genome is a glycosyltransferase that might 
be responsible for hygrolide glycosylation (GenBank accession WP_051422100), given its 34% 
protein sequence identity and 49% similarity to the K. sp. MBT66 leucanicidin glycosyltransferase. 
This homologue is also found in the genome of S. sp. DpondAA-B6, an organism closely related 
to S. halstedii (GenBank accession WP_051422100). 
BafBCDEF are responsible for the biosynthesis of the methoxymalonate extender unit that 
is incorporated once in hygrobafilomycins and hygrolidins, and twice in bafilomycins. The 
absence of the methyoxymalonyl extender unit biosynthetic subcluster in the hygrolidin BGC from 
S. hygroscopicus is thus puzzling.44 However, there is precedence for this subcluster to be found 
elsewhere in the genome, as is the case for galbonolide produced by S. galbus.76 Moreover, some 
S. hygroscopicus strains produce FK520, whose BGC harbors this subcluster.86 Markedly, the S. 
hygroscopicus hygrolidin cluster also lacks a bafX homologue. Unfortunately, the genome 
sequence of the S. hygroscopicus strain that produces hygrolidin is not available, so it cannot be 
determined if bafBCDEF and bafX lie elsewhere in the genome. 
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While some of the structural diversity found within the hygrolide family can be explained 
bioinformatically, there is no clear genetic basis for some other structural aspects, including acetal 
methylation, ring-opening, and elimination. Instead, these variants may represent biosynthetic 
intermediates, off-pathway compounds, combinatorial products due to enzyme promiscuity, or 
even degradation products. For example, isobutyrylleucanicidin bears a 7-O-acylation, for which 
no corresponding genes have been identified.87 There is currently also no confirmed BGC for the 
micromonospolides, which are so far exclusively derived from Nocardia and Micromonospora 
spp., and further genome sequencing-driven investigation of these clusters is warranted.88,89  
Unlike RiPPs, whose modifications are easy to predict based on the BGC,90 facilitating 
rational labeling of functional groups, the link between genes and structure is less direct for other 
types of natural products, such as the polyketides. For example, the biosynthetic origin of the 
fumaryl appendage that is present in many hygrolide natural products is unclear. By identifying or 
postulating signature genes that would reliably result in the installation of this functional group, 
strains encoding fumarate-containing hygrolides could be prioritized for thiol labeling with the 
aim of identifying new, biologically active metabolites. Indeed, HbaJ/HbaK (ORF2/ORF3 in S. 
lohii) may be the mostly likely candidates for fumaryl activation into CoA (HbaK) and transfer 
(HbaJ), as proposed by Hwang et al.43 This is supported by the presence of orf2/orf3 homologues 
in all known fumarate-bearing hygrolide BGCs. One known hygrolide cluster—the recently 
disclosed leucanicidin BGC from Kitasatospora sp. MBT66—lacks orf2/orf3 homologues, and 
this is consistent with the fact that the known hygrolides from this organism are fumarate-free, 
instead functionalized with a sugar at the same site.59 The presence of orf2/orf3 homologues in the 
concanamycin BGC is not consistent with the lack of a fumaryl appendage in concanamycin A, 
but is worth noting that virustomycin and viranamycin, members of the concanamycin family also 
isolated from Streptomyces spp., indeed bear a fumarate, and these proteins may be responsible 
for their biosynthesis.91,92 The reveromycins are antifungal spiroacetals which are, like some 
hygrolides, ester-substituted at an alcohol. Although the originally-reported compound 
reveromycin A contains a succinyl group,93 it was found recently that the parent organism produces 
an array of compounds, among them reveromycins H–K, which instead bear a fumaryl moiety.94 
Additionally, the reveromycin BGC contains a pair of proteins including the transferase RevK 
(36% protein sequence identity, 55% similarity to S. lohii ORF2) and acyl-CoA ligase RevL (61% 
identity, 73% similarity to S. lohii ORF3).95 Although the functions of these two proteins were not 
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interrogated in the original report,95 it is most probable that they install succinyl and fumaryl 
moieties into the corresponding reveromycin congeners.  
 
Figure 3.10 Representative plecomacrolide BGCs and their products. (A) Alignment of representative 
plecomacrolide BGCs. BGCs from S. griseus, S. hygroscopicus, S. neyagawaensis, and S. lohii were previously 
confirmed by genetic manipulation. BGCs from S. halstedii, K. cheerisanensis, K. setae, and S. varsoviensis were 
identified bioinformatically by homology to reported BGCs and biosynthetic logic. In S. halstedii, the BGCs are split 
between multiple partial-cluster contigs, as indicated. Interestingly, the methoxymalonate biosynthesis cassette is 
absent in the BGC from S. hygroscopicus despite the presence of this moiety in the molecule. S. varsoviensis lacks 
bafXYZ homologues thought to be responsible for 5-aminolevinulate installation; this structural moiety is not present 
in identified metabolites from this organism. (B) Representative natural products from the above BGCs are shown. 
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Figure 3.11 Phylogenetic tree of homologues from hygrolide/concanamycin BGCs. Shown are maximum-
likelihood trees for (a) ORF3 homologues and (b) BafD homologues. The structural class of compound predicted or 
known to correspond to an organism is indicated. For organisms listed in black, a compound class could not be 
predicted and novelty is suspected. The actinomycete Frankia alni was chosen as an outgroup and is not predicted to 
contain a hygrolide BGC. 
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Figure 3.12 Phylogenetic tree of hygrolide producers. (a) A maximum-likelihood phylogenetic tree was generated 
using 16S rRNA gene sequences of known producing organisms for various hygrolides. For the genus 
Micromonospora, no 16S sequence corresponding to a confirmed producer was available, so M. inyonensis and M. 
peucetia were used as placeholders. For organisms listed in black, a compound class could not be predicted and novelty 
is suspected. The actinomycete Frankia alni was chosen as an outgroup and is not predicted to contain a hygrolide 
BGC. (b) Core scaffolds of the families shown in (a) are given. Within each family, variation is seen at various 
positions of the core. Features distinguishing the families from each other are shown in red. 
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3.7 Bioinformatic survey of known and unknown hygrolide biosynthetic gene clusters 
We next sought to determine the phylogenetic context of the JBIR-100 (hygrobafilomycin-
type scaffold) BGC and survey the hygrolide biosynthetic sequence space. Using representative 
genes from the bafilomycin, hygrolidin, hygrobafilomycin, and concanamycin BGCs (Table 3.5), 
we created pHMMs of the conserved biosynthetic machinery from each using HMMER3.85 Using 
BafD and ORF3 sequences from S. lohii, S. varsoviensis, and S. neyagawaensis as BLAST queries, 
we identified the most closely-related homologues of these genes and inspected the local genomic 
region using HMMER3 and our pHMMs. On the basis of HMM hits and cluster organization, we 
thus assembled a list of 34 predicted and known hygrolide BGCs. In cases where only a partial 
BGC sequence was available due to the presence of small contigs, clustering of BafD homologues 
with confirmed BGCs on a BafD homologue sequence similarity network was used for 
classification (data not shown).96 Each BGC was assigned to a structural family by pairwise 
comparison of the BafD and ORF3 homologues to those from known producers (Table 3.6). In 
most cases, this allowed clear assignment, although some organisms harbored genes not close to 
any of the standards (<75% identity at the protein level). Interestingly, no clusters with sequence 
identities >90% to the S. varsoviensis cluster were found, despite many other hygrolide clusters 
having >90% identity to S. lohii and to each other.  
Using phylogenetic trees built on 16S rRNA, BafD, and ORF3 homologue alignments, we 
compared phylogeny and molecular scaffold (Figures 3.11 and 3.12). In general, the hygrolide 
producers are highly related to each other and group closely, but this is unsurprising given that 
most are part of the Streptomyces or Kitasatospora genera. Interestingly, 16S rRNA sequence 
comparison showed that the known JBIR-100 producers S. varsoviensis and S. sp. IR027-SDHV6 
are not only distinct organisms, but are also more closely related to other hygrolide producers of 
different structural subfamilies than to each other. The concanamycin producer Streptomyces 
neyagawaensis and the micromonospolide producers do not group closely by 16S rRNA sequence 
(Figure 3.12), which was somewhat unexpected given the structural similarity of the alkene 
terminus of the acetal ring in the two scaffolds. We found that the phylogenic relationship of BafD 
and ORF3 homologues seemed to parallel the overall hygrolide scaffold from each producing 
organism (Figure 3.11). In particular, the BGCs for eight known classical bafilomycins formed a 
clade that includes 12 other putative bafilomycin producers. The BafD and ORF3 homologues 
from the hygrobafilomycin cluster from S. varsoviensis are near, but outside of, this highly-related 
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bafilomycin clade; also outside are one known (S. neyagawaensis) and two predicted (S. scabiei 
and S. stelliscabiei) concanamycin clusters, one known (S. hygroscopicus subsp. hygroscopicus) 
and three predicted (S. sp. 150FB, S. ghanaensis, and S. viridosporus) hygrolidin producers, as 
well as several organisms for which a confident scaffold prediction could not be made. 
We identified a number of organisms not previously known to harbor hygrolide BGCs 
(Table 3.6). To our knowledge, the biosynthetic capabilities of these organisms, with respect to 
hygrolide biosynthesis, have not been investigated. The BGCs from a number of organisms (Table 
3.6) were not highly related to any known BGC but still appear hygrolide-like in gene architecture, 
suggesting that the products of these BGCs may represent novel hygrolide scaffolds. Given the 
elusiveness of micromonospolide, demethylbafilomycin, and didemethylbafilomycin BGCs, it is 
possible that future investigation of these organisms will shed light into the genomic origin of these 
compounds or could yield new scaffolds entirely. Overall, we identified 22 BGCs to which natural 
products have not yet been linked. 
 
Table 3.5 Accession numbers for hygrolide BGCs. Nearest homologues of compounds from the baf BGC in S. lohii 
are shown. In some cases, locus tags or nucleotide coordinates are given in lieu of accessions for nucleotide-only 
records. The bafAIV homologue in S. halstedii is split between two contigs and so its percent identity was not assessed. 
In S. hygroscopicus, the protein corresponding to CCF2302 is a fusion of BafAIII and BafAIV. 
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Scaffold 
Prediction 
Known 
Natural 
 Product 
Structural 
Family 
288965957 288965964 Streptomyces lohii 100 89 82 67 74 100 90 75 69 73 bafilomycin bafilomycin 
482661949 482661956 Streptomyces griseus 97 88 80 67 74 98 90 76 69 73 bafilomycin bafilomycin 
493388797 493388790 Streptomyces tsukubaensis  88 86 83 68 75 85 86 74 68 72 bafilomycin – 
517298471 517298478 Streptomyces sp. CcalMP-8W 97 89 80 66 74 97 90 73 68 72 bafilomycin – 
517394815 517394807 Streptomyces sp. PsTaAH-124 93 88 81 66 74 92 91 74 68 71 bafilomycin – 
517791715 517791722 Streptomyces sp. CNB091 96 88 79 66 74 98 90 73 67 72 bafilomycin – 
654969407 654969414 Streptomyces sp. SolWspMP-sol2th 97 89 80 67 74 98 90 73 68 72 bafilomycin – 
654979441 654979377 Streptomyces sp. TAA040 94 88 80 66 74 93 91 74 68 72 bafilomycin – 
654993951 n.a. Streptomyces sp. DpondAA-B6 - - - - - 94 92 74 70 71 bafilomycin – 
663401407 n.a. Streptomyces purpeofuscus - - - - - 91 92 74 71 74 bafilomycin – 
664093809 654993958 Streptomyces halstedii 94 90 82 67 75 94 93 74 70 72 bafilomycin bafilomycin 
726969199 726969206 Streptomyces sp. M10 97 88 80 67 74 98 90 76 69 73 bafilomycin bafilomycin 
737891878 737891867 Kitasatospora cheerisanensis 90 93 80 68 73 90 92 74 71 74 bafilomycin bafilomycin 
740031905 654993958 Streptomyces sp. NTK 937 94 90 82 67 75 93 93 74 70 72 bafilomycin – 
740068110 740068128 Streptomyces sp. PCS3-D2 89 86 84 67 76 88 90 75 71 73 bafilomycin – 
759764416 n.a. Kitasatospora sp. MBT66 - - - - - 91 92 74 71 74 bafilomycin bafilomycin 
763023462 763023454 Kitasatospora griseola 90 92 79 67 72 91 93 74 70 73 bafilomycin bafilomycin 
799307788 n.a. Streptomyces sp. XY431 - - - - - 91 91 74 71 74 bafilomycin – 
916321000 503906410 Kitasatospora setae 89 100 79 67 73 90 100 75 69 73 bafilomycin bafilomycin 
924906653 924906647 Streptomyces sp. CFMR 7 98 89 80 66 74 99 91 73 68 72 bafilomycin – 
502770800 n.a. Streptomyces scabiei - - - - - 73 72 69 67 98 concanamycin – 
822059630 822063703 Streptomyces stelliscabiei 76 76 74 69 93 73 72 69 67 98 concanamycin – 
943900294 943905490 Streptomyces neyagawaensis 74 75 73 69 100 73 72 69 68 100 concanamycin concanamycin 
n.a. 889609429 Streptomyces varsoviensis 82 81 100 65 73 75 72 100 64 67 hygrobafilomycin hygrobafilomycin 
491120173 491120212 Streptomyces ghanaensis  67 67 66 96 68 69 69 65 100 68 hygrolidin hygrolidin 
515242709 515242729 Streptomyces viridosporus T7A 67 67 66 96 68 69 69 65 100 68 hygrolidin – 
748767887 748767878 Streptomyces sp. 150FB 68 67 66 86 69 68 68 68 79 70 hygrolidin – 
n.a. 466860673 Streptomyces hygroscopicus 67 67 65 100 69 - - - - - hygrolidin hygrolidin 
655029786 655029979 Nocardia sp. CNY236 71 72 68 69 75 71 70 65 66 70 n.d. – 
490056513 490056911 Streptomyces clavuligerus  70 72 74 64 68 70 71 70 64 71 n.d. – 
739855312 n.a. Streptomyces sp. AA1529 - - - - - 67 67 64 66 69 n.d. – 
739934956 n.a. Streptomyces sp. CNT318 - - - - - 67 67 64 66 69 n.d. – 
916734751 n.a. Pseudonocardia spinosispora  - - - - - 64 64 62 63 64 n.d. – 
925291620 917236896 Streptomyces caelestis 71 71 72 65 68 74 75 73 67 73 n.d. – 
Table 3.6 Phylogenetic classification of known and predicted hygrolide BGCs. BafD and ORF3 homologues are 
given from each organism as GI numbers. The percent amino acid identity of each gene to a set of representative genes 
from organisms harboring bafilomycin, hygrobafilomycin, hygrolidin, or concanamycin BGCs was found using 
BLAST and is indicated by the depth of color shade. BGCs were classified by similarity. BGCs where a hygrolide 
compound has been isolated are indicated, along with the structural family of compounds. For several BGCs (bottom 
of the table), a definitive assignment could not be made due to a lack of strong relatedness to any of the model 
sequences.  n.d., not determinable.  Twenty-two BGCs have no known associated natural product(s). For BafD, where 
no homologue exists in the S. hygroscopicus BGC, the homologue from S. ghanaensis was used instead for 
comparison.  
 
3.8 Conclusions 
There is a pressing need to discover new compounds to combat the increasing number of 
infections caused by drug resistant bacteria. To this end, natural products and derivatives thereof 
have served as a primary source of leads for the development of antibacterial agents.97 In the 
present study, we identified Streptomyces varsoviensis as a novel producer of the 
hygrobafilomycin JBIR-100, described its BGC, and provided spectral and bioinformatic evidence 
for the previously unknown stereochemistry of the natural product. Currently, the antibacterial 
MOA(s) of the hygolides is not known. This study shows that JBIR-100 has promising 
antibacterial activity and that treatment of B. subtilis with JBIR-100 leads to cell membrane 
permeabilization and depolarization, although other bactericidal mechanisms have yet to be 
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investigated. The modestly JBIR-100 resistant mutants contained a number of polymorphisms but 
the genomic locations of the polymorphisms and the phenotypes of the mutants did not permit a 
precise biological target for JBIR-100 to be proposed in the present work. Future work can focus 
on further elucidation of the MOA; however, our data suggest that hygrolide scaffolds could be 
investigated as a potential avenue for antibiotic development.  
The successful identification of JBIR-100 by nucleophilic 1,4-addition in a S. varsoviensis 
extract indicates that this simple reaction will be useful in discovering other fumarate-containing 
plecomacrolides and other natural products containing electron-deficient alkenes. Importantly, 
fumaryl substitution is not limited to macrolides, but is present in other polyketides, including 
reveromycin H–J,94 the antibiotic fumimycin,98 and some nonribosomal peptide natural products 
such as the thrombin inhibitor Ro 09-1679.99 Our attempt to reconcile the molecular and genetic 
phylogenies of the hygrolide family resulted in the identification of 22 orphan hygrolide gene 
clusters, indicating that potential remains to find novel hygrolide variants among the 
Actinomycetes. 
3.9 Experimental 
3.9.1 Bacterial strains and culture 
S. varsoviensis NRRL B-3589 was grown in 5 mL of MMS (mannitol-malt-soy) broth (1 
L contains 10 g mannitol [BDH Chemicals], 10 g malt extract [BD, Franklin Lakes, NJ], 10 g 
roasted soybean flour [Wel-Pac]) at 30 °C for 3 d with aeration, before subculturing to MMS agar 
followed by incubation at 30 °C for 7 d. Firmicutes and Mycobacterium smegmatis were grown in 
LB (Luria-Bertani) broth (BD) and incubated at 37 °C with aeration. In the case of M. smegmatis, 
broth contained 0.05% Tween 80. Media was solidified by adding 1.5% agar (BD) where relevant. 
Ascomycota were grown in YPD (yeast-peptone-dextrose) broth (1 L contains 10 g yeast extract, 
20 g peptone and 20 g D-glucose) at 30 °C with aeration. 
3.9.2 Isolation of JBIR-100 
For production of JBIR-100, S. varsoviensis NRRL B-3589 was grown on 1 L MMS agar 
for 7 d. The cell mass was scraped from the solid medium and exported metabolites were extracted 
by gentle agitation in n-BuOH for 4 h at ~22 °C. The solid medium was frozen, thawed, and the 
resulting liquid was removed by filtration through cheesecloth with pressure and extracted 
similarly. After centrifugation (4000 × g, 5 min) of the crude extract, the organic layer was 
removed from the intact, harvested cells. Solvent was removed and the residue was suspended in 
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MeCN (100 mL) and EtOAc (20 mL) before being concentrated onto 10 g of Celite 545 (Sigma-
Aldrich) by rotary evaporation (25 °C). The dried suspension was purified by MPLC (TeleDyne 
Isco 130 g C18 cartridge; 15–100% gradient of MeCN in aq. 10 mM NH4HCO3, pH 8). Fractions 
containing JBIR-100, as determined by MALDI-TOF MS, were combined and concentrated. The 
combined fractions were redissolved in 50% aq. MeCN (4 mL), centrifuged (17,000 × g, 5 min), 
and purified by HPLC (Teledyne Isco C18Aq column; 5 µm particle size; 20 × 150 mm; 19 
mL/min; 20–100% gradient of MeCN in aq. 10 mM NH4HCO3, pH 8). The residual undissolved 
material was resuspended, sonicated, centrifuged, and purified analogously until no more JBIR-
100 was detected by MALDI in the eluent. Combined fractions from all 4 HPLC batches, when 
combined and evaporated, yielded 150 mg of light yellow solid. This was then dissolved in 75% 
aq. MeCN (3.5 mL) and purified by HPLC (Teledyne Isco C18Aq column; 5 µm particle size; 20 
× 150 mm; 19 mL/min; 35–55% gradient of MeCN in aq. 10 mM NH4HCO3, pH 8). Fractions 
containing JBIR-100 were combined and evaporated overnight. The isolated material was 
analyzed by HPLC (Thermo Betasil C18; 5 µm particle size; 4.6 × 150 mm; 1 mL/min; gradient 
of MeCN (B) in aq. 10 mM NH4HCO3, pH 8 (A); 5% B for 3 min, 15 min ramp to 95% B, 10 min 
hold at 95% B). Suspension in H2O, flash-freezing, and lyophilization yielded JBIR-100 as a 
colorless powder (30 mg). 
3.9.3 Thiol labeling 
JBIR-100 was subjected to labeling as previously described 50. An aliquot (14 μL) of a 
crude n-BuOH extract of S. varsoviensis NRRL B-3589 or of isolated material in n-BuOH was 
mixed with DTT (in MeOH) and DIPEA (N,N-diisopropylethylamine; in MeOH) to a final volume 
of 20 μL. The final concentration of DTT was 500 mM and that of DIPEA was 10 mM in 7:3 n-
BuOH/MeOH. The mixture was allowed to react for 16 h at ~22 °C. The sample was analyzed for 
DTT incorporation by MALDI-TOF MS. 
3.9.4 Mass Spectrometry 
3.9.4.1 MALDI-TOF MS analysis 
An aliquot (1 μL) of extract was mixed with 9 μL of saturated α-cyano-4-hydroxycinnamic 
acid matrix solution in 1:1 MeCN/H2O containing 0.1% trifluoroacetic acid. Samples (1.5 μL) 
were spotted on a steel plate and air-dried at ~22 °C. Mass spectra were obtained using a Bruker 
Daltonics UltrafleXtreme MALDI-TOF/TOF mass spectrometer in positive reflector mode. The 
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instrument was calibrated using a peptide calibration kit (AnaSpec Peptide Mass Standard Kit). 
Data were analyzed using flexAnalysis 3.3 (Bruker). 
3.9.4.2 FT-MS/MS analysis 
Samples were dried by centrifugal vacuum concentration and dissolved in 50% aq. MeCN 
containing 1% (v/v) acetic acid. The diluted samples were directly infused using an Advion 
Nanomate 100 to an LTQ-FT hybrid linear ion trap-FTMS system (ThermoFisher) operating at 11 
T. The MS was calibrated weekly using calibration mixture following the manufacturer's 
instructions, and tuned daily with Pierce LTQ Velos ESI Positive Ion Calibration Solution 
(ThermoFisher). Spectra were collected in profile mode with a resolution of 100,000. The singly 
charged ions were targeted for CID using an isolation width of 2 m/z, a normalized collision energy 
of 35, an activation q value of 0.4, and an activation time of 30 ms. Data analysis was performed 
using Thermo Xcalibur software. 
3.9.5 NMR spectroscopy  
HPLC-purified and lyophilized JBIR-100 (ca. 5 mg, 12 mM) was dissolved in CD3OD 
(99.96% D, Sigma-Aldrich; 600 µL). NMR spectra were obtained using an Agilent VNMRS 750 
MHz narrow bore magnet spectrometer equipped with a 5 mm triple resonance (1H-13C-15N) 
triaxial gradient probe and pulse-shaping capabilities. Samples were held at 296 K during 
acquisition. Standard Varian pulse sequences were used for each of the following experiments: 1H 
(s2pul; 32768 points; 64 scans), 1H-1H DQF-COSY (gDQCOSY; 1234 × 256 points; 4 scans), 1H-
1H TOCSY (zTOCSY; 80 ms mixing time; 1234 × 256 points; 8 scans), multiplicity-edited 1H-13C 
HSQC (HSQCAD; 1234 × 256 points; 32 scans), and 1H-13C HMBC (gHMBCAD; optimized for 
8 Hz heteronuclear couplings; 1234 × 256 points; 64 scans). Spectra were recorded with VNMRJ 
3.2A software, and data was processed using MestReNova 8.1.1. Chemical shifts (δ, ppm) were 
referenced internally to the solvent peak (MeOH, 3.30 ppm). 
3.9.6 Biological activity of JBIR-100 
3.9.6.1 Minimum inhibitory concentration determination 
MIC determinations were performed by microbroth dilution assay as described by Clinical 
and Laboratory Standards Institute 100. Briefly, JBIR-100 was added at a starting concentration of 
64 µM (except in the case of C. albicans at a starting concentration of 128 µM) and two-fold serial 
dilutions added to wells containing ~5 × 104 colony forming units of test strain in the relevant 
medium (see Section 4.1). Wells were inspected for turbidity after 16–18 h incubation (40-42 h in 
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the case of Z. rouxii) under the relevant conditions (see Section 4.1) and the MIC was recorded as 
the lowest compound concentration causing inhibition of visible growth. The procedure was 
identical for kanamycin (starting concentration 256 µM), chloramphenicol and triclosan (starting 
concentration 64 µM), and ampicillin, ciprofloxacin, rifampicin, and vancomycin (starting 
concentration 8 µM). 
3.9.6.2 Minimum bactericidal concentration determination 
The MBC is the lowest concentration of antibacterial agent that reduces the viability of an 
initial bacterial inoculum by ≥99.9% 60. After performance of the B. subtilis 47096 MIC, the MBC 
of JBIR-100 was determined by subculturing those wells with no visible growth to LB agar. After 
16 h incubation at 37 °C, the plates were inspected for the presence of colonies; the MBC was 
recorded as the lowest compound concentration required to kill B. subtilis (i.e. no colonies 
recovered) in three independent replicates.   
3.9.6.3 Growth curve 
Three independent stationary cultures of B. subtilis ATCC 47096 were diluted 1000-fold 
in fresh LB broth and grown to mid-exponential phase (OD600 of 0.4). The cultures were then 
distributed into a microtiter plate and treated with DMSO (vehicle), 1× (8 µM), 2× (16 µM), or 4× 
(32 µM) MIC JBIR-100. The plate was covered with a clear plastic lid and placed in a pre-warmed 
(37 °C) plate reader (Molecular Devices FilterMax F5). After shaking for 5 s in linear mode at 
medium intensity, the initial density (t = 0) was read. The plate was then monitored at 595 nm 
every 10 min for 16 h with 565 s of linear mode, medium intensity shaking between reads. OD 
values were averaged and normalized to an initial read value of 0.4 at t = 0. 
3.9.6.4 Fluorescence microscopy 
Aliquots (200 µL) of stationary phase cultures of B. subtilis ATCC 47096 were used to 
inoculate fresh LB (5 mL). After growing cells to OD600 of 0.5 at 37 °C with shaking, aliquots (1 
mL) were centrifuged and resuspended in sterile PBS (phosphate-buffered saline; pH 7.4; 1 L 
contains 8 g NaCl, 0.2 g KCl, 1.44 g NaH2PO4, 0.24 g KH2PO4) containing vehicle alone (DMSO), 
1× (8 µM), 4× (32 µM), or 8× (64 µM) MIC of JBIR-100. Cells were exposed for 30 min at ~22 
°C before being washed and subsequently treated with 10 µM PI in PBS for 15 min at ~22 °C. 
After washing in PBS, cells were resuspended in PBS and immobilized on glass slides by mixing 
1:1 (v/v) cell suspensions with liquefied low gelling temperature agarose (Sigma-Aldrich, 2% w/v 
in sterile H2O). Images were obtained on the same day using a Zeiss LSM 700 confocal microscope 
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with a 63×/1.4 Oil DIC objective. A 405 nm laser was used for DIC and a 555 nm laser was used 
to excite PI (emission detected at 585 nm). Laser intensity and gain were kept to a minimum and 
held constant for all experiments. Images were processed using Zen 2012 software. Linear contrast 
was equally applied during image processing. 
3.9.6.5 Membrane depolarization assay 
Three independent stationary phase cultures of B. subtilis ATCC 47096 were used to 
inoculate fresh LB and grown at 37 °C with shaking to OD600 = 0.5. Aliquots (10 µL) were diluted 
to 1 mL in PBS containing 0.1 mM 3,3′-diethyloxacarbocyanine iodide and compounds (DMSO – 
vehicle, 5 µM carbonyl cyanide m-chlorophenyl hydrazone – positive control, 0.1 µM JBIR-100, 
0.2 µM JBIR-100, 0.5 µM JBIR-100, 1.0 µM JBIR-100). Cells were mixed at ~22 °C for 30 min 
prior to analysis by flow cytometry (BD LSR II Flow Cytometry Analyzer). Voltages for 
fluorescein isothiocyanate and PI fluorescence were set so that average counts per cell were 
between 103 and 104 for the vehicle control samples and kept constant for all subsequent samples. 
Cells were gated with forward scatter of 1100 and side scatter of 1800. Geometric means for 
fluorescence ratios were normalized to the vehicle control samples.  
3.9.6.6. Isolation of JBIR-100-resistant mutants 
For each attempt to obtain spontaneous JBIR-100-resistant mutants of B. subtilis ATCC 
47096, three independent cultures were grown overnight in LB medium at 37 °C. From each 
culture, a portion containing ~ 106 cells was spread on LB agar containing 4× MIC (32 µM) JBIR-
100, resulting in no growth after 48 h at 37 °C. In a second and third attempt, ~ 107 and 108 cells 
were spread from each culture on LB containing 2× MIC  (16 µM) JBIR-100, again resulting in 
no growth after 48 h at 37 °C. 
Dose-escalation mutants of B. subtilis ATCC 47096 were isolated by serial passaging in 
the presence of increasing concentrations of JBIR-100. Three independent cultures (A, B & C) 
were started at an OD600 of 0.1 in LB containing 0.5× MIC JBIR-100. After incubation for 24 h at 
37 °C, the cultures were diluted to an OD600 of 0.1 in LB containing the same concentration of 
JBIR-100 as the originating culture, as well as in LB containing a 0.5× MIC increase in JBIR-100. 
For subsequent passages, the inoculum was taken from the culture from the previous passage 
containing the higher concentration of JBIR-100, if growth was obtained. Again, the cultures were 
diluted to an OD600 of 0.1 in LB containing the same concentration of JBIR-100 as the originating 
culture, as well as in LB containing a 0.5× MIC increase in JBIR-100. In this way, the B. 
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subtilis ATCC 47096 cultures were subjected to increasing concentrations of JBIR-100 over 10 
passages. These cultures were then streaked on LB agar lacking JBIR-100 and incubated for 24 h 
at 37 °C. For each replicate, an isolated colony was picked and restreaked onto fresh LB agar plates 
lacking JBIR-100. This process was repeated a further two times to confirm mutant stability. The 
three mutant strains (named P10A, P10B and P10C) were tested for JBIR-100 resistance via MIC 
as described above. 
3.9.7 Whole-genome sequencing 
Genomic DNA from the parent B. subtilis ATCC 47096 and three JBIR-100-resistant 
mutants was isolated using an UltraClean Microbial DNA Isolation Kit (MO BIO). Shotgun 
genomic libraries were constructed and sequenced by the Roy J. Carver Biotechnology Center 
(University of Illinois, Urbana, IL, USA). The genomic libraries were prepared using a KAPA 
Hyper Prep Kit (Kapa Biosystems), with average gDNA fragment of 400 bp (from 80 bp to 700 
bp). The libraries were quantified by qPCR, and sequenced on one lane on an Illumina HiSeq2500 
with single-reads 100 nt in length using a HiSeq SBS sequencing kit version 4. Fastq files were 
generated and demultiplexed with the bcl2fastq v1.8.4 Conversion Software (Illumina). The parent 
genome was assembled relative to a reference genome (AL009126.3) using both CLC Genomics 
Workbench (CLC bio) and Geneious (Biomatters). Polymorphisms in the genomes of the JBIR-
100-resistant mutants (P10A, P10B and P10C) were mapped relative to the parent genome and 
verified by PCR amplification followed by Sanger sequencing.   
3.9.8 Bioinformatic analysis 
3.9.8.1 Ketoreductase domain classification  
KR sequences were extracted from the JBIR-100 BGC of S. varsoviensis NRRL ISP-5346 
using PRISM (http://magarveylab.ca/prism/).70 KR sequences were aligned using MUSCLE (v. 
3.8.31, http://www.ebi.ac.uk/Tools/msa/muscle/) on default settings.101,102 Classification was 
performed by the absence or presence of diagnostic motifs identified by previous studies as well 
as by use of the ScoreDiff web tool (https://akitsche.shinyapps.io/profileHMM_App).78-80 
Alignments with indicated motifs are given in Figure 3.9. 
3.9.8.2 Analysis of gene clusters  
Clusters were analyzed using PRISM,70 antiSMASH,51 HMMER3,85 and BLAST.71 The 
function of genes was inferred by homology as identified by BLAST against the nr database from 
GenBank.71,103 PKS domains were identified with antiSMASH51 and PRISM.70 To generate 
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bafilomycin biosynthetic protein pHMMs, the sequences of homologues of BafB–H, BafX–Z, and 
ORF1–3 from S. lohii, K. setae, S. varsoviensis, S. hygroscopicus subsp. hygroscopicus, and S. 
neyagawaensis were aligned using MUSCLE101 on default settings; pHMMs were generated from 
the alignments using HMMER3. For analysis of predicted hygrolide producers, the local genomic 
region (+/- 16 genes) of S. lohii BafD or ORF3 homologues, as identified by BLAST, were 
analyzed using HMMER3 against a set of custom pHMMs. Clusters containing several pHMM 
hits were then analyzed by BLAST to determine similarity of BafD and ORF3 homologues to 
those from known BGCs. Clusters were classified on the basis of overall architecture and amino 
acid percent identity of BafD and ORF3 homologues to the corresponding proteins from S. lohii 
(bafilomycin), K. setae (bafilomycin), S. varsoviensis (hygrobafilomycin), S. hygroscopicus subsp. 
hygroscopicus (hygrolidin), and S. neyagawaensis (concanamycin). 16S rRNA sequences were 
not available for some organisms, nor were genomes and/or BafD/ORF3 sequences available for 
all organisms for which 16S rRNA sequences were obtained. As no micromonospolide BGC has 
been reported, producers were grouped together by 16S rRNA sequence alone.  
3.9.8.3. Generation of phylogenetic trees  
16S rRNA sequences were downloaded from the SILVA database.104 Alignment of 
sequences was done using MUSCLE with default parameters within MEGA6.101,105 Phylogenetic 
trees were created in MEGA6 using the maximum-likelihood method with default parameters.105 
Trees were annotated using FigTree (v.1.4.2; http://tree.bio.ed.ac.uk/software/figtree/) and Adobe 
Illustrator. The actinomycete Frankia alni was used as an outgroup to root the tree in all cases. 
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CHAPTER 4: DEVELOPMENT OF A GENOME MINING TOOL AND ITS 
APPLICATION TO THE LASSO PEPTIDE BIOINFORMATIC LANDSCAPE 
This work is in review for publication.* 
4.1 Introduction 
The influence of natural products on the chemical, biological, and medical disciplines is 
difficult to overstate. In particular, natural products (NPs) transformed the practice of medicine, 
where a major percentage of clinically relevant molecules are NPs, mimics, or derivatives.1 
Despite this, the discovery of novel NPs remains an endeavor largely based on trial and error; the 
traditional bioassay-guided isolation method has historically been fruitful, but abundant, long-
known compounds dominate such screens, resulting in the costly and time-consuming 
“rediscovery problem”.2 Reconciling the challenges of traditional NP discovery with the 
opportunities of modern genomics, computational methods represent a promising bridge between 
genes and molecules.3,4 In this way, genomic information allows for NP structural prediction, 
facilitates prioritization based on structural novelty, and guides structure elucidation.5-7 
Biosynthetic gene cluster (BGC) analysis tools which predict compound structure based 
on functional domain content and architecture (e.g. antiSMASH and PRISM), have been 
developed for modular assembly-line complexes such as polyketide synthases (PKS) and non-
ribosomal peptide synthases (NRPS).3,7-11 These tools have enabled broad-scale profiling of non-
ribosomal peptides and polyketides.12,13 Ideally, this type of analysis could be applied to other NPs 
classes, such as the ribosomally synthesized and post-translationally modified peptides (RiPPs).14  
                                                 
* This chapter is adapted in part from Tietz, J.I.; Schwalen, C.J.; Patel, P.S.; Maxson, T.; Blair, P.M.; Tai, C.-H.; Zakai, 
U.I.; Mitchell, D.A. “A new genome mining tool redefines the lasso peptide biosynthetic landscape.” Submitted. J.I.T. 
and C.J.S. were co-first authors. J.I.T. and C.J.S. are co-first authors. J.I.T. and C.J.S. wrote the paper with significant 
editorial input from D.A.M. J.I.T. wrote code, conducted bioinformatic analysis, performed screening, performed 
compound isolation, solved structures, and ran and analyzed NMR. C.J.S. conducted bioinformatic analysis, 
performed screening, performed compound isolation, and performed and analyzed microbiological experiments, and. 
P.S.P. wrote code. T.M. performed compound isolation, structure elucidation, heterologous expression, and prepared 
genomic DNA for sequencing. P.M.B. performed and analyzed HR-MS/MS. H.C.T. performed chirality analysis. 
U.I.Z. performed compound isolation. D.A.M. oversaw the project and analyzed data. All authors assisted in the 
writing and revision process. We thank Lingyang Zhu (Univ. Illinois Urbana-Champaign) and Ben Ramirez (Univ. 
Illinois Chicago) for NMR assistance. We acknowledge Courtney Cox (Univ. Illinois Urbana-Champaign) and 
Nicholas Tietz for valuable discussions regarding bioinformatics and machine learning. This work was supported in 
part by a NIH Director’s New Innovator Award Program (DP2 OD008463 to D.A.M.), the David and Lucile Packard 
Fellowship for Science and Engineering (to D.A.M.), the Robert C. and Carolyn J. Springborn Endowment (to J.I.T.), 
and ACS Division of Medicinal Chemistry Predoctoral Fellowships (to P.M.B. and J.I.T.). The Bruker UltrafleXtreme 
MALDI TOF/TOF mass spectrometer was purchased in part with a grant from the National Center for Research 
Resources, National Institutes of Health (S10 RR027109 A). The 900 MHz NMR spectrometer was purchased with 
funds provided by GM068944.  
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As gene-encoded peptides, RiPP precursors are tailored by various biosynthetic enzymes 
to produce structurally and functionally diverse compounds (Figure 4.1a). RiPPs also present 
unique characteristics for genomic identification: (i) their BGCs are relatively small, (ii) RiPP 
precursors are typically encoded near the modification enzymes, (iii) their sequence can be used 
to predict novelty and aid structure elucidation,5 and (iv) RiPP precursors have separate sites for 
enzyme-binding and modification (referred to as the leader and core regions, respectively). The 
unmodified leader region is proteolytically removed during maturation. This provides a facile route 
to evolving new NPs since RiPP enzymes can be highly selective for a particular leader sequence 
but promiscuously process many core sequences (Figure 4.1a).15 
 Given these characteristics, RiPP genome mining has unique yet-unmet challenges.3 For 
instance, the biosynthetic enzymes for some RiPP classes are similar to those from primary 
metabolism, making genomic context analysis, not just sequence conservation, critical for 
identification. Additionally, RiPP precursors are small (often <60 aa) and hypervariable, which 
leads to frequent evasion of gene annotation and renders common sequence comparison tools 
inadequate. Methods for mining RiPPs include single-input whole-genome analysis (i.e. 
antiSMASH and BAGEL3)11,16 and RiPPquest, a  mass spectrometry-based method for connecting 
BGCs to molecules.17 However, a customizable platform to predict RiPP BGCs across all taxa in 
a single query remains an unmet challenge. To develop such a platform, we have initially focused 
on lasso peptides, a RiPP subfamily (Figure 4.1b). Lasso peptides present particular challenges, 
even compared to other RiPPs. For instance, there can be as few as 2 essential biosynthetic 
enzymes, both closely related to primary metabolism. The BGCs are thus very small and easily 
overlooked. Furthermore, nearly all lasso precursors are not recognized as coding sequences and 
their hypervariability makes their identification nontrivial even by RiPP standards.  
Lasso peptides biosynthesis requires two enzymes: a lasso cyclase (C-protein) homologous 
to asparagine synthase and a leader peptidase (B-protein) homologous to transglutaminase. Lasso 
peptides contain a macrocyclic loop formed via the C-protein consisting of a linkage between an 
Asp or Glu side chain to the N-terminus of the core peptide, formed by the action of the leader 
peptidase. The macrocycle encircles the C-terminal tail, giving a lariat topology for which the lasso 
peptides are named (Figure 4.1b). Threading is maintained either by disulfide bonds between the 
loop and tail or by bulky tail residues.18 These features impart exceptional stability towards 
proteases and thermal denaturation, as well as a diversity of bioactivities. Lasso peptide BGCs 
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frequently feature transporters, a lasso-linearizing isopeptidase, and/or a RiPP recognition element 
(RRE) which binds the leader peptide and directs enzymatic modification (E-protein).15 Interest in 
these scaffolds is evident from the numerous studies geared toward generating unnatural lasso 
peptides.19-23 
Herein is reported the development of RODEO (Rapid ORF Description and Evaluation 
Online) (Figures 4.1c and 4.2), an algorithm developed to analyze RiPP BGCs via a combination 
of profile hidden Markov model (pHMM)-based local genomic region analysis and precursor 
peptide/structure prediction using a combination of heuristic scoring, motif analysis, and machine 
learning. The benefit of this approach is the ability to validate a small set of standards which can 
then confidently assess a much larger, more diverse group of candidates. Identification of novel 
NPs is an ideal application, particularly where there are only a few known examples but a higher 
expected level of prevalence.  
We have demonstrated the utility of RODEO by surveying and annotating the observable 
lasso peptide genomic space, revealing >1,300 BGCs, which expands the family by an order of 
magnitude. Our data revealed unforeseen trends in both precursor sequences and BGC architecture 
that allowed us to generate the most complete picture the lasso peptides to date. In addition to 
connecting all previously isolated lasso peptides to their respective BGCs, our analysis revealed a 
large number of conserved lasso peptide families containing structurally related precursor 
peptides. Furthermore, trends in amino acid sequence of core peptides and BGC architecture, 
including co-occurrence of previously-unrecognized tailoring enzymes are described. Lastly, we 
leveraged this new data set to isolate and characterize several new lasso peptides, which revealed 
a modification heretofore unseen in any RiPP, as well as a novel lasso topology. Hence, RODEO 
aids in generation of a high-quality, extensive meta-genomic data set, uncovering the extent of 
chemical/genetic diversity in a RiPP class, providing evolutionary context, and facilitating the 
discovery of new NPs. 
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Figure 4.1 Ribosomal natural product (RiPP) biosynthesis and overview of RODEO. (a) General overview of 
RiPP biosynthesis. (b) Overview of lasso peptide biosynthesis by leader peptidase, lasso cyclase, and RRE. (c) 
RODEO workflow and output. (d) Comparison of scoring accuracy on a randomly selected training set using heuristic 
scoring only or scoring with combined motif analysis (MEME) and machine learning (SVM). Sensitivity is 
represented by recall; specificity is represented by precision. (e) Comparative scoring distribution on the final peptide 
dataset using either heuristics only or scoring with MEME and SVM integrated. Scoring distributions were practically 
indistinguishable between training and full data sets (Figure 4.3). 
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Figure 4.2 Precursor peptide scoring algorithm. 
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4.2 Development of an algorithm for gene cluster analysis and precursor prediction 
The previously mentioned challenges regarding the confident identification of RiPP 
precursors render traditional methods insufficient. For example, in our final set of lasso peptide 
precursors, ~85% were not recognized as protein coding sequences in GenBank. Moreover, 
nucleotide and protein BLAST searches using all known lasso peptides as the query sequences 
cumulatively returned <300 hits, of which validation without laborious manual inspection of each 
BGC was unreliable. Low alignment scores between even closely-related peptides made 
distinguishing false positives from true lasso precursors impossible in most cases.  
To address these shortcomings, RODEO allows for high-throughput analysis of BGCs by 
first annotating the functions of all locally encoded genes. This is accomplished by retrieving 
protein sequences from GenBank and then analyzing these sequence using HMMER3. These 
results are compared against the Pfam database with the results being returned to the user in 
spreadsheet and HTML format (Figure 4.1c).24-26 For analysis of BGCs encoding proteins not 
covered by Pfam, RODEO allows usage of additional pHMMs (either curated databases or user-
generated). Hence, while RODEO was originally developed for lasso peptides, it also provides an 
expandable framework for targeting other RiPP and non-RiPP BGCs.27 Source code and tutorials 
for RODEO are available at http://www.ripprodeo.org.  
To confidently predict lasso precursors, RODEO next performs a six-frame translation of 
the intergenic regions within each potential BGC. The resulting peptides are assessed based on 
length and essential sequence features and split into predicted leader and core regions (Figure 4.1). 
A series of heuristics based on characteristics of known lasso peptides18,28 were defined to predict 
precursors from a large pool of false positives (Table 4.1). After optimization of heuristic scoring, 
we obtained good prediction accuracy, but only for BGCs closely related to known lasso peptides 
(Figures 4.1d and 4.3a). 
We reasoned that machine learning, particularly support vector machine (SVM) 
classification, would be more effective in evaluating precursor peptides from predicted BGCs more 
distant to known lasso peptides.29 Although SVM has been previously used to predict NRPS 
substrate specificity,30 to our knowledge, it has not yet been used to predict NP structures 
themselves. SVM is well-suited for RiPP discovery due to availability of SVM libraries that 
perform well with large data sets of numerous variables.31 After calculation of >100 features for 
each peptide in a manually curated training set (Table 4.2), we performed optimization of SVM 
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parameters using a randomly selected training set from the unrefined whole data which we 
manually classified (Figure 4.2). We found that combining SVM classification with motif 
(MEME) analysis32 and our original heuristic scoring greatly enhanced prediction accuracy, as 
evaluated by recall (sensitivity) and precision (specificity) metrics (Figures 4.1d, 4.3, 4.4a, and 
Table 4.1). The tripartite procedure yielded a high-scoring, well-separated population of 1,315 
lasso precursor peptides from >24,000 candidate peptides (Figures 4.1e and 4.3c). The training set 
was found to display nearly identical scoring distributions upon comparison to the full data set 
(Figure 4.4b). Our SVM optimization and classification scripts are included with the RODEO 
source code. 
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Figure 4.3 Scoring distributions for peptides. This figure expands upon what is shown in Figure 4.1e. (a) Peptide 
scoring distribution using only heuristics-based linear combination scoring; (b) Scoring in panel A with the addition 
of MEME/FIMO-identified sequence motif presence; (c) Scoring in panel B with addition of support vector machine 
(SVM) classification. 
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Figure 4.4 Evaluation of scoring accuracy and generality. This figure expands upon what is shown in Figure 4.1d. 
Shown are accuracy scores, as represented by precision (specificity) and recall (sensitivity) as well as a multiplied 
optimization score, for various score cutoffs used to classify lasso peptides as true positives. Shown accuracy rates are 
for the randomly selected training set. Accuracy progressively improves from a heuristic-only approach (a) when 
motif presence (b) or motif presence and SVM classification (c) are used in scoring. Scoring distributions are nearly 
identical between the training dataset (25% of full set) and the full dataset, as shown comparatively in (d). 
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 Feature Weight 
H
eu
ris
tic
 s
co
rin
g 
Within 500 nucleotides of any biosynthetic protein (E, B, C) +1 
Within 150 nucleotides of any biosynthetic protein (E, B, C) +1 
Greater than 1000 nucleotides from every biosynthetic protein (E, B, C) -2 
Core region has 2 or 4 Cys residues +1 
Leader region is longer than core region +2 
Core has 7 (Glu) or 8(Glu/Asp) or 9 (Asp) membered ring possible +1 
Core starts with G +2 
Leader region contains GxxxxxT +3 
Peptide and lasso cyclase are on same strand +1 
Leader/core region length ratio < 2 and > 0.5 +1 
Core starts with Cys and has an even number of Cys 0 
Core contains no Gly -4 
Core has at least one aromatic residue +1 
Core has at least 2 aromatic residues +2 
Core has odd number of Cys -2 
Leader region contains Trp -1 
Leader region contains Lys +1 
Leader region has Cys -2 
Gene cluster does not contain PF13471 -2 
+M
EM
E Peptide contains sequence motif #2 +2 
Peptide contains ANY lasso sequence motif +2 
Peptide contains NO lasso sequence motifs -1 
Peptide utilizes alternate start codon -1 
+S
VM
 
SVM classifies as valid +10 
Table 4.1  Features and weights used in linear-combination scoring. 
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Feature Data type Feature Data type 
Calcd. lasso peptide mass (Da) Float Core has adjacent identical aas Boolean 
Minimum distance from C, E, or B 
protein (nt) 
Integer Core length (aa) Integer 
Within 500 nt of C, E, or B Boolean Leader length (aa) Integer 
Within 150 nt of C, E, or B Boolean Precursor length (aa) Integer 
Further than 1000 nt from C, E, or B Boolean Leader/core ratio Float 
Core has 2 or 4 Cys Boolean Number of Pro in first 9 aa of core Integer 
Leader is longer than core Boolean Estimated core charge at neutral pH Integer 
Can form most common size ring Boolean Estimated leader charge at neutral 
pH 
Integer 
Leader has GxxxxxT motif? Boolean Estimated precursor charge at 
neutral pH 
Integer 
Core starts with G? Boolean Absolute value of core charge at 
neutral pH 
Integer 
Core and BGC in same direction? Boolean Absolute value of leader charge at 
neutral pH 
Integer 
Ratio leader/core < 2 and > 0.5 Boolean Absolute value of precursor charge 
at neutral pH 
Integer 
Core starts with Cys and has even 
number of Cys 
Boolean Number in leader of each amino acid Integer 
No Gly in core Boolean Number in leader of each amino acid 
type (aromatic, aliphatic, hydroxyl, 
basic, acidic) 
Integer 
Core has at least 1 aromatic aa Boolean Number in core of each amino acid Integer 
Core has at least 2 aromatic aa Boolean Number in core of each amino acid 
type (aromatic, aliphatic, hydroxyl, 
basic, acidic) 
Integer 
Core has odd number of Cys Boolean Number in entire precursor of each 
amino acid 
Integer 
Leader has Trp Boolean Number in entire precursor of each 
amino acid type (aromatic, aliphatic, 
hydroxyl, basic, acidic) 
Integer 
Leader has Lys Boolean Presence of each of motifs 1–16 Boolean 
Leader has Cys Boolean Total motifs hit Integer 
Cluster has PF00733 Boolean MEME/FIMO score of each of motifs 
1–16 
Float 
Cluster has PF05402 Boolean Sum of MEME scores Float 
Cluster has PF13471 Boolean No motifs present Boolean 
Leader has LxxxxxT motif Boolean Alternate start codon used Boolean 
Core starts with aa (for each) Boolean  
Table 4.2 Features used for SVM classification. Features and their data types are shown. Features were calculated 
for each prospective peptide using RODEO or using Excel on the RODEO output. Feature lists were then used with 
the SVM scripts as described in the Experimental. 
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4.3 Genomic analysis of all identified lasso peptide BGCs 
Taking advantage of RODEO’s ability to accurately identify lasso peptide BGCs, we 
compiled a list of all observable lasso peptides in GenBank (Appendix C.2; Figures 4.5 and 4.6). 
We reasoned that a comprehensive evaluation of this data set would provide unprecedented insight 
into a widespread, but understudied, NP family. BGCs were defined by the presence of a set of 
genes encoding proteins matching the Pfams for the lasso cyclase, leader peptidase, and RRE 
(Figure 4.1b). Confidence in assignment was further bolstered by the presence of a locally-
encoded, high-scoring precursor peptide(s). This procedure identified 1,419 prospective lasso 
BGCs harboring 1,315 identifiable precursors. Most clusters contain one precursor, although a few 
contain as many as six (Figure 4.7a). For the cases where a precursor was not identified, it is 
possible the peptide deviated too far from prediction guidelines, is encoded elsewhere in the 
genome, or the BGC is defunct. 
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Figure 4.5 Phylogenetic map of all identified lasso peptides. A SSN of precursor peptides is shown with an E-value 
cutoff of 10-8. Background shading indicates phylum. Node shading indicates if the NP has been isolated or detected 
in culture (including this study). Co-occurrence of conserved genes in the local genomic region for the peptides above 
are indicated in Figure 4.6 and 4.15, Table 4.4 and Appendix C.2.  
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Figure 4.6 All bioinformatically identified lasso peptides and their genomic contexts. Cross-ring connections 
indicate sequence similarity. Lasso families with 8 or more bioinformatically identified members are shown with 
representative sequence logos indicating conservation and site of cyclization. Phylum, presence of key Pfams, and co-
occurrence with the most common Pfams are also indicated for each precursor. Already-known lassos, vastly 
outnumbered by yet-unknown lassos, are indicated. Radial diagram was generated with Circos.33 
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Figure 4.7 Lasso peptide distribution and %GC. (a) Number of precursor peptides per cluster. (b) Taxonomic 
distribution of lasso peptide producers. Genera with more than 10 identified lasso BGCs are indicated. (c) Counts of 
class I, II, and III lasso peptides (based on number of Cys, and h disulfides, in predicted core regions). (d) GC content 
analysis. Parametric analysis for horizontal gene transfer was performed by comparing GC content of the lasso 
synthase to the organism genome on 1,089 RODEO-mined lasso clusters. Linear regression was calculated and the 
five percent with the highest residual deviation were analyzed. Points corresponding to the well-known microcin J25 
and lariatin B lasso peptide gene clusters are labeled. 
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4.4 Analysis of lasso peptide core sequences 
A sequence similarity network (SSN) of the 1,315 identified lasso precursors was 
constructed to illustrate taxonomic relationships, phylogenetic distribution, and discovery status 
(Figure 4.5).34 First, it was apparent that the majority of lasso peptide structural diversity remains 
unexplored, particularly in the Firmicutes, Cyanobacteria, Euryarchaeota, and Bacteroidetes phyla. 
Intriguingly, many large lasso peptide families (defined as precursors with distinct, conserved 
motifs), currently do not have any isolated members. Perhaps surprisingly, many known cases, 
such as the extensively studied, model lasso peptides microcin J25 and lariatin, are in fact 
genetically unique examples. 
As sequence biases have important discovery and re-engineering implications, we next 
analyzed precursor composition using our RODEO-assembled set of 1,315 lasso peptides. We 
surmised this would reveal a more universal perspective on sequence trends compared to rules 
inferred from the limited number of previously-isolated examples. For instance, it was long 
believed that lasso peptide biosynthesis required Gly, or rarely, Cys, to be the first residue of the 
core peptide, which guided earlier mining.28,35 Recently, lasso peptides with N-terminal Ala and 
Ser have been reported,36,37 demonstrating that sequence conservation at this position has been 
markedly overestimated. The first core position does, however, display remarkable preference for 
small residues, with the majority having Gly (62%) or Ala (16%) at this position. However, Leu 
is unexpectedly common (7%) compared to previously known lasso peptides; indeed, we isolated 
members of the lagmysin and citrulassin families (Figure 4.8) that contain N-terminal Leu. Pro is 
the only amino acid not represented as the first core residue, possibly due to conformational 
constraints.  
The hallmark lasso macrocycle poses many questions that only a comprehensive set of 
lasso peptides is poised to address (Figure 4.1b). For instance, the conformation-restricting Pro 
residues of caulosegnin aids in maintaining stability,38 but do similar trends broadly hold true? We 
found that within the global lasso peptide set, Pro is only slightly overrepresented in the 
macrocycle region of the core, accounting for 6.1% (compared to the expected frequency of 4.7% 
based on all proteins in UniProt, Table 4.3).39 In contrast, the conformation-enabling Gly is 
significantly more overrepresented than Pro in the macrocycle (22.8% versus 7.1% for all proteins 
in UniProt), suggesting that instead, flexibility is biosynthetically crucial (Table 4.3). Aromatic 
residues are overrepresented in the tail region, likely a consequence of their role in maintaining 
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the threaded lariat topology (Figure 4.8a, Table 4.3).18 The unexpected prevalence of C-terminal 
Ser (Figure 4.8a) strongly correlates with the co-occurrence of a Ser kinase gene in several lasso 
peptide families, including the recently described paeninodins40 and yet-unexplored mesonodins 
and aneurinodins (Table 4.4), suggesting a probable O-phosphorylation target. A complete 
analysis of amino acid preferences is provided in Table 4.3. These sequence biases point to 
functional roles for particular residues for interaction with enzymes, maintenance of threading, and 
bioactivity. Knowledge of these broad trends will facilitate future biosynthetic, engineering, and 
functional studies on these chemically-inaccessible peptides. 
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Figure 4.8 Lasso peptide sequence analysis. (a) Lasso peptide structural features and common residues mined from 
RODEO analysis. (b) Organization of predicted lasso peptides into families. Roughly half of the identified BGCs had 
identical or closely related clusters in other organisms. (c) Sequence logos for lasso peptide families with >20 members 
show wide variance in sequence composition and degree of conservation. Numbers in parentheses refer to number of 
instances found per family. Residues are color-coded according to basic (green), acidic (purple), or hydrophobic 
(orange) character. 
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Table 4.3 Residue frequencies within lasso precursor peptides. 
 
4.5 Evolutionary insights into lasso peptide biosynthesis 
Akin to many other RiPPs, lasso peptide biosynthesis is orchestrated by the binding of the 
leader region of the precursor peptide by a ~90 residue RRE domain.15 This facilitates interaction 
with modification enzymes and largely accounts for the substrate specificity of RiPP biosynthesis. 
With rare exception (discussed later), the lasso peptide RRE is present as a discrete protein (E; 
previously, B1) or fused to the leader peptidase (B; previously, B2) (Figure 4.13). We noted from 
our survey that E-B fusions occur only in a subset of Proteobacteria (and a few scattered additional 
examples), distinct E and B proteins are present in all phyla and vastly outnumber fused cases 
(Figure 4.15). Therefore, we recommend adoption of the E/B nomenclature, as it is clearer and 
more descriptive than the older B1/B2 nomenclature. More broadly, SSNs of the lasso peptide 
biosynthetic enzymes show strong correlation to those with closely-related precursor peptides and 
related phylogenetic classes, suggesting this broad-spanning class of NPs is primarily vertically 
inherited (Figure 4.9). 
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In addition to inferring evolutionary lineages, bioinformatics analysis of the data set 
enabled us to evaluate interactions between the lasso precursor and biosynthetic proteins.  We 
reasoned that physically interacting residues would be discernable via co-evolutionary analysis, 
given that if one binding partner were to acquire a mutation at a critical location, the other would 
need a compensatory mutation to maintain a functional biosynthetic pathway.41,42 Paired 
alignments of lasso precursors and RREs were analyzed for the presence of gapless sequence 
motifs using MEME, and the motifs were analyzed for RRE/precursor co-occurrence (Figure 
4.16). Whereas most RRE motifs did not correlate to any core motifs (and vice versa), this analysis 
revealed a widely-distributed leader sequence motif (motif L1: YxxPxLx3Gx5Tx) that showed 
excellent correlation to three motifs in the RRE (all >90% co-occurring). Motif L1 is present in 
800 (63% of total) lasso precursors with the first portion of the motif, YxxP/WxxP, represented in 
all lasso peptide-containing phyla (Figure 4.17). However, the very strong correlation between the 
presence of YxxP/WxxP in the leader peptide only was observed with BGC harboring distinct E- 
and B-proteins (i.e. leader peptidase not fused to the RRE; Figure 4.14). Upon surveying BGCs 
with fused E-B proteins, the correlation to one motif (R1) in the RRE was more modest at 62% 
while the correlations to the other two RRE motifs were considerably diminished (4% and 5%, 
Figure 4.16d). 
In addition to motif correlations, we employed GREMLIN to identify residues under co-
evolutionary pressure to predict sites of peptide-protein interaction (Figure 4.16a) 42,43. The 
GREMLIN results agree well with previously-reported binding constants of point substitutions of 
StmE, the RRE from the streptomonomicin BGC (e.g. StmE-D69A displayed a 75-fold loss of 
affinity for its YxxP-containing leader peptide compared to StmE wild-type) 15,37. Several locations 
of the leader peptide are clearly co-evolving with the RRE, especially towards regions of the RRE 
involved in peptide binding (α3/β3). Mapping of the co-evolving residues onto a StmE homology 
model built from the RRE of LynD showed a high degree of localization to one particular pocket 
of the protein (Figure 4.16e).44 No evidence of co-evolution was found between the core region 
and the RRE, underscoring the functionally bipartite nature of RiPP precursor peptides.14 These 
RODEO-enabled results provide an evolutionary model for leader peptide recognition by RRE-
containing proteins. More broadly, these data support the hypothesis that variation in RiPP core 
peptides seeds NP diversification, provided that the leader region and RRE co-evolve to maintain 
their interaction. 
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Figure 4.9 SSNs of lasso cyclase protein. Network was visualized with an edge cutoff E-value threshold of 10-80 with 
nodes colored by phylum. Location within the network of known lasso peptides (including this study) are indicated. 
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Figure 4.10 Sequence similarity network of lasso peptide cyclases (PF00733). Only PF00733 proteins predicted 
to belong to lasso peptide BGCs are shown. This figure, which expands upon Figure. 4.9, was generated using 
Cytoscape and the EFI-EST. 
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Figure 4.11 Sequence similarity network of lasso peptide protease (PF13471). Only PF13471 proteins predicted 
to belong to lasso peptide BGCs are shown. This figure was generated using Cytoscape and the EFI-EST. 
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Figure 4.12 Sequence similarity network of lasso peptide RRE (PF05402). Only PF05402 proteins predicted to 
belong to lasso peptide BGCs are shown. This figure was generated using Cytoscape and the EFI-EST. 
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Figure 4.13 Histogram of lengths of B proteins in clusters for which a discrete E protein was or was not detected 
by RODEO. The histogram was binned in increments of 2 amino acids. Only B proteins for which at least one 
precursor peptide was detected were considered.  
 
 
Figure 4.14 Discrete E/B lasso BGCs are strongly associated with the YxxP/WxxP motif. A sorted graph is given 
showing lengths of proteases associated with detectable leader peptides. From this, all samples spanning the 1st and 
3rd quartiles of protease (B protein) lengths in fused vs discrete E/B BGCs were taken (indicated with light grey 
horizontal bars) and analyzed for the presence of the YxxP/WxxP motif in the leader region. This motif was 
overwhelmingly found in discrete E/B clusters and only rarely found in fused E/B clusters. 
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Figure 4.15 Phylogenetic and co-occurrence analysis of lasso BGCs. A maximum-likelihood tree was generated 
from a representative 10% of lasso cyclases. Non-lasso Asn synthases are given as outgroups. Co-occurrence with 
seven common Pfams are indicated by symbols defined in the legend. The lasso cyclases form three large clades: the 
kinase/nucleotidyltransferase-containing clade, the fused RRE-leader protease clade within Proteobacteria, and the 
Actinobacterial clade. Comprising ~50% of the Proteobacterial clade are BGCs also containing the lasso-linearizing 
isopeptidase. Fused and discrete E/B proteins are indicated with open or filled black circles, respectively.  
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Figure 4.16 Precursor peptide/RRE co-evolution analysis. (a) Plot of GREMLIN-derived co-evolving residues for 
a paired alignment of precursor peptides (site 1–40) and RREs (41–125). Dot size corresponds to probability. (b) 
Alignment of precursor peptides with motif L1 site indicated. (c) Alignment of RREs with motifs R1, R2, and R3 
indicated. (d) Co-occurring motifs between leader regions and RREs. (e) Motifs and co-evolving residues mapped 
onto a homology model of the RRE StmE (streptomonomicin biosynthesis), based on structure of LynD. 
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Figure 4.17 Distribution of the YxxP motif in lasso precursor peptides. A sequence-similarity map with an E-
value threshold cutoff of 10-8 is shown. Nodes represent precursor peptide. Sequences where the leader region 
contains a YxxP motif are indicated in dark grey. This figure uses the same view as Figure 4.5. 
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4.6 Identification of BGCs with unusual architectures 
Our survey revealed a large number of lasso peptide BGCs containing unusual 
permutations of the biosynthetic genes. Fusions of the leader peptidase and ABC transporter, for 
instance, are found in 38 BGCs, including various Ruminococcus species (Figure 4.18) as well as 
Streptococcus, Enterococcus, Ruminococcus, Actinomyces, Lactococcus, Actinobaculum, and 
Paenibacillus. Other fusion events include a lasso cyclase fusion to the RRE and a leader peptidase 
fusion to the lasso cyclase in Bifidobacterium reuteri and Acidobacteriaceae bacterium TAA166, 
respectively. Also remarkable is the precursor from Acidobacteriaceae, which replaces the 
otherwise invariant Thr at the penultimate position of the leader with Ile, representing the first 
reported BGC where this is the case (Figure 4.18). The identification of a rare BGC lacking the 
penultimate leader Thr reconciles previous heterologous expression data where conservative 
substitutions at this site still produced microcin J25 and capistruin.21  
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Figure 4.18 Unusual lasso peptide BGCs discovered using RODEO. Examples of unusual gene fusions in lasso 
peptide biosynthetic gene clusters. Lasso peptide cyclase GenBank accession numbers are indicated. 
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4.7 Other genes preferentially co-occur with lasso peptide BGCs 
In addition to essential biosynthetic genes, additional proteins matching certain Pfams were 
found to frequently co-occur with lasso peptide BGCs (Table 4.4). As expected, ABC transporters 
were common, appearing in 62% of BGCs (Table 4.4; Figure 4.15). Many transferases also 
frequently co-occur, including kinases (32% of BGCs), nucleotidyltransferases (26%), 
glycosyltransferases (14%), and acetyltransferases (6.6%), among others (Table S6). Taken 
together, we propose there exist undiscovered lasso peptides bearing additional modifications 45. 
Whereas the transferases mentioned above are found in many phyla, there is a clear subset of 
proteobacteria devoid of these genes. Instead, these proteobacteria, accounting for ~15% of all 
lasso peptide producers, encode an isopeptidase reported to linearize the lasso macrocycle (Table 
4.4).46  
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Pfam Count  Title Name 
none 1748 none none 
PF00733 1437 Asn_synthase Asparagine synthase (lasso cyclase) 
PF13471 1164 Transglut_core3 Transglutaminase-like superfamily (leader peptidase) 
PF05402 959 PqqD Coenzyme PQQ synthesis protein D (PqqD, RRE) 
PF00005 841 ABC_tran ABC transporter 
PF07475 456 Hpr_kinase_C HPr Serine kinase C-terminal domain 
PF14907 387 NTP_transf_5 Uncharacterised nucleotidyltransferase 
PF00664 243 ABC_membrane ABC transporter transmembrane region 
PF00593 240 TonB_dep_Rec TonB dependent receptor 
PF00535 221 Glycos_transf_2 Glycosyl transferase family 2 
PF00326 199 Peptidase_S9 Prolyl oligopeptidase family 
PF08281 192 Sigma70_r4_2 Sigma-70, region 4 
PF00392 163 GntR Bacterial regulatory proteins, gntR family 
PF02397 132 Bac_transf Bacterial sugar transferase 
PF04773 130 FecR FecR protein 
PF00072 127 Response_reg Response regulator receiver domain 
PF12730 119 ABC2_membrane_4 ABC-2 family transporter protein 
PF13560 117 HTH_31 Helix-turn-helix domain 
PF00419 99 Fimbrial Fimbrial protein 
PF07690 98 MFS_1 Major Facilitator Superfamily 
PF13302 95 Acetyltransf_3 Acetyltransferase (GNAT) domain 
PF12833 86 HTH_18 Helix-turn-helix domain 
PF00440 81 TetR_N Bacterial regulatory proteins, tetR family 
PF00106 74 adh_short short chain dehydrogenase 
PF01381 74 HTH_3 Helix-turn-helix 
PF00722 69 Glyco_hydro_16 Glycosyl hydrolases family 16 
PF00196 66 GerE Bacterial regulatory proteins, luxR family 
PF02563 63 Poly_export Polysaccharide biosynthesis/export protein 
PF13407 63 Peripla_BP_4 Periplasmic binding protein domain 
PF00291 61 PALP Pyridoxal-phosphate dependent enzyme 
PF01943 61 Polysacc_synt Polysaccharide biosynthesis protein 
PF02653 61 BPD_transp_2 Branched-chain amino acid transport system / permease 
component 
PF00528 60 BPD_transp_1 Binding-protein-dependent transport system inner membrane 
component 
PF00534 60 Glycos_transf_1 Glycosyl transferases group 1 
PF00132 59 Hexapep Bacterial transferase hexapeptide (six repeats) 
PF00501 59 AMP-binding AMP-binding enzyme 
PF01757 59 Acyl_transf_3 Acyltransferase family 
PF05721 59 PhyH Phytanoyl-CoA dioxygenase (PhyH) 
PF01041 57 DegT_DnrJ_EryC1 DegT/DnrJ/EryC1/StrS aminotransferase family 
PF07730 56 HisKA_3 Histidine kinase 
PF13614 55 AAA_31 AAA domain 
PF11089 53 SyrA Exopolysaccharide production repressor 
PF00583 52 Acetyltransf_1 Acetyltransferase (GNAT) family 
PF03466 51 LysR_substrate LysR substrate binding domain 
PF08240 51 ADH_N Alcohol dehydrogenase GroES-like domain 
Table 4.4 Pfam co-occurrence analysis for all lasso peptide gene clusters. Pfams with >50 occurrences are 
indicated (which represents a co-occurrence within at least 3.5% of all lasso peptide BGCs). A comprehensive list can 
be found in the Supplementary Data Set. Counts indicate number of proteins for which the given Pfam was the top 
match. In bold are the required, universal lasso peptide biosynthetic genes.  
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4.8 Assignment of BGCs to known lasso peptides 
Although the first reported lasso peptide, anantin, was discovered 25 years ago,47 the BGC 
has not yet been reported, despite its commercial availability and wide usage as an atrial natriuretic 
factor antagonist. In fact, BGCs for 10 known lasso peptides from 6 families remain elusive due 
to the unavailability of the producer’s genome.  We sought to connect all known lasso peptides to 
BGCs by querying our data set with the core sequences of the known lasso peptides. Owing to the 
high percentage of lasso peptides that belong to families (Figure 4.8b), we expected that those with 
unknown BGCs could be traced to RODEO-predicted precursor peptides with identical or nearly 
identical sequences. Indeed, search queries using 4–5 contiguous amino acids located precursor 
peptides within BGCs for every lasso peptide of previously unknown origin. (Figure 4.19). All 
lasso peptides with newly assigned BGCs were from Actinobacteria. Consistent with other BGCs 
from this phylum, each encode a single lasso precursor immediately upstream of discrete C, E, and 
B proteins, and four of the six BGCs include ABC transporters. In one case, the RODEO-identified 
BGCs contained unannotated leader peptidase genes, suggesting a probable explanation for many 
BGCs being previously overlooked. By assigning BGCs to all known lasso peptide families, this 
study underscores the utility of comparative genomics in providing insight into NP biosynthesis 
even in the absence of a genome for the original producing organism. 
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Figure 4.19 Previously known lasso peptides with newly assigned BGCs. (a) Gene cluster diagrams. Accession 
numbers of de-orphaned lasso peptide BGCs are given in Table 4.5. (b) Precursor peptides from identified clusters 
compared to the primary sequence of the orphaned lasso peptides from organisms without sequenced genomes. In 
multiple cases, several candidate precursor peptides and clusters were found, shown aligned on the right against the 
known core sequence of the identified lasso peptide. Minor differences between the identified core peptides and the 
known compounds are indicated in red. The BI-32169 homologue required a BLAST-P search against the JGI-IMG 
database, which returned an intact cluster in Streptomyces sp. AmelKG-E11A. 
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4.9 Structure-prioritized discovery of lasso peptides 
 We next applied the predictive capabilities of RODEO to the discovery of new lasso 
peptides. Our analysis indicated wide distribution of lasso peptide BGCs across many taxa, yet 
very few structures have been disclosed and remarkably, members of many of the largest lasso 
peptide families have not yet been isolated (Table 4.6). To this end, RODEO was used to facilitate 
NP discovery by screening for lasso peptides from novel families expected to harbor intriguing 
structural features. 
We examined our data set for interesting lasso peptides predicted in the USDA-ARS 
actinomycete collection (http://nrrl.ncaur.usda.gov/). Instances of widely-distributed families, as 
well as rare ones, with unique variations in primary sequence and topology, were selected for 
further investigation. Thirty-seven strains were chosen, grown on three media, and screened by 
MALDI-TOF-MS for the presence of peaks consistent with the RODEO predictions. Of these, 
metabolites from five cultures were isolated for further study (Figure 4.20). The identity of all 
lasso peptides was confirmed by high-resolution, tandem MS (Appendix B.3–7). Marfey-type 
analysis confirmed all amino acids to be in the L-configuration. All six lasso peptides (two were 
from NRRL S-146) were thermally and proteolytically stable, showing no unthreading after 
heating at 95 °C for 4 h or detectable proteolysis upon carboxypeptidase Y treatment, as evidenced 
by HPLC (data not shown). 
The lasso precursor from Nocardiopsis alba appeared particularly interesting because it 
was predicted to bear a novel topology (Figure 4.20d). This lasso peptide, LP2006, contains two 
Cys presumably in a disulfide; however, both Cys residues were predicted to reside on the tail 
whereas in all other known cases, disulfide bonds link the tail to the macrocycle. This resulting 
“handcuff” topology of LP2006 was confirmed by solution-state NMR (PDB code 5JPL). We 
propose lasso peptides of this topology be referred to as class IV lasso peptides. 
Moomysin, isolated from Streptomyces cattleya, has no known structural analogues but 
toplogically belongs to the class II lasso peptides (Figure 4.20). Lagmysin, another class II lasso 
peptide from Streptomyes sp. NRRL S-118, belongs to one of the largest families (Figure 4.8b) 
and contains an unprecedented N-terminal Leu. NMR was used to corroborate the presence of Leu 
as the first core residue (Figures 4.20 and Appendix B.4) and currently, this is the largest residue 
with demonstrated compatibility with lasso peptide biosynthesis. Additionally, we characterized 
by HR-MS/MS anantin B1 and a congener lacking the C-terminal Phe (anantin B2) from a 
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previously unknown producer, Streptomyces sp. NRRL S-146 (Figures 4.20, Appendix B.6). 
Together with anantin A, the first isolated lasso peptides, the anantins comprised a lasso peptide 
family with 8 currently identifiable members (Table 4.6).  
Citrulassins A also contains an N-terminal Leu and typifies a large lasso peptide family 
with 55 identified members (Table 4.6, Figures 4.5 and 4.8). During screening, the masses of seven 
of nine screened putative citrulassins were 1 Da heavier than predicted (Table 4.7). This 
immediately caught our attention, as additional tailoring of lasso peptides is rare (currently limited 
to Trp-hydroxylation, esterification, and phosphorylation).40,48,49 One previously unsequenced 
organism, Streptomyces albulus NRRL B-3066, also produced a citrulassin that we noticed via its 
C-terminal tail MS/MS fragmentation. This compound purified most readily of all screened 
citrulassins, and so we sequenced the organism of the genome, deemed the compound citrulassin 
A, and characterized it as a representative member of the family. NMR, HR-MS/MS, and 
quantitative amino acid analysis of citrulassin A confirmed that its genetically encoded Arg9 was 
modified to citrulline (Figures 4.20 4.21, and Appendix B.5), accounting for the mass difference. 
Intriguingly, Arg9 is invariant among the 55 citrulassins identified (Table 4.6), although codon 
usage varies. To our knowledge, this is the first known instance of citrulline in any RiPP, but also, 
only the second known instance of peptidylarginine deiminase (PAD) activity in the entire 
bacterial domain.50-52  In an attempt to locate the responsible PAD, we performed conservation 
analysis of the genes flanking the citrulassin BGCs. Not only were these flanking genes highly 
variable, no obvious candidate for a PAD was found (Table 4.6). To determine if the responsible 
PAD was locally encoded, we generated a fosmid library of S. albulus in order to heterologous 
express the citrulassin A BGC. Two fosmids were chosen for expression in Streptomyces lividans, 
together covering ~20 kb upstream and downstream of the BGC (Figure 4.21c). MS analysis 
revealed that expression of either fosmid led to the production of des-citrulassin, which was 
identical to citrulassin but lacked the citrulline modification (Figures 4.21c, Appendix B.5.2). 
These data suggest the responsible PAD is distally encoded. 
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Figure 4.20 Lasso peptides discovered via RODEO-based prioritization. (a) Five gene cluster diagrams for the six 
investigated lasso peptides. (b) Precursor sequences and calculated [M+H]+ values from BGCs in (a). (c) MALDI-
TOF-MS screen indicating lasso production by cultured bacteria (note two from NRRL S-146). (d) NOE-based NMR 
ensemble structure and schematic diagram of LP2006 showing the looped-handcuff topology. (e) Comparison of 
LP2006 to previous lasso topologies. (f) Antibacterial activity screen. 
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Table 4.5 Biosynthetic proteins for lasso peptide screening hits and known compounds. 
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Table 4.6 Major lasso peptide families. Structural families with >7 members are indicated. Families with italicized 
names have no isolated members. Novel families were named based on either conserved sequence features or 
predominant taxonomic location. 
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Table 4.6 (cont.) 
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Table 4.6 (cont.) 
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Table 4.6 (cont.) 
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Table 4.6 (cont.) 
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Table 4.7 Lasso peptides detected during MS-based screening. 
 
 
226 
 
Figure 4.21 Citrulassin, a rare example of bacterial PAD activity. (a) The two-dimensional structure of citrulassin 
A with Cit9 highlighted. (b) Two-dimensional structure of heterologously expressed des-citrulassin A with Arg9 
highlighted. (c) Gene cluster diagrams are shown for two fosmids (3H4 and 1F3) from S. albulus NRRL B-3066 
expressed in S. lividans. (d) Production of heterologous des-citrulassin A as indicated by MALDI-TOF MS. 
4.10 Antibacterial activity of lasso peptides 
We tested all of the lasso peptides isolated herein for growth-suppressive activity against a 
panel of bacteria (Figure 4.20f). Citrulassin A, moomysin, and lagmysin lacked growth 
suppressive activity towards all organisms tested. In contrast, LP2006 was active against 
Enterococcus faecium, Bacillus subtilis, Bacillus anthracis, and Mycobacterium smegmatis while 
anantin B1/B2 showed weak activity against E. coli. Interestingly, the anantin B2 was also 
moderately active against B. subtilis, whereas anantin B1 was not. 
4.11 Conclusions 
Genome mining tools have been invaluable in closing the gap between the large number of 
predicted BGCs and the significantly smaller number of known NPs. Despite the development of 
sophisticated methods for identification and structure prediction for NRPS and PKS BGCs, 
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ribosomal natural product (RiPP) genome mining is hampered by unique challenges arising from 
the close relation of some RiPP enzymes to those involved in primary metabolism and relatively 
short length and hypervariable precursor sequences.3 However, the gene-encoded nature of RiPP 
precursor provides an opportunity: a confident precursor prediction near a reasonable BGC is 
strong evidence for a valid BGC. Thus, a robust platform for both precursor and BGC scoring 
provides predictive power not possible in other NP classes where the substrate is unknown. 
Although manual identification of RiPP precursors is possible, it is performed on a case-by-case 
basis, and thus tedious and inefficient. Methods that facilitate predictions for large numbers of 
BGCs will be increasingly necessary as the number of sequenced genomes outpaces the rate of 
annotation. This challenge is amplified for lasso peptides, which are sequence hypervariable. 
Machine learning is an ideal tool to address these challenges. In addition to its scalability for large 
data sets, supervised learning models such as SVM are able to sort a vast number of variables for 
classification. In the context of NP prediction, SVM determines which parameters are given 
priority in an unbiased fashion – weighting attributes such as peptide length and macrocycle size. 
This results in a powerful, adaptive scoring metric that only requires a comparatively small (but 
diverse) training set of manually-validated examples. Despite its strengths and feasibility of 
implementation, machine learning remains underutilized in NP discovery. 
We herein describe the development and utility of RODEO, an algorithm for BGC analysis 
geared towards RiPPs. For protein functional prediction, RODEO uses profile hidden Markov 
model (pHMM) analysis to define and characterize BGCs. To predict RiPP precursors, RODEO 
performs a six-frame translation of all local intergenic regions and scores these candidates based 
on heuristic rules, sequence motif analysis, and SVM-based machine learning. By iteration, users 
can survey large datasets starting from only a small number of input examples—here we described 
1,315 lasso peptides starting from a basis set of only 28 unique characterized BGCs. This is notable 
in light of the sequence variability seen in lasso peptides relative to other RiPPs – despite their 
simple biosynthesis, remarkably few amino acid requirements appear to exist, resulting in 
extremely sequence-diverse structures. 
RODEO provides a graphical HTML output of BGCs and peptides as well as a tabular, 
spreadsheet output that can be imported into other downstream analysis tools for the purposes of 
statistical evaluation, phylogenetic analysis, gene co-occurrence determination, and sequence 
similarity network generation. Moreover, RODEO enabled the compilation of the most 
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comprehensive dataset for a RiPP family to date. The customizability of the program in taking 
user-supplied configuration and pHMMs renders RODEO extensible to any gene neighborhood 
analysis. In this sense, RODEO complements existing genome mining tools focused on individual 
whole genomes, such as BAGEL3,16 as well as general gene context tools such as the Gene 
Ortholog Neighborhood analysis option within JGI-IMG and the Prokaryotic Sequence homology 
Analysis Tool, PSAT.53,54 Beyond RiPPs, we have already used RODEO to analyze polyketide 
BGCs by constructing pHMMs for enzymes responsible for plecomacrolide-specific polyketide 
backbone tailoring.27 The source code, tutorials, and user manual for RODEO are available at 
http://www.ripprodeo.org. 
 This study revealed that roughly half of the observable lasso peptides exist as closely-
related structural families with up to 141 members. That many lasso peptides exist with no apparent 
relatives suggests that lasso peptides are pervasive as a general scaffold but fill distinct and diverse 
biological roles, which is consistent with their sequence hypervariability. In addition to locating 
BGCs for all genetically unassigned lasso peptides, we isolated six new lassos, four of which were 
chosen on the basis of predicted structural novelty, and subsequently characterized their structures 
and antibacterial activities. Of these LP2006 was found to adopt an unprecedented “handcuff” 
(class IV) topology and displayed activity against several human pathogens. Lasso peptides are 
reported to display diverse bioactivities, such as hormone antagonists, viral entry inhibitors, and 
enzyme inhibitors; however, it is common for lasso peptides to be reported without an associated 
activity. This suggests some may display very narrow antimicrobial spectra, esoteric activities, or 
influence signaling by acting as chemical messengers. This last possibility is consistent sviceucin’s 
inhibition of Enterococcus faecalis quorum sensing.45 
Another novel lasso peptide described herein, citrulassin A, belongs to a 55-membered 
family. Citrulassin A is exemplified by the post-translational conversion of an Arg to citrulline by 
a yet-unidentified peptidylarginine deiminase (PAD). MS-based screening suggests that additional 
citrulassins contain citrulline. This simple modification is remarkable: not only was citrulline 
previously unknown in RiPPs, but only one example of PAD activity—a virulence factor—is 
known in the entire bacterial domain.50-52 
The RODEO-enabled genome mining methods described here has allowed for broad-scale 
investigations of a NP family only possible with a large, high-confidence dataset. Our analysis 
indicates that lasso peptide BGCs are widely distributed among bacteria, with Streptomyces 
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harboring the plurality. We identified rare cases of lasso peptide BGCs in unprecedented phyla, 
although most appear to be inherited vertically. Despite their widespread nature, <50 lasso peptides 
have previously been isolated, two-thirds being from Proteobacteria. Remarkably, many identified 
BGCs encode enzymes suggesting further tailoring of lasso peptides. This work provides a 
roadmap for the future discovery of additional lasso peptides, novel RiPP classes, and allows for 
a rapid and informed means to curation and interpret any prokaryotic gene cluster pathway. 
4.12 Experimental 
4.12.1 General methods 
Unless otherwise specified, chemicals were purchased from Sigma, Fisher Scientific, or 
GoldBio. DNA sequencing was performed by the Roy J. Carver Biotechnology Center (Univ. of 
Illinois at Urbana-Champaign). Restriction enzymes were purchased from New England Biolabs 
(NEB), Platinum Taq HiFi was purchased from Thermo Scientific, and dNTPs were purchased 
from NEB. Oligonucleotide primers were synthesized by Integrated DNA Technologies (IDT). 
4.12.2 Description of RODEO algorithm 
RODEO (Rapid ORF Description and Evaluation Online) runs using Perl and requires a 
Unix operating system or a Unix-environment for Windows (such as Cygwin). The Pfam 28.0 
pHMM database was downloaded from http://pfam.xfam.org/ as Pfam-A.hmm55. HMMER3 was 
used by RODEO for protein homology analysis and for generation of custom Supplementary 
pHMMs25. FASTA files for protein and nucleotide sequences were retrieved by RODEO using the 
NCBI E-Utilities (Entrez Direct)24. RODEO fetches protein and nucleotide sequences from 
GenBank in order to minimize computational resources while still integrating our platform with 
the massive publicly available genome database. As of June 2016, GenBank consists of >213B 
bases (amounting to >194M sequences) with nearly 64M unique proteins annotated in RefSeq. 
The source code and tutorials for RODEO installation and use are available at 
http://www.ripprodeo.org. 
RODEO input consists of a list of the genes to be analyzed (supplied as GenBank protein 
GI numbers or accession numbers). Command line options include whether or not lasso peptide 
scoring is desired, whether or not custom pHMMs are to be analyzed, in addition to the Pfam 
database, output filenames, and if comma-separated value (CSV) lists of proteins and peptides are 
desired for output. For more specialized analysis of biosynthetic gene clusters (BGCs) and NP 
families, RODEO was designed to accept a modifiable configuration file and pHMMs for cluster 
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annotation. Upon finishing, the program outputs the HTML and optional CSV files and stores them 
locally; optionally, they can be emailed automatically to the user. 
RODEO first downloads from GenBank the peptide sequence and coordinates of each input 
GI/accession number as well as those of the genes immediately flanking it (6 genes in either 
direction is the default). Using the hmmscan function of HMMER3, each gene is analyzed for the 
presence of conserved domains via the Pfam HMM database25,55. The top two Pfam hits, if any, 
and their E-values are stored for each gene; if the Pfam corresponds to a conserved biosynthetic 
gene (for lasso peptides, PF00733, PF13471, and PF05402; others can be user specified via an 
optional configuration file), the gene is assigned a function accordingly. If custom pHMMs are 
supplied, the top two hits of these, if any, are also given. 
Second, RODEO then downloads from GenBank the nucleotide sequence corresponding 
to the coordinates spanning the fetched gene cluster, with an additional margin on either end (600 
nucleotides by default). This is translated in all six frames, with ATG, GTG, and TTG as possible 
start codons (as particularly seen in Actinobacteria). Peptide boundaries are compared to gene 
boundaries and all intragenic peptides are discarded unless the peptide falls within an annotated 
ORF that is below the maximum allowable peptide length (to avoid discarding already-annotated 
precursors). If lasso peptide scoring is not desired, a list of sequences and coordinates for all 
peptides within a user-specified length range is returned. If lasso peptide scoring is desired, 
peptides are split further into leader and core regions based on the presence of a conserved 
penultimate Thr in the leader residue, followed by any seven to ten residues, followed by Asp or 
Glu. Based on the core peptide sequence, a lasso peptide molecular weight is predicted. Peptides 
are scored based on the presence or absence of certain features (Table 4.1) and assigned a point 
bonus or penalty for each; the total of the points is then reported, with a higher score indicating a 
likely candidate lasso precursor and a lower score indicating that the peptide is likely invalid.  
Alternatively, the linear-combination scoring feature of RODEO can be turned off, in 
which case all possible non-intragenic peptides within a user-specified amino acid length range 
are returned. This can be useful for analyzing non-lasso BGCs or in cases where a non-conforming 
lasso precursor is suspected. In the absence of linear-combination scoring, retrieved peptides can 
still be subjected to FIMO/MEME (motif analysis) and support vector machine (SVM) analysis. 
Customization options are specified in a modifiable configuration file. This allows user-supplied 
pHMMs to be evaluated in addition to the default Pfam database. Parameters include minimum 
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and maximum peptide lengths, number of nucleotides to fetch beyond cluster boundaries, number 
of genes upstream/downstream of the query GI/accession to analyze, and output gene colors/labels 
corresponding to user-specified Pfams or custom pHMMs. 
For output, RODEO generates a graphical representation of each gene cluster with 
individual genes scaled by size and distance and colored/labeled based on the presence of domains 
as indicated by pHMM hits. Output is given as HTML format. This includes a diagram of each 
BGC in scalable vector graphic (SVG) format, with genes labeled and colored according to pHMM 
hits and user specifications in an optional configuration file (for examples, see 
http://www.ripprodeo.org). Output includes a gene table with corresponding accession identifiers, 
coordinates, directions, and top pHMM matches with expectation values (E-values). For 
convenience, hyperlinks to GenBank and Pfam are given for each accession identifier and pHMM 
match, respectively. Lastly, a table of predicted precursors and their coordinates is provided. For 
lasso BGCs, precursors are analyzed and scored using RODEO’s linear combination scoring 
feature and printed with predicted molecular masses to assist screening (Figure 4.1). 
To facilitate automated analysis of BGCs, the lists of genes and predicted precursors can 
be written to CSV files which can be readily used in downstream data mining applications. This 
output format was used to quickly ascertain the presence of certain Pfams in a large number of 
clusters, determine frequency of co-occurring Pfams (important given the plug-and-play nature of 
RiPP biosynthesis14), classify BGCs automatically based on gene functions, perform statistical 
analysis of clusters or peptides, and annotate sequence similarity networks (SSNs)34. For scored 
peptides, a scoring matrix of features and weights is also printed, allowing the user to view the 
basis for a peptide’s classification and manually adjust feature weights 
4.12.3 Lasso peptide cluster dataset assembly 
GenBank GI numbers for essential biosynthetic genes (lasso cyclase, lasso protease, and 
RRE) of all known lasso peptides were collected. The set of lasso cyclases was then used as a 
BLAST-P query against the nr database in GenBank, returning the top 1,000 hits for each with 
default settings. Hits were ranked by maximum similarity to any query sequence, and the top local 
genomic region (6 genes in either direction of cyclase) of top hits were sequentially analyzed with 
RODEO until no new lasso peptide-like BGCs were returned. Because our initial query set 
contained only Actinobacteria and Proteobacteria, we repeated the above using as queries 
representative lasso peptide cyclases, obtained during the first search, from the Bacteroidetes, 
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Cyanobacteria, Firmicutes, Fusobacteria, and Veruccomicrobia, and Archaea. The RODEO data 
sets were then merged for analysis, giving a set of 4,672 potential BGCs with 25,506 potential 
precursor peptides. Refinement and scoring (below) of this data yielded a final dataset of 1,419 
lasso peptide BGCs and 1,315 lasso peptide precursors. 
4.12.4 Precursor peptide scoring optimization 
From the initial set of prospective lasso peptide BGCs, the RODEO output of a randomly-
chosen sample (~25%; whole training set) were inspected, and gene clusters were classified 
qualitatively as lasso, non-lasso, or indeterminate. Peptides in each cluster were also classified as 
valid likely precursors, non-precursors, or indeterminate. This formed an unbiased training set for 
scoring optimization. In addition to the scoring features output by RODEO directly, an additional 
set of features were calculated in Excel for each peptide (Tables 4.1 and 4.2). The linear 
combination score of each peptide was calculated as the dot product S of weight vector A and 
feature vector X, 
𝑆𝑆 = 𝑨𝑨 ∙ 𝑿𝑿 = �𝐴𝐴𝑖𝑖𝑋𝑋𝑖𝑖𝑛𝑛
𝑖𝑖=1
 
where for each of i features n, Ai is the feature point weight and Xi is the absence, 0, or presence, 
1, of the feature.  
For analysis and optimization, 80% of the manually classified set was randomly selected 
(“training set”), with the other 20% retained as a validation set to avoid over-fitting. Feature 
weighting optimization was done by plotting comparative score histograms of classified precursor 
peptides and stochastically adjusting individual weights to minimize overlap. For final analysis, 
additional points were given to any peptide classified as valid by the SVM classifier (see below) 
or showing MEME/FIMO-identified sequence motifs (see below), resulting in two minimally 
overlapping populations (Figure 4.3). 
4.12.5 Sequence motif-based unsupervised learning of precursor peptides 
Precursor peptide sequences from the training set (see above) were analyzed for the top 16 
sequence motifs with zero or one occurrences per sequence using MEME (parameters: -nmotif 16 
-mod zoops).56 All output peptides from RODEO (n = 25,506) were scanned for these motifs using 
FIMO,56 and both the presence of motifs and the resulting scores were passed to final linear-
combination scoring and used as features for SVM. Motifs were only considered for linear-
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combination scoring if their score from FIMO was greater than 1, which we found to increase 
accuracy. The sequence motifs used by FIMO are included in Appendix C.2. 
4.12.6 Support vector machine (SVM) supervised learning classifier 
Machine learning model training and classification was performed using the scikit-learn 
library for Python.57 The manually classified training set (see above) was used as model data. Five-
fold cross-validation (i.e. randomly witholding one-fifth of the training data as a testing data set) 
was used to optimize the prediction method and avoid over-fitting. Kernel modes (linear, 
polynomial, rbf) and parameters (C, gamma, polynomial degree, class weight) were systematically 
varied to optimize prediction accuracy, assessed as the product of precision [precision = true 
positives/(true positives + false positives)] and recall [recall = true positives/(true positives + false 
negatives)]. Optimal parameters used an rbf kernel with C = 25, gamma = 2.75E-06, and ‘auto’ 
class weight. This gave 97.9% precision and 92.8% recall, which we estimated would likely result 
in ~30 false positives and ~100 false negatives when applied to the entire data set. Thus, we 
subjected the entire 25,506-member RODEO-derived peptide set to classification. The Python 
scripts used for SVM optimization and classification, as well as features, are available with the 
RODEO source code (http://www.ripprodeo.org/) and Table 4.2. 
4.12.7 Precursor peptide set determination 
We utilized a combination of SVM classification, motif analysis, linear-combination 
scoring, and SSN analysis to determine valid lasso precursor peptides. To minimize the false 
positive and negative rate, we compared SVM classifications to linear-combination scores and 
inspected the highest-scoring SVM negatives and lowest-scoring SVM positives, resulting in 
reclassification of several peptides. We also manually inspected peptides that clustered abnormally 
on an SSN (alignment score cutoff = 1E-6) of the precursor peptides (e.g. singleton SVM negatives 
clustering with SVM). SVM positives and negatives with high or low scores, respectively, that 
clustered with valid or invalid precursor peptides were assumed to be most likely correct. 
Leader/core alignment verification: RODEO predicts the leader/core cut site on the basis of a 
conserved Thr found in the penultimate leader position and a putative cyclization site (Asp/Glu) 
in the core. We manually refined the RODEO-generated leader/core split sites based on conserved 
leader residues (YxxP and Gx5T motifs); although correct in 94% of cases, 75 required manual 
adjustment due to the presence of multiple possible Thr and Asp/Glu residues in the precursor. 
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4.12.8 Gene cluster classification 
Gene clusters were classified on the basis of cluster architecture (identifiable E, B, or C 
proteins) as well as the presence of valid precursor peptides. Any cluster with a valid lasso 
precursor was classified as a lasso peptide BGC. Those containing only one identifiable E, B, or 
C protein and no precursor peptide were discarded. The remaining clusters were classified by 
analysis of an SSN of the lasso cyclases. Those that contained two or more identifiable lasso 
biosynthetic genes and showed high similarity to valid BGCs, as judged by network connectivity, 
were retained. In this way, the initial data set of 4,672 potential gene clusters was refined to a set 
of 1,419 predicted lasso peptide BGCs, 1,165 of which (82%) contained a RODEO-identified lasso 
peptide precursor. 
4.12.9 RRE/precursor peptide co-evolution analysis 
A paired alignment of precursor peptide sequences and RREs (PF05402 in lasso BGCs) (n 
= 846) was generated; RRE sequences were aligned using MUSCLE on default settings in 
MEGA7.58 The aligned precursor peptides and RREs were concatenated. (1) Residue/residue co-
evolution analysis. The paired alignment was analyzed using the GREMLIN web server 
(http://gremlin.bakerlab.org/)42 on default settings, filtered at 75% gap removal and 25% coverage 
thresholds. No multiple sequence alignment (MSA) generation was performed. The precursor 
peptide and RRE (GenBank: WP_040271204.1) from the streptomonomicin BGC were used as a 
reference.59 (2) Sequence motif analysis with MEME/FIMO. Sets of paired precursor 
peptides/RREs were analyzed using MEME 4.11.1, which detects ungapped sequence motifs56. 
Precursor sequences were trimmed to include only the leader region and analyzed to find the 8 
most significant motifs with zero or one occurrences per sequence (parameters: -nmotif 8 -mod 
zoops). All precursors and RREs were then analyzed for the presence of each discovered motif 
using FIMO on default settings.56 Motif correlation was calculated as the number of co-
occurrences of each of two motifs divided by the number of total occurrences of each. Sequence 
motifs were mapped onto the StmE homology model generated as previously described.15 (3) 
Homology modeling. HHpred (http://toolkit.tuebingen.mpg.de)60 was used to generate sequence 
alignments for the RRE from the gene cluster of streptomonomicin (GenBank: WP_040271204.1). 
LynD (PDB ID: 4V1T) was used to generate a model using the HHpred modeling toolkit (aligned 
residues 8-84). Inter-protein GREMLIN-output probability scores of residue-residue co-evolution 
were used to map regions of predicted evolutionary significance 
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4.12.10 Analysis of GC content 
The %GC of nucleotide sequences for the set of lasso cyclases (n = 1,085) were calculated 
and compared to NCBI Taxonomy records (organism %GC content). Lasso cyclase %GC was 
plotted against average organism genome %GC. Linear regression was calculated to draw a best-
fit line and calculate absolute residual regression for each point. The top 5% of outliers (n = 54) 
were highlighted. 
4.12.11 Phylogenetic tree generation 
For visual clarity, we chose to represent only a representative subset of lasso cyclases (n = 
185 of 1,419). From the phyla with the most lasso BGCs (Actinobacteria, Proteobacteria, 
Firmicutes), approximately ~10% of sequences were randomly selected. From all others, which 
had many fewer lasso BGCs, approximately half were selected in order ensure qualitative 
representation of all phyla. As diverse outgroups, non-lasso asparagine synthases (PF00733) were 
chosen from E. coli (GenBank: KJW30448.1; tree root), B. subtilis (GenBank: AID00505.1), and 
Streptomyces rimosus (GenBank: KEF03673.1). Protein sequences were first aligned in MEGA758 
using MUSCLE on default settings. A tree was generated from the alignment using the Maximum 
Likelihood method based on the JTT matrix-based model in MEGA7 on otherwise default 
settings58 and visualized with iTOL (http://itol.embl.de/)61 and Adobe Illustrator.  
4.12.12 Sequence similarity network (SSN) generation 
SSNs were generated using EFI-EST (http://efi.igb.illinois.edu/efi-est/).34 Initial networks 
were generated using alignment score cutoffs of 1E-1 (precursor peptides), 1E-5 (RREs), 1E-7 
(leader proteases), or 1E-25 (lasso cyclases) as clustering thresholds. Networks were visualized 
using the Organic layout within Cytoscape v. 3.2.062 and Adobe Illustrator. Nodes were annotated 
using RODEO output (via Microsoft Excel) and the NCBI Taxonomy database.63-66  
4.12.13 Lasso data set Circos visualization 
Alignment scores for precursor peptides were obtained during SSN generation. Individual 
precursor peptides were annotated from a RODEO-generated and curated spreadsheet for the 
presence of co-occurring Pfams, structural novelty, phylum, and structural family. Lasso peptide, 
BGCs, and and their genomic contexts were visualized using Circos (Figure 4.6).33 
4.12.14 Sequence logo generation.  
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Sequence logos were generated using WebLogo 2.8.2 (http://weblogo.berkeley.edu/)67. 
Core sequences of some families (i.e. sphingonodin, caulonodin, sphingopyxin and paeninodin) 
were first aligned using MUSCLE v.3.8.3168 prior to sequence logo generation. 
4.12.15 Microbiological methods 
All actinomyces strains were grown in either ATCC medium 172 [ATCC172] (per L: 
glucose, 10 g; soluble starch, 20 g; yeast extract, 5 g; N-Z-Amine type A, 5 g; CaCO3, 1 g; pH 
7.3), ISP Medium no. 4 [ISP4] (per L: soluble starch, 10 g; K2HPO4, 1 g; MgSO4·7H2O, 1 g; NaCl, 
1 g; (NH4)2SO4, 2 g; CaCO3, 2 g; FeSO4, 1 mg; MnCl2, 1 mg; ZnSO4, 1 mg), or AltMS (per L: 
mannitol, 10 g; soy flour, 10 g; malt extract, 10 g). All solid media included 1.5% (w/v) agar. 
Neisseria meningitidis was grown on gonococcal broth [GCB] (per L: proteose peptone #3, 15 g; 
K2HPO4, 4 g; KH2PO4, 1 g; NaCl, 1 g) with sterile filtered bicarbonate (100x: NaHCO3, 0.42 g to 
10 mL H2O) and sterile filtered Kellogg’s Supplements I (100x to 500 mL: D-glucose, 200 g; L-
glutamine, 5 g; thiamine pyrophosphate, 0.01 g) and II (1000x to 50 mL: Fe(NO3)3·9H2O, 0.025 
g). 
Escherichia coli strains for DNA manipulation were DH5α, grown in LB medium (10 g 
tryptone, 10 g NaCl, 5 g yeast extract to 1 L of deionized water; Fisher Scientific) with 50 µg/mL 
kanamycin. A Gibson assembly master mix (NEB) was used to clone the anantin gene cluster from 
Streptomyces sp. S-146 into a pET28a backbone. Qiagen QIAprep Spin Miniprep Kit was used to 
purify plasmids. Primer walk sequencing was used to generate overlapping sequencing reads 
connecting the biosynthetic machinery for anantin. 
4.12.16 Screening of Actinomycetes for lasso peptide production 
Prioritized strains were grown on each ATCC Media 172, ISP Media 4, and AltMS on 6-
well plates with 5 mL of agar media per well. Cultures were incubated at 30 °C for 7 d prior to 
whole-cell mass spectrometry. A portion of cell mass (pinhead-sized) including aerial hyphae was 
picked from the plate and placed in 2 µL of sat. 50% aq. MeCN solution of α-cyano-4-
hydroxycinnamic acid (CHCA) with 0.1% trifluoroacetic acid (v/v) on a ground steel MALDI 
target. Additional aliquots of matrix (2 µL) were spotted and allowed to dry on the cell mass three 
times to extract metabolites onto the plate. Samples were analyzed using a Bruker UltrafleXtreme 
MALDI-TOF MS using manufacturer methods for reflector positive mode. 
4.12.17 Lasso peptide isolation 
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Isolation of anantin B1 and B2. Streptomyces sp. S-146 was grown on ATCC 172 with 1.5% 
agar on 15 cm sterilized petri dishes (n = 48) and incubated at 30 °C for 7 d. Cells were harvested 
by scraping cell mass from the plates with razors and collectively extracted with 600 mL MeOH 
with shaking at room temperature overnight. The methanolic extract was vacuum-filtered and dried 
under reduced pressure onto 5 g of Celite 545 adsorbent.  
Spent agar was frozen at ˗ 20 °C overnight and then allowed to thaw. The agar was squeezed 
and filtered through cheesecloth to harvest the aqueous portion, which was vacuum-filtered with 
Whatman filter paper and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-
equilibrated with H2O. The loaded column was washed with 200 mL of H2O, and bound material 
was eluted with successive 50 mL portions of 5%, 10%, 25%, 50% and 75% aq. MeCN, followed 
by 100 mL of MeCN. Fractions were analyzed via MALDI-TOF MS. Fractions containing anantin 
B1 and B2 were pooled with the methanolic extract and dried under reduced pressure onto 5 g of 
Celite 545 adsorbent. 
Anantin adsorbed onto Celite was purified by medium pressure liquid chromatography 
(MPLC) using a Teledyne Isco Combiflash EZprep equipped with a RediSep Rf C18 cartridge 
(130 g media, 60 Å pore size, 40–63 µm particle size, 230–400 mesh) using a mobile phase of 10 
mM aq. NH4HCO3/MeCN at 85 mL min-1 over a gradient from 20–60% MeCN (10 column 
volumes), then 60–95% MeCN (5 column volumes). Fractions were analyzed via MALDI-TOF 
and dried under reduced pressure.  
Anantin B1 and B2 were dissolved in 7 mL of water each and filtered with a 0.22 µm syringe 
filter (BD Technologies) prior to injection. HPLC was performed using a Teledyne Isco 
Combiflash EZprep equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 
5 µM particle size) with a mobile phase of 10 mM aq. NH4HCO3/MeCN (gradient from 10 to 95% 
MeCN) at 19 mL min-1. Fractions containing either anantin B1 or B2 were dried under reduced 
pressure, resuspended in H2O, flash-frozen, and lyophilized overnight to dryness.  
Preparative HPLC was performed with a Perkin Elmer Flexar HPLC equipped with a Betasil C18 
(Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). Anantin B1 and B2 
were dissolved separately in 1.5 mL of water, subjected to centrifugation at 17,000 × g to remove 
precipitate, and injected with a mobile phase of water/MeCN + 0.1% formic acid (v/v) with a 
gradient from 10–95% over 30 min. Elution was monitored at 220 nm and appropriate fractions 
were dried under reduced pressure, dissolved in water (2 mL), flash-frozen, and lyophilized 
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overnight to dryness. Anantin B1 and B2 were collected as colorless powders (1.8 mg and 2.1 mg, 
respectively). Yields for anantin B1 and B2 were 75 µg/15 cm dish and 88 µg/15 cm dish 
respectively. 
Analytical HPLC to assess purity was performed using a Betasil C18 column (100 Å pore 
size, 250 × 4.6 mm, 5 µM particle size) (Thermo Scientific) with a mobile phase of H2O/MeCN + 
0.1% (v/v) formic acid (FA) gradient from 10% to 95% aq. MeCN over 30 minutes at 1 mL min-
1. For anantin B2, a mobile phase of 10 mM aq. NH4HCO3/MeCN gradient from 5 to 25% MeCN 
over 30 minutes, then ramp to 95% MeCN over 5 minutes and held at 95% MeCN for 10 minutes 
at 1 mL min-1. Both anantin B1 and anantin B2 were detected eluting at 220 nm.  
Isolation of LP2006. Nocardiopsis alba NRRL B-24146 was grown on ATCC 172 and 
1.5% agar in sterilized aluminum cake pans (12-¼ inches by 8-¼ inches; n = 12; ~300 mL media 
ea.) and incubated at 30 °C for 21 d. Cells were harvested by scraping cell mass from the plates 
with a razor blade and collectively extracted with 100 mL MeOH with shaking at rt overnight. 
Following filtration, the remaining cell mass was re-extracted with 100 mL of n-BuOH shaking at 
rt overnight. The MeOH and n-BuOH extract was vacuum-filtered and dried under reduced 
pressure onto 10 g of Celite 545 adsorbent. 
LP2006 adsorbed on Celite was purified by MPLC using a Teledyne Isco Combiflash 
EZprep equipped with a RediSep Rf C18 cartridge (86 g media, 60 Å pore size, 40–63 µm particle 
size, 230–400 mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 60 mL min-1 over a 
gradient from 10–95% MeCN (12 column volumes), and held at 95% MeCN (5 column volumes). 
Fractions were analyzed via MALDI-TOF MS. Fractions containing LP2006 were combined and 
the solvent was evaporated. 
HPLC was performed using a Teledyne Isco Combiflash EZprep equipped with a RediSep 
Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) with a mobile phase of 
10 mM aq. NH4HCO3/MeCN (gradient from 25 to 95% MeCN) at 19 mL min-1. Fractions found 
by MALDI-TOF to contain LP2006 were combined and evaporated to dryness. 
Preparative chromatography on a Perkin Elmer Flexar HPLC equipped with a Betasil C18 (Thermo 
Scientific) reverse phase column (250 × 10 mm, 5 µm particle size) was performed with a mobile 
phase of 10 mM aq. NH4HCO3/MeCN (gradient from 20–40% MeCN for 20 min, then 40–95% 
MeCN for 5 min) at 4 mL min-1. This yielded 1.9 mg of LP2006, which was dissolved in water, 
flash-frozen, and lyophilized to dryness with a final yield of 158 µg/pan.  
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The purity of LP2006 was checked by HPLC with a Perkin Elmer Flexar HPLC equipped 
with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 
100 Å pore size). A mobile phase of 10 mM aq. NH4HCO3/MeCN gradient from 5–25% MeCN 
over 15 minutes, then ramped to 95% MeCN over 5 min and held at 95% MeCN for 10 min at a 
flow rate of 1 mL min-1. Elution of LP2006 was detected at 220 nm. 
Isolation of moomysin. Streptomyces cattleya NRRL 8057 was grown on AltMS medium 
with 1.5% agar on sterilized aluminum cakepans (12-¼ inches by 8-¼ inches; n = 12; ~300 mL 
media ea.) and incubated at 30 °C for 14 d. Cells were harvested by scraping cell mass from the 
plates with razors and cell material was extracted with 200 mL of 50% aq. MeCN overnight with 
shaking at room temperature. The cell mass was filtered with Whatman filter paper and the filter 
cake was re-extracted 3 additional times. Extracts were combined and dried under reduced pressure 
onto ~5 g Celite 545 adsorbent. Agar extracts did not contain detectable quantities of moomysin 
by MALDI-TOF MS, and were not purified or analyzed further. 
 Adsorbed moomysin was purified by MPLC using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle size, 
230–400 mesh) using a mobile phase of 10 mM NH4HCO3/MeCN at 85 mL min-1 over a gradient 
from 10–20% MeCN (5 column volumes), 20–50% MeCN (5 column volumes), then 50–100% 
MeCN (2.5 column volumes) then holding at 100% MeCN (5 column volumes). Fractions were 
analyzed via MALDI-TOF MS, and fractions containing moomysin were pooled and dried under 
reduced pressure and stored at -20 °C. 
 Samples for HPLC were resuspended in 7 mL of water, subjected to centrifugation at 
17,000 × g to remove precipitate and filtered with a 0.22 µm syringe filter (BD Technologies) prior 
to injection. Moomysin was injected onto a Teledyne Isco Combiflash EZprep equipped with a 
RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 5 µM particle size) at 19 mL min-1 
with a mobile phase of 10 mM NH4HCO3/MeCN gradient starting at 10% MeCN (10 column 
volumes), 10 to 45% MeCN (7 column volumes) then 45 to 100% MeCN (5 column volumes) and 
held at 100% MeCN for 5 column volumes. Elution of moomysin was monitored at 214 nm, and 
the corresponding fractions were dried under reduced pressure and stored at -20 °C. 
 Preparative chromatography was performed with a Perkin Elmer Flexar HPLC equipped 
with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm particle size). 
Moomysin was dissolved in 1.5 mL of H2O, subjected to centrifugation at 17,000 × g to remove 
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precipitate and injected with a mobile phase of water/MeCN + 0.1% formic acid (v/v) gradient 
from 10–95% over 30 min with a flow rate of 4 mL min-1. Elution was monitored at 220 nm and 
fractions containing moomysin were dried under reduced pressure, resuspended in 2 mL water, 
flash-frozen, and lyophilized overnight to dryness. Moomysin was collected as a colorless powder 
(0.8 mg) after lyophilization, with an overall yield of 133 µg/pan.  
The purity of moomysin was verified by HPLC with a Perkin Elmer Flexar HPLC equipped with 
a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å 
pore size). A mobile phase of 10 mM aq. NH4HCO3/MeCN gradient from 5–15% MeCN over 25 
minutes, then ramped to 95% MeCN for 5 minutes and held at 95% for 10 minutes at a flow rate 
of 1 mL min-1. Elution of moomysin was monitored at 220 nm. 
 Isolation of citrulassin A. Streptomyces albulus NRRL B-3066 was grown on ATCC172 
medium with 1.5% agar on sterilized, aluminum half sheet cake pans (n = 4; 750 mL per pan) and 
incubated at 30 °C for 10 d. The agar was frozen, thawed, and squeezed (filtering through 
cheesecloth) to collect the bulk aqueous extract. The solid agar was then extracted with 600 mL of 
50% methanol in water for 2 h. The methanol was removed under vacuum and the remaining 
aqueous extraction was combined with the liquid from the agar squeeze. The combined aqueous 
extract was vacuum filtered through Whatman filter paper to remove residual solid material. The 
extract was loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-equilibrated 
with 100 mL MeCN, 100 mL 50% aq. MeCN, and 200 mL water prior to loading. The column 
was washed with an additional 200 mL of water. Product was eluted with successive 50 mL 
portions of 10%, 20%, 30%, 40%, and 50% aq. MeCN, followed by 100 mL of MeCN. Fractions 
were analyzed via MALDI-TOF MS (Supplementary Methods: screening Actinomycetes for lasso 
peptide production). Fractions containing citrulassin A were pooled and dried under reduced 
pressure onto ~15 g Celite 545 adsorbent. 
Adsorbed citrulassin A was purified by MPLC using a Teledyne Isco Combiflash EZprep 
equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle size, 
230-400 mesh) using a mobile phase of 10 mM aq. NH4HCO3/MeCN at 85 mL min-1 over a 
gradient from 10–100% MeCN (25 column volumes). Fractions were analyzed via MALDI-TOF 
MS, pooled, and dried under reduced pressure. Partially purified material was stored at -20 °C 
between purification steps. 
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The partially purified material was resuspended in 5 mL water and was injected onto a Teledyne 
Isco Combiflash EZprep equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 
20 mm, 5 µM particle size). The product was purified with a mobile phase of 10 mM aq. 
NH4HCO3/MeCN at a flow rate of 19 mL min-1 utilizing a method of: 5% MeCN (isocratic, 5 
min), 5–40% MeCN (gradient, 20 min), 40–100% MeCN (gradient, 5 min), 100% MeCN 
(isocratic, 5 min). Elution of citrulassin A was monitored at 214 nm. Fractions containing the 
product were dried under reduced pressure and stored at -20 °C. 
Final preparative chromatography was performed with a Perkin Elmer Flexar HPLC equipped with 
a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 µm particle size, 100 Å 
pore size). The partially purified product was dissolved in 6 mL of water and injected over 6 
consecutive runs. A mobile phase of 10 mM aq. NH4HCO3/MeCN was utilized at a flow rate of 1 
mL min-1 with a method of: 20% MeCN (isocratic, 5 min), 20%–30% MeCN (gradient, 35 min), 
30%–95% MeCN (gradient, 5 min), 100% MeCN (isocratic, 3 min). Elution was monitored at 220 
nm and fractions containing citrulassin A were dried under reduced pressure, resuspended in 5 mL 
water, flash frozen, and lyophilized overnight to yield a white, cotton-like solid (8 mg, ~2 mg/half 
sheet cake pan). 
The purity of isolated citrulassin A was checked by HPLC with a Perkin Elmer Flexar 
HPLC equipped with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 4.6 mm, 5 
µm particle size, 100 Å pore size). A mobile phase of 10 mM aq. NH4HCO3/MeCN was utilized 
at a flow rate of 1 mL min-1. Citrulassin A was injected as 10 µL of a 1 mM solution with a method 
of: 15% MeCN (isocratic, 5 min), 15–27% MeCN (gradient, 20 min). Elution was monitored at 
220 nm. 
 Isolation of lagmysin. Streptomyces sp. S-118 was grown on ISP Medium 4 
(Supplementary Methods: microbiological methods) with 1.5% agar on 15 cm sterilized petri 
dishes (n = 24) and incubated at 30 °C for 10 d. Cells were harvested by scraping cell mass from 
the plates with razors and collectively extracted with 600 mL MeOH with shaking at room 
temperature overnight. The cell mass was filtered with Whatman filter paper and re-extracted with 
600 mL BuOH with shaking at room temperature overnight before filtering again. Cell extracts 
were combined and dried under reduced pressure onto ~5 g Celite 545 adsorbent. 
 Spent agar was frozen at -20 °C overnight and then allowed to thaw. The agar was squeezed 
and filtered through cheesecloth to harvest the aqueous portion, then vacuum filtered with 
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Whatman filter paper and loaded onto a HyperSep C18 10 g SPE column (Thermo Scientific) pre-
equilibrated with 100 mL MeCN, 100 mL 50% aq. MeCN, and 200 mL water prior to loading. 
The column was then washed with an additional 200 mL of water, then eluted with successive 50 
mL portions of 5%, 10%, 25%, 50%, 75% aq. MeCN, followed by 100 mL MeCN. Fractions were 
analyzed via MALDI-TOF MS. Fractions containing lagmysin were pooled and dried under 
reduced pressure onto ~5 g Celite 545 adsorbent and combined with the adsorbed cell extract. 
 Adsorbed lagmysin was chromatographed by MPLC using a Teledyne Isco Combiflash 
EZprep equipped with a RediSep Rf C18 cartridge (130 g media, 60 Å pore size, 40–63 µm particle 
size, 230–400 mesh) using a mobile phase of 10 mM NH4HCO3/MeCN at 85 mL min-1 over a 
gradient from 20–60% MeCN (10 column volumes), then 60–95% MeCN (5 column volumes) 
then holding at 95% MeCN (5 column volumes). Fractions were analyzed via MALDI-TOF MS, 
pooled and dried under reduced pressure and stored at -20 °C. 
 To prepare samples for preparatory HPLC, dried lagmysin was resuspended in 7 mL of 
water, subjected to centrifugation at 17,000 × g to remove precipitate, and filtered with a 0.22 µm 
syringe filter (BD Technologies) prior to injection. Lagmysin was injected onto a Teledyne Isco 
Combiflash EZprep equipped with a RediSep Prep C18Aq column (100 Å pore size, 150 × 20 mm, 
5 µM particle size) utilizing a flow rate of 19 mL min-1 with a mobile phase of 10 mM 
NH4HCO3/MeCN gradient from 10 to 50% MeCN (15 column volumes) then 50 to 100% MeCN 
(5 column volumes) and held for an additional 5 column volumes. Elution of lagmysin was 
monitored at 214 nm, and fractions containing the desired material were dried under reduced 
pressure and stored at -20 °C. 
 Final preparative chromatography was performed with a Perkin Elmer Flexar HPLC 
equipped with a Betasil C18 (Thermo Scientific) reverse phase column (250 × 10 mm, 5 µm 
particle size). Lagmysin was dissolved in 1.5 mL of water, subjected to centrifugation at 17,000 × 
g to remove precipitate and injected with a mobile phase of water/MeCN + 0.1% formic acid (v/v) 
gradient from 20–95% over 30 min with a flow rate of 4 mL min-1. Elution was monitored at 220 
nm and fractions containing lagmysin were dried under reduced pressure, resuspended in 2 mL 
water, flash frozen and lyophilized overnight to dryness. Lagmysin was collected as a colorless 
powder (6.5 mg) after lyophilization, with an overall yield of 270 µg/15 cm plate.  
Analytical HPLC to assess purity of lagmysin was performed with a Perkin Elmer Flexar HPLC 
equipped with a Betasil C18 column (100 Å pore size, 250 × 4.6 mm, 5 µM particle size) (Thermo 
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Scientific) with a mobile phase of H2O/MeCN + 0.1% (v/v) formic acid (FA) gradient from 10% 
to 95% aq. MeCN over 30 minutes and held at 95% MeCN for 10 minutes at 1 mL min-1. Elution 
was monitored at 220 nm. 
4.12.18 Broth microdilution antimicrobial assay 
A broth microdilution assay was used to determine the minimum inhibitory concentration 
(MIC) against a panel of bacteria. E. coli MC4100, Pseudomonas aeruginosa PA01, Klebsiella 
pneumoniae ATCC 27736, Acinetobacter baumannii ATCC 19606, Enterococcus faecium U503 
(VRE), Staphylococcus aureus USA300 (MRSA), Bacillus subtilis 168, Bacillus anthracis Sterne, 
Listeria monocytogenes serotype 4b str. F2365, and Mycobacterium smegmatis NRRL B-14616 
were grown in Mueller-Hinton broth (BD). Neisseria meningitidis 8013 was grown in gonococcal 
broth (GBC) with Kellogg’s supplements. Bacteria were grown overnight in 5 mL of medium at 
37 °C to stationary phase. Cultures were diluted 50-fold into 5 mL of fresh media, allowed to grow 
back to mid-exponential phase (OD600 = 0.500), and diluted to OD600 = 0.01. Lasso peptide stocks 
(10 mM in DMSO; or 1 mM in 0.2 µm filtered H2O for citrulassin A) were serially diluted (2-fold) 
in broth in a 96-well microplate. An equal volume of bacterial culture in broth was added to each 
well (final vol. 100 μL/well) to give a final range of 100 µM to 49 nM compound. Plates were 
sealed with Parafilm M and incubated at 37 °C with shaking. The MIC is the concentration that 
resulted in no visible growth after 18 h, or 24 h for M. smegmatis. All measurements were made 
with at least 2 replicates. 
4.12.19 Quantitative amino acid analysis of citrulassin A 
Purified citrulassin A was submitted to the Texas A&M Protein Chemistry Laboratory 
(http://tamupcl.com/) for quantitative amino acid analysis in triplicate using a total of 75 µg.. 
4.12.20 Chiral amino acid analysis 
Microwave assisted vapor phase acid hydrolysis of peptides was performed in a CEM 
Discover 3000 Microwave System (CEM). Peptides were hydrolyzed in a sealed chamber with 6 
N deuterium chloride (DCl) at 150 °C for 30 min under anaerobic conditions. Hydrolysates were 
derivatized with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) 
(Thermo-Fisher Scientific) to enhance separation of L-/D-amino acids. Hydrolysates were 
reconstituted in 25 μL of 0.5 M NaHCO3, combined with 20 μL of 1 mg/mL FDAA in MeCN, 
and incubated at 60 °C for 3 h. Derivatized amino acids from each peptide sample were analyzed 
using a LC-MS/MS-MRM system consisting of an Advance Ultra-High Pressure Liquid 
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Chromatography (UHPLC) (Bruker) system coupled to an EVOQ Elite Triple-Quadrupole MS 
(Bruker) with a Kinetex 2.6 μm Phenyl-Hexyl 100 Å LC column (100 × 2.1 mm) (Phenomenex). 
Gradient elution was performed with binary solvents (Solvent A: 25 mM ammonium formate, 
Solvent B: MeOH) at 300 μL/min. The gradient was 5% B for 2 min, 5–15% B for 5 min, 15–60% 
B for 5 min, 60% B for 3 min, 60–100% B for 3 min, 100% B for 3 min, 100–5% B for 1 min, 5% 
B for 2 min. Data Review (Bruker) was used to analyze the MRM data. 
4.12.21 Heterologous expression of citrulassin gene cluster 
Isolation of high molecular weight DNA. Streptomyces albulus str. NRRL B-3066 was 
grown in liquid ATCC172 media supplemented with 0.8% glycine at 30 °C with agitation until a 
dense culture had developed (~5 d). A 30 mL portion of the culture was pelleted (4,000 × g, 10 
min), and the supernatant was removed by aspiration. The cells were resuspended in 2 mL of 
TE25S buffer (25 mM Tris, 25 mM EDTA disodium salt, 30% sucrose, pH 8) and large clumps of 
cells were broken up by physical disruption with a glass rod. Lysozyme was added to a final 
concentration of 10 mg/mL and the suspension was incubated at 37 °C with agitation. After 1 h, 6 
mL of modified lysis buffer (569 mM 4-aminosalicylic acid sodium salt, 69 mM sodium dodecyl 
sulfate, 100 mM Tris, pH 8) and 20 µL of proteinase K (NEB, 30 U/mg at 20 mg/mL) were added. 
The suspension was then incubated at 75 °C for 30 min, with the suspension being mixed once by 
gentle inversion several times after 15 min. An equal volume of phenol:chloroform:isoamyl 
alcohol (25:24:1, v/v) was then added and mixed by gentle inversion several times. The mixture 
was centrifuged at 10,000 × g at 4 °C for 10 min, and the aqueous phase was transferred to a new 
container using a wide bore pipet (or pipet tips with the ends cut off to provide a wider opening). 
To the aqueous phase, an equal volume of chloroform:isoamyl alcohol (24:1, v/v) was added and 
mixed by gentle inversion several times. The mixture was again centrifuged at 10,000 × g at 4 °C 
for 10 min, and the aqueous phase was transferred to a new container using a wide bore pipet. 
Another round of chloroform:isoamyl alcohol extraction was performed if solid material was still 
present in the aqueous phase. The aqueous phase was then transferred to a 50 mL conical tube, to 
which 0.1 volume equivalents of 5 M NaCl was added. The tube was then filled to the top with 
isopropyl alcohol and the mixture was gently inverted several times to mix. A small glass hook 
fashioned from a melted Pasteur pipet was used to collect the precipitated DNA. The DNA was 
washed twice with 75% aq. EtOH followed by a single wash with 100% EtOH. The DNA was 
then allowed to air dry on the glass hook overnight. 
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Fosmid library generation. High molecular weight DNA was resuspended in 600 µL TE 
buffer (10 mM Tris, 1 mM EDTA, pH 8), 330 µL 10x CutSmart buffer (NEB), and 2310 µL 
DNase-free water. Gentle pipetting with a wide bore pipet and heating at 65 °C were used to help 
dissolve the DNA. After the majority of the DNA was dissolved, 30 µL of RNase A was added 
and the solution was mixed by gentle inversion. The DNA solution was split into 14 fractions and 
Sau3AI (NEB) was added to each in a 2-fold serial dilution, starting with 2.5 µL of Sau3AI into 
400 µL of DNA solution. Solutions were mixed by gentle pipetting with a wide bore pipet. Digest 
reactions were incubated at 37 °C for 1 h and were then inactivated by incubation at 75 °C for 30 
min. Fractions were analyzed by field-inversion gel electrophoresis, and fractions containing 
approximately 40 kb pieces of DNA were utilized in cosmid construction. These fractions were 
dephosphorylated by the addition of 20 µL of shrimp alkaline phosphatase and incubation at 37 
°C for 1 h. DNA fragments were isolated by phenol:chloroform:isoamyl alcohol extraction and air 
dried for 3 h. 
The previously reported vector pJK050 was used for fosmid construction69. pJK050 was 
doubly digested with NheI-HF and BamHI-HF (NEB) and dephosphorylated with shrimp alkaline 
phosphatase. Cut vector was purified with a GeneJET PCR Purification Kit (Thermo Scientific). 
Approximately 1 µg of cut vector, 2 µL of 10x T4 ligase buffer (NEB), and water (to give 20 µL 
total volume) was used to resuspend the digested high molecular weight DNA. A portion (5 µL) 
was removed as a control and 1 µL of high concentration T4 ligase (NEB, 2,000,000 U/mL) was 
added to the remainder. The ligation reaction was incubated at 4 °C overnight and used without 
further modification. 
A culture of E. coli WM4489 was started in LB and grown at 37 °C overnight. The culture 
was then used to inoculate a new 10 mL culture of LB supplemented with 10 mM maltose. This 
culture was grown at 37 °C with shaking until it reached an optical density of 0.8 to 1.0. The 
culture was pelleted at 4,000 × g for 10 min, and the supernatant was removed by aspiration. The 
pellet was resuspended in 2 mL of sterile 10 mM MgCl2 and chilled on ice until needed. Ligated 
DNA was then packaged into phage and transfected into E. coli WM4489 with MaxPlax Lambda 
Packaging Extracts (Epicentre) following the manufacturer’s instructions. The transfection 
reaction (2 mL) was pelleted at 17,000 × g for 5 min and 1.4 mL of the supernatant was discarded. 
The remaining supernatant was used to resuspend the pellet and the suspension was plated onto 5 
LB agar plates (100 µL/plate) containing 12.5 µg/mL chloramphenicol. The plates were incubated 
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at 37 °C overnight, resulting in thousands of colonies per plate. Colonies were scraped from the 
plates utilizing 1 mL of LB per plate, pooled together, and mixed with 3 mL of sterile 50% glycerol 
in water to give a library stock solution. The solution was plated on fresh LB agar plates containing 
12.5 µg/mL chloramphenicol at an appropriate dilution to provide individual colonies. Colonies 
were screened by PCR for the presence of approximately 650 base sequences before and after the 
citrulassin A gene cluster. Positive hits were verified by an additional round of PCR screening and 
were then grown in LB containing 12.5 µg/mL chloramphenicol and 20 mM rhamnose at 37 °C 
with agitation overnight. Two hits were found to contain the citrulassin A gene cluster and were 
named p1F3 and p3H4. Cosmid DNA was isolated with a GeneJET Plasmid Miniprep Kit (Thermo 
Scientific). The start and end of the genomic insert in each cosmid was determined via sequencing 
with primers designed to anneal up- and downstream of the BamHI or NheI cut sites. 
Heterologous expression of citrulassin A gene cluster. Cosmid DNA was recombined in 
vitro with pAE4 using Gateway BP Clonase II (Thermo Scientific) following the manufacturer’s 
instructions to insert the functions necessary for transfer and integration into Streptomyces lividans 
69. The resulting fosmids were transformed into the conjugation strain E. coli WM6026 by 
electroporation, with 20 µg/mL of sterile diaminopimelic acid (DAP) added during the recovery 
step (E. coli WM6026 is a DAP auxotroph). Transformants were plated on LB agar containing 
12.5 µg/mL chloramphenicol, 50 µg/mL apramycin, and 20 µg/mL DAP. Cultures of E. coli 
WM6026 containing the fosmids were started in LB supplemented with 12.5 µg/mL 
chloramphenicol, 50 µg/mL apramycin, and 20 µg/mL DAP and grown overnight at 37 °C with 
agitation. The overnight cultures were then used to inoculate fresh 5 mL cultures with the same 
supplements, which were grown to an optical density of 0.4 to 0.6. The cultures were pelleted by 
centrifugation at 4,000 × g for 10 min, and the supernatants were discarded. The pellets were 
washed twice with sterile 2xYT media (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl), 
resuspended in 1 mL of 2xYT containing 20 µg/mL DAP, and chilled on ice until use. A frozen 
suspension of S. lividans 66 spores was heat shocked at 56 °C for 15 min straight from the freezer. 
After 15 min, 500 µL of 2xYT was added and mixed by pipetting. Conjugation reactions were set 
up with 200 µL of the spore suspension and either 4 µL (50:1), 40 µL (5:1), or 200 µL (1:1) of a 
fosmid containing E. coli WM6026 solution. The suspensions were briefly centrifuged to settle 
the cells together at the bottom of the tubes and were incubated at room temperature for 10 min. 
The cells were then resuspended by pipet and the entire solutions were plated on individual 
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mannitol-soy plates (20 g/L mannitol, 20 g/L soy flour, 16 g/L agar) supplemented with 10 mM 
MgCl2. The plates were incubated at 30 °C for 16 h, and then the plates were flooded with 2 mL 
of a 1 mg/mL aqueous apramycin solution. The plates were dried while open in a biosafety cabinet 
and then incubated at 30 °C until colonies appeared. The strains were named S. lividans 1F3 and 
S. lividans 3H4, corresponding to the respective cosmids used to construct them. 
Colonies of S. lividans 1F3 and S. lividans 3H4 were used to inoculate ATCC172 liquid 
media containing 12.5 µg/mL chloramphenicol and 50 µg/mL apramycin. The cultures were 
grown at 30 °C with agitation until a dense culture was obtained. These cultures were plated on 5 
ATCC172 agar plates each (antibiotic free) to generate a lawn and these plates were grown at 30 
°C for 10 d. The plates were frozen, thawed, and squeezed to collect the liquid from the agar. The 
liquid was filtered through Whatman paper by vacuum filtration and then applied to a 0.5 g 
Hypersep C18 solid phase extraction column (Thermo Scientific) that had been equilibrated with 
20 mL of MeCN, 20 mL of 50% aq. MeCN, and 30 mL of H2O. The column was washed with 20 
mL of water and eluted with 5 mL each of 10%, 20%, 40%, 60%, and 100% aq. MeCN. Fractions 
were analyzed by MALDI MS with CHCA as a matrix. Des-citrulassin A was detected in the 40%, 
60%, and 100% fractions. The 60% fraction was subsequently utilized for HRMS and MS/MS 
analysis. 
Primer Sequence (5′ to 3′) Description 
Construct Generation 
Citrulassin_start_f CGTCATGAAGAAGGCCTACGAGG 
Forward primer for screening for the 
genomic region immediately upstream of 
the citrulassin cluster 
Citrulassin_start_r GGCCACAACAGCCGTACG 
Reverse primer for screening for the 
genomic region immediately upstream of 
the citrulassin cluster 
Citrulassin-end-f CCTCGACCAGCGCAACGG 
Forward primer for screening for the 
genomic region immediately downstream 
of the citrulassin cluster 
Citrulassin-end-r CGGAGCGGTCAGTGGTGC 
Reverse primer for screening for the 
genomic region immediately downstream 
of the citrulassin cluster 
pJK050-BamHI-f GGCGAAGTTCCTATACTTTCTAGAGAATAGG Forward primer for sequencing the BamHI cut site in pJK050 
pJK050-BamHI-r CGTATAGCATACATTATACGAAGTTATCAAGAAGC Reverse primer for sequencing the BamHI cut site in pJK050 
pJK050-NheI-f GCACAGCAAAGCCGCCG Forward primer for sequencing the NheI cut site in pJK050 
pJK050-Nhe1-r GTCAACAAAAAGCAGACGTATCTAGACACG Reverse primer for sequencing the NheI cut site in pJK050 
Table 4.8 Primers used for heterologous expression of citrulassin A. 
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4.12.22 High resolution mass spectrometry 
Lasso peptides were dissolved in 80% aq. MeCN with 1% AcOH and subjected to 
centrifugation (17,000 × g, 5 min). Samples were infused onto a ThermoFisher Orbitrap Fusion 
ESI-MS using an Advion TriVersa NanoMate. The MS was calibrated weekly using calibration 
mixture, following manufacturer instructions, and tuned daily with Pierce LTQ Velos ESI Positive 
Ion Calibration Solution (ThermoFisher). Spectra were collected in profile mode with a resolution 
of 100,000. Ions were selected for fragmentation in the Ultra-High-Field Orbitrap Mass Analyzer 
using an isolation width of 5 m/z, a normalized collision energy of 35, an activation q value of 0.4, 
and an activation time of 30 ms. Data analysis was performed using Thermo Xcalibur software. 
4.12.23 NMR spectroscopy 
HPLC-purified and lyophilized samples (ca. 1–5 mg) were dissolved in 600 µL of CD3OD 
(99.96 atom % D; Sigma-Aldrich) or CD3OH (99.5 atom % D; Cambridge Isotope Labs). Spectra 
were obtained with either a Bruker AVANCE 900 MHz narrow bore spectrometer equipped with 
an inverse 5 mm TCI cryogenic probe with z-axis pulsed field gradient (pfg) capability or on an 
Agilent VNMRS 750 MHz narrow bore magnet spectrometer equipped with a 5 mm triple 
resonance (1H-13C-15N) triaxial gradient probe and pulse-shaping capabilities. Samples were held 
at 298 K during acquisition. Standard Bruker or Varian pulse sequences were used for each of the 
following experiments: 1H, 1H with solvent suppression using excitation sculpting (Bruker: 
zgesgp), 1H-1H TOCSY (80 ms mixing time; Bruker: dipsi2esgpph), 1H-13C HSQC (multiplicity-
edited; Bruker: hsqcedetgpsisp2), and 1H-1H NOESY (400 ms mixing time; Bruker: noesyesgpph; 
Varian: dpfgse_noesy). 2D spectra in CD3OH employed solvent suppression as per the listed pulse 
sequences. Spectra were recorded with Bruker TopSpin 1.3 or VNMRJ 3.2A software, and data 
was processed using MestReNova 8.1.1. Chemical shifts (δ, ppm) were referenced internally to 
the solvent peak. 
4.12.24 Three-dimensional solution structure calculation 
Solution structures were calculated by simulated annealing using distance and angle 
restraints within XPLOR-NIH v 2.3670,71. Standard XPLOR-NIH potentials for bond angles, 
improper angles, van der Waals, and favored/allowed Ramachandran regions were used. The lasso-
forming isopeptide linkage was specified using a manual patch of the “protein-1.0.top” XPLOR-
NIH file (Figure 4.22); the disulfide linkage was created using a pre-installed patch (DISL). 
Distance restraints were derived from peak area integrations in the NOESY data. The program 
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nmrPipe was used for processing of NOESY data and conversion from Bruker to UCSF format 
(Sparky), and Sparky was used for peak picking, volume integration, and creation of the distance 
restraint table for use in XPLOR.  Two hundred structures were calculated, of which the 20 of 
lowest energy were retained.  
 
 
presidue ISOG               ! isopeptide linkage - mod of ISOP - N terminal 
                            !  2015/10/26 
  group 
   modify   atom -CD   charge = 0.480 end 
   modify   atom -OE1 type=O  charge = -0.480 end 
   delete  atom -OE2     end 
  group 
   delete   atom +HT3    end 
   delete   atom +HT2    end 
   delete   atom +HT1  charge = 0.260  end 
   add   atom +HN  type=H   charge = 0.260   end 
   modify   atom +N  type=NH1 charge = -0.360  end 
 
  add bond -CD +N 
  add bond +N +HN 
  add angle -CB -CD +N 
  add angle -OE1 -CD +N 
  add angle -CD +N +CA 
  add angle -CD +N +HN 
   
      ADD DIHEdral  -CG   -CD     +N   +HN 
      ADD DIHEdral  -CG   -CD     +N   +CA 
      ADD DIHEdral  -OE1  -CD     +N   +HN  ! double dihedral 
      ADD DIHEdral  -OE1  -CD     +N   +HN  ! double dihedral 
      ADD DIHEdral  -OE1  -CD     +N   +CA 
 
  add improper -OE1 -CD +N +CA 
  add improper -CG  -CD +N +CA 
end 
 
Figure 4.22 Manual patch used with XPLOR-NIH.  
 
4.12.25 Thermal unthreading assay.  
Lasso peptide stock solutions were diluted to 40 µM in a final volume of 50 µL, heated at 
95 °C for 4 h, and cooled to rt. Samples were then analyzed by liquid chromatography electrospray 
ionization tandem mass spectrometry (LC/ESI-Q/TOF MS) using a Synapt ESI quadrupole TOF 
Mass Spectrometry System (Waters) equipped with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). Lasso peptides were analyzed from 2 to 98% aq. 
MeCN (with 0.1% formic acid) over 24 min at a flow rate of 130 µL min-1. Total ion 
chromatograms were used to monitor retention times via Waters MassLynx MS Software. 
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APPENDIX B: COMPOUND CHARACTERIZATION DATA
B.1 Characterization data for streptomonomicin
B.1.1 HPLC-ESI and -UV analysis of streptomonomicin HPLC analysis employed an Agilent
1200 HPLC system outfitted with an Agilent G1956B single quadrupole mass analyzer and an
analytical Thermo-Scientific Betasil C18 HPLC column (300 Å, 250 × 4.6 mm, 5 µM particle size)
operating at 1.0 mL/min. (A) and (B) represent data from the same HPLC injection. (A) UV-HPLC
trace (220 nm) of Sep-Pak-purified STM. (B) Single-ion monitoring (SIM) mass spectral trace of
Sep-Pak-purified STM. The monitored m/z, 1117.5, corresponds to [M+2H]2+ for STM. (C) UV-
vis spectrum (diode array detector) of HPLC-purified STM acquired during a separate HPLC run.
STM displays absorbance maxima (228 nm, 276 nm) characteristic of a tyrosine-containing
peptide.
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B.1.2 High resolution FT-MS/MS fragmentation analysis of streptomonomicin (A) An m/z
scan of purified STM that was directly infused into an 11T FTMS resulted in a 2+ charge ion
consistent with the calculated m/z for STM. (B) An m/z scan of purified, carboxypeptidase Y and
thermolysin-digested STM that was directly infused into an 11T FTMS resulted in a 1+ charge ion
consistent with the first 10 residues of STM. (C) MS/MS of purified STM resulted in the fragment
ions shown in the table and in Figure 2A. Charge state, expected m/z, observed m/z, and error are
shown. (D) MS/MS of purified carboxypeptidase Y- and thermolysin-digested STM resulted in
the fragment ions shown in the table and in Figure 2B. Charge state, expected m/z, observed m/z,
and error are shown.
Ion Charge Expected m/z Observed m/z Error, ppm Ion Charge Expected m/z Observed m/z Error, ppm
y3 +1 392.2180 392.2182 0.51 b5 +1 442.2296 442.2302 1.36
y4 +1 491.2864 491.2869 1.02 y3 +1 448.2038 448.2042 0.89
y5 +1 604.3705 604.3709 0.66 b6 +1 605.2930 605.2934 0.66
y6 +1 717.4545 717.4554 1.25 y4 +1 611.2671 611.2676 0.82
y7 +1 788.4917 788.4924 0.89 y5 +1 708.3199 708.3203 0.56
y8 +1 885.5444 885.5443 0.11 b7 +1 719.3359 719.3364 0.70
b8 +1 903.3843 903.3852 1.00 y6 +1 795.3519 795.3525 0.75
b9 +1 1016.4684 1016.4689 0.49 y7 +1 882.3840 882.3847 0.79
y9 +1 1048.6077 1048.6087 0.95 b8 +1 921.3949 921.3956 0.76
b19 +2 1060.0594 1060.0600 0.57 b8* +1 947.4469 947.4477 0.84
b10 +1 1129.5524 1129.5536 1.06 y8 +1 939.4054 939.4064 1.06
b11 +1 1186.5739 1186.5751 1.01
y11 +1 1218.7133 1218.7138 0.41
b12 +1 1349.6372 1349.6371 0.07
b13 +1 1446.6900 1446.6917 1.18
b14 +1 1517.7271 1517.7302 2.04
b15 +1 1630.8111 1630.8129 1.10
b16 +1 1743.8952 1743.8958 0.34
b17 +1 1842.9636 1842.9669 1.79
b18 +1 1956.0477 1956.0518 2.10
C D
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B.1.3 1H NMR spectrum of STM (CD3OD, 750 MHz)
305
B.1.4 1H-1H DQF-COSY NMR spectrum of STM in CD3OD (750 MHz)
306
B.1.5 1H-1H TOCSY spectrum of STM in CD3OD (750 MHz)
307
B.1.6 1H-1H NOESY spectrum of STM in CD3OD (750 MHz)
308
B.1.7 1H-13C HSQCAD spectrum of STM in CD3OD (750 MHz) CH3 and CH peaks appear in
red; CH2 peaks appear in blue. Cuts in spectra appear for clarity.
309
B.1.8 1H-13C HMBCAD spectrum of STM in CD3OD (750 MHz)
310
B.1.8 (cont.)
311
B.1.9 1H NMR spectrum of STM in CD3OH (750 MHz), employing water presaturation
312
B.1.10 1H-1H DQF-COSY spectrum of STM in CD3OH (750 MHz)
313
B.1.11 1H-1H TOCSY spectrum of STM in CD3OH (750 MHz)
314
B.1.12 1H-1H NOESY spectrum of STM in CD3OH (750 MHz)
315
B.1.13 1H-13C HMBCAD spectrum of STM in CD3OH (750 MHz)
316
B.1.14 1H-1H TOCSY spectrum of STM, taken in CD3OD (750 MHz) after 2 d
317
B.1.15 NMR chemical shift assignments for streptomonomicin.
δ (ppm)
HN Hα Cα Hβ Cβ Others, H (group) Others, C
(group)
Ser1 7.81 4.14 56.2 4.26,
3.84
61.0 - -
Leu2 8.06 3.74 54.6 2.25,
1.75
37.5 1.73 (γ, CH), 1.06, 0.88
(δ, CH3)
22.5, 19.6 (δ),
ambig (γ)
Gly3 8.32 4.71,
3.36
41.6 - - - -
Ser4 7.68 4.56 54.5 3.97,
3.69
61.5 - -
Ser5 8.17 4.52 55.2 4.04,
3.97
61.3 - -
Pro6 - 4.37 60.6 1.99,
1.76
27.9 1.87, 1.65 (γ, CH2),
3.74, 3.67 (δ, CH2)
24.3 (γ), 47.1 (δ)
Tyr7 6.66 4.53 53.4 2.96,
2.67
36.8 6.93 (δ, CH), 6.63 (ε,
CH)
127.7 (γ), 130.1
(δ), 114.5 (ε),
155.8 (ζ)
Asn8 8.52 5.05 50.0 2.73,
2.50
37.1 7.14, 6.31 (δ, NH2) -
Asp9 8.89 4.84 48.5 3.67,
2.99
37.6 - -
Ile10 8.23 4.05 60.3 1.99 36.4 1.59, 1.44 (γ, CH2),
1.05 (γ, CH3), 0.98 (δ,
CH3)
14.8 (γ, CH3),
25.4 (γ, CH2),
11.1 (δ)
Leu11 7.28 4.52 51.8 1.94,
1.80
39.6 1.74 (γ, CH), 1.04, 0.94
(δ, CH3)
24.8 (γ), 22.4,
21.2 (δ)
Gly12 8.39 4.08,
3.47
42.3 - - - -
Tyr13 6.98 4.83 52.9 3.22,
2.45
38.7 7.00 (δ, CH), 6.70 (ε,
CH)
128.0 (γ), 130.1
(δ), 114.9 (ε),
155.8 (ζ)
Pro14 - 4.31 62.0 2.65,
1.87
28.0 1.97 (γ, CH2), 3.78,
3.58 (δ, CH2)
25.0 (γ), 47.7 (δ)
Ala15 8.57 4.20 49.8 1.36 17.6 - -
Leu16 8.20 4.56 52.4 1.83,
1.60
39.8 1.73 (γ, CH), 1.02, 0.93
(δ, CH3)
24.6 (γ), 21.4,
22.3 (δ)
Ile17 7.67 4.24 57.9 1.90 36.8 1.59, 1.17 (γ, CH2),
0.92 (γ, CH3), 0.91 (δ,
CH3)
14.5 (γ, CH3),
24.7 (γ, CH2), 9.9
(δ)
Val18 8.33 4.19 58.7 2.01 30.7 0.91, 0.81 (γ, CH3) 18.5, 17.6 (γ)
Ile19 8.06 4.25 ambig. 1.73 ambig. 1.45, 1.11 (γ, CH2),
0.91 (γ, CH3), 0.83 (δ,
CH3)
ambig.
Tyr20 8.15 4.77 52.8 3.05,
2.82
36.2 7.09 (δ, CH), 6.67 (ε,
CH)
126.5 (γ), 130.1
(δ), 114.9 (ε),
155.9 (ζ)
Pro21 - 4.39 59.1 2.19,
2.00
28.8 1.96 (γ, CH2), 3.74,
3.42 (δ, CH2)
24.4 (γ), 46.9 (δ)
318
B.1.16 Amino acid analysis.Quantitative amino acid analysis (n = 3; columns 2–4) was consistent
with the 21 amino acids present in STM. Chiral amino acid analysis (last column) by microwave-
assisted peptide hydrolysis and derivatization with Marfey’s reagent, as described in Chapter 2,
revealed all amino acids to be present exclusively as their natural L stereoisomer.
Amino
acid
Nanomoles
in sample
Percent
composition
Predicted amino
acid count
Chirality
Asp/Asn 18.84 ± 1.84 9.8% 2 L
Gln/Glu - - - -
Ser 26.6 ± 2.56 13.9% 3 L
His - - - -
Gly 18.67 ± 2.18 9.8% 2 L
Thr - - - -
Ala 10.32 ± 1.11 5.4% 1 L
Arg - - -
Tyr 32.9 ± 3.34 17.2% 3 L
Val 6.07 ± 0.6 3.2% 1 L
Met - - - -
Phe - - - -
Ile 21.72 ± 2.09 11.4% 3 L
Leu 27.45 ± 2.81 14.4% 3 L
Lys - - - -
Pro 28.72 ± 4.16 15.0% 3 L
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B.2 Characterization data for JBIR-100
B.2.1 1H and 13C NMR chemical shift assignments of JBIR-100
Position Group 13C δ(ppm)
1H δ
(ppm)
m
(J, Hz) Position Group
13C δ
(ppm)
1H δ
(ppm)
m
(J, Hz)
1 C=O 171.7 - - 15 CH 75.6 4.98 dd(7.8, 1.6)
2 C 121.3 - - 16 CH 37.9 2.08 m
2-CH3 CH3 12.6 2.03 s 16-CH3 CH3 8.9 0.84 d (6.5)
3 CH 146.7 7.26 br s 17 CH 70.3 4.10 dd(10.8, 1.9)
4 C 133.3 - - 18 CH 41.9 1.79 qd(7.1, 2.0)
4-CH3 CH3 13.9 1.98 s 18-CH3 CH3 5.8 0.98 d (7.1)
5 CH 146.2 5.96 d (8.7) 19 C 98.8 - -
6 CH 37.0 2.55 dq(7.1, 8.7) 20 CH(a) 39.0 2.30
dd
(11.9, 4.8)
6-CH3 CH3 16.7 1.06 d (7.0) CH(b) 1.31 t (11.6)
7 CH 79.8 3.23 m 21 CH 74.8 5.02 td(10.9, 4.8)
8 CH 40.2 1.87 m 22 CH 37.9 1.64 ddq (10.9,10.5, 6.5)
8-CH3 CH3 20.8 0.92 d (6.9) 22-CH3 CH3 11.2 0.83 d (6.2)
9 CH(a) 41.1 2.05 m 23 CH 75.7 3.58 dd(10.4, 2.2)
CH(b) 1.98 m 24 CH 27.8 1.93 td(6.8, 2.2)
10 C 143.5 - - 25 CH3 20.1 0.94 d (6.9)
10-CH3 CH3 18.8 1.90 s 26 CH3 13.2 0.81 d (6.8)
11 CH 123.9 5.76 d (10.7) 1' C=O 165 - -
12 CH 133.1 6.59 dd(15.0, 10.8) 2' CH 132.3 6.72 d (15.8)
13 CH 125.5 5.10 dd(14.9, 9.0) 3' CH 135.6 6.81 d (15.8)
14 CH 83.1 4.00 dd(9.1, 7.7) 4' C=O 167.5 - -
14-OCH3 CH3 54.5 3.25 s
320
B.2.2 1H NMR spectrum of JBIR-100 (750 MHz, CD3OD)
321
B.2.3 1H-1H DQF-COSY spectrum of JBIR-100 (750 MHz, CD3OD)
322
B.2.4 1H-1H TOCSY spectrum of JBIR-100 (750 MHz, CD3OD)
323
B.2.5 1H-13C HSQC spectrum of JBIR-100 (750 MHz, CD3OD)
324
B.2.6 1H-13C HMBC spectrum of JBIR-100 (750 MHz, CD3OD)
325
B.3 Characterization data for LP2006
B.3.1 HR-MS/MS and HPLC characterization of LP2006. (A) High resolution mass spectrum
of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error from
chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks correspond
to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram with
identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels B and
C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
326
B.3.2 1H NMR (CD3OH, 900 MHz) of LP2006
327
B.3.3 1H-13C HSQC (CD3OH, 900 MHz) of LP2006, 13C 0-80 ppm
328
B.3.4 1H-13C HSQC (CD3OH, 900 MHz) of LP2006, 13C 110-135 ppm
329
B.3.5 1H-1H TOCSY (CD3OH, 900 MHz) of LP2006
330
B.3.6 1H-1H NOESY (CD3OH, 900 MHz) of LP2006. Annotated in red are strong NOESY
correlations confirming the Gly1-Glu8 isopeptide linkage.
331
B.3.7 NMR chemical shift assignments for LP2006
δ (ppm)
Resid
ue NH Hα Cα Hβ Cβ Others, H (group) Others, C (group)
Gly1 9.38 4.51,3.65 42.6 3.65 – – –
Arg2 9.24 4.86 49.6 1.87,1.83 26.3
1.81, 1.70 (γ, CH2),
3.26, 3.17 (δ, CH2) 23.9 (γ), 39.4 (δ)
Pro3 – 4.37 61.2 2.10,1.97 28.2
2.01, 1.96 (γ, CH2),
3.64, 3.50 (δ, CH2) 25.4 (γ), 47.3 (δ)
Asn4 8.22 4.13 53.6 2.72,2.67 35.2 7.65, 6.86 (δ, NH2) –
Trp5 8.26 5.14 54.5 3.32,3.08 28.4
7.88, 7.29, 7.06,
6.98, 7.31 (arom,
CH)
118.7, 110.9, 121.1,
118.5, 123.0 (arom)
Gly6 8.15 3.90,3.26 45.0 3.26 – – –
Phe7 7.46 4.90 54.5 3.64,2.60 36.4
7.39, 7.31, 7.31
(arom, CH)
128.3, 128.8, 126.4
(arom)
Glu8 8.93 4.34 56.3 2.18,2.08 25.9 2.47, 1.97 (γ, CH2) 37.1 (γ)
Asn9 8.20 4.13 51.1 3.29,3.23 36.8 7.87, 6.95 (δ, NH2) –
Asp10 7.96 4.48 49.7 3.10,2.33 37.0 – –
Trp11 7.98 4.70 56.3 3.88,3.84 22.3
7.81, 7.38, 7.13,
7.02, 7.11 (arom,
CH)
118.9, 110.8, 120.8,
118.2, 123.0 (arom)
Ser12 7.43 5.42 56.0 4.96,3.64 60.8 – –
Cys13 8.14 4.28 54.5 3.02,2.90 40.4 – –
Val14 8.50 3.94 60.5 2.25 29.9 1.07, 1.01 (γ, CH3) 19.7, 17.9 (γ)
Arg15 n.d. 3.95 58.7 2.13,2.03 28.7
1.69, 1.65 (γ, CH2),
3.24 (δ, CH2) 25.8 (γ), 40.4 (δ)
Val16 n.d. 4.17 60.3 2.41 29.3 1.05, 1.03 (γ, CH3) 18.9, 16.7 (γ)
Cys17 7.25 4.60 55.0 3.47,2.84 42.2 – –
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B.4 Characterization data for lagmysin
B.4.1 HR-MS/MS and HPLC characterization of lagmysin (A) High resolution mass spectrum
of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error from
chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks correspond
to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram with
identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels B and
C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
333
B.4.2 1H NMR (CD3OH, 900 MHz) of lagmysin
334
B.4.3 1H-13C HSQC (CD3OH, 900 MHz) of lagmysin, 13C 0-70 ppm
335
B.4.4 1H-13C HSQC (CD3OH, 900 MHz) of lagmysin, 13C 112-147 ppm
336
B.4.5 1H-1H TOCSY (CD3OH, 900 MHz) of lagmysin
337
B.4.6 1H-1H NOESY (CD3OH, 750 MHz) of lagmysin Annotated in red are strong NOE
correlations confirming the Leu1-Asp8 isopeptide linkage.
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B.4.7 NMR chemical shift assignments for lagmysin
δ (ppm)
Resi-
due NH Hα Cα Hβ Cβ Others, H (group) Others, C (group)
Leu1 8.16 4.44 53.6 1.63 42.9 1.63 (γ, CH), 0.94,0.924 (δ, CH3)
24.7 (γ), 21.7, 22.5
(δ)
Ala2 7.45 4.73 49.4 1.67 15.8 – –
Gly3 8.41 4.62,3.64 42.7 – – – –
Gln4 7.60 4.45 52.7 2.03,1.90 29.6
2.21 (γ, CH2),
7.54, 6.83 (ε,
NH2)
31.1 (γ)
Gly5 8.67 4.29,3.58 41.6 – – – –
Ser6 8.69 4.85 obsc. 3.93,3.79 60.7 – –
Pro7 – 4.21 61.4 2.16,1.83 29.1
2.15, 1.98 (γ,
CH2), 3.99, 3.70
(δ, CH2)
25.4 (γ), 47.3 (δ)
Asp8 8.88 4.87 obsc. 3.40,2.69 37.6 – –
Leu9 8.02 3.99 54.9 1.63 42.9 1.74 (γ, CH), 0.97,0.92 (δ, CH3)
24.7 (γ), 21.9, 20.5
(δ)
Leu10 7.49 4.62 50.9 1.94,1.47 40.2
1.61 (γ, CH), 0.96,
0.92 (δ, CH3)
24.7 (γ), 21.7, 20.0
(δ)
Gly11 7.97 4.34,3.57 42.5 – – – –
Gly12 7.26 4.63,3.57 40.9 – – – –
His13 8.45 4.95 obsc. 2.51,2.25 n.d.
7.51 (δ, CH), 6.71
(δ, NH), 8.55 (ε,
CH)
134.7 (δ), 128.8 (ε)
Ser14 9.4 5.11 obsc. 4.16,3.82 64.6 – –
Leu15 8.58 4.52 5.3 1.68 40.5 1.81 (γ, CH), 0.99,0.96 (δ, CH3)
24.2 (γ), 22.2, 20.8
(δ)
Leu16 7.65 4.34 53.5 1.68,1.59 42.2
1.69 (γ, CH), 0.97,
0.96 (δ, CH3)
24.8 (γ), 21.3, 22.5
(δ)
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B.5 Characterization data for citrulassin A and des-citrulassin A
B.5.1 HR-MS/MS and HPLC characterization of citrulassin A (A) High resolution mass
spectrum of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error
from chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks
correspond to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram
with identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels
B and C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
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B.5.2 HR-MS/MS characterization of des-citrulassin A (A) High resolution mass spectrum of
either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error from
chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks correspond
to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram with
identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels B and
C.
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B.5.3 1H NMR (CD3OD, 750 MHz) of citrulassin A
342
B.5.4 1H-13C HSQC (CD3OH, 900 MHz) of citrulassin A
343
B.5.5 1H-1H TOCSY (CD3OH, 900 MHz) of citrulassin A
344
B.5.6 1H-1H NOESY NMR (CD3OH, 750 MHz) of citrulassin A Annotated in red are strong
NOE correlations confirming the Leu1-Asp9 linkage.
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B.5.7 NMR chemical shift assignments for citrulassin A
δ (ppm)
Resi-
due NH Hα Cα Hβ Cβ Others, H (group) Others, C (group)
Leu1 7.87 4.29 55.88 1.91,1.89 44.35
1.64 (γ, CH), 1.00,
0.93 (δ, CH3)
25.5 (γ), 22.5, 22.9
(δ)
Leu2 7.77 4.59 51.7 1.86,1.63 40.3
1.57 (γ, CH), 1.03,
0.92 (δ, CH3)
25.8 (γ), 23.7, 21.0
(δ)
Gly3 7.66 3.68,3.64 44.5 – – – –
Leu4 7.89 4.47 50.9 1.75,1.63 40.25
1.69 (γ, CH), 0.97,
0.94 (δ, CH3)
24.8 (γ), 22.5, 19.6
(δ)
Ala5 8.01 4.59 50.6 1.36 16.2 – –
Gly6 8.80 4.44,3.44 42.5 – – – –
Asn7 8.22 5.09 49.6 2.88,2.63 36.9 7.54, 6.78 (δ, NH) –
Asp8 9.46 4.65 52.2 3.47,2.51 35.4 – –
Cit9 8.56 3.98 57.8 1.85,1.76 32.4
1.66, 1.64 (γ,
CH2), 3.19, 3.12
(δ, CH2), 6.26 (ε,
NH)
26.9 (γ), 38.9 (δ)
Leu10 8.39 4.72 51.3 1.52,1.44 44.1
1.55 (γ, CH), 0.92,
0.87 (δ, CH3)
24.8 (γ), 19.6, 22.7
(δ)
Val11 8.4 3.72 60.0 2.69 27.6 1.26, 0.85 (γ,CH3) 22.2, 19.4 (γ)
Leu12 7.35 5.09 50.9 1.57,1.40 44.2
1.48 (γ, CH), 0.74,
0.86 (δ, CH3)
24.9 (γ), 20.5, 20.5
(δ)
Ser13 7.83 4.45 50.9 4.06,3.84 62.3 – –
Lys14 9.06 4.71 51.3 1.88,1.79 33.5
1.59, 1.55 (γ,
CH2), 1.68 (δ,
CH2), 2.94 (ε,
CH2)
22.8 (γ), 27.8 (δ),
40.1 (ε)
Asn15 8.35 4.68 52.9 2.92,2.69 37.8
7.65, 7.05 (δ,
NH2) –
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B.6 Characterization data for anantin B1 and B2
B.6.1 HR-MS/MS and HPLC characterization of anantin B1 (A) High resolution mass
spectrum of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error
from chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks
correspond to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram
with identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels
B and C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
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B.6.2 HR-MS/MS and HPLC characterization of anantin B2 (A) High resolution mass
spectrum of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error
from chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks
correspond to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram
with identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels
B and C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
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B.7 Characterization data for moomysin
B.7.1 HR-MS/MS and HPLC characterization of anantin B2 (A) High resolution mass
spectrum of either the [M+H]+ or [M+2H]2+ (indicated) was used to calculate exact mass and error
from chemical formula. (B) CID spectrum of the [M+H]+ or [M+2H]2+ ion. Labeled peaks
correspond to identified b- and y- ions. (C) schematized unthreaded lasso peptide bubble diagram
with identified fragment ions. (D) Table of masses of the observed b- and y-ions shown in panels
B and C. (E) Analytical HPLC trace of purified lasso peptides monitored at 220 nm.
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APPENDIX C: DESCRIPTION OF SUPPLEMENTARY DATA FILES
C.1 Profile hidden Markov models (pHMMs) used in RODEO analyses
Custom pHMMs were created in Chapter 2 for profiling of hygrobafilomycin-like
biosynthetic gene clusters. Custom pHMMs were also created for the manuscript referenced in
Appendix A.5 for profiling of peptide aldehyde biosynthetic gene clusters.
The above pHMMs (4.6 MB) are accessible via DropBox at
https://www.dropbox.com/sh/lo0dxzj6r95k0x1/AADsw9s0s0IIgKce0f_ZIoIja?dl=0 using the
password BCNx0BaqyB.
C.2 Lasso peptide comprehensive dataset
An Excel file was created with a list of all RODEO-identified lasso peptide BGCs, the
initial input lasso data set including precursor peptide sequences and genes, all putative precursor
peptides with scores, and the MEME parameters used for motif analysis.
The above spreadsheet (14.6 MB) is accessible via DropBox at
https://www.dropbox.com/sh/lo0dxzj6r95k0x1/AADsw9s0s0IIgKce0f_ZIoIja?dl=0 using the
password BCNx0BaqyB.
C.3 RODEO source code
RODEO is currently maintained by the Mitchell lab and is updated as features are added
or bugs are fixed.
The current version of the source code (ca. 100 kb) is accessible at
http://www.ripprodeo.org/.
C.4 Sequence-similarity network files for lasso peptides
The sequence-similarity network files referenced in Chapter 4 are included as an annotated
Cytoscape file. This file (20.1 MB) is accessible via DropBox at
https://www.dropbox.com/sh/lo0dxzj6r95k0x1/AADsw9s0s0IIgKce0f_ZIoIja?dl=0 using the
password BCNx0BaqyB.
